disorder;disorder_OMIM;disorder_cat;symptom;symptom_cat;gene_symb;gene_OMIM;gene_cytoloc
3-M syndrome;273750;autosomal recessive disease;short thorax;Abnormality of the thorax;CUL7, 3M1;609577;6p21.1
3-M syndrome;612921;autosomal recessive disease;prominent nasal tip;Abnormality of the nasal tip;OBSL1, KIAA0657, 3M2;610991;2q35
3-M syndrome;614205;autosomal recessive disease;midface retrusion;Abnormality of the midface;CCDC8, 3M3;614145;19q13.32
3-Methylcrotonyl-CoA carboxylase deficiency;210200;amino acid metabolic disorder;feeding difficulties in infancy;Feeding difficulties;MCCC1, MCCA;609010;3q27.1
3-Methylcrotonyl-CoA carboxylase deficiency;210210;amino acid metabolic disorder;propionyl-coa carboxylase deficiency;Abnormality of amino acid metabolism;MCCC2, MCCB;609014;5q13.2
3MC syndrome;257920;syndrome;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;MASP1, CRARF, 3MC1;600521;3q27.3
3MC syndrome;265050;syndrome;premaxillary prominence;Abnormality of the premaxilla;COLEC11, CLK1, 3MC2;612502;2p25.3
46 XX gonadal dysgenesis;233300;gonadal dysgenesis;osteoporosis;Reduced bone mineral density;FSHR, ODG1;136435;2p16.3
46 XX gonadal dysgenesis;400045;gonadal dysgenesis;urogenital sinus anomaly;Abnormality of the urethra;SRY, TDF, TDY, SRXX1, SRXY1;480000;Yp11.31
46 XX gonadal dysgenesis;614324;gonadal dysgenesis;primary amenorrhea;Amenorrhea;PSMC3IP, TBPIP, GT198, HOP2, ODG3;608665;17q21.2
46 XY gonadal dysgenesis;233420;gonadal dysgenesis;sex reversal;Abnormal sex determination;DHH, SRXY7, GDXYM;605423;12q13.12
46 XY gonadal dysgenesis;300018;gonadal dysgenesis;sex reversal;Abnormal sex determination;DAX1, AHC, AHX, NR0B1, SRXY2;300473;Xp21.2
46 XY gonadal dysgenesis;400044;gonadal dysgenesis;sex reversal;Abnormal sex determination;SRY, TDF, TDY, SRXX1, SRXY1;480000;Yp11.31
46 XY gonadal dysgenesis;612965;gonadal dysgenesis;sex reversal;Abnormal sex determination;NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8;184757;9q33.3
46 XY gonadal dysgenesis;613080;gonadal dysgenesis;sex reversal;Abnormal sex determination;CBX2, M33, SRXY5;602770;17q25.3
46 XY gonadal dysgenesis;613762;gonadal dysgenesis;dysgerminoma;Germinoma;MAP3K1, MEKK1, MEKK, SRXY6;600982;5q11.2
46 XY gonadal dysgenesis;614279;gonadal dysgenesis;sex reversal;Abnormal sex determination;AKR1C2, DDH2, DD2, HAKRD, SRXY8;600450;10p15.1
46 XY gonadal dysgenesis;614279;gonadal dysgenesis;sex reversal;Abnormal sex determination;AKR1C4, CHDR, CDR, HAKRA, DD4;600451;10p15.1
ABCD syndrome;600501;autosomal recessive disease;hypopigmentation of the fundus;Abnormality of the retinal pigment epithelium;EDNRB, HSCR2, ABCDS, WS4A;131244;13q22.3
ACTH-secreting pituitary adenoma;219090;functioning pituitary adenoma;skin ulcer;Localized skin lesion;AIP, XAP2, ARA9;605555;11q13.2
ADULT syndrome;103285;autosomal dominant disease;scalp hair loss;Early balding;TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8;603273;3q28
AGAT deficiency;612718;cerebral creatine deficiency syndrome;abnormality of creatine metabolism;Abnormality of amino acid metabolism;GATM, AGAT, CCDS3;602360;15q21.1
ARC syndrome;208085;syndrome;giant cell hepatitis;Hepatitis;VPS33B;608552;15q26.1
ARC syndrome;613404;syndrome;giant cell hepatitis;Hepatitis;VIPAS39, VIPAR, SPE39, C14orf133;613401;14q24.3
Aarskog-Scott syndrome;305400;autosomal dominant disease;clinodactyly;Abnormality of digit;FGD1, FGDY, AAS, MRXS16;300546;Xp11.22
Adams-Oliver syndrome;100300;syndrome;aplasia cutis congenita over posterior parietal area;Aplasia cutis congenita over parietal area;ARHGAP31, CDGAP, KIAA1204, AOS1;610911;3q13.33
Adams-Oliver syndrome;614219;syndrome;small palpebral fissure;Abnormal size of the palpebral fissures;DOCK6, KIAA1395, AOS2;614194;19p13.2
Adams-Oliver syndrome;614814;syndrome;short palpebral fissure;Abnormal size of the palpebral fissures;RBPJ, RBPSUH, IGKJRB1, AOS3;147183;4p15.2
Adams-Oliver syndrome;615297;syndrome;toenail dysplasia;Abnormality of the toenails;EOGT, EOGT1, C3orf64, AOS4;614789;3p14.1
Aicardi-Goutieres syndrome;225750;autosomal recessive disease;chilblain lesions;Abnormality of finger;TREX1, AGS1, CRV, HERNS;606609;3p21.31
Aicardi-Goutieres syndrome;610181;autosomal recessive disease;chronic csf lymphocytosis;CSF lymphocytic pleiocytosis;RNASEH2B, DLEU8, FLJ11712, AGS2;610326;13q14.3
Aicardi-Goutieres syndrome;610329;autosomal recessive disease;severe global developmental delay;Global developmental delay;RNASEH2C, AYP1, FLJ20974, AGS3;610330;11q13.1
Aicardi-Goutieres syndrome;610333;autosomal recessive disease;csf lymphocytic pleiocytosis;CSF pleocytosis;RNASEH2A, RNHIA, AGS4;606034;19p13.2
Aicardi-Goutieres syndrome;612952;autosomal recessive disease;chilblain lesions;Abnormality of finger;SAMHD1, AGS5, DCIP, CHBL2;606754;20q11.23
Aicardi-Goutieres syndrome;615010;autosomal recessive disease;loss of ability to walk;Progressive inability to walk;ADAR, DRADA, DSH, DSRAD, IFI4, G1P1, AGS6;146920;1q21.3
Aicardi-Goutieres syndrome;615846;autosomal recessive disease;feeding difficulties;Abdominal symptom;IFIH1, MDA5, AGS7;606951;2q24.2
Alagille syndrome;118450;liver disease;short distal phalanx of finger;Aplasia/Hypoplasia of the distal phalanges of the hand;JAG1, AGS, AHD;601920;20p12.2
Alagille syndrome;610205;liver disease;peripheral pulmonary artery stenosis;Pulmonary artery stenosis;NOTCH2, AGS2, HJCYS;600275;1p12-p11
Aland Island eye disease;300600;eye disease;hypoplasia of the fovea;Aplasia/Hypoplasia of the fovea;CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2;300110;Xp11.23
Albright's hereditary osteodystrophy;103580;pseudohypoparathyroidism;cognitive impairment;Abnormality of higher mental function;GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C;139320;20q13.32
Alexander disease;203450;leukodystrophy;large face;Abnormal facial shape;GFAP;137780;17q21.31
Allan-Herndon-Dudley syndrome;300523;X-linked disease;type i diabetes mellitus;Diabetes mellitus;SLC16A2, DXS128, XPCT;300095;Xq13.2
Alpers syndrome;203700;cerebral degeneration;cortical visual impairment;Visual impairment;POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS;174763;15q26.1
Alport syndrome;104200;autosomal recessive disease;diffuse glomerular basement membrane lamellation;Abnormality of the glomerulus;COL4A3;120070;2q36.3
Alport syndrome;203780;autosomal recessive disease;corneal erosion;Abnormality of corneal epithelium;COL4A3;120070;2q36.3
Alport syndrome;203780;autosomal recessive disease;corneal erosion;Abnormality of corneal epithelium;COL4A4;120131;2q36.3
Alport syndrome;301050;autosomal recessive disease;corneal erosion;Abnormality of corneal epithelium;COL4A5, ATS, ASLN;303630;Xq22.3
Alstrom syndrome;203800;autosomal recessive disease;chronic active hepatitis;Chronic hepatitis;ALMS1, ALSS, KIAA0328;606844;2p13.1
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;A2M , A2MD;103950;12p13.31
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;ACE, DCP1, ACE1, MVCD3, ICH;106180;17q23.3
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;AD10;609636;7q36
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;AD5;602096;12p11.23-q13.12
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;AD6;605526;10q24
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;AD8;607116;20p
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;AD9;608907;19p13.2
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;APBB2, FE65L1;602710;4p14-p13
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;APP, AAA, CVAP, AD1;104760;21q21.3
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;BLMH, BMH;602403;17q11.2
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;HFE, HLA-H, HFE1, MVCD7, TFQTL2;613609;6p22.2
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;MPO;606989;17q22
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;NOS3;163729;7q36.1
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;PACIP1, PAXIP1L, PTIP;608254;7q36.2
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;PLAU, URK, QPD, BDPLT5;191840;10q22.2
Alzheimer's disease;104300;tauopathy;alzheimer disease;Morphological abnormality of the central nervous system;SORL1, LR11, SORLA;602005;11q24.1
Alzheimer's disease;104310;tauopathy;late onset;Adult onset;APOE, AD2, LPG, LDLCQ5;107741;19q13.32
Alzheimer's disease;606889;tauopathy;cerebral amyloid angiopathy;Amyloidosis;PSEN2, AD4, STM2, CMD1V;600759;1q42.13
Alzheimer's disease;607822;tauopathy;agnosia;Abnormality of higher mental function;PSEN1, AD3;104311;14q24.2
Andersen-Tawil syndrome;170390;long QT syndrome;small hand;Aplasia/hypoplasia involving bones of the hand;KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9;600681;17q24.3
Angelman syndrome;105830;chromosomal disease;limb tremor;Tremor by anatomical site;CDKL5, STK9, ISSX, EIEE2;300203;Xp22.13
Angelman syndrome;105830;chromosomal disease;limb tremor;Tremor by anatomical site;MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16;300005;Xq28
Angelman syndrome;105830;chromosomal disease;limb tremor;Tremor by anatomical site;UBE3A, ANCR;601623;15q11.2
Antley-Bixler syndrome;201750;autosomal recessive disease;camptodactyly;Flexion contracture of digit;POR;124015;7q11.23
Antley-Bixler syndrome;207410;autosomal recessive disease;camptodactyly of finger;Flexion contracture of finger;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
Arts syndrome;301835;X-linked disease;pancreatic fibrosis;Abnormality of pancreas morphology;PRPS1, CMTX5, DFNX1, DFN2;311850;Xq22.3
Asperger syndrome;300494;autism spectrum disorder;sporadic;Mode of inheritance;NLGN3, ASPGX1, AUTSX1;300336;Xq13.1
Asperger syndrome;300497;autism spectrum disorder;juvenile onset;Onset;NLGN4, KIAA1260, AUTSX2, ASPGX2;300427;Xp22.32-p22.31
Athabaskan brainstem dysgenesis syndrome;601536;autosomal recessive disease;abnormality of cerebral artery;Abnormality of the cerebral vasculature;HOXA1, HOX1F, BSAS;142955;7p15.2
Axenfeld-Rieger syndrome;180500;autosomal dominant disease;polycoria;Abnormality of the pupil;PITX2, IDG2, RIEG1, RGS, IGDS2;601542;4q25
Axenfeld-Rieger syndrome;602482;autosomal dominant disease;concave nasal ridge;Abnormality of the nasal dorsum;FOXC1, FKHL7, FREAC3, IRID1, RIEG3;601090;6p25.3
Baller-Gerold syndrome;218600;synostosis;urogenital fistula;Abnormality of the genitourinary system;RECQL4, RTS, RECQ4;603780;8q24.3
Bamforth-Lazarus syndrome;241850;hypothyroidism;cognitive impairment;Abnormality of higher mental function;FOXE1, FKHL15, TITF2, TTF2;602617;9q22.33
Bannayan-Riley-Ruvalcaba syndrome;153480;autosomal dominant disease;intestinal polyposis;Intestinal polyp;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
Baraitser-Winter syndrome;243310;syndrome;postnatal growth retardation;Growth delay;ACTB, BRWS1;102630;7p22.1
Baraitser-Winter syndrome;614583;syndrome;postnatal microcephaly;Microcephaly;ACTG1, DFNA20, DFNA26, BRWS2;102560;17q25.3
Bardet-Biedl syndrome;209900;autosomal recessive disease;nephrogenic diabetes insipidus;Diabetes insipidus;ARL6, BBS3, RP55;608845;3q11.2
Bardet-Biedl syndrome;209900;autosomal recessive disease;nephrogenic diabetes insipidus;Diabetes insipidus;BBS1;209901;11q13.2
Bardet-Biedl syndrome;209900;autosomal recessive disease;nephrogenic diabetes insipidus;Diabetes insipidus;CCDC28B, MGC1203;610162;1p35.1
Bardet-Biedl syndrome;209900;autosomal recessive disease;nephrogenic diabetes insipidus;Diabetes insipidus;TMEM67, MKS3, JBTS6, NPHP11;609884;8q22.1
Bart-Pumphrey syndrome;149200;autosomal dominant disease;abnormality of nail color;Abnormality of the nail;GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID;121011;13q12.11
Barth syndrome;302060;lipid metabolism disorder;fatigue;Behavioral abnormality;TAZ, EFE2, BTHS, CMD3A, LVNCX;300394;Xq28
Bartter disease;241200;renal tubular transport disease;prominent forehead;Abnormality of the forehead;KCNJ1, ROMK1;600359;11q24.3
Bartter disease;601678;renal tubular transport disease;short stature;Growth delay;SLC12A1, NKCC2;600839;15q21.1
Bartter disease;602522;renal tubular transport disease;hypernatriuria;Abnormal urine sodium concentration;BSND;606412;1p32.3
Bartter disease;607364;renal tubular transport disease;abnormality of the retinal vasculature;Abnormality of the vasculature of the eye;CLCNKB;602023;1p36.13
Bartter disease;613090;renal tubular transport disease;hypernatriuria;Abnormal urine sodium concentration;CLCNKA;602024;1p36.13
Bartter disease;613090;renal tubular transport disease;hypernatriuria;Abnormal urine sodium concentration;CLCNKB;602023;1p36.13
Beare-Stevenson cutis gyrata syndrome;123790;autosomal dominant disease;visceral angiomatosis;Hemangiomatosis;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
Becker muscular dystrophy;300376;muscular dystrophy;arrhythmia;Abnormality of cardiovascular system physiology;DMD, BMD, CMD3B;300377;Xp21.2-p21.1
Beckwith-Wiedemann syndrome;130650;syndrome;urogenital fistula;Abnormality of the genitourinary system;CDKN1C, KIP2, BWS, IMAGE;600856;11p15.4
Beckwith-Wiedemann syndrome;130650;syndrome;urogenital fistula;Abnormality of the genitourinary system;H19, D11S813E, ASM1, BWS, WT2;103280;11p15.5
Beckwith-Wiedemann syndrome;130650;syndrome;urogenital fistula;Abnormality of the genitourinary system;ICR1;616186;11p15.5
Beckwith-Wiedemann syndrome;130650;syndrome;urogenital fistula;Abnormality of the genitourinary system;KCNQ1OT1, LIT1;604115;11p15.5
Beckwith-Wiedemann syndrome;130650;syndrome;urogenital fistula;Abnormality of the genitourinary system;NSD1, ARA267, STO, SOTOS1;606681;5q35.2-q35.3
Bernard-Soulier syndrome;153670;blood platelet disease;increased mean platelet volume;Abnormal platelet volume;GP1BA, BSS, BDPLT1, VWDP, BDPLT3;606672;17p13.2
Bernard-Soulier syndrome;231200;blood platelet disease;increased mean platelet volume;Abnormal platelet volume;GP1BA, BSS, BDPLT1, VWDP, BDPLT3;606672;17p13.2
Bernard-Soulier syndrome;231200;blood platelet disease;increased mean platelet volume;Abnormal platelet volume;GP1BB, BS, BDPLT1;138720;22q11.21
Bernard-Soulier syndrome;231200;blood platelet disease;increased mean platelet volume;Abnormal platelet volume;GP9;173515;3q21.3
Bethlem myopathy;158810;congenital muscular dystrophy;camptodactyly of finger;Flexion contracture of finger;COL6A1;120220;21q22.3
Bethlem myopathy;158810;congenital muscular dystrophy;camptodactyly of finger;Flexion contracture of finger;COL6A2;120240;21q22.3
Bethlem myopathy;158810;congenital muscular dystrophy;camptodactyly of finger;Flexion contracture of finger;COL6A3;120250;2q37.3
Bietti crystalline corneoretinal dystrophy;210370;retinal degeneration;marginal corneal dystrophy;Corneal dystrophy;CYP4V2, BCD;608614;4q35.2
Birk-Barel syndrome;612292;autosomal dominant disease;submucous cleft soft palate;Cleft soft palate;KCNK9, TASK3;605874;8q24.3
Birt-Hogg-Dube syndrome;135150;autosomal dominant disease;neoplasm of the parathyroid gland;Neoplasm of the endocrine system;FLCN, BHD;607273;17p11.2
Bjornstad syndrome;262000;autosomal recessive disease;aplasia/hypoplasia of the eyebrow;Abnormality of the eyebrow;BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1;603647;2q35
Blau syndrome;186580;autosomal dominant disease;skin ulcer;Localized skin lesion;NOD2, CARD15, IBD1, CD, ACUG, PSORAS1;605956;16q12.1
Bloch-Sulzberger syndrome;308300;pigmentation disease;verrucae;Papilloma;IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1, IMD33;300248;Xq28
Boomerang dysplasia;112310;osteochondrodysplasia;abnormal vertebral ossification;Abnormality of the vertebrae;FLNB, SCT, AOI, LRS1;603381;3p14.3
Borjeson-Forssman-Lehmann syndrome;301900;X-linked disease;cognitive impairment;Abnormality of higher mental function;PHF6, BFLS;300414;Xq26.2
Bothnia retinal dystrophy;607475;fundus dystrophy;night blindness;Abnormality of vision;RLBP1;180090;15q26.1
Bowen-Conradi syndrome;211180;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;EMG1, NEP1, C2F, BWCNS;611531;12p13.31
Brody myopathy;601003;neuromuscular disease;muscle cramps;Abnormality of muscle physiology;ATP2A1, SERCA1;108730;16p11.2
Brooke-Spiegler syndrome;605041;autosomal dominant disease;adult onset;Onset;CYLD, CDMT, EAC, MFT1, KIAA0849, BRSS;605018;16q12.1
Brown-Vialetto-Van Laere syndrome;211530;autosomal dominant disease;tongue atrophy;Abnormality of the tongue;SLC52A3, C20orf54, RFT2, BVVLS1;613350;20p13
Bruck syndrome;259450;syndrome;vertebral wedging;Abnormal form of the vertebral bodies;FKBP10, FKBP65, OI11, BRKS1;607063;17q21.2
Bruck syndrome;609220;syndrome;knee flexion contracture;Contractures of the joints of the lower limbs;PLOD2, LH2, TLH, BRKS2;601865;3q24
Brugada syndrome;601144;heart conduction disease;sudden death;Time of death;SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;600163;3p22.2
Brugada syndrome;611777;heart conduction disease;prolonged pr interval;Abnormal EKG;GPD1L, KIAA0089;611778;3p22.3
Brugada syndrome;611875;heart conduction disease;j wave;Abnormal EKG;CACNA1C, CACNL1A1, CCHL1A1, TS;114205;12p13.33
Brugada syndrome;611876;heart conduction disease;shortened qt interval;Abnormal EKG;CACNB2;600003;10p12.33-p12.31
Brugada syndrome;612838;heart conduction disease;st segment elevation;Abnormal ST segment;SCN1B, GEFSP1, BRGDA5, ATFB13;600235;19q13.12
Brugada syndrome;613119;heart conduction disease;st segment elevation;Abnormal ST segment;KCNE3, HOKPP, HYPP;604433;11q13.4
Brugada syndrome;613120;heart conduction disease;st segment elevation;Abnormal ST segment;DSC3, DSC4;600271;18q12.1
Brugada syndrome;613120;heart conduction disease;st segment elevation;Abnormal ST segment;SCN3B, SCNB3, BRGDA7, ATFB16;608214;11q24.1
Brugada syndrome;613123;heart conduction disease;st segment elevation;Abnormal ST segment;HCN4, SSS2;605206;15q24.1
Bruton-type agammaglobulinemia;300755;agammaglobulinemia;agammaglobulinemia;Abnormal immunoglobulin level;BTK, AGMX1, IMD1, XLA, AT;300300;Xq22.1
Burkitt lymphoma;113970;mature B-cell neoplasm;burkitt lymphoma;Non-Hodgkin lymphoma;MYC;190080;8q24.21
CHARGE syndrome;214800;syndrome;down-sloping shoulders;Abnormality of the shoulder;CHD7, IS3, HH5;608892;8q12.1-q12.2
CHARGE syndrome;214800;syndrome;down-sloping shoulders;Abnormality of the shoulder;SEMA3E, SEMAH, KIAA0331;608166;7q21.11
CLONE OF congenital afibrinogenemia;202400;;splenic rupture;Abnormality of the spleen;FGA;134820;4q31.3
CLONE OF congenital afibrinogenemia;202400;;splenic rupture;Abnormality of the spleen;FGB;134830;4q31.3
CLONE OF congenital afibrinogenemia;202400;;splenic rupture;Abnormality of the spleen;FGG;134850;4q31.3
Caffey disease;114000;bone inflammation disease;cellulitis;Abnormality of connective tissue;COL1A1;120150;17q21.33
Camurati-Engelmann disease;131300;osteosclerosis;hyperostosis;Abnormality of skeletal morphology;TGFB1, DPD1, CED;190180;19q13.2
Canavan disease;271900;leukodystrophy;cognitive impairment;Abnormality of higher mental function;ASPA;608034;17p13.2
Carney complex;160980;autosomal dominant disease;schwannoma;Neoplasm of the peripheral nervous system;PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1;188830;17q24.2
Carney complex;608837;autosomal dominant disease;cardiac myxoma;Neoplasm of the heart;MYH8;160741;17p13.1
Carpenter syndrome;201000;acrocephalosyndactylia;camptodactyly;Flexion contracture of digit;RAB23;606144;6p11.2
Carpenter syndrome;614976;acrocephalosyndactylia;postaxial polydactyly;Polydactyly;MEGF8, EGFL4, CRPT2;604267;19q13.2
Charcot-Marie-Tooth disease intermediate type;606482;Charcot-Marie-Tooth disease;axonal degeneration;Peripheral axonal degeneration;DNM2, CMTDIB, CMTDI1, CMT2M, LCCS5;602378;19p13.2
Charcot-Marie-Tooth disease intermediate type;607791;Charcot-Marie-Tooth disease;distal amyotrophy;Skeletal muscle atrophy;MPZ, CMT1B, CMTDID, CHM, DSS;159440;1q23.3
Charcot-Marie-Tooth disease intermediate type;608323;Charcot-Marie-Tooth disease;distal amyotrophy;Skeletal muscle atrophy;YARS, CMTDIC, TYRRS, YTS, YRS;603623;1p35.1
Charcot-Marie-Tooth disease intermediate type;608340;Charcot-Marie-Tooth disease;childhood onset;Onset;GDAP1, CMT4A, CMT2K, CMTRIA;606598;8q21.11
Charcot-Marie-Tooth disease intermediate type;613641;Charcot-Marie-Tooth disease;vestibular schwannoma;Schwannoma;KARS, CMTRIB, DFNB89;601421;16q23.1
Charcot-Marie-Tooth disease intermediate type;614455;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;INF2, FSGS5, C14orf173, CMTDIE;610982;14q32.33
Charcot-Marie-Tooth disease intermediate type;615185;Charcot-Marie-Tooth disease;slow progression;Pace of progression;GNB4, CMTD1F;610863;3q26.33
Charcot-Marie-Tooth disease intermediate type;615376;Charcot-Marie-Tooth disease;mildly elevated creatine phosphokinase;Elevated serum creatine phosphokinase;PLEKHG5, KIAA0720, DSMA4, CMTRIC;611101;1p36.31
Charcot-Marie-Tooth disease type 1;118200;Charcot-Marie-Tooth disease;tonic pupil;Abnormal pupillary function;MPZ, CMT1B, CMTDID, CHM, DSS;159440;1q23.3
Charcot-Marie-Tooth disease type 1;118220;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;PMP22, CMT1A, CMT1E, DSS;601097;17p12
Charcot-Marie-Tooth disease type 1;118300;Charcot-Marie-Tooth disease;childhood onset;Onset;PMP22, CMT1A, CMT1E, DSS;601097;17p12
Charcot-Marie-Tooth disease type 1;601098;Charcot-Marie-Tooth disease;distal amyotrophy;Skeletal muscle atrophy;LITAF, CMT1C;603795;16p13.13
Charcot-Marie-Tooth disease type 1;607678;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;EGR2, KROX20;129010;10q21.3
Charcot-Marie-Tooth disease type 1;607734;Charcot-Marie-Tooth disease;clusters of axonal regeneration;Axonal regeneration;NEFL, CMT2E, CMT1F;162280;8p21.2
Charcot-Marie-Tooth disease type 2;118210;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;KIF1B, CMT2A, CMT2A1, NBLST1;605995;1p36.22
Charcot-Marie-Tooth disease type 2;600882;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;RAB7, CMT2B, PSN;602298;3q21.3
Charcot-Marie-Tooth disease type 2;601472;Charcot-Marie-Tooth disease;upper limb amyotrophy;Skeletal muscle atrophy;GARS, SMAD1, CMT2D, HMN5;600287;7p14.3
Charcot-Marie-Tooth disease type 2;605588;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;1q22
Charcot-Marie-Tooth disease type 2;605589;Charcot-Marie-Tooth disease;distal amyotrophy;Skeletal muscle atrophy;MED25, PTOV2, ARC92, CMT2B2;610197;19q13.33
Charcot-Marie-Tooth disease type 2;606071;Charcot-Marie-Tooth disease;down-sloping shoulders;Abnormality of the shoulder;TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL;605427;12q24.11
Charcot-Marie-Tooth disease type 2;606595;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;HSPB1, HSP27, CMT2F, HMN2B;602195;7q11.23
Charcot-Marie-Tooth disease type 2;607677;Charcot-Marie-Tooth disease;distal amyotrophy;Skeletal muscle atrophy;MPZ, CMT1B, CMTDID, CHM, DSS;159440;1q23.3
Charcot-Marie-Tooth disease type 2;607684;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;NEFL, CMT2E, CMT1F;162280;8p21.2
Charcot-Marie-Tooth disease type 2;607736;Charcot-Marie-Tooth disease;peripheral demyelination;Abnormal peripheral myelination;MPZ, CMT1B, CMTDID, CHM, DSS;159440;1q23.3
Charcot-Marie-Tooth disease type 2;607831;Charcot-Marie-Tooth disease;proximal muscle weakness;Muscle weakness;GDAP1, CMT4A, CMT2K, CMTRIA;606598;8q21.11
Charcot-Marie-Tooth disease type 2;608673;Charcot-Marie-Tooth disease;decreased amplitude of sensory action potentials;Abnormal peripheral action potential amplitude;HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A;608014;12q24.23
Charcot-Marie-Tooth disease type 2;609260;Charcot-Marie-Tooth disease;pain;Abnormality of nervous system physiology;MFN2, KIAA0214, CMT2A2;608507;1p36.22
Charcot-Marie-Tooth disease type 2;613287;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;AARS, CMT2N;601065;16q22.1
Charcot-Marie-Tooth disease type 2;614228;Charcot-Marie-Tooth disease;difficulty running;Functional motor problems.;DYNC1H1, DNCL, DNECL, CMT20, MRD13, SMALED1;600112;14q32.31
Charcot-Marie-Tooth disease type 2;614436;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;LRSAM1, TAL, RIFLE, CMT2P;610933;9q33.3
Charcot-Marie-Tooth disease type 2;615025;Charcot-Marie-Tooth disease;skeletal muscle atrophy;Abnormality of muscle size;DHTKD1, KIAA1630, AMOXAD, CMT2Q;614984;10p14
Charcot-Marie-Tooth disease type 2;615490;Charcot-Marie-Tooth disease;peripheral axonal neuropathy;Peripheral neuropathy;TRIM2, KIAA0517, CMT2R;614141;4q31.3
Charcot-Marie-Tooth disease type 3;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;EGR2, KROX20;129010;10q21.3
Charcot-Marie-Tooth disease type 3;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;MPZ, CMT1B, CMTDID, CHM, DSS;159440;1q23.3
Charcot-Marie-Tooth disease type 3;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;PMP22, CMT1A, CMT1E, DSS;601097;17p12
Charcot-Marie-Tooth disease type 3;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;PRX, CMT4F;605725;19q13.2
Charcot-Marie-Tooth disease type 4;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;EGR2, KROX20;129010;10q21.3
Charcot-Marie-Tooth disease type 4;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;MPZ, CMT1B, CMTDID, CHM, DSS;159440;1q23.3
Charcot-Marie-Tooth disease type 4;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;PMP22, CMT1A, CMT1E, DSS;601097;17p12
Charcot-Marie-Tooth disease type 4;145900;Charcot-Marie-Tooth disease;sensory ataxia;Impaired proprioception;PRX, CMT4F;605725;19q13.2
Charcot-Marie-Tooth disease type 4;214400;Charcot-Marie-Tooth disease;peripheral hypomyelination;Abnormal peripheral myelination;GDAP1, CMT4A, CMT2K, CMTRIA;606598;8q21.11
Charcot-Marie-Tooth disease type 4;601382;Charcot-Marie-Tooth disease;facial palsy;Abnormality of the seventh cranial nerve;MTMR2, CMT4B1;603557;11q21
Charcot-Marie-Tooth disease type 4;601455;Charcot-Marie-Tooth disease;abnormal auditory evoked potentials;Abnormality of central nervous system electrophysiology;NDRG1, HMSNL, CMT4D;605262;8q24.22
Charcot-Marie-Tooth disease type 4;601596;Charcot-Marie-Tooth disease;tongue atrophy;Abnormality of the tongue;SH3TC2, KIAA1985, MNMN;608206;5q32
Charcot-Marie-Tooth disease type 4;604563;Charcot-Marie-Tooth disease;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;SBF2, MTMR13, CMT4B2;607697;11p15.4
Charcot-Marie-Tooth disease type 4;605253;Charcot-Marie-Tooth disease;peripheral neuropathy;Abnormal peripheral nervous system morphology;EGR2, KROX20;129010;10q21.3
Charcot-Marie-Tooth disease type 4;605253;Charcot-Marie-Tooth disease;peripheral neuropathy;Abnormal peripheral nervous system morphology;MPZ, CMT1B, CMTDID, CHM, DSS;159440;1q23.3
Charcot-Marie-Tooth disease type 4;607706;Charcot-Marie-Tooth disease;spinal deformities;Abnormality of the vertebral column;GDAP1, CMT4A, CMT2K, CMTRIA;606598;8q21.11
Charcot-Marie-Tooth disease type 4;609311;Charcot-Marie-Tooth disease;peripheral demyelination;Abnormal peripheral myelination;FGD4, FRABIN, CMT4H;611104;12p11.21
Charcot-Marie-Tooth disease type 4;611228;Charcot-Marie-Tooth disease;peripheral hypomyelination;Abnormal peripheral myelination;FIG4, KIAA0274, SAC3, ALS11, YVS, BTOP;609390;6q21
Charcot-Marie-Tooth disease type 4;614895;Charcot-Marie-Tooth disease;peripheral demyelination;Abnormal peripheral myelination;PRX, CMT4F;605725;19q13.2
Charcot-Marie-Tooth disease type 4;615284;Charcot-Marie-Tooth disease;progressive disorder;Pace of progression;SBF1, MTMR5, CMT4B3;603560;22q13.33
Charcot-Marie-Tooth disease type X;300905;Charcot-Marie-Tooth disease;hand muscle weakness;Abnormality of the musculature of the hand;PDK3, CMTX6;300906;Xp22.11
Charcot-Marie-Tooth disease type X;302800;Charcot-Marie-Tooth disease;toe walking;Gait disturbance;GJB1, CX32, CMTX1;304040;Xq13.1
Charcot-Marie-Tooth disease type X;310490;Charcot-Marie-Tooth disease;cognitive impairment;Abnormality of higher mental function;AIFM1, PDCD8, AIF, COXPD6, COWCK, CMTX4;300169;Xq26.1
Charcot-Marie-Tooth disease type X;311070;Charcot-Marie-Tooth disease;childhood onset;Onset;PRPS1, CMTX5, DFNX1, DFN2;311850;Xq22.3
Chediak-Higashi syndrome;214500;autosomal recessive disease;skin ulcer;Localized skin lesion;LYST, CHS1;606897;1q42.3
Clouston syndrome;129500;autosomal dominant disease;skin ulcer;Localized skin lesion;GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2;604418;13q12.11
Cockayne syndrome;133540;autosomal recessive disease;arrhythmia;Abnormality of cardiovascular system physiology;ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1;609413;10q11.23
Cockayne syndrome;216400;autosomal recessive disease;arrhythmia;Abnormality of cardiovascular system physiology;ERCC8, CKN1, CSA, UVSS2;609412;5q12.1
Coffin-Lowry syndrome;303600;X-linked disease;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;RPS6KA3, RSK2, MRX19;300075;Xp22.12
Cornelia de Lange syndrome;122470;genetic disease;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;NIPBL, CDLS1;608667;5p13.2
Cornelia de Lange syndrome;300590;genetic disease;short stature;Growth delay;DXS423E, SMC1, CDLS2;300040;Xp11.22
Cornelia de Lange syndrome;300882;genetic disease;small hand;Aplasia/hypoplasia involving bones of the hand;HDAC8, WTS, MRXS6, CDLS5;300269;Xq13.1
Cornelia de Lange syndrome;610759;genetic disease;small hand;Aplasia/hypoplasia involving bones of the hand;CSPG6, SMC3, HCAP, BAM, CDLS3;606062;10q25.2
Cornelia de Lange syndrome;614701;genetic disease;exostoses;Neoplasm of the skeletal system;RAD21, SCC1, NXP1, KIAA0078, CDLS4;606462;8q24.11
Costello syndrome;218040;autosomal dominant disease;verrucae;Papilloma;HRAS;190020;11p15.5
Cowden disease;158350;autosomal dominant disease;intestinal polyposis;Intestinal polyp;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
Cowden disease;612359;autosomal dominant disease;endometrial carcinoma;Abnormality of the endometrium;SDHB, SDH2, SDHIP, PGL4, CWS2;185470;1p36.13
Creutzfeldt-Jakob disease;123400;prion disease;extrapyramidal muscular rigidity;Abnormality of extrapyramidal motor function;HLA-DQB1, CELIAC1;604305;6p21.32
Creutzfeldt-Jakob disease;123400;prion disease;extrapyramidal muscular rigidity;Abnormality of extrapyramidal motor function;PRNP, PRIP, KURU, CJD;176640;20p13
Crigler-Najjar syndrome;218800;bilirubin metabolic disorder;unconjugated hyperbilirubinemia;Hyperbilirubinemia;UGT1A1, UGT1, GNT1, BILIQTL1;191740;2q37.1
Crouzon syndrome;123500;craniosynostosis;sleep apnea;Sleep disturbance;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
D-2-hydroxyglutaric aciduria;600721;2-hydroxyglutaric aciduria;d-2-hydroxyglutaric aciduria;Dicarboxylic aciduria;D2HGDH, D2HGD;609186;2q37.3
D-2-hydroxyglutaric aciduria;613657;2-hydroxyglutaric aciduria;d-2-hydroxyglutaric aciduria;Dicarboxylic aciduria;IDH2, IDPM, D2HGA2;147650;15q26.1
DNA ligase IV deficiency;606593;combined T cell and B cell immunodeficiency;teleangiectasia of the skin;Telangiectasia;LIG4, LIG4S;601837;13q33.3
Danon disease;300257;lysosomal storage disease;cognitive impairment;Abnormality of higher mental function;LAMP2, LAMPB, LGP110;309060;Xq24
Denys-Drash syndrome;194080;autosomal dominant disease;true hermaphroditism;Abnormal external genitalia;WT1, NPHS4;607102;11p13
DiGeorge syndrome;188400;T cell deficiency;schizophrenia;Behavioral abnormality;TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR;602054;22q11.21
Diamond-Blackfan anemia;105650;congenital hypoplastic anemia;elevated red cell adenosine deaminase activity;Abnormal erythrocyte enzyme activity;RPS19, DBA, DBA1;603474;19q13.2
Diamond-Blackfan anemia;610629;congenital hypoplastic anemia;persistence of hemoglobin f;Abnormal hemoglobin;RPS24, DBA3;602412;10q22.3
Diamond-Blackfan anemia;612527;congenital hypoplastic anemia;erythroid hypoplasia;Abnormal number of erythroid precursors;RPS17, RPS17L1, RPS17L2, DBA4;180472;15q25.2
Diamond-Blackfan anemia;612528;congenital hypoplastic anemia;erythroid hypoplasia;Abnormal number of erythroid precursors;RPL35A, DBA5;180468;3q29
Diamond-Blackfan anemia;612561;congenital hypoplastic anemia;persistence of hemoglobin f;Abnormal hemoglobin;RPL5, DBA6;603634;1p22.1
Diamond-Blackfan anemia;612562;congenital hypoplastic anemia;small hypothenar eminence;Abnormality of the hypothenar eminence;RPL11, DBA7;604175;1p36.11
Diamond-Blackfan anemia;612563;congenital hypoplastic anemia;erythrocyte macrocytosis;Abnormality of erythrocytes;RPS7, DBA8;603658;2p25.3
Diamond-Blackfan anemia;613308;congenital hypoplastic anemia;anemia;Abnormality of erythrocytes;RPS10, DBA9;603632;6p21.31
Diamond-Blackfan anemia;613309;congenital hypoplastic anemia;anemia;Abnormality of erythrocytes;RPS26, DBA10;603701;12q13.2
Diamond-Blackfan anemia;614900;congenital hypoplastic anemia;absent thumb;Aplasia/Hypoplasia of the thumb;RPL26, DBA11;603704;17p13.1
Diamond-Blackfan anemia;615550;congenital hypoplastic anemia;elevated red cell adenosine deaminase activity;Abnormal erythrocyte enzyme activity;RPL15, DBA12;604174;3p24.2
Diamond-Blackfan anemia;615909;congenital hypoplastic anemia;elevated red cell adenosine deaminase activity;Abnormal erythrocyte enzyme activity;RPS29, DBA13;603633;14q21.3
Donohue Syndrome;246200;autosomal recessive disease;lipoatrophy;Lipodystrophy;INSR, HHF5;147670;19p13.2
Dowling-Degos disease;179850;pigmentation disease;progressive reticulate hyperpigmentation;Irregular hyperpigmentation;KRT5, DDD1;148040;12q13.13
Dowling-Degos disease;615327;pigmentation disease;autosomal dominant inheritance;Mode of inheritance;POFUT1, OFUCT1, KIAA0180, DDD2;607491;20q11.21
Dowling-Degos disease;615696;pigmentation disease;autosomal dominant inheritance;Mode of inheritance;POGLUT1, CLP46, KTELC1, RUMI, C3orf9, DDD4;615618;3q13.33
Down syndrome;190685;chromosomal disease;duodenal stenosis;Small intestinal stenosis;GATA1, GF1, ERYF1, NFE1, XLTDA, XLTT, XLANP;305371;Xp11.23
Dravet Syndrome;607208;infancy electroclinical syndrome;epileptic encephalopathy;Encephalopathy;SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3;182389;2q24.3
Dravet Syndrome;607208;infancy electroclinical syndrome;epileptic encephalopathy;Encephalopathy;SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP, HSAN2D;603415;2q24.3
Duane retraction syndrome;604356;strabismus;duane anomaly;Abnormality of eye movement;CHN1, CHN, ARHGAP2, RHOGAP2, DURS2;118423;2q31.1
Dubin-Johnson syndrome;237500;bilirubin metabolic disorder;abnormality of temperature regulation;Abnormality of metabolism/homeostasis;ABCC2, CMOAT;601107;10q24.2
Duchenne muscular dystrophy;310200;muscular dystrophy;arrhythmia;Abnormality of cardiovascular system physiology;DMD, BMD, CMD3B;300377;Xp21.2-p21.1
Ehlers-Danlos syndrome progeroid type;615349;Ehlers-Danlos syndrome;flat face;Abnormal facial shape;B3GALT6, SEMDJL1, EDSP2;615291;1p36.33
Ehlers-Danlos syndrome;130070;collagen disease;slender toe;Abnormality of toe;B4GALT7, XGALT1, XGPT1, EDSP1;604327;5q35.3
Ehlers-Danlos syndrome;225400;collagen disease;decreased corneal thickness;Abnormality of corneal thickness;PLOD1, LH1, LLH, EDS6;153454;1p36.22
Ellis-Van Creveld syndrome;225500;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;EVC;604831;4p16.2
Ellis-Van Creveld syndrome;225500;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;LBN, EVC2;607261;4p16.2
Emery-Dreifuss muscular dystrophy;181350;muscular dystrophy;peroneal muscle weakness;Distal lower limb muscle weakness;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;1q22
Emery-Dreifuss muscular dystrophy;300696;muscular dystrophy;arrhythmia;Abnormality of cardiovascular system physiology;FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B;300163;Xq26.3
Emery-Dreifuss muscular dystrophy;310300;muscular dystrophy;type 1 muscle fiber atrophy;Muscle fiber atrophy;EMD, EDMD, STA;300384;Xq28
Emery-Dreifuss muscular dystrophy;612998;muscular dystrophy;childhood onset;Onset;SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4;608441;6q25.1-q25.2
Emery-Dreifuss muscular dystrophy;612999;muscular dystrophy;arrhythmia;Abnormality of cardiovascular system physiology;SYNE2, NUANCE, KIAA1011, EDMD5;608442;14q23.2
Emery-Dreifuss muscular dystrophy;614302;muscular dystrophy;proximal amyotrophy;Skeletal muscle atrophy;TMEM43, ARVD5, ARVC5, EDMD7;612048;3p25.1
FG syndrome;300321;X-linked disease;underdeveloped superior crus of antihelix;Abnormality of superior crus of antihelix;FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS;300017;Xq28
FG syndrome;300422;X-linked disease;prominent forehead;Abnormality of the forehead;CASK, MICPCH, FGS4, CMG, MRXSNA;300172;Xp11.4
FG syndrome;305450;X-linked disease;clinodactyly;Abnormality of digit;MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1, OHDOX;300188;Xq13.1
Fabry disease;301500;sphingolipidosis;glomerulopathy;Abnormality of the glomerulus;GLA;300644;Xq22.1
Fanconi syndrome;613388;renal tubular transport disease;elevated alkaline phosphatase of bone origin;Elevated tissue non-specific alkaline phosphatase;SLC34A1, SLC17A2, NPT2, NPHLOP1, FRTS2;182309;5q35.3
Fanconi syndrome;615605;renal tubular transport disease;short stature;Growth delay;EHHADH, PBFE, LBFP, FRTS3;607037;3q27.2
Fanconi's anemia;227645;congenital hypoplastic anemia;complete duplication of thumb phalanx;Complete duplication of phalanx of hand;FANCC, FACC;613899;9q22.32
Fanconi's anemia;227646;congenital hypoplastic anemia;complete duplication of thumb phalanx;Complete duplication of phalanx of hand;FANCD2, FANCD, FACD, FAD;613984;3p25.3
Fanconi's anemia;227650;congenital hypoplastic anemia;complete duplication of thumb phalanx;Complete duplication of phalanx of hand;FANCA, FACA, FA1, FA, FAA;607139;16q24.3
Fanconi's anemia;300514;congenital hypoplastic anemia;absent thumb;Aplasia/Hypoplasia of the thumb;FAAP95, FAAP90, FLJ34064, FANCB;300515;Xp22.2
Fanconi's anemia;600901;congenital hypoplastic anemia;complete duplication of thumb phalanx;Complete duplication of phalanx of hand;FANCE, FACE;613976;6p21.31
Fanconi's anemia;603467;congenital hypoplastic anemia;bone marrow hypocellularity;Abnormality of multiple cell lineages in the bone marrow;FANCF;613897;11p14.3
Fanconi's anemia;605724;congenital hypoplastic anemia;short thumb;Aplasia/Hypoplasia of the thumb;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
Fanconi's anemia;609053;congenital hypoplastic anemia;abnormal renal morphology;Abnormality of the kidney;FANCI, KIAA1794;611360;15q26.1
Fanconi's anemia;609054;congenital hypoplastic anemia;short thumb;Aplasia/Hypoplasia of the thumb;BRIP1, BACH1, FANCJ;605882;17q23.2
Fanconi's anemia;610832;congenital hypoplastic anemia;short thumb;Aplasia/Hypoplasia of the thumb;PALB2, FANCN, PNCA3;610355;16p12.2
Fanconi's anemia;613390;congenital hypoplastic anemia;short thumb;Aplasia/Hypoplasia of the thumb;RAD51C, FANCO, BROVCA3;602774;17q22
Fanconi's anemia;613951;congenital hypoplastic anemia;short palpebral fissure;Abnormal size of the palpebral fissures;SLX4, BTBD12, MUS312, KIAA1784, KIAA1987, FANCP;613278;16p13.3
Fanconi's anemia;614082;congenital hypoplastic anemia;multiple cafe-au-lait spots;Cafe-au-lait spot;XRCC9, FANCG;602956;9p13.3
Fanconi's anemia;614083;congenital hypoplastic anemia;abnormality of chromosome stability;Abnormality of cell physiology;PHF9, FANCL;608111;2p16.1
Fanconi's anemia;614087;congenital hypoplastic anemia;abnormality of chromosome stability;Abnormality of cell physiology;FANCM, KIAA1596;609644;14q21.2
Fanconi's anemia;615272;congenital hypoplastic anemia;absent thumb;Aplasia/Hypoplasia of the thumb;ERCC4, XPF, FANCQ;133520;16p13.12
Farber lipogranulomatosis;228000;lipid storage disease;cognitive impairment;Abnormality of higher mental function;ASAH1, AC, SMAPME;613468;8p22
Finnish type amyloidosis;105120;amyloidosis;adult onset;Onset;GSN;137350;9q33.2
Frasier syndrome;136680;autosomal dominant disease;glomerulopathy;Abnormality of the glomerulus;WT1, NPHS4;607102;11p13
Friedreich ataxia;229300;spinocerebellar ataxia;impaired proprioception;Sensory impairment;FXN, FRDA, FARR, X25;606829;9q21.11
Fuchs' endothelial dystrophy;136800;corneal dystrophy;corneal stromal edema;Abnormality of corneal stroma;COL8A2, FECD1, PPCD2;120252;1p34.3
Fuchs' endothelial dystrophy;613268;corneal dystrophy;corneal dystrophy;Abnormality of the cornea;SLC4A11, BTR1, NABC1, CHED2, CDPD, FECD4;610206;20p13
Fuchs' endothelial dystrophy;613270;corneal dystrophy;corneal dystrophy;Abnormality of the cornea;ZEB1, TCF8, NIL2A, PPCD3, FECD6;189909;10p11.22
Fuchs' endothelial dystrophy;615523;corneal dystrophy;corneal dystrophy;Abnormality of the cornea;AGBL1, CCP4, FECD8;615496;15q25.3
Fukuyama congenital muscular dystrophy;253800;congenital muscular dystrophy;calf muscle hypertrophy;Muscle hypertrophy of the lower extremities;FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4;607440;9q31.2
GABA aminotransferase deficiency;613163;gamma-amino butyric acid metabolism disorder;posterior fossa cyst;Intracranial cystic lesion;ABAT, GABAT;137150;16p13.2
Gamstorp-Wohlfart syndrome;137200;;foot dorsiflexor weakness;Proximal muscle weakness in lower limbs;HINT1, PRKCNH1, NMAN;601314;5q23.3
Gaucher's disease;230800;sphingolipidosis;increased bone mineral density;Abnormality of bone mineral density;GBA;606463;1q22
Gaucher's disease;230900;sphingolipidosis;feeding difficulties;Abdominal symptom;GBA;606463;1q22
Gaucher's disease;231000;sphingolipidosis;increased bone mineral density;Abnormality of bone mineral density;GBA;606463;1q22
Gaucher's disease;608013;sphingolipidosis;everted upper lip vermilion;Eclabion;GBA;606463;1q22
Gaucher's disease;610539;sphingolipidosis;increased cerebral lipofuscin;Atrophy/Degeneration affecting the central nervous system;PSAP, SAP1;176801;10q22.1
Gerstmann-Straussler-Scheinker syndrome;137440;prion disease;perseveration;Behavioral abnormality;PRNP, PRIP, KURU, CJD;176640;20p13
Gilbert syndrome;143500;bilirubin metabolic disorder;unconjugated hyperbilirubinemia;Hyperbilirubinemia;UGT1A1, UGT1, GNT1, BILIQTL1;191740;2q37.1
Gilles de la Tourette syndrome;137580;tic disorder;phonic tics;Tics;HDC;142704;15q21.2
Gilles de la Tourette syndrome;137580;tic disorder;phonic tics;Tics;SLITRK1, KIAA1910, TTM;609678;13q31.1
Gitelman syndrome;263800;renal tubular transport disease;renal magnesium wasting;Abnormal urine magnesium concentration;SLC12A3, NCCT, TSC;600968;16q13
Glanzmann's thrombasthenia;273800;blood platelet disease;impaired platelet aggregation;Abnormal platelet function;ITGA2B, GP2B, CD41B, GT, BDPLT2, BDPLT16;607759;17q21.31
Glanzmann's thrombasthenia;273800;blood platelet disease;impaired platelet aggregation;Abnormal platelet function;ITGB3, GP3A, GT, BDPLT2, BDPLT16;173470;17q21.32
Greig cephalopolysyndactyly syndrome;175700;acrocephalosyndactylia;cognitive impairment;Abnormality of higher mental function;GLI3, PAPA, PAPB;165240;7p14.1
Guillain-Barre syndrome;139393;autoimmune disease of peripheral nervous system;acute demyelinating polyneuropathy;Demyelinating peripheral neuropathy;PMP22, CMT1A, CMT1E, DSS;601097;17p12
Hailey-Hailey disease;169600;skin disease;skin ulcer;Localized skin lesion;ATP2C1, BCPM, HHD;604384;3q22.1
Hajdu-Cheney syndrome;102500;autosomal dominant disease;osteolytic defects of the phalanges of the hand;Osteolytic defects of the hand bones;NOTCH2, AGS2, HJCYS;600275;1p12-p11
Hartnup disease;234500;amino acid metabolic disorder;cognitive impairment;Abnormality of higher mental function;SLC6A19, HND;608893;5p15.33
Hermansky-Pudlak syndrome;203300;autosomal recessive disease;freckles in sun-exposed areas;Hyperpigmentation in sun-exposed areas;HPS1;604982;10q24.2
Hermansky-Pudlak syndrome;608233;autosomal recessive disease;acetabular dysplasia;Abnormality of the acetabulum;AP3B1, ADTB3A, HPS2;603401;5q14.1
Hermansky-Pudlak syndrome;614072;autosomal recessive disease;abnormal platelet granules;Abnormal platelet morphology;HPS3;606118;3q24
Hermansky-Pudlak syndrome;614073;autosomal recessive disease;abnormal platelet granules;Abnormal platelet morphology;HPS4;606682;22q12.1
Hermansky-Pudlak syndrome;614074;autosomal recessive disease;thrombocytopenia;Abnormal platelet count;HPS5, RU2, KIAA1017;607521;11p15.1
Hermansky-Pudlak syndrome;614075;autosomal recessive disease;abnormal platelet granules;Abnormal platelet morphology;HPS6, RU;607522;10q24.32
Hermansky-Pudlak syndrome;614076;autosomal recessive disease;impaired platelet aggregation;Abnormal platelet function;DTNBP1, HPS7;607145;6p22.3
Hermansky-Pudlak syndrome;614077;autosomal recessive disease;ocular albinism;Iris hypopigmentation;BLOC1S3, BLOS3, HPS8;609762;19q13.32
Hermansky-Pudlak syndrome;614171;autosomal recessive disease;hypopigmentation of the fundus;Abnormality of the retinal pigment epithelium;BLOC1S6, BLOS6, PLDN, PA, HPS9;604310;15q21.1
Hirschsprung's disease;142623;megacolon;enterocolitis;Acute colitis;RET, MEN2A, HSCR1;164761;10q11.21
Hirschsprung's disease;600155;megacolon;aganglionic megacolon;Abnormality of the enteric ganglia;EDNRB, HSCR2, ABCDS, WS4A;131244;13q22.3
Huntington's disease;143100;neurodegenerative disease;abnormality of movement;Abnormality of nervous system physiology;HTT, HD, IT15;613004;4p16.3
IMAGe syndrome;614732;syndrome;displacement of the external urethral meatus;Abnormality of the urethra;CDKN1C, KIP2, BWS, IMAGE;600856;11p15.4
Jensen syndrome;311150;syndrome;infantile sensorineural hearing impairment;Childhood onset sensorineural hearing impairment;TIMM8A, DFN1, DDP, MTS, DDP1;300356;Xq22.1
Jervell-Lange Nielsen syndrome;220400;long QT syndrome;congenital sensorineural hearing impairment;Sensorineural hearing impairment;KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2;607542;11p15.5-p15.4
Jervell-Lange Nielsen syndrome;612347;long QT syndrome;prolonged qt interval;Abnormal EKG;KCNE1, JLNS, LQT5, JLNS2;176261;21q22.11-q22.12
Job's syndrome;147060;hyperimmunoglobulin syndrome;skin ulcer;Localized skin lesion;STAT3, APRF, HIES, ADMIO;102582;17q21.2
Johanson-Blizzard syndrome;243800;autosomal recessive disease;displacement of the external urethral meatus;Abnormality of the urethra;UBR1, JBS;605981;15q15.2
Joubert syndrome;213300;autosomal recessive disease;triangular-shaped open mouth;Triangular mouth;INPP5E, MORMS, JBTS1, CORS1;613037;9q34.3
Joubert syndrome;300804;autosomal recessive disease;postaxial polydactyly;Polydactyly;OFD1, CXorf5, SGBS2, JBTS10, RP23;300170;Xp22.2
Joubert syndrome;608091;autosomal recessive disease;enlarged fossa interpeduncularis;Ventriculomegaly;TMEM216, JBTS2, CORS2, MKS2;613277;11q12.2
Joubert syndrome;608629;autosomal recessive disease;enlarged fossa interpeduncularis;Ventriculomegaly;AHI1;608894;6q23.3
Joubert syndrome;609583;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;NPHP1, NPH1, SLSN1, JBTS4;607100;2q13
Joubert syndrome;610188;autosomal recessive disease;congenital blindness;Blindness;CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14;610142;12q21.32
Joubert syndrome;610688;autosomal recessive disease;enlarged fossa interpeduncularis;Ventriculomegaly;TMEM67, MKS3, JBTS6, NPHP11;609884;8q22.1
Joubert syndrome;611560;autosomal recessive disease;postaxial polydactyly;Polydactyly;RPGRIP1L, KIAA1005, JBTS7, MKS5;610937;16q12.2
Joubert syndrome;612285;autosomal recessive disease;molar tooth sign on mri;Abnormality of midbrain morphology;CC2D2A, KIAA1345, MKS6;612013;4p15.32
Joubert syndrome;612291;autosomal recessive disease;molar tooth sign on mri;Abnormality of midbrain morphology;ARL13B, ARL2L1, JBTS8;608922;3q11.1
Joubert syndrome;614173;autosomal recessive disease;cerebellar vermis hypoplasia;Aplasia/Hypoplasia of the  cerebellar vermis;TECT1, JBTS13;609863;12q24.11
Joubert syndrome;614424;autosomal recessive disease;postaxial polydactyly;Polydactyly;TMEM237, ALS2CR4, JBTS14;614423;2q33.1
Joubert syndrome;614464;autosomal recessive disease;polydactyly;Abnormality of digit;CEP41, TSGA14, JBTS15;610523;7q32.2
Joubert syndrome;614465;autosomal recessive disease;polydactyly;Abnormality of digit;TMEM138, JBTS16;614459;11q12.2
Joubert syndrome;614615;autosomal recessive disease;polydactyly;Abnormality of digit;C5orf42, JBTS17, OFD6;614571;5p13.2
Joubert syndrome;614815;autosomal recessive disease;camptodactyly;Flexion contracture of digit;TCTN3, TECT3, C10orf61, OFD4, JBTS18;613847;10q24.1
Joubert syndrome;614970;autosomal recessive disease;postaxial polydactyly;Polydactyly;TMEM231, JBTS20, MKS11;614949;16q23.1
Joubert syndrome;615636;autosomal recessive disease;elongated superior cerebellar peduncle;Abnormality of the superior cerebellar peduncle;CSPP1, CSPP, JBTS21;611654;8q13.1-q13.2
Joubert syndrome;615665;autosomal recessive disease;retinal dysplasia;Abnormality of the retina;PDE6D, JBTS22;602676;2q37.1
KBG syndrome;148050;syndrome;aplasia/hypoplasia of the eyebrow;Abnormality of the eyebrow;ANKRD11, ANCO1, KBGS;611192;16q24.3
Kahrizi syndrome;612713;autosomal recessive disease;intellectual disability, severe;Intellectual disability;SRD5A3, SRD5A2L, CDG1Q, KRIZI;611715;4q12
Kallmann syndrome;147950;hypogonadism;clinodactyly;Abnormality of digit;FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS;136350;8p11.23-p11.22
Kallmann syndrome;244200;hypogonadism;pes planus;Abnormality of the foot;PROKR2, PKR2, GPR73L1, HH3;607123;20p12.3
Kallmann syndrome;610628;hypogonadism;decreased testicular size;Aplasia/Hypoplasia of the testes;PROK2, PK2, BV8, HH4;607002;3p13
Kallmann syndrome;612370;hypogonadism;anosmia;Abnormality of the sense of smell;CHD7, IS3, HH5;608892;8q12.1-q12.2
Kallmann syndrome;612702;hypogonadism;anosmia;Abnormality of the sense of smell;FGF8, HH6;600483;10q24.32
Kaposi's sarcoma;148000;connective tissue cancer;glomerulopathy;Abnormality of the glomerulus;IL6, IFNB2, BSF2, HSF, HGF;147620;7p15.3
Kartagener syndrome;244400;primary ciliary dyskinesia;nasal polyposis;Abnormality of the nasal mucosa;DNAI1, CILD1, ICS, PCD;604366;9p13.3
Kawasaki disease;611775;lymphadenitis;cheilitis;Abnormality of the lip;ITPKC;606476;19q13.2
Kennedy's disease;313200;spinal muscular atrophy;erectile abnormalities;Abnormality of the penis;AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1;313700;Xq12
Klippel-Feil syndrome;118100;physical disorder;posterior fossa cyst;Intracranial cystic lesion;GDF6, MCOP4, KFS1, MCOPCB6, LCA17;601147;8q22.1
Klippel-Feil syndrome;214300;physical disorder;cervical vertebral fusion (c2/c3);Fused cervical vertebrae;MEOX1, MOX1, KFS2;600147;17q21.31
Klippel-Feil syndrome;613702;physical disorder;irido-fundal coloboma;Iris coloboma;GDF3, KFS3, MCOPCB6, MCOP7;606522;12p13.31
Koolen de Vries syndrome;610443;syndrome;displacement of the external urethral meatus;Abnormality of the urethra;KANSL1, KIAA1267, MSL1V1, KDVS;612452;17q21.31
Krabbe disease;245200;sphingolipidosis;peripheral demyelination;Abnormal peripheral myelination;GALC;606890;14q31.3
L-2-hydroxyglutaric aciduria;236792;2-hydroxyglutaric aciduria;cognitive impairment;Abnormality of higher mental function;L2HGDH, C14orf160;609584;14q21.3
LADD syndrome;149730;autosomal dominant disease;corneal erosion;Abnormality of corneal epithelium;FGF10;602115;5p12
LADD syndrome;149730;autosomal dominant disease;corneal erosion;Abnormality of corneal epithelium;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
LADD syndrome;149730;autosomal dominant disease;corneal erosion;Abnormality of corneal epithelium;FGFR3, ACH;134934;4p16.3
LEOPARD syndrome;151100;autosomal dominant disease;delayed menarche;Delayed puberty;PTPN11, PTP2C, SHP2, NS1;176876;12q24.13
LEOPARD syndrome;611554;autosomal dominant disease;depressed nasal bridge;Abnormality of the nasal bridge;RAF1, CRAF, NS5, CMD1NN;164760;3p25.2
LEOPARD syndrome;613707;autosomal dominant disease;multiple cafe-au-lait spots;Cafe-au-lait spot;BRAF, NS7;164757;7q34
Lafora disease;254780;progressive myoclonus epilepsy;visual auras;Auras;EPM2A, MELF, EPM2;607566;6q24.3
Lafora disease;254780;progressive myoclonus epilepsy;visual auras;Auras;NHLRC1, EPM2A, EPM2B;608072;6p22.3
Landau-Kleffner syndrome;245570;childhood electroclinical syndrome;eeg with centrotemporal focal spike waves;EEG with focal spike waves;GRIN2A, NMDAR2A, FESD, LKS;138253;16p13.2
Laron syndrome;262500;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;GHR, GHIP;600946;5p13-p12
Larsen syndrome;150250;autosomal dominant disease;cognitive impairment;Abnormality of higher mental function;FLNB, SCT, AOI, LRS1;603381;3p14.3
Leber congenital amaurosis;204000;retinal disease;decreased central vision;Visual loss;GUCY2D, GUC2D, LCA1, CORD6, RCD2;600179;17p13.1
Leber congenital amaurosis;204100;retinal disease;decreased central vision;Visual loss;RPE65, RP20, LCA2;180069;1p31.3-p31.2
Leber congenital amaurosis;604232;retinal disease;constricted visual fields;Visual field defect;SPATA7, HSD3, LCA3;609868;14q31.3
Leber congenital amaurosis;604393;retinal disease;pendular nystagmus;Nystagmus;AIPL1, LCA4;604392;17p13.2
Leber congenital amaurosis;604537;retinal disease;nystagmus;Abnormal involuntary eye movements;LCA5, C6orf152;611408;6q14.1
Leber congenital amaurosis;608553;retinal disease;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;NMNAT1, NMNAT, PNAT1, LCA9;608700;1p36.22
Leber congenital amaurosis;610612;retinal disease;abnormality of macular pigmentation;Abnormality of the macula;RD3, LCA12, C1orf36;180040;1q32.3
Leber congenital amaurosis;611755;retinal disease;hyposmia;Abnormality of the sense of smell;CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14;610142;12q21.32
Leber congenital amaurosis;612712;retinal disease;retinal dystrophy;Abnormality of the retina;RDH12, LCA13;608830;14q24.1
Leber congenital amaurosis;613341;retinal disease;congenital blindness;Blindness;LRAT, LCA14;604863;4q32.1
Leber congenital amaurosis;613826;retinal disease;pendular nystagmus;Nystagmus;RPGRIP1, LCA6, CORD13;605446;14q11.2
Leber congenital amaurosis;613829;retinal disease;pendular nystagmus;Nystagmus;CRX, CORD2, CRD, LCA7;602225;19q13.33
Leber congenital amaurosis;613835;retinal disease;pendular nystagmus;Nystagmus;CRB1, RP12, LCA8;604210;1q31.3
Leber congenital amaurosis;613837;retinal disease;nystagmus;Abnormal involuntary eye movements;IMPDH1, RP10, LCA11;146690;7q32.1
Leber congenital amaurosis;614186;retinal disease;nystagmus;Abnormal involuntary eye movements;KCNJ13, SVD, LCA16;603208;2q37.1
Leber congenital amaurosis;615360;retinal disease;autosomal recessive inheritance;Mode of inheritance;GDF6, MCOP4, KFS1, MCOPCB6, LCA17;601147;8q22.1
Legg-Calve-Perthes Disease;150600;osteochondrosis;cartilage destruction;Abnormal cartilage morphology;COL2A1;120140;12q13.11
Leigh disease;220111;mitochondrial metabolism disease;midface retrusion;Abnormality of the midface;LRPPRC, LRP130, LSFC;607544;2p21
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1;603647;2q35
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;COX10;602125;17p12
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;COX15, CEMCOX2;603646;10q24.2
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;FOXRED1;613622;11q24.2
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFA10;603835;2q37.3
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFA12;614530;12q22
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFA2;602137;5q31.3
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFA9;603834;12p13.32
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFAF2, NDUFA12L, MMTN, B17.2L;609653;5q12.1
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFAF6, C8orf38;612392;8q22.1
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFS3;603846;11p11.2
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFS4, AQDQ;602694;5q11.2
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFS7, PSST;601825;19p13.3
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;NDUFS8;602141;11q13.2
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;SDHA, SDH1, SDHF, CMD1GG, PGL5;600857;5p15.33
Leigh disease;256000;mitochondrial metabolism disease;cns demyelination;Abnormal CNS myelination;SURF1;185620;9q34.2
Lesch-Nyhan syndrome;300322;purine-pyrimidine metabolic disorder;short stature;Growth delay;HPRT1, HPRT;308000;Xq26.2-q26.3
Lewy body dementia;127750;dementia;fluctuations in consciousness;Reduced consciousness/confusion;GBA;606463;1q22
Lewy body dementia;127750;dementia;fluctuations in consciousness;Reduced consciousness/confusion;SNCA, NACP, PARK1, PARK4;163890;4q22.1
Lewy body dementia;127750;dementia;fluctuations in consciousness;Reduced consciousness/confusion;SNCB;602569;5q35.2
Li-Fraumeni syndrome;151623;autosomal dominant disease;prostate neoplasm;Abnormality of the prostate;TP53, P53, LFS1 , BCC7;191170;17p13.1
Li-Fraumeni syndrome;609265;autosomal dominant disease;sarcoma;Neoplasm by histology;CHEK2, RAD53, CHK2, CDS1, LFS2;604373;22q12.1
Liddle syndrome;177200;renal tubular transport disease;arrhythmia;Abnormality of cardiovascular system physiology;SCNN1B, BESC1;600760;16p12.2
Liddle syndrome;177200;renal tubular transport disease;arrhythmia;Abnormality of cardiovascular system physiology;SCNN1G, PHA1, BESC3;600761;16p12.2
Loeys-Dietz syndrome;609192;autosomal dominant disease;camptodactyly;Flexion contracture of digit;TGFBR1, ALK5, AAT5, LDS1, MSSE;190181;9q22.33
Loeys-Dietz syndrome;610168;autosomal dominant disease;postaxial polydactyly;Polydactyly;TGFBR2, HNPCC6, AAT3, MFS2, LDS2;190182;3p24.1
Loeys-Dietz syndrome;613795;autosomal dominant disease;dural ectasia;Abnormality of the spinal meninges;SMAD3, MADH3, LDS3;603109;15q22.33
Loeys-Dietz syndrome;614816;autosomal dominant disease;dural ectasia;Abnormality of the spinal meninges;TGFB2, LDS4;190220;1q41
Lynch syndrome;120435;autosomal dominant disease;colon cancer;Neoplasm of the colon;MSH2, COCA1, FCC1, HNPCC1;609309;2p21
Lynch syndrome;609310;autosomal dominant disease;colon cancer;Neoplasm of the colon;MLH1, COCA2, HNPCC2;120436;3p22.2
Lynch syndrome;613244;autosomal dominant disease;hereditary nonpolyposis colorectal carcinoma;Neoplasm of the large intestine;EPCAM, ACSTD1, TROP1, M4S1, MIC18, DIAR5, HNPCC8;185535;2p21
MASA syndrome;303350;syndrome;cognitive impairment;Abnormality of higher mental function;L1CAM, CAML1, HSAS1, MASA, SPG1;308840;Xq28
MEN2A;171400;autosomal dominant disease;elevated urinary epinephrine;Elevated urinary catecholamines;RET, MEN2A, HSCR1;164761;10q11.21
MEN2B;162300;autosomal dominant disease;parathyroid hyperplasia;Abnormality of the parathyroid morphology;RET, MEN2A, HSCR1;164761;10q11.21
MHC class I deficiency;604571;severe combined immunodeficiency;skin ulcer;Localized skin lesion;TAP1, ABCB2, TAP1, RING4, PSF1;170260;6p21.32
MHC class I deficiency;604571;severe combined immunodeficiency;skin ulcer;Localized skin lesion;TAP2, ABCB3, PSF2, RING11;170261;6p21.32
MHC class I deficiency;604571;severe combined immunodeficiency;skin ulcer;Localized skin lesion;TAPBP, TPSN;601962;6p21.32
MHC class II deficiency;209920;severe combined immunodeficiency;villous atrophy;Abnormality of small intestinal villus morphology;MHC2TA, C2TA;600005;16p13.13
MHC class II deficiency;209920;severe combined immunodeficiency;villous atrophy;Abnormality of small intestinal villus morphology;RFX5;601863;1q21.3
MHC class II deficiency;209920;severe combined immunodeficiency;villous atrophy;Abnormality of small intestinal villus morphology;RFXANK;603200;19p13.11
MHC class II deficiency;209920;severe combined immunodeficiency;villous atrophy;Abnormality of small intestinal villus morphology;RFXAP;601861;13q13.3
Machado-Joseph disease;109150;spinocerebellar ataxia;chronic pain;Pain;ATXN3, MJD, SCA3;607047;14q32.12
Majewski syndrome;263520;;hamartoma of tongue;Neoplasm of the tongue;NEK1, SRTD6, SRPS2A;604588;4q33
Marfan syndrome;154700;autosomal dominant disease;dural ectasia;Abnormality of the spinal meninges;FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1;134797;15q21.1
Marshall-Smith syndrome;602535;syndrome;cognitive impairment;Abnormality of higher mental function;NFIX, NF1A, SOTOS2, MRSHSS;164005;19p13.2
Mast syndrome;248900;hereditary spastic paraplegia;akinetic mutism;Diminished motivation;ACP33, MAST, SPG21;608181;15q22.31
Matthew-Wood syndrome;601186;autosomal genetic disease;diaphragmatic eventration;Abnormality of the diaphragm;STRA6, MCOPS9, MCOPCB8;610745;15q24.1
Meckel syndrome;249000;autosomal recessive disease;clinodactyly;Abnormality of digit;MKS1, MKS, BBS13;609883;17q22
Meckel syndrome;267010;autosomal recessive disease;aplasia/hypoplasia of the lungs;Abnormality of the lung;NPHP3, NPH3, RHPD1, MKS7;608002;3q22.1
Meckel syndrome;603194;autosomal recessive disease;polydactyly;Abnormality of digit;TMEM216, JBTS2, CORS2, MKS2;613277;11q12.2
Meckel syndrome;607361;autosomal recessive disease;polydactyly;Abnormality of digit;TMEM67, MKS3, JBTS6, NPHP11;609884;8q22.1
Meckel syndrome;611134;autosomal recessive disease;agenesis of cerebellar vermis;Aplasia/Hypoplasia of the  cerebellar vermis;CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14;610142;12q21.32
Meckel syndrome;611561;autosomal recessive disease;bowing of the long bones;Abnormality of long bone morphology;RPGRIP1L, KIAA1005, JBTS7, MKS5;610937;16q12.2
Meckel syndrome;612284;autosomal recessive disease;cystic liver disease;Abnormality of the liver;CC2D2A, KIAA1345, MKS6;612013;4p15.32
Meckel syndrome;613885;autosomal recessive disease;polydactyly;Abnormality of digit;TCTN2, TECT2, MKS8;613846;12q24.31
Meckel syndrome;614175;autosomal recessive disease;postaxial polydactyly;Polydactyly;B9D2, MKS10;611951;19q13.2
Meckel syndrome;614209;autosomal recessive disease;occipital encephalocele;Encephalocele;B9D1, MKSR1, MKS9;614144;17p11.2
Meckel syndrome;615397;autosomal recessive disease;polydactyly;Abnormality of digit;TMEM231, JBTS20, MKS11;614949;16q23.1
Meier-Gorlin syndrome;224690;autosomal recessive disease;small hand;Aplasia/hypoplasia involving bones of the hand;ORC1, ORC1L;601902;1p32.3
Meier-Gorlin syndrome;613800;autosomal recessive disease;feeding difficulties;Abdominal symptom;ORC4, ORC4L;603056;2q22.3-q23.1
Meier-Gorlin syndrome;613803;autosomal recessive disease;feeding difficulties;Abdominal symptom;ORC6, ORC6L;607213;16q11.2
Meier-Gorlin syndrome;613804;autosomal recessive disease;feeding difficulties;Abdominal symptom;CDT1;605525;16q24.3
Meier-Gorlin syndrome;613805;autosomal recessive disease;feeding difficulties;Abdominal symptom;CDC6, CDC18L;602627;17q21.2
Menkes disease;309400;metal metabolism disorder;sepsis;Abnormality of immune system physiology;ATP7A, MNK, MK, OHS, SMAX3;300011;Xq21.1
Moyamoya disease;614042;cerebral arterial disease;moyamoya phenomenon;Abnormality of circle of Willis;ACTA2, ACTSA, AAT6, MYMY5;102620;10q23.31
Moyamoya disease;615750;cerebral arterial disease;achalasia;Gastrointestinal dysmotility;GUCY1A3, GUC1A3, GUCSA3, MYMY6;139396;4q32.1
Muir-Torre syndrome;158320;Lynch syndrome;salivary gland neoplasm;Neoplasm of the oral cavity;MLH1, COCA2, HNPCC2;120436;3p22.2
Muir-Torre syndrome;158320;Lynch syndrome;salivary gland neoplasm;Neoplasm of the oral cavity;MSH2, COCA1, FCC1, HNPCC1;609309;2p21
N syndrome;310465;syndrome;displacement of the external urethral meatus;Abnormality of the urethra;POLA1;312040;Xp22.1-p21.3
Nager syndrome;154400;;aplasia/hypoplasia of the eyebrow;Abnormality of the eyebrow;SF3B4, SF3B49, SAP49, AFD1;605593;1q21.2
Netherton syndrome;256500;autosomal recessive disease;aplasia/hypoplasia of the eyebrow;Abnormality of the eyebrow;SPINK5, LEKTI;605010;5q32
Niemann-Pick disease;257200;non-langerhans-cell histiocytosis;cherry red spot of the macula;Abnormality of the macula;SMPD1, NPD;607608;11p15.4
Niemann-Pick disease;257220;non-langerhans-cell histiocytosis;fatal liver failure in infancy;Hepatic failure;NPC1, NPC;607623;18q11.2
Niemann-Pick disease;607616;non-langerhans-cell histiocytosis;bone-marrow foam cells;Abnormality of macrophages;SMPD1, NPD;607608;11p15.4
Niemann-Pick disease;607625;non-langerhans-cell histiocytosis;perseveration;Behavioral abnormality;NPC2, HE1;601015;14q24.3
Nijmegen breakage syndrome;251260;autosomal recessive disease;urogenital fistula;Abnormality of the genitourinary system;NBS1, NBS;602667;8q21.3
Noonan syndrome;163950;autosomal dominant disease;synovitis;Abnormality of the synovia;PTPN11, PTP2C, SHP2, NS1;176876;12q24.13
Noonan syndrome;609942;autosomal dominant disease;juvenile myelomonocytic leukemia;Myeloid leukemia;KRAS, KRAS2, RASK2, NS, CFC2;190070;12p12.1
Noonan syndrome;610733;autosomal dominant disease;high anterior hairline;Abnormality of the frontal hairline;SOS1, GINGF, GF1, HGF, NS4;182530;2p22.1
Noonan syndrome;611553;autosomal dominant disease;short stature;Growth delay;RAF1, CRAF, NS5, CMD1NN;164760;3p25.2
Noonan syndrome;613224;autosomal dominant disease;short stature;Growth delay;NRAS, ALPS4, NS6, CMNS, NCMS;164790;1p13.2
Noonan syndrome;613706;autosomal dominant disease;prominent forehead;Abnormality of the forehead;BRAF, NS7;164757;7q34
Norum disease;245900;hypolipoproteinemia;opacification of the corneal stroma;Abnormality of corneal stroma;LCAT;606967;16q22.1
Ogden syndrome;300855;X-linked disease;broad hallux;Abnormality of the hallux;NAA10, ARD1A, ARD1, TE2, NATD, MCOPS1;300013;Xq28
Ohdo syndrome;300895;syndrome;clinodactyly;Abnormality of digit;MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1, OHDOX;300188;Xq13.1
Ohtahara syndrome;300088;neonatal period electroclinical syndrome;atonic seizures;Generalized seizures;PCDH19, KIAA1313, EFMR, EIEE9;300460;Xq22.1
Ohtahara syndrome;300607;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;ARHGEF9, PEM2, KIAA0424, EIEE8;300429;Xq11.1-q11.2
Ohtahara syndrome;300672;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;CDKL5, STK9, ISSX, EIEE2;300203;Xp22.13
Ohtahara syndrome;308350;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32;300382;Xp21.3
Ohtahara syndrome;609304;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;SLC25A22, GC1, EIEE3;609302;11p15.5
Ohtahara syndrome;612164;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;STXBP1, UNC18, EIEE4;602926;9q34.11
Ohtahara syndrome;613402;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;PNKP, PNK, MCSZ, EIEE10, MCSZ;605610;19q13.33
Ohtahara syndrome;613477;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;SPTAN1, NEAS, EIEE5;182810;9q34.11
Ohtahara syndrome;613720;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;KCNQ2, EBN1, EIEE7, BFNS1;602235;20q13.33
Ohtahara syndrome;613721;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;SCN2A, SCN2A1, BFIC3, EIEE11, BFIS3, BFNIS;182390;2q24.3
Ohtahara syndrome;613722;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;PLCB1, KIAA0581, PLCB1A, PLCB1B, EIEE12;607120;20p12.3
Ohtahara syndrome;614558;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;SCN8A, CIAT, EIEE13;600702;12q13.13
Ohtahara syndrome;614959;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;KCNT1, KIAA1422, EIEE14, ENFL5;608167;9q34.3
Ohtahara syndrome;615006;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;ST3GAL3, SIAT6, ST3GALII, MRT12, EIEE15;606494;1p34.1
Ohtahara syndrome;615338;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;TBC1D24, KIAA1171, FIME, EIEE16, DOORS, DFNB86, DFNA65;613577;16p13.3
Ohtahara syndrome;615473;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;GNAO1, EIEE17;139311;16q12.2
Ohtahara syndrome;615476;neonatal period electroclinical syndrome;epileptic encephalopathy;Encephalopathy;SZT2, KIAA0467, EIEE18;615463;1p34.2
Opitz-GBBB syndrome;300000;monogenic disease;prominent forehead;Abnormality of the forehead;MID1, OGS1, BBBG1, FXY, OSX;300552;Xp22.2
PHGDH deficiency;601815;serine deficiency;congenital microcephaly;Microcephaly;PHGDH, NLS1, PHGDHD;606879;1p12
PSAT deficiency;610992;serine deficiency;hyposerinemia;Abnormality of serine metabolism;PSAT1, PSAT, EPIP, PSATD, NLS2;610936;9q21.2
PSPH deficiency;614023;serine deficiency;postnatal growth retardation;Growth delay;PSPH, PSP, PSPHD;172480;7p11.2
Paget's disease of bone;602080;hyperostosis;bilateral conductive hearing impairment;Conductive hearing impairment;PDB4;606263;5q31
Paget's disease of bone;602080;hyperostosis;bilateral conductive hearing impairment;Conductive hearing impairment;SQSTM1, P62, PDB3;601530;5q35.3
Paget's disease of bone;602080;hyperostosis;bilateral conductive hearing impairment;Conductive hearing impairment;TNFRSF11A, RANK, ODFR, OFE, OPTB7;603499;18q21.33
Pallister-Hall syndrome;146510;physical disorder;urogenital fistula;Abnormality of the genitourinary system;GLI3, PAPA, PAPB;165240;7p14.1
Papillon-Lefevre disease;245000;palmoplantar keratosis;skin ulcer;Localized skin lesion;CTSC, CPPI, PALS, PLS, HMS, PDON1, JPD;602365;11q14.2
Parkinson's disease;168600;synucleinopathy;lewy bodies;Cerebral inclusion bodies;ADH1C, ADH3;103730;4q23
Parkinson's disease;168600;synucleinopathy;lewy bodies;Cerebral inclusion bodies;GBA;606463;1q22
Parkinson's disease;168600;synucleinopathy;lewy bodies;Cerebral inclusion bodies;MAPT, MTBT1, DDPAC, MSTD;157140;17q21.31
Parkinson's disease;168600;synucleinopathy;lewy bodies;Cerebral inclusion bodies;TBP, SCA17, HDL4;600075;6q27
Parkinson's disease;168601;synucleinopathy;hypokinesia;Diminished movement;SNCA, NACP, PARK1, PARK4;163890;4q22.1
Parkinson's disease;260300;synucleinopathy;scissor gait;Gait disturbance;FBXO7, FBX7, FBX, PKPS, PARK15;605648;22q12.3
Parkinson's disease;600116;synucleinopathy;substantia nigra gliosis;Abnormality of the substantia nigra;PRKN, PARK2, PDJ, LPRS2;602544;6q26
Parkinson's disease;605543;synucleinopathy;lewy bodies;Cerebral inclusion bodies;SNCA, NACP, PARK1, PARK4;163890;4q22.1
Parkinson's disease;605909;synucleinopathy;slow progression;Pace of progression;PINK1, PARK6;608309;1p36.12
Parkinson's disease;606324;synucleinopathy;slow progression;Pace of progression;DJ1, PARK7;602533;1p36.23
Parkinson's disease;606693;synucleinopathy;hyposmia;Abnormality of the sense of smell;ATP13A2, PARK9, KRPPD, CLN12;610513;1p36.13
Parkinson's disease;607060;synucleinopathy;substantia nigra gliosis;Abnormality of the substantia nigra;LRRK2, PARK8;609007;12q12
Parkinson's disease;607688;synucleinopathy;parkinsonism with favorable response to dopaminergic medication;Parkinsonism;GIGYF2, KIAA0642, PARK11;612003;2q37.1
Parkinson's disease;610297;synucleinopathy;parkinsonism with favorable response to dopaminergic medication;Parkinsonism;HTRA2, OMI, PARK13, PRSS25;606441;2p13.1
Parkinson's disease;612953;synucleinopathy;frontotemporal cerebral atrophy;Cerebral atrophy;PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14;603604;22q13.1
Parkinson's disease;614203;synucleinopathy;dyskinesia;Abnormality of movement;VPS35, MEM3, PARK17;601501;16q11.2
Parkinson's disease;614251;synucleinopathy;lewy bodies;Cerebral inclusion bodies;EIF4G1, EIF4G, PARK18;600495;3q27.1
Parkinson's disease;615528;synucleinopathy;abnormal pyramidal signs;Upper motor neuron dysfunction;DNAJC6, DJC6, KIAA0473, PARK19;608375;1p31.3
Parkinson's disease;615530;synucleinopathy;progressive disorder;Pace of progression;SYNJ1, PARK20;604297;21q22.11
Partington syndrome;309510;syndrome;focal dystonia;Dystonia;ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32;300382;Xp21.3
Pelger-Huet anomaly;169400;autosomal dominant disease;hyposegmentation of neutrophil nuclei;Abnormality of neutrophil morphology;LBR, PHA;600024;1q42.12
Pelizaeus-Merzbacher disease;312080;leukodystrophy;reduction of oligodendroglia;Abnormality of the oligodendroglia;PLP1, PMD, HLD1, SPG2;300401;Xq22.2
Perrault syndrome;233400;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;HSD17B4, PRLTS1;601860;5q23.1
Perrault syndrome;614129;autosomal recessive disease;short stature;Growth delay;CLPP, PRLTS3, DFNB81;601119;19p13.3
Perrault syndrome;614926;autosomal recessive disease;sensorineural hearing impairment;Functional abnormality of the inner ear;HARS2, HARSL, HARSR, HO3, PRLTS2;600783;5q31.3
Perrault syndrome;615300;autosomal recessive disease;premature ovarian failure;Abnormality of the ovary;LARS2, PRLTS4;604544;3p21.31
Peutz-Jeghers syndrome;175200;intestinal disease;intestinal polyposis;Intestinal polyp;STK11, PJS, LKB1;602216;19p13.3
Pfeiffer syndrome;101600;acrocephalosyndactylia;broad thumb;Broad phalanges of the hand;FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS;136350;8p11.23-p11.22
Pfeiffer syndrome;101600;acrocephalosyndactylia;broad thumb;Broad phalanges of the hand;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
Pick's disease;172700;neurodegenerative disease;perseveration;Behavioral abnormality;MAPT, MTBT1, DDPAC, MSTD;157140;17q21.31
Pick's disease;172700;neurodegenerative disease;perseveration;Behavioral abnormality;PSEN1, AD3;104311;14q24.2
Prader-Willi syndrome;176270;chromosomal disease;clinodactyly;Abnormality of digit;NDN;602117;15q11.2
Prader-Willi syndrome;176270;chromosomal disease;clinodactyly;Abnormality of digit;SNRPN;182279;15q11.2
Proteus syndrome;176920;physical disorder;conjunctival hamartoma;Hamartoma of the eye;AKT1, CWS6;164730;14q32.33
Refsum disease;266500;lipid metabolism disorder;abnormal renal physiology;Abnormality of the urinary system physiology;PHYH, PAHX;602026;10p13
Refsum disease;266510;lipid metabolism disorder;flat face;Abnormal facial shape;PEX12, PBD3A;601758;17q12
Renpenning syndrome;309500;syndromic intellectual disability;aplasia/hypoplasia of the eyebrow;Abnormality of the eyebrow;PQBP1, NPW38, SHS, MRX55, MRXS3, RENS1, MRXS8;300463;Xp11.23
Rett syndrome;312750;pervasive developmental disorder;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16;300005;Xq28
Rett syndrome;613454;pervasive developmental disorder;tongue thrusting;Stereotypic behavior;FOXG1, FOXG1B, FKHL1, FKH2, QIN, BF1;164874;14q12
Rh deficiency syndrome;268150;hemolytic anemia;unconjugated hyperbilirubinemia;Hyperbilirubinemia;RHAG, RH50A;180297;6p12.3
Riley-Day syndrome;223900;hereditary sensory neuropathy;corneal erosion;Abnormality of corneal epithelium;IKBKAP, IKAP;603722;9q31.3
Roberts syndrome;268300;autosomal recessive disease;clinodactyly;Abnormality of digit;ESCO2;609353;8p21.1
Robinow syndrome;180700;syndrome;small hand;Aplasia/hypoplasia involving bones of the hand;WNT5A;164975;3p14.3
Robinow syndrome;300695;syndrome;arrhythmia;Abnormality of cardiovascular system physiology;FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B;300163;Xq26.3
Rothmund-Thomson syndrome;268400;skin disease;small hand;Aplasia/hypoplasia involving bones of the hand;RECQL4, RTS, RECQ4;603780;8q24.3
Rubinstein-Taybi syndrome;180849;autosomal dominant disease;impulsivity;Abnormal aggressive, impulsive or violent behavior;CREBBP, CBP, RSTS;600140;16p13.3
Rubinstein-Taybi syndrome;613684;autosomal dominant disease;broad thumb;Broad phalanges of the hand;EP300, RSTS2;602700;22q13.2
SC phocomelia syndrome;269000;autosomal recessive disease;clinodactyly;Abnormality of digit;ESCO2;609353;8p21.1
Saethre-Chotzen syndrome;101400;acrocephalosyndactylia;cognitive impairment;Abnormality of higher mental function;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
Saethre-Chotzen syndrome;101400;acrocephalosyndactylia;cognitive impairment;Abnormality of higher mental function;TWIST1, ACS3, SCS, CRS1;601622;7p21.1
Sandhoff disease;268800;gangliosidosis GM2;cognitive impairment;Abnormality of higher mental function;HEXB;606873;5q13.3
Scheie syndrome;607016;mucopolysaccharidosis;cerebral palsy;Abnormality of movement;IDUA, IDA;252800;4p16.3
Schmid metaphyseal chondrodysplasia;156500;metaphyseal dysplasia;short distal phalanx of finger;Aplasia/Hypoplasia of the distal phalanges of the hand;COL10A1;120110;6q22.1
Seckel syndrome;210600;autosomal recessive disease;ivory epiphyses;Abnormality of the epiphyses;ATR, FRP1, SCKL1, FCTCS;601215;3q23
Seckel syndrome;606744;autosomal recessive disease;heart murmur;Abnormality of cardiovascular system physiology;RBBP8, RIM, SCKL2, JWDS;604124;18q11.2
Seckel syndrome;613676;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;CENPJ, CPAP, MCPH6, SCKL4;609279;13q12.12
Seckel syndrome;613823;autosomal recessive disease;large beaked nose;Abnormality of the nasal dorsum;CEP152, KIAA0912, MCPH9, SCKL5;613529;15q21.1
Seckel syndrome;614728;autosomal recessive disease;short stature;Growth delay;CEP63, SCKL6;614724;3q22.2
Seckel syndrome;614851;autosomal recessive disease;central hypothyroidism;Hypothyroidism;NIN, KIAA1565, SCKL7;608684;14q22.1
Seckel syndrome;615807;autosomal recessive disease;short stature;Growth delay;DNA2, DNA2L, KIAA0083, PEOA6, SCKL8;601810;10q21.3
Senior-Loken syndrome;266900;autosomal recessive disease;stage 5 chronic kidney disease;Chronic kidney disease;NPHP1, NPH1, SLSN1, JBTS4;607100;2q13
Senior-Loken syndrome;606996;autosomal recessive disease;stage 5 chronic kidney disease;Chronic kidney disease;NPHP4, SLSN4;607215;1p36.31
Senior-Loken syndrome;609254;autosomal recessive disease;stage 5 chronic kidney disease;Chronic kidney disease;IQCB1, NPHP5, KIAA0036;609237;3q13.33
Senior-Loken syndrome;610189;autosomal recessive disease;stage 5 chronic kidney disease;Chronic kidney disease;CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14;610142;12q21.32
Senior-Loken syndrome;613615;autosomal recessive disease;retinal degeneration;Abnormality of the retina;SDCCAG8, CCCAP, SLSN7, BBS16;613524;1q43
Sensenbrenner syndrome;218330;autosomal recessive disease;chronic kidney disease;Renal insufficiency;IFT122, WDR10, CED1;606045;3q21.3-q22.1
Sensenbrenner syndrome;613610;autosomal recessive disease;rhizomelia;Limb undergrowth;WDR35, NAOFEN, KIAA1336, CED2, SRTD7;613602;2p24.1
Silver-Russell syndrome;180860;chromosomal disease;testicular seminoma;Germinoma;H19, D11S813E, ASM1, BWS, WT2;103280;11p15.5
Simpson-Golabi-Behmel syndrome;300209;X-linked disease;clinodactyly;Abnormality of digit;OFD1, CXorf5, SGBS2, JBTS10, RP23;300170;Xp22.2
Simpson-Golabi-Behmel syndrome;312870;X-linked disease;displacement of the external urethral meatus;Abnormality of the urethra;GPC3, SDYS, SGBS1;300037;Xq26.2
Sjogren-Larsson syndrome;270200;autosomal recessive disease;corneal erosion;Abnormality of corneal epithelium;ALDH3A2, ALDH10, SLS, FALDH;609523;17p11.2
Sly syndrome;253220;mucopolysaccharidosis;enlarged thorax;Abnormality of the rib cage;GUSB, MPS7;611499;7q11.21
Smith-Lemli-Opitz syndrome;270400;lipid metabolism disorder;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;DHCR7, SLOS;602858;11q13.4
Smith-McCort dysplasia;607326;osteochondrodysplasia;irregular epiphyses;Abnormality of the epiphyses;DYM, FLJ90130, DMC, SMC;607461;18q21.1
Smith-McCort dysplasia;615222;osteochondrodysplasia;short metatarsal;Abnormal morphology of bones of the lower limbs;RAB33B, SMC2;605950;4q31.1
Sneddon syndrome;182410;artery disease;amaurosis fugax;Visual impairment;CECR1, PAN, SNEDS;607575;22q11.1
Sotos syndrome;117550;autosomal recessive disease;high anterior hairline;Abnormality of the frontal hairline;NSD1, ARA267, STO, SOTOS1;606681;5q35.2-q35.3
Sotos syndrome;614753;autosomal recessive disease;accelerated skeletal maturation;Abnormality of skeletal maturation;NFIX, NF1A, SOTOS2, MRSHSS;164005;19p13.2
Stargardt disease;248200;age related macular degeneration;bull's eye maculopathy;Abnormality of macular pigmentation;ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2;601691;1p22.1
Stargardt disease;248200;age related macular degeneration;bull's eye maculopathy;Abnormality of macular pigmentation;CNGB3, ACHM3, ACHM1;605080;8q21.3
Stargardt disease;600110;age related macular degeneration;macular flecks;Abnormality of the macula;ELOVL4, ADMD, STGD2, STGD3, ISQMR, SCA34;605512;6q14.1
Stargardt disease;603786;age related macular degeneration;retinal flecks;Abnormality of the retina;PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4;604365;4p15.32
Stickler syndrome;108300;autosomal dominant disease;abnormality of femoral epiphyses;Abnormality involving the epiphyses of the lower limbs;COL2A1;120140;12q13.11
Stickler syndrome;184840;autosomal dominant disease;exostoses;Neoplasm of the skeletal system;COL11A2, STL3, DFNA13, DFNB53, FBCG2;120290;6p21.32
Stickler syndrome;604841;autosomal dominant disease;long fingers;Abnormality of finger;COL11A1, STL2;120280;1p21.1
Sugio-Kajii syndrome;190351;autosomal dominant disease;increased number of teeth;Abnormal number of teeth;TRPS1;604386;8q23.3
Tangier disease;205400;hypolipoproteinemia;peripheral demyelination;Abnormal peripheral myelination;ABCA1, ABC1, HDLDT1, TGD;600046;9q31.1
Tay-Sachs disease AB variant;272750;gangliosidosis GM2;gm2-ganglioside accumulation;Abnormality of ganglioside metabolism;GM2A;613109;5q33.1
Tay-Sachs disease;272800;gangliosidosis GM2;abnormality of movement;Abnormality of nervous system physiology;HEXA, TSD;606869;15q23
Thomsen disease;160800;myotonic disease;handgrip myotonia;Myotonia;CLCN1;118425;7q34
Townes-Brocks syndrome;107480;autosomal dominant disease;displacement of the external urethral meatus;Abnormality of the urethra;SALL1, HSAL1, TBS;602218;16q12.1
Treacher Collins syndrome;154500;autosomal dominant disease;hypoplasia of the pharynx;Abnormality of the pharynx;TCOF1, MFD1, TCS1;606847;5q32
Treacher Collins syndrome;248390;autosomal dominant disease;mandibulofacial dysostosis;Craniofacial dysostosis;POLR1C, RPA39, RPA40, RPAC1, RPA5, TCS3;610060;6p21.1
Treacher Collins syndrome;613717;autosomal dominant disease;downslanted palpebral fissures;Slanting of the palpebral fissure;POLR1D, RPA16, RPAC2, TCS2;613715;13q12.2
Troyer syndrome;275900;hereditary spastic paraplegia;clinodactyly;Abnormality of digit;SPG20;607111;13q13.3
UV-sensitive syndrome;600630;autosomal recessive disease;pigmentation anomalies of sun-exposed skin;Abnormality of skin pigmentation;ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1;609413;10q11.23
UV-sensitive syndrome;614621;autosomal recessive disease;infantile onset;Onset;ERCC8, CKN1, CSA, UVSS2;609412;5q12.1
UV-sensitive syndrome;614640;autosomal recessive disease;infantile onset;Onset;UVSSA, KIAA1530, UVSS3;614632;4p16.3
Ullrich congenital muscular dystrophy;254090;congenital muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;COL6A1;120220;21q22.3
Ullrich congenital muscular dystrophy;254090;congenital muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;COL6A2;120240;21q22.3
Ullrich congenital muscular dystrophy;254090;congenital muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;COL6A3;120250;2q37.3
Unverricht-Lundborg syndrome;254800;progressive myoclonus epilepsy;absence seizures;Dialeptic seizures;CSTB, STFB, EPM1, PME, EPM1A, ULD;601145;21q22.3
Usher syndrome;276900;autosomal recessive disease;absent vestibular function;Vestibular hypofunction;MYO7A, USH1B, DFNB2, DFNA11;276903;11q13.5
Usher syndrome;276901;autosomal recessive disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;PDZD7;612971;10q24.31
Usher syndrome;276901;autosomal recessive disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;USH2A, RP39;608400;1q41
Usher syndrome;276902;autosomal recessive disease;decreased central vision;Visual loss;CLRN1, USH3A, USH3, RP61;606397;3q25.1
Usher syndrome;276904;autosomal recessive disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;USH1C, DFNB18A;605242;11p15.1
Usher syndrome;601067;autosomal recessive disease;vestibular dysfunction;Functional abnormality of the inner ear;CDH23, USH1D;605516;10q22.1
Usher syndrome;601067;autosomal recessive disease;vestibular dysfunction;Functional abnormality of the inner ear;PCDH15, DFNB23, USH1F;605514;10q21.1
Usher syndrome;602083;autosomal recessive disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;PCDH15, DFNB23, USH1F;605514;10q21.1
Usher syndrome;605472;autosomal recessive disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C;602851;5q14.3
Usher syndrome;605472;autosomal recessive disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;PDZD7;612971;10q24.31
Usher syndrome;606943;autosomal recessive disease;hypoplasia of the nasal bone;Aplasia/Hypoplasia of the nasal bone;SANS, USH1G;607696;17q25.1
Usher syndrome;611383;autosomal recessive disease;retinitis pigmentosa;Abnormal retinal pigmentation;WHRN, CIP98, KIAA1526, DFNB31, USH2D;607928;9q32
Usher syndrome;614504;autosomal recessive disease;delayed gross motor development;Motor delay;HARS, USH3B;142810;5q31.3
Usher syndrome;614869;autosomal recessive disease;congenital onset;Onset;CIB2, KIP2;605564;15q25.1
VACTERL association;192350;syndrome;displacement of the external urethral meatus;Abnormality of the urethra;HOXD13, HOX4I, SPD, BDSD;142989;2q31.1
VACTERL association;276950;syndrome;absent thumb;Aplasia/Hypoplasia of the thumb;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
Van Maldergem syndrome;601390;syndrome;irregular dentition;Abnormality of the teeth;DCHS1, PCDH16, FIB1, CDH19, VMLDS1;603057;11p15.4
Van Maldergem syndrome;615546;syndrome;irregular dentition;Abnormality of the teeth;FAT4, VMLDS2, HKLLS2;612411;4q28.1
Van der Woude syndrome;119300;syndrome;hypodontia;Reduced number of teeth;IRF6, VWS, LPS, PIT, PPS1, OFC6;607199;1q32.2
Van der Woude syndrome;606713;syndrome;anodontia;Reduced number of teeth;GRHL3, SOM, TFCP2L4, VWS2;608317;1p36.11
Waardenburg's syndrome;148820;autosomal dominant disease;atelectasis;Abnormality of the lung;PAX3, WS1, HUP2, CDHS, WS3;606597;2q36.1
Waardenburg's syndrome;193500;autosomal dominant disease;tented upper lip vermilion;Abnormality of upper lip vermillion;PAX3, WS1, HUP2, CDHS, WS3;606597;2q36.1
Waardenburg's syndrome;193510;autosomal dominant disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;MITF, WS2A, CMM8;156845;3p14-p13
Waardenburg's syndrome;277580;autosomal dominant disease;leukodystrophy;Abnormal CNS myelination;EDNRB, HSCR2, ABCDS, WS4A;131244;13q22.3
Waardenburg's syndrome;608890;autosomal dominant disease;congenital sensorineural hearing impairment;Sensorineural hearing impairment;SNAI2, SLUG, WS2D;602150;8q11.21
Waardenburg's syndrome;611584;autosomal dominant disease;hypoplasia of the semicircular canal;Morphological abnormality of the semicircular canal;SOX10, WS4, WS4C, PCWH;602229;22q13.1
Waardenburg's syndrome;613265;autosomal dominant disease;aganglionic megacolon;Abnormality of the enteric ganglia;EDN3, WS4B, HSCR4;131242;20q13.32
Waardenburg's syndrome;613266;autosomal dominant disease;aganglionic megacolon;Abnormality of the enteric ganglia;SOX10, WS4, WS4C, PCWH;602229;22q13.1
Walker-Warburg syndrome;236670;congenital muscular dystrophy;intellectual disability, severe;Intellectual disability;POMT1, MDDGA1, MDDGB1, MDDGC1;607423;9q34.13
Walker-Warburg syndrome;253280;congenital muscular dystrophy;midface retrusion;Abnormality of the midface;POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3;606822;1p34.1
Warburg micro syndrome;600118;autosomal recessive disease;short stature;Growth delay;RAB3GAP1, WARBM1, P130;602536;2q21.3
Warburg micro syndrome;614222;autosomal recessive disease;ankle clonus;Abnormality of the ankles;RAB18, WARBM3;602207;10p12.1
Warburg micro syndrome;614225;autosomal recessive disease;severe global developmental delay;Global developmental delay;RAB3GAP2, RAB3GAP150, p150, KIAA0839, WARBM2;609275;1q41
Warburg micro syndrome;615663;autosomal recessive disease;intellectual disability, severe;Intellectual disability;TBC1D20, C20orf140, WARBM4;611663;20p13
Weaver syndrome;277590;physical disorder;dysharmonic bone age;Abnormality of skeletal maturation;EZH2, EZH1, WVS;601573;7q36.1
Weill-Marchesani syndrome;277600;autosomal genetic disease;severe myopia;Myopia;ADAMTS10, WMS1;608990;19p13.2
Weill-Marchesani syndrome;608328;autosomal genetic disease;severe myopia;Myopia;FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1;134797;15q21.1
Weill-Marchesani syndrome;613195;autosomal genetic disease;short stature;Growth delay;ADAMTS17;607511;15q26.3
Weill-Marchesani syndrome;614819;autosomal genetic disease;increased intraocular pressure;Abnormal intraocular pressure;LTBP2, LTBP3, GLC3D, MSPKA, WMS3;602091;14q24.3
Werdnig-Hoffmann disease;253300;survival motor neuron spinal muscular atrophy;proximal muscle weakness in lower limbs;Proximal muscle weakness;SMN1, SMA1, SMA2, SMA3, SMA4;600354;5q13.2
Wermer syndrome;131100;autosomal dominant disease;esophagitis;Gastrointestinal inflammation;MEN1;613733;11q13.1
Werner syndrome;277700;autosomal recessive disease;skin ulcer;Localized skin lesion;RECQL2, RECQ3, WRN;604611;8p12
Wilson disease;277900;metal metabolism disorder;atypical or prolonged hepatitis;Hepatitis;ATP7B, WND;606882;13q14.3
Wiskott-Aldrich syndrome;301000;X-linked disease;small vessel vasculitis;Vasculitis;WAS, IMD2, THC1, SCNX;300392;Xp11.23
Wolff-Parkinson-White syndrome;194200;heart conduction disease;ventricular preexcitation with multiple accessory pathways;Ventricular preexcitation;PRKAG2, WPWS, CMH6;602743;7q36.1
Wolfram syndrome;222300;genetic disease;limited mobility of proximal interphalangeal joint;Abnormality of phalangeal joints of the hand;WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41;606201;4p16.1
Wolfram syndrome;604928;genetic disease;impaired collagen-induced platelet aggregation;Impaired platelet aggregation;CISD2, WFS2, ZCD2, ERIS;611507;4q24
X-linked chondrodysplasia punctata;302950;chondrodysplasia punctata;epiphyseal stippling;Ectopic calcification;ARSE, CDPX1, CDPXR;300180;Xp22.33
X-linked chondrodysplasia punctata;302960;chondrodysplasia punctata;hemiatrophy;Asymmetric growth;EBP, CDPX2, CPXD, CPX;300205;Xp11.23
X-linked hypophosphatemia;193100;metal metabolism disorder;hypophosphatemic rickets;Rickets;FGF23, ADHR, HPDR2, PHPTC;605380;12p13.32
X-linked hypophosphatemia;241520;metal metabolism disorder;increased bone mineral density;Abnormality of bone mineral density;DMP1, ARHR, ARHP;600980;4q22.1
X-linked hypophosphatemia;300554;metal metabolism disorder;chronic kidney disease;Renal insufficiency;CLCN5, CLCK2, NPHL2, DENTS, NPHL1;300008;Xp11.23-p11.22
X-linked hypophosphatemia;307800;metal metabolism disorder;enthesitis;Abnormality of Sharpey fibers;PHEX, HYP, HPDR1, LXHR;300550;Xp22.11
X-linked hypophosphatemia;613312;metal metabolism disorder;hypophosphatemic rickets;Rickets;ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED;173335;6q23.2
X-linked ichthyosis;308100;X-linked disease;cognitive impairment;Abnormality of higher mental function;STS, ARSC1, ARSC, SSDD, XLI;300747;Xp22.31
X-linked nonsyndromic deafness;304400;nonsyndromic deafness;dilatated internal auditory canal;Abnormality of the internal auditory canal;POU3F4, DFN3, DFNX2;300039;Xq21.1
X-linked nonsyndromic deafness;304500;nonsyndromic deafness;x-linked recessive inheritance;X-linked inheritance;PRPS1, CMTX5, DFNX1, DFN2;311850;Xq22.3
X-linked sideroblastic anemia with ataxia;301310;spinocerebellar ataxia;cognitive impairment;Abnormality of higher mental function;ABCB7, ABC7, ASAT;300135;Xq13.3
X-linked sideroblastic anemia;300751;sideroblastic anemia;irregular hyperpigmentation;Hyperpigmentation of the skin;ALAS2, ANH1, ASB, XLEPP, XLSA, ANH1;301300;Xp11.21
Zellweger syndrome;214100;peroxisomal disease;albuminuria;Proteinuria;PEX1, ZWS1, PBD1A, PBD1B;602136;7q21.2
abetalipoproteinemia;200100;hypolipoproteinemia;abnormality of movement;Abnormality of nervous system physiology;MTP;157147;4q23
acatalasia;614097;peroxisomal disease;reduced catalase activity;Abnormal enzyme/coenzyme activity;CAT;115500;11p13
aceruloplasminemia;604290;iron metabolism disease;abnormal renal physiology;Abnormality of the urinary system physiology;CP;117700;3q24-q25
acheiropody;200500;osteochondrodysplasia;absent toe;Aplasia/Hypoplasia of toe;LMBR1, ACHP, C7orf2, PPD2, THYP, LSS;605522;7q36.3
achondrogenesis type IA;200600;achondrogenesis;abnormal foot bone ossification;Abnormal enchondral ossification;TRIP11, TRIP230, CEV14, ACG1A;604505;14q32.12
achondrogenesis type IB;600972;achondrogenesis;flat face;Abnormal facial shape;SLC26A2, DTD, DTDST, D5S1708, EDM4;606718;5q32
achondrogenesis type II;200610;achondrogenesis;short thorax;Abnormality of the thorax;COL2A1;120140;12q13.11
achondroplasia;100800;osteochondrodysplasia;short femoral neck;Aplasia/Hypoplasia involving the femoral head and neck;FGFR3, ACH;134934;4p16.3
achromatopsia;216900;color blindness;rod monochromacy;Monochromacy;CNGA3, CNG3, ACHM2;600053;2q11.2
achromatopsia;262300;color blindness;severe myopia;Myopia;CNGB3, ACHM3, ACHM1;605080;8q21.3
achromatopsia;610024;color blindness;progressive cone degeneration;Retinal degeneration;PDE6H, RCD3, ACHM6;601190;12p12.3
achromatopsia;613093;color blindness;nystagmus;Abnormal involuntary eye movements;PDE6C, PDEA2, COD4;600827;10q23.33
achromatopsia;613856;color blindness;rod monochromacy;Monochromacy;GNAT2, ACHM4;139340;1p13.3
acrocallosal syndrome;200990;syndrome;displacement of the external urethral meatus;Abnormality of the urethra;KIF7, HLS2, ACLS, JBTS12;611254;15q26.1
acrocapitofemoral dysplasia;607778;osteochondrodysplasia;short femoral neck;Aplasia/Hypoplasia involving the femoral head and neck;IHH, BDA1;600726;2q35
acrocephalosyndactylia;101200;synostosis;corneal erosion;Abnormality of corneal epithelium;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
acrodermatitis enteropathica;201100;metal metabolism disorder;skin ulcer;Localized skin lesion;SLC39A4, ZIP4;607059;8q24.3
acrodysostosis;101800;dysostosis;short metatarsal;Abnormal morphology of bones of the lower limbs;PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1;188830;17q24.2
acrodysostosis;614613;dysostosis;midface retrusion;Abnormality of the midface;PDE4D, DPDE3, STRK1, ACRDYS2;600129;5q11.2-q12.1
acrofrontofacionasal dysostosis;301310;dysostosis;cognitive impairment;Abnormality of higher mental function;ABCB7, ABC7, ASAT;300135;Xq13.3
acrokeratosis verruciformis;101900;keratosis;acrokeratosis;Skin nodule;ATP2A2, ATP2B, DAR;108740;12q24.11
acromesomelic dysplasia, Grebe type;200700;acromesomelic dysplasia;short digit;Abnormality of digit;GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;20q11.22
acromesomelic dysplasia, Hunter-Thompson type;201250;acromesomelic dysplasia;cognitive impairment;Abnormality of higher mental function;GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;20q11.22
acromesomelic dysplasia, Maroteaux type;602875;acromesomelic dysplasia;prominent forehead;Abnormality of the forehead;NPR2, ANPRB, AMDM, ECDM;108961;9p13.3
acute intermittent porphyria;176000;acute porphyria;insomnia;Sleep disturbance;HMBS, PBGD, UPS;609806;11q23.3
acute lymphocytic leukemia;613065;lymphoblastic leukemia;polygenic inheritance;Multifactorial inheritance;BAX;600040;19q13.33
acute lymphocytic leukemia;613065;lymphoblastic leukemia;polygenic inheritance;Multifactorial inheritance;BCR, CML, PHL, ALL;151410;22q11.23
acute lymphocytic leukemia;613065;lymphoblastic leukemia;polygenic inheritance;Multifactorial inheritance;FLT3;136351;13q12.2
acute lymphocytic leukemia;613065;lymphoblastic leukemia;polygenic inheritance;Multifactorial inheritance;NBS1, NBS;602667;8q21.3
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;AF10;602409;10p12.31
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;ARHGEF12, LARG, KIAA0382;604763;11q23.3
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;CBFB, PEBP2B;121360;16q22.1
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;CEBPA, CEBP;116897;19q13.11
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;CHIC2, BTL;604332;4q12
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;ETV6, TEL, THC5;600618;12p13.2
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;FLT3;136351;13q12.2
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;GATA2, DCML, MONOMAC, IMD21;137295;3q21.3
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;GMPS;600358;3q25.31
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;JAK2, THCYT3;147796;9p24.1
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;KIT, PBT;164920;4q12
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;LPP;600700;3q27-q28
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;MLF1;601402;3q25.32
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;NPM1;164040;5q35.1
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;NSD1, ARA267, STO, SOTOS1;606681;5q35.2-q35.3
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;NUP214, D9S46E, CAN, CAIN;114350;9q34.13
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;PICALM, CALM, CLTH, LAP;603025;11q14.2
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;RUNX1, CBFA2, AML1;151385;21q22.12
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;SH3GL1, EEN;601768;19p13.3
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9;187270;5p15.33
acute myeloid leukemia;601626;myeloid leukemia;acute myeloid leukemia;Acute leukemia;WHSC1L1, NSD3;607083;8p11.23
acute porphyria;612740;porphyria;cerebral palsy;Abnormality of movement;ALAD, ALADH, PBGS;125270;9q32
adenosine deaminase deficiency;102700;severe combined immunodeficiency;reduced red cell adenosine deaminase activity;Abnormal erythrocyte enzyme activity;ADA;608958;20q13.12
adrenocortical carcinoma;202300;adrenal cortex cancer;adrenocortical carcinoma;Neoplasm of the adrenal cortex;TP53, P53, LFS1 , BCC7;191170;17p13.1
adrenoleukodystrophy;202370;leukodystrophy;polar cataract;Cataract;PEX5, PXR1, PTS1R, PBD2A, PBD2B;600414;12p13.31
adrenoleukodystrophy;300100;leukodystrophy;primary adrenal insufficiency;Adrenal insufficiency;ABCD1, ALD, AMN;300371;Xq28
adult spinal muscular atrophy;271150;spinal muscular atrophy;spinal muscular atrophy;Skeletal muscle atrophy;SMN1, SMA1, SMA2, SMA3, SMA4;600354;5q13.2
advanced sleep phase syndrome;604348;sleep disorder;sleep-wake cycle disturbance;Sleep disturbance;PER2, FASPS1, KIAA0347;603426;2q37.3
advanced sleep phase syndrome;615224;sleep disorder;autosomal dominant inheritance;Mode of inheritance;CSNK1D, ASPS, FASPS2;600864;17q25.3
agammaglobulinemia;601495;blood protein disease;crohn's disease;Chronic colitis;IGHM, MU, AGM1;147020;14q32.33
agammaglobulinemia;612692;blood protein disease;chronic sinusitis;Sinusitis;CD79B, IGB, B29, AGM6;147245;17q23.3
agammaglobulinemia;613500;blood protein disease;recurrent pneumonia;Recurrent lower respiratory tract infections;IGLL1, IGO, IGL5, VPREB2, AGM2;146770;22q11.23
agammaglobulinemia;613501;blood protein disease;agammaglobulinemia;Abnormal immunoglobulin level;CD79A, IGA;112205;19q13.2
agammaglobulinemia;613502;blood protein disease;chronic sinusitis;Sinusitis;BLNK, SLP65, AGM4;604515;10q24.1
agammaglobulinemia;613506;blood protein disease;agammaglobulinemia;Abnormal immunoglobulin level;LRRC8A, KIAA1437, AGM5;608360;9q34.11
agammaglobulinemia;615214;blood protein disease;agammaglobulinemia;Abnormal immunoglobulin level;PIK3R1, GRB1, AGM7, SHORT, IMD36;171833;5q13.1
age related macular degeneration;153800;degeneration of macula and posterior pole;age-related macular degeneration;Macular degeneration;ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2;601691;1p22.1
age related macular degeneration;608895;degeneration of macula and posterior pole;drusen;Abnormality of the macula;FBLN5, ARMD3, ADCL2, ARCL1A;604580;14q32.12
age related macular degeneration;610698;degeneration of macula and posterior pole;polygenic inheritance;Multifactorial inheritance;HF1, CFH, HUS, ARMD4, AHUS1;134370;1q31.3
age related macular degeneration;611953;degeneration of macula and posterior pole;polygenic inheritance;Multifactorial inheritance;CST3, ARMD11;604312;20p11.21
age related macular degeneration;613757;degeneration of macula and posterior pole;macular degeneration;Abnormality of the macula;RAXL1, QRX, CORD11, ARMD6;610362;19p13.3
age related macular degeneration;615439;degeneration of macula and posterior pole;macular degeneration;Abnormality of the macula;CFI, FI, AHUS3, ARMD13;217030;4q25
aggressive periodontitis;170650;periodontitis;premature loss of teeth;Abnormality of the teeth;CTSC, CPPI, PALS, PLS, HMS, PDON1, JPD;602365;11q14.2
alcohol dependence;103780;substance dependence;abnormality of the nervous system;Phenotypic abnormality;ADH1B, ADH2;103720;4q23
alcohol dependence;103780;substance dependence;abnormality of the nervous system;Phenotypic abnormality;ADH1C, ADH3;103730;4q23
alcohol dependence;103780;substance dependence;abnormality of the nervous system;Phenotypic abnormality;GABRA2;137140;4p12
alcohol dependence;103780;substance dependence;abnormality of the nervous system;Phenotypic abnormality;HTR2A;182135;13q14.2
alcohol dependence;103780;substance dependence;abnormality of the nervous system;Phenotypic abnormality;RCBTB1, CLLD7, GLP;607867;13q14.2
alcohol dependence;103780;substance dependence;abnormality of the nervous system;Phenotypic abnormality;TAS2R16, T2R16;604867;7q31.32
alkaptonuria;203500;organic acidemia;cartilage destruction;Abnormal cartilage morphology;HGD, AKU;607474;3q13.33
alopecia universalis;203655;alopecia;alopecia universalis;Alopecia;HR, AU, MUHH1, HYPT4;602302;8p21.3
alpha 1-antitrypsin deficiency;613490;plasma protein metabolism disease;chronic obstructive pulmonary disease;Obstructive lung disease;SERPINA1, PI, AAT;107400;14q32.13
alpha thalassemia;301040;thalassemia;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;ATRX, XH2, XNP, SHS, SFM1, MRXHF1;300032;Xq21.1
alpha thalassemia;604131;thalassemia;cognitive impairment;Abnormality of higher mental function;HBA1, HBH;141800;16p13.3
alpha thalassemia;604131;thalassemia;cognitive impairment;Abnormality of higher mental function;HBA2, HBH;141850;16p13.3
alpha thalassemia;613978;thalassemia;reduced alpha/beta synthesis ratio;Imbalanced hemoglobin synthesis;HBA1, HBH;141800;16p13.3
alpha thalassemia;613978;thalassemia;reduced alpha/beta synthesis ratio;Imbalanced hemoglobin synthesis;HBA2, HBH;141850;16p13.3
alpha-mannosidosis;248500;lysosomal storage disease;cognitive impairment;Abnormality of higher mental function;MAN2B1, MANB;609458;19p13.2
alternating hemiplegia of childhood;104290;hemiplegia;episodic quadriplegia;Tetraplegia;ATP1A2, FHM2, MHP2;182340;1q23.2
alternating hemiplegia of childhood;614820;hemiplegia;episodic quadriplegia;Tetraplegia;ATP1A3, DYT12, RDP, AHC2, CAPOS;182350;19q13.2
alveolar rhabdomyosarcoma;268220;rhabdomyosarcoma;alveolar rhabdomyosarcoma;Rhabdomyosarcoma;FOXO1A, FKHR;136533;13q14.11
alveolar rhabdomyosarcoma;268220;rhabdomyosarcoma;alveolar rhabdomyosarcoma;Rhabdomyosarcoma;PAX3, WS1, HUP2, CDHS, WS3;606597;2q36.1
alveolar rhabdomyosarcoma;268220;rhabdomyosarcoma;alveolar rhabdomyosarcoma;Rhabdomyosarcoma;PAX7, RMS2;167410;1p36.13
alveolar soft part sarcoma;606243;skeletal muscle cancer;alveolar soft part sarcoma;Sarcoma;ASPSCR1, RCC17, ASPL, ASPS;606236;17q25.3
amelogenesis imperfecta;104500;dental enamel hypoplasia;amelogenesis imperfecta;Abnormality of dental enamel;ENAM, AIH2, AI1C;606585;4q13.3
amelogenesis imperfecta;104510;dental enamel hypoplasia;amelogenesis imperfecta;Abnormality of dental enamel;DLX3, TDO, AI4;600525;17q21.33
amelogenesis imperfecta;104530;dental enamel hypoplasia;generalized microdontia;Microdontia;LAMB3, AI1A;150310;1q32.2
amelogenesis imperfecta;130900;dental enamel hypoplasia;anterior open bite;Open bite;FAM83H, AI3;611927;8q24.3
amelogenesis imperfecta;204650;dental enamel hypoplasia;anterior open-bite malocclusion;Dental malocclusion;ENAM, AIH2, AI1C;606585;4q13.3
amelogenesis imperfecta;204700;dental enamel hypoplasia;amelogenesis imperfecta;Abnormality of dental enamel;KLK4, EMSP1, PRSS17, AI2A1;603767;19q13.41
amelogenesis imperfecta;301200;dental enamel hypoplasia;anterior open bite;Open bite;AMELX, AMG, AIH1, AMGX, AI1E;300391;Xp22.2
amelogenesis imperfecta;612529;dental enamel hypoplasia;anterior open bite;Open bite;MMP20, AI2A2;604629;11q22.2
amelogenesis imperfecta;613211;dental enamel hypoplasia;hypomature dental enamel;Hypomineralization of enamel;WDR72, AI2A3;613214;15q21.3
amelogenesis imperfecta;614832;dental enamel hypoplasia;hypomineralization of enamel;Abnormality of dental enamel;C4orf26, AI2A4;614829;4q21.1
amelogenesis imperfecta;615887;dental enamel hypoplasia;amelogenesis imperfecta;Abnormality of dental enamel;SLC24A4, NCKX4, SHEP6, AI2A5;609840;14q32.12
amyotrophic lateral sclerosis type 10;612069;amyotrophic lateral sclerosis;perseveration;Behavioral abnormality;TARDBP, TDP43, ALS10;605078;1p36.22
amyotrophic lateral sclerosis type 11;612577;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;FIG4, KIAA0274, SAC3, ALS11, YVS, BTOP;609390;6q21
amyotrophic lateral sclerosis type 12;613435;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;OPTN, GLC1E, FIP2, HYPL, NRP, ALS12;602432;10p13
amyotrophic lateral sclerosis type 13;183090;amyotrophic lateral sclerosis;genetic anticipation;Mode of inheritance;ATXN2, ATX2, SCA2, ASL13;601517;12q24.12
amyotrophic lateral sclerosis type 14;613954;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;VCP, IBMPFD1, ALS14;601023;9p13.3
amyotrophic lateral sclerosis type 15;300857;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;UBQLN2, PLIC2, CHAP1, ALS15;300264;Xp11.21
amyotrophic lateral sclerosis type 16;614373;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;SIGMAR1, SRBP, ALS16;601978;9p13.3
amyotrophic lateral sclerosis type 17;614696;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;CHMP2B, DMT1, VPS2B, ALS17;609512;3p11.2
amyotrophic lateral sclerosis type 18;614808;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;PFN1, ALS18;176610;17p13.2
amyotrophic lateral sclerosis type 19;615515;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;ERBB4, HER4, ALS19;600543;2q34
amyotrophic lateral sclerosis type 1;105400;amyotrophic lateral sclerosis;sleep apnea;Sleep disturbance;DCTN1, HMN7B;601143;2p13.1
amyotrophic lateral sclerosis type 1;105400;amyotrophic lateral sclerosis;sleep apnea;Sleep disturbance;NEFH;162230;22q12.2
amyotrophic lateral sclerosis type 1;105400;amyotrophic lateral sclerosis;sleep apnea;Sleep disturbance;PRPH;170710;12q13.12
amyotrophic lateral sclerosis type 1;105400;amyotrophic lateral sclerosis;sleep apnea;Sleep disturbance;SOD1, ALS1;147450;21q22.11
amyotrophic lateral sclerosis type 21;606070;amyotrophic lateral sclerosis;bowing of the vocal cords;Abnormality of the vocal cords;MATR3, MPD2, ALS21;164015;5q31.2
amyotrophic lateral sclerosis type 2;205100;amyotrophic lateral sclerosis;hand muscle atrophy;Distal upper limb amyotrophy;ALS2, ALSJ, PLSJ, IAHSP;606352;2q33.1
amyotrophic lateral sclerosis type 4;602433;amyotrophic lateral sclerosis;axonal degeneration;Peripheral axonal degeneration;SETX, SCAR1, AOA2, ALS4;608465;9q34.13
amyotrophic lateral sclerosis type 6;608030;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;FUS, TLS, ALS6, ETM4;137070;16p11.2
amyotrophic lateral sclerosis type 8;608627;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;VAPB, VAPC, ALS8;605704;20q13.32
amyotrophic lateral sclerosis type 9;611895;amyotrophic lateral sclerosis;amyotrophic lateral sclerosis;Motor neuron atrophy;ANG, RNASE5, ALS9;105850;14q11.2
amyotrophic lateral sclerosis;105400;motor neuron disease;sleep apnea;Sleep disturbance;DCTN1, HMN7B;601143;2p13.1
amyotrophic lateral sclerosis;105400;motor neuron disease;sleep apnea;Sleep disturbance;NEFH;162230;22q12.2
amyotrophic lateral sclerosis;105400;motor neuron disease;sleep apnea;Sleep disturbance;PRPH;170710;12q13.12
amyotrophic lateral sclerosis;105400;motor neuron disease;sleep apnea;Sleep disturbance;SOD1, ALS1;147450;21q22.11
amyotrophic lateral sclerosis;205100;motor neuron disease;hand muscle atrophy;Distal upper limb amyotrophy;ALS2, ALSJ, PLSJ, IAHSP;606352;2q33.1
amyotrophic lateral sclerosis;602433;motor neuron disease;axonal degeneration;Peripheral axonal degeneration;SETX, SCAR1, AOA2, ALS4;608465;9q34.13
amyotrophic lateral sclerosis;608030;motor neuron disease;amyotrophic lateral sclerosis;Motor neuron atrophy;FUS, TLS, ALS6, ETM4;137070;16p11.2
amyotrophic lateral sclerosis;611895;motor neuron disease;amyotrophic lateral sclerosis;Motor neuron atrophy;ANG, RNASE5, ALS9;105850;14q11.2
amyotrophic lateral sclerosis;612069;motor neuron disease;perseveration;Behavioral abnormality;TARDBP, TDP43, ALS10;605078;1p36.22
amyotrophic lateral sclerosis;612577;motor neuron disease;amyotrophic lateral sclerosis;Motor neuron atrophy;FIG4, KIAA0274, SAC3, ALS11, YVS, BTOP;609390;6q21
amyotrophic lateral sclerosis;613435;motor neuron disease;amyotrophic lateral sclerosis;Motor neuron atrophy;OPTN, GLC1E, FIP2, HYPL, NRP, ALS12;602432;10p13
amyotrophic neuralgia;162100;brachial plexus neuropathy;axonal degeneration;Peripheral axonal degeneration;SEPT9, MSF, MSF1, NAPB;604061;17q25.2-q25.3
anauxetic dysplasia;607095;spondyloepimetaphyseal dysplasia;small epiphyses;Abnormality of the epiphyses;RMRP, RMRPR, CHH;157660;9p13.3
androgen insensitivity syndrome;300068;hermaphroditism;female external genitalia in individual with 46,xy karyotype;Abnormality of male external genitalia;AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1;313700;Xq12
angioma serpiginosum;600652;skin hemangioma;progressive sensorineural hearing impairment;Progressive hearing impairment;MYH14, KIAA2034, DFNA4A, PNMHH;608568;19q13.33
aniridia;106210;iris disease;aplasia/hypoplasia of the iris;Aplasia/Hypoplasia affecting the anterior segment of the eye;ELP4, PAX6NEB, AN;606985;11p13
aniridia;106210;iris disease;aplasia/hypoplasia of the iris;Aplasia/Hypoplasia affecting the anterior segment of the eye;PAX6, AN2, MGDA, FVH1;607108;11p13
anonychia congenita;206800;nail disease;anonychia;Aplasia/Hypoplasia of the nails;RSPO4, CRISTIN4;610573;20p13
antithrombin III deficiency;613118;inherited blood coagulation disease;cerebral venous thrombosis;Venous thrombosis;SERPINC1, AT3, AT3D, THPH7;107300;1q25.1
aortic valve stenosis;109730;aortic valve disease;aortic valve stenosis;Abnormality of the aortic valve;NOTCH1, TAN1, AOS5, AOVD1;190198;9q34.3
aortic valve stenosis;614823;aortic valve disease;calcification of the aorta;Arterial calcification;SMAD6, MADH6, AOVD2;602931;15q22.31
argininosuccinic aciduria;207900;amino acid metabolic disorder;cognitive impairment;Abnormality of higher mental function;ASL;608310;7q11.21
arrhythmogenic right ventricular cardiomyopathy;107970;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;TGFB3, ARVD1, RNHF;190230;14q24.3
arrhythmogenic right ventricular cardiomyopathy;600996;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;RYR2, VTSIP, ARVD2, ARVC2;180902;1q43
arrhythmogenic right ventricular cardiomyopathy;604400;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;TMEM43, ARVD5, ARVC5, EDMD7;612048;3p25.1
arrhythmogenic right ventricular cardiomyopathy;607450;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;DSP, KPPS2, PPKS2, DCWHKTA;125647;6p24.3
arrhythmogenic right ventricular cardiomyopathy;609040;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;PKP2, ARVD9;602861;12p11.21
arrhythmogenic right ventricular cardiomyopathy;610193;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;DSG2, ARVD10, ARVC10, CMD1BB;125671;18q12.1
arrhythmogenic right ventricular cardiomyopathy;610476;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;DSC2, DSC3, ARVD11;125645;18q12.1
arrhythmogenic right ventricular cardiomyopathy;611528;intrinsic cardiomyopathy;right ventricular cardiomyopathy;Cardiomyopathy;JUP, DP3, PDGB, ARVD12;173325;17q21.2
arrhythmogenic right ventricular cardiomyopathy;615616;intrinsic cardiomyopathy;bundle branch block;Heart block;CTNNA3, ARVD13;607667;10q21.3
arterial calcification of infancy;208000;vascular disease;generalized arterial calcification;Arterial calcification;ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED;173335;6q23.2
arterial calcification of infancy;614473;vascular disease;hypophosphatemic rickets;Rickets;ABCC6, ARA, ABC34, MLP1, PXE, GACI2;603234;16p13.11
arterial tortuosity syndrome;208050;connective tissue disease;decreased corneal thickness;Abnormality of corneal thickness;SLC2A10, GLUT10, ATS;606145;20q13.12
aspartylglucosaminuria;208400;lysosomal storage disease;hernia;Abnormality of connective tissue;AGA;613228;4q34.3
asphyxiating thoracic dystrophy;611263;autosomal recessive disease;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;IFT80, KIAA1374, WDR56, SRTD2, ATD2;611177;3q25.33
asphyxiating thoracic dystrophy;613091;autosomal recessive disease;postaxial polydactyly;Polydactyly;DYNC2H1, DNCH2, DHC2, ATD3, SRPS2B, SRTD3;603297;11q22.3
asphyxiating thoracic dystrophy;613819;autosomal recessive disease;short stature;Growth delay;TTC21B, THM1, NPHP12, SRTD4, ATD4;612014;2q24.3
asphyxiating thoracic dystrophy;614376;autosomal recessive disease;short iliac bones;Hypoplastic ilia;WDR19, SRTD5, ATD5, NPHP13, CED4;608151;4p14
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;ADRB2;109690;5q32
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;ALOX5;152390;10q11.21
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;CCL11, SCYA11;601156;17q12
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;HLA-G;142871;6p22.1
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;HNMT;605238;2q22.1
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;IL12B, NKSF2, IMD29;161561;5q33.3
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;IL13, ALRH, BHR1;147683;5q31.1
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;MUC7;158375;4q13.3
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;PHF11, NYREN34;607796;13q14.2
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;PLA2G7, PAFAH, PAFAD;601690;6p12.3
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;SCGB3A2, UGRP1;606531;5q32
asthma;600807;obstructive lung disease;asthma;Immunologic hypersensitivity;TNF, TNFA;191160;6p21.33
ataxia telangiectasia;208900;autosomal recessive disease;non-hodgkin lymphoma;Lymphoma;ATM, ATA, AT1;607585;11q22.3
atelosteogenesis;108720;osteochondrodysplasia;midface retrusion;Abnormality of the midface;FLNB, SCT, AOI, LRS1;603381;3p14.3
atelosteogenesis;108721;osteochondrodysplasia;midface retrusion;Abnormality of the midface;FLNB, SCT, AOI, LRS1;603381;3p14.3
atelosteogenesis;256050;osteochondrodysplasia;midface retrusion;Abnormality of the midface;SLC26A2, DTD, DTDST, D5S1708, EDM4;606718;5q32
atransferrinemia;209300;metal metabolism disorder;atransferrinemia;Abnormality of circulating protein level;TF, TFQTL1;190000;3q22.1
atrial heart septal defect;108900;heart septal defect;prolonged pr interval;Abnormal EKG;NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;600584;5q35.1
atrial heart septal defect;607941;heart septal defect;atrioventricular canal defect;Abnormality of the cardiac septa;GATA4, ASD2, VSD1, TACHD, TOF;600576;8p23.1
atrial heart septal defect;611363;heart septal defect;coarctation of aorta;Abnormality of the aorta;TBX20, ASD4;606061;7p14.2
atrial heart septal defect;612794;heart septal defect;defect in the atrial septum;Abnormality of the atrial septum;ACTC1, CMD1R, CMH11, ASD5, LVNC4;102540;15q14
atrial heart septal defect;613087;heart septal defect;atrial fibrillation;Primary atrial arrhythmia;TLL1, TLL, ASD6;606742;4q32.3
atrial heart septal defect;614089;heart septal defect;secundum atrial septal defect;Defect in the atrial septum;MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3;160710;14q11.2
atrial heart septal defect;614433;heart septal defect;defect in the atrial septum;Abnormality of the atrial septum;CITED2, MRG1, P35SRJ, VSD2, ASD8;602937;6q24.1
atrial heart septal defect;614475;heart septal defect;pulmonary hypertension;Elevated pulmonary artery pressure;GATA6, AVSD5, ASD9, AVSD5, PACHD;601656;18q11.2
atrioventricular septal defect;600309;heart septal defect;first degree atrioventricular block;Atrioventricular block;GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR;121014;6q22.31
atrioventricular septal defect;606217;heart septal defect;atrioventricular canal defect with right ventricle aorta and pulmonary atresia;Atrioventricular canal defect;CRELD1, AVSD2;607170;3p25.3
atrioventricular septal defect;614430;heart septal defect;primum atrial septal defect;Atrioventricular canal defect;GATA4, ASD2, VSD1, TACHD, TOF;600576;8p23.1
atrioventricular septal defect;614474;heart septal defect;muscular ventricular septal defect;Ventricular septal defect;GATA6, AVSD5, ASD9, AVSD5, PACHD;601656;18q11.2
attention deficit hyperactivity disorder;143465;specific developmental disorder;attention deficit hyperactivity disorder;Hyperactivity;ADHD1;608903;16p13
attention deficit hyperactivity disorder;143465;specific developmental disorder;attention deficit hyperactivity disorder;Hyperactivity;ADHD2;608904;17p11
attention deficit hyperactivity disorder;143465;specific developmental disorder;attention deficit hyperactivity disorder;Hyperactivity;ADHD3;608905;6q12
attention deficit hyperactivity disorder;143465;specific developmental disorder;attention deficit hyperactivity disorder;Hyperactivity;ADHD4;608906;5p13
attention deficit hyperactivity disorder;143465;specific developmental disorder;attention deficit hyperactivity disorder;Hyperactivity;DRD4;126452;11p15.5
attention deficit hyperactivity disorder;143465;specific developmental disorder;attention deficit hyperactivity disorder;Hyperactivity;DRD5, DRD1B, DRD1L2;126453;4p16.1
atypical teratoid rhabdoid tumor;609322;brain cancer;cerebral palsy;Abnormality of movement;SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1;601607;22q11.23
autistic disorder;300425;autism spectrum disorder;childhood onset;Onset;NLGN3, ASPGX1, AUTSX1;300336;Xq13.1
autistic disorder;300495;autism spectrum disorder;childhood onset;Onset;NLGN4, KIAA1260, AUTSX2, ASPGX2;300427;Xp22.32-p22.31
autistic disorder;300496;autism spectrum disorder;childhood onset;Onset;MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16;300005;Xq28
autistic disorder;300872;autism spectrum disorder;seizures;Abnormality of nervous system physiology;TMLHE, BBOX2, TMLH, TMLHED, AUTSX6;300777;Xq28
autoimmune lymphoproliferative syndrome;601859;hypersensitivity reaction type IV disease;coombs-positive hemolytic anemia;Hemolytic anemia;FAS, TNFRSF6, APT1, CD95, ALPS1A;134637;10q23.31
autoimmune lymphoproliferative syndrome;601859;hypersensitivity reaction type IV disease;coombs-positive hemolytic anemia;Hemolytic anemia;FASLG, TNFSF6, APT1LG1, FASL, ALPS1B;134638;1q24.3
autoimmune lymphoproliferative syndrome;603909;hypersensitivity reaction type IV disease;increase in b cell number;Lymphocytosis;CASP10, MCH4, ALPS2;601762;2q33.1
autoimmune lymphoproliferative syndrome;607271;hypersensitivity reaction type IV disease;recurrent sinopulmonary infections;Recurrent respiratory infections;CASP8, MCH5, ALPS2B;601763;2q33.1
autoimmune lymphoproliferative syndrome;614470;hypersensitivity reaction type IV disease;monocytosis;Abnormal monocyte count;NRAS, ALPS4, NS6, CMNS, NCMS;164790;1p13.2
autoimmune thrombocytopenic purpura;188030;primary thrombocytopenia;platelet antibody positive;Autoimmune antibody positivity;FCGR2C, CD32C;612169;1q23.3
autosomal dominant non-syndromic intellectual disability;156200;non-syndromic intellectual disability;small hand;Aplasia/hypoplasia involving bones of the hand;MBD5, KIAA1461, MRD1;611472;2q23.1
autosomal dominant non-syndromic intellectual disability;612337;non-syndromic intellectual disability;prominent forehead;Abnormality of the forehead;ZBTB18, ZNF238, RP58, MRD22;608433;1q44
autosomal dominant non-syndromic intellectual disability;612580;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;CDH15, CDH14, CDH3, MRD3;114019;16q24.3
autosomal dominant non-syndromic intellectual disability;612581;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;KIRREL3, NEPH2, KIAA1867, KIRRE, MRD4;607761;11q24.2
autosomal dominant non-syndromic intellectual disability;612621;non-syndromic intellectual disability;epileptic encephalopathy;Encephalopathy;SYNGAP1, MRD5;603384;6p21.32
autosomal dominant non-syndromic intellectual disability;613443;non-syndromic intellectual disability;epileptic encephalopathy;Encephalopathy;MEF2C, C5DELq14.3, DEL5q14.3;600662;5q14.3
autosomal dominant non-syndromic intellectual disability;613970;non-syndromic intellectual disability;eeg abnormality;Abnormality of central nervous system electrophysiology;GRIN2B, NMDAR2B, MRD6, EIEE27;138252;12p13.1
autosomal dominant non-syndromic intellectual disability;614104;non-syndromic intellectual disability;severe global developmental delay;Global developmental delay;DYRK1A, MNBH, MNB, MRD7;600855;21q22.13
autosomal dominant non-syndromic intellectual disability;614113;non-syndromic intellectual disability;global developmental delay;Neurodevelopmental delay;DOCK8, MRD2;611432;9p24.3
autosomal dominant non-syndromic intellectual disability;614254;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;GRIN1, NMDAR1, MRD8;138249;9q34.3
autosomal dominant non-syndromic intellectual disability;614255;non-syndromic intellectual disability;muscular hypotonia of the trunk;Muscular hypotonia;KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9;601255;2q37.3
autosomal dominant non-syndromic intellectual disability;614256;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;CACNG2, MRD10;602911;22q12.3
autosomal dominant non-syndromic intellectual disability;614257;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;EPB41L1, MRD11;602879;20q11.23
autosomal dominant non-syndromic intellectual disability;614562;non-syndromic intellectual disability;short stature;Growth delay;ARID1B, BAF250B, KIAA1235, MRD12;614556;6q25.3
autosomal dominant non-syndromic intellectual disability;614563;non-syndromic intellectual disability;small hand;Aplasia/hypoplasia involving bones of the hand;DYNC1H1, DNCL, DNECL, CMT20, MRD13, SMALED1;600112;14q32.31
autosomal dominant non-syndromic intellectual disability;614607;non-syndromic intellectual disability;absent fifth toenail;Absent toenail;ARID1A, C1orf4, B120, SMARCF1, MRD14;603024;1p36.11
autosomal dominant non-syndromic intellectual disability;614608;non-syndromic intellectual disability;feeding difficulties;Abdominal symptom;SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1;601607;22q11.23
autosomal dominant non-syndromic intellectual disability;614609;non-syndromic intellectual disability;sparse scalp hair;Abnormality of the scalp hair;SMARCA4, BRG1, RTPS2, MRD16;603254;19p13.2
autosomal dominant non-syndromic intellectual disability;615075;non-syndromic intellectual disability;hypoplasia of the corpus callosum;Aplasia/Hypoplasia of the corpus callosum;CTNNB1, MRD19;116806;3p22.1
autosomal dominant non-syndromic intellectual disability;615502;non-syndromic intellectual disability;feeding difficulties;Abdominal symptom;CTCF, MRD21;604167;16q22.1
autosomal dominant non-syndromic intellectual disability;615761;non-syndromic intellectual disability;depressed nasal bridge;Abnormality of the nasal bridge;SETD5, KIAA1757;615743;3p25.3
autosomal dominant non-syndromic intellectual disability;615828;non-syndromic intellectual disability;horizontal eyebrow;Abnormality of the eyebrow;DEAF1, SPN, ZMYND5, MRD24;602635;11p15.5
autosomal dominant non-syndromic intellectual disability;615873;non-syndromic intellectual disability;small hand;Aplasia/hypoplasia involving bones of the hand;ADNP, ADNP1, KIAA0784, MRD28;611386;20q13.13
autosomal dominant nonsyndromic deafness;124900;nonsyndromic deafness;childhood onset;Onset;DIAPH1, DFNA1, LFHL1;602121;5q31.3
autosomal dominant nonsyndromic deafness;600101;nonsyndromic deafness;progressive disorder;Pace of progression;KCNQ4, DFNA2A;603537;1p34.2
autosomal dominant nonsyndromic deafness;600652;nonsyndromic deafness;progressive sensorineural hearing impairment;Progressive hearing impairment;MYH14, KIAA2034, DFNA4A, PNMHH;608568;19q13.33
autosomal dominant nonsyndromic deafness;600994;nonsyndromic deafness;progressive sensorineural hearing impairment;Progressive hearing impairment;DFNA5;608798;7p15.3
autosomal dominant nonsyndromic deafness;601316;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;EYA4, DFNA10, CMD1J;603550;6q23.2
autosomal dominant nonsyndromic deafness;601317;nonsyndromic deafness;bilateral sensorineural hearing impairment;Sensorineural hearing impairment;MYO7A, USH1B, DFNB2, DFNA11;276903;11q13.5
autosomal dominant nonsyndromic deafness;601369;nonsyndromic deafness;young adult onset;Adult onset;COCH, DFNA9;603196;14q12
autosomal dominant nonsyndromic deafness;601543;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;TECTA, DFNA8, DFNA12, DFNB21;602574;11q23.3
autosomal dominant nonsyndromic deafness;601544;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID;121011;13q12.11
autosomal dominant nonsyndromic deafness;601868;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;COL11A2, STL3, DFNA13, DFNB53, FBCG2;120290;6p21.32
autosomal dominant nonsyndromic deafness;602459;nonsyndromic deafness;hearing impairment;Hearing abnormality;POU4F3, BRN3C;602460;5q32
autosomal dominant nonsyndromic deafness;603622;nonsyndromic deafness;high-frequency hearing impairment;Hearing impairment;MYH9, MHA, FTNS, DFNA17, BDPLT6;160775;22q12.3
autosomal dominant nonsyndromic deafness;604717;nonsyndromic deafness;young adult onset;Adult onset;ACTG1, DFNA20, DFNA26, BRWS2;102560;17q25.3
autosomal dominant nonsyndromic deafness;605192;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;SIX1, BOS3, DFNA23;601205;14q23.1
autosomal dominant nonsyndromic deafness;605583;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;SLC17A8, VGLUT3, DFNA25;607557;12q23.1
autosomal dominant nonsyndromic deafness;605594;nonsyndromic deafness;bilateral sensorineural hearing impairment;Sensorineural hearing impairment;DSPP, DPP, DGI1, DFNA39, DTDP2;125485;4q22.1
autosomal dominant nonsyndromic deafness;606346;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;MYO6, DFNA22, DFNB37;600970;6q14.1
autosomal dominant nonsyndromic deafness;606705;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;TMC1, DFNB7, DFNB11, DFNA36;606706;9q21.13
autosomal dominant nonsyndromic deafness;607453;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;CCDC50, C3orf6, DFNA44;611051;3q28
autosomal dominant nonsyndromic deafness;607841;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;MYO1A, DFNA48;601478;12q13.3
autosomal dominant nonsyndromic deafness;608641;nonsyndromic deafness;progressive disorder;Pace of progression;GRHL2, TFCP2L3, DFNA28, ECTDS;608576;8q22.3
autosomal dominant nonsyndromic deafness;612643;nonsyndromic deafness;adult onset sensorineural hearing impairment;Sensorineural hearing impairment;GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2;604418;13q12.11
autosomal dominant nonsyndromic deafness;612644;nonsyndromic deafness;high-frequency hearing impairment;Hearing impairment;GJB3, CX31, DFNA2B;603324;1p34.3
autosomal dominant nonsyndromic deafness;613074;nonsyndromic deafness;progressive hearing impairment;Hearing impairment;MIR96, MIRN96, DFNA50;611606;7q32.2
autosomal dominant polycystic kidney;173900;;cerebral aneurysm;Abnormality of cerebral artery;PKD1;601313;16p13.3
autosomal dominant type IV Ehlers-Danlos syndrome;130050;Ehlers-Danlos syndrome;aplasia/hypoplasia of the eyebrow;Abnormality of the eyebrow;COL3A1;120180;2q32.2
autosomal recessive non-syndromic intellectual disability;249500;non-syndromic intellectual disability;hyperactive deep tendon reflexes;Hyperreflexia;PRSS12, BSSP3, MRT1;606709;4q26
autosomal recessive non-syndromic intellectual disability;607417;non-syndromic intellectual disability;global developmental delay;Neurodevelopmental delay;CRBN, MRT2;609262;3p26.2
autosomal recessive non-syndromic intellectual disability;608443;non-syndromic intellectual disability;intellectual disability, severe;Intellectual disability;CC2D1A, MRT3;610055;19p13.12
autosomal recessive non-syndromic intellectual disability;611090;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;ST3GAL3, SIAT6, ST3GALII, MRT12, EIEE15;606494;1p34.1
autosomal recessive non-syndromic intellectual disability;611091;non-syndromic intellectual disability;muscular hypotonia of the trunk;Muscular hypotonia;NSUN2, TRM4, SAKI, MISU, MRT5;610916;5p15.31
autosomal recessive non-syndromic intellectual disability;611092;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;GRIK2, GLUR6, MRT6;138244;6q16.3
autosomal recessive non-syndromic intellectual disability;611093;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;TUSC3, M33, D8S1992, MRT7, MRT22;601385;8p22
autosomal recessive non-syndromic intellectual disability;614020;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;TECR, GPSN2, TER, SC2, MRT14;610057;19p13.12
autosomal recessive non-syndromic intellectual disability;614249;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;MED23, MRT18;605042;6q23.2
autosomal recessive non-syndromic intellectual disability;614286;non-syndromic intellectual disability;myelodysplasia;Hematological neoplasm;ASXL1, KIAA0978, BOPS, MDS;612990;20q11.21
autosomal recessive non-syndromic intellectual disability;614286;non-syndromic intellectual disability;myelodysplasia;Hematological neoplasm;GATA2, DCML, MONOMAC, IMD21;137295;3q21.3
autosomal recessive non-syndromic intellectual disability;614286;non-syndromic intellectual disability;myelodysplasia;Hematological neoplasm;SF3B1, SF3B155, SAP155, MDS;605590;2q33.1
autosomal recessive non-syndromic intellectual disability;614286;non-syndromic intellectual disability;myelodysplasia;Hematological neoplasm;TET2, KIAA1546, MDS;612839;4q24
autosomal recessive non-syndromic intellectual disability;614340;non-syndromic intellectual disability;midface retrusion;Abnormality of the midface;LINS1, WINS1, FLJ10583, MRT27;610350;15q26.3
autosomal recessive non-syndromic intellectual disability;614499;non-syndromic intellectual disability;intellectual disability;Neurodevelopmental abnormality;CRADD, RAIDD, MRT34;603454;12q22
autosomal recessive non-syndromic intellectual disability;614562;non-syndromic intellectual disability;short stature;Growth delay;ARID1B, BAF250B, KIAA1235, MRD12;614556;6q25.3
autosomal recessive non-syndromic intellectual disability;615493;non-syndromic intellectual disability;sleep disturbance;Abnormality of nervous system physiology;ANK3, MRT37;600465;10q21.2
autosomal recessive non-syndromic intellectual disability;615516;non-syndromic intellectual disability;infantile onset;Onset;HERC2, SHEP1, MRT38;605837;15q13.1
autosomal recessive non-syndromic intellectual disability;615541;non-syndromic intellectual disability;anteverted ears;Abnormal location of ears;TTI2, C8orf41, MRT39;614426;8p12
autosomal recessive non-syndromic intellectual disability;615599;non-syndromic intellectual disability;delayed myelination;Abnormal myelination;TAF2, TAF2B, TAFII150, CIF150, MRT40;604912;8q24.12
autosomal recessive non-syndromic intellectual disability;615637;non-syndromic intellectual disability;clinodactyly of the 5th finger;Finger clinodactyly;KPTN, 2E4, MRT41;615620;19q13.32
autosomal recessive non-syndromic intellectual disability;615802;non-syndromic intellectual disability;cerebral atrophy;Atrophy/Degeneration affecting the cerebrum;PGAP1, MRT42;611655;2q33.1
autosomal recessive non-syndromic intellectual disability;615817;non-syndromic intellectual disability;short stature;Growth delay;KIAA1033, SWIP, MRT43;615748;12q23.3
autosomal recessive non-syndromic intellectual disability;615942;non-syndromic intellectual disability;flat occiput;Abnormal shape of the occiput;METTL23, C17orf95, MRT44;615262;17q25.1
autosomal recessive nonsyndromic deafness;220290;nonsyndromic deafness;digenic inheritance;Multifactorial inheritance;GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID;121011;13q12.11
autosomal recessive nonsyndromic deafness;220290;nonsyndromic deafness;digenic inheritance;Multifactorial inheritance;GJB3, CX31, DFNA2B;603324;1p34.3
autosomal recessive nonsyndromic deafness;220290;nonsyndromic deafness;digenic inheritance;Multifactorial inheritance;GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2;604418;13q12.11
autosomal recessive nonsyndromic deafness;600060;nonsyndromic deafness;congenital onset;Onset;MYO7A, USH1B, DFNB2, DFNA11;276903;11q13.5
autosomal recessive nonsyndromic deafness;600316;nonsyndromic deafness;profound sensorineural hearing impairment;Profound hearing impairment;MYO15A, DFNB3;602666;17p11.2
autosomal recessive nonsyndromic deafness;600971;nonsyndromic deafness;hearing impairment;Hearing abnormality;TMIE, DFNB6;607237;3p21.31
autosomal recessive nonsyndromic deafness;600974;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;TMC1, DFNB7, DFNB11, DFNA36;606706;9q21.13
autosomal recessive nonsyndromic deafness;601071;nonsyndromic deafness;absence of acoustic reflex;Abnormality of the acoustic reflex;OTOF, DFNB9, NSRD9, AUNB1;603681;2p23.3
autosomal recessive nonsyndromic deafness;601072;nonsyndromic deafness;childhood onset;Onset;TMPRSS3, ECHOS1, DFNB8, DFNB10;605511;21q22.3
autosomal recessive nonsyndromic deafness;601386;nonsyndromic deafness;abnormality of the eye;Phenotypic abnormality;ATP2B2, PMCA2;108733;3p25.3
autosomal recessive nonsyndromic deafness;601386;nonsyndromic deafness;abnormality of the eye;Phenotypic abnormality;CDH23, USH1D;605516;10q22.1
autosomal recessive nonsyndromic deafness;602092;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;USH1C, DFNB18A;605242;11p15.1
autosomal recessive nonsyndromic deafness;603629;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;TECTA, DFNA8, DFNA12, DFNB21;602574;11q23.3
autosomal recessive nonsyndromic deafness;603720;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;STRC, DFNB16;606440;15q15.3
autosomal recessive nonsyndromic deafness;607039;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;OTOA, DFNB22;607038;16p12.2
autosomal recessive nonsyndromic deafness;607084;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;WHRN, CIP98, KIAA1526, DFNB31, USH2D;607928;9q32
autosomal recessive nonsyndromic deafness;607101;nonsyndromic deafness;progressive hearing impairment;Hearing impairment;MYO3A, DFNB30;606808;10p12.1
autosomal recessive nonsyndromic deafness;607821;nonsyndromic deafness;vestibular dysfunction;Functional abnormality of the inner ear;MYO6, DFNA22, DFNB37;600970;6q14.1
autosomal recessive nonsyndromic deafness;608265;nonsyndromic deafness;prelingual sensorineural hearing impairment;Childhood onset sensorineural hearing impairment;HGF, DFNB39;142409;7q21.11
autosomal recessive nonsyndromic deafness;608565;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;ESRRB, ESRL2, DFNB35;602167;14q24.3
autosomal recessive nonsyndromic deafness;609006;nonsyndromic deafness;vestibular areflexia;Abnormal vestibulo-ocular reflex;ESPN;606351;1p36.31
autosomal recessive nonsyndromic deafness;609533;nonsyndromic deafness;infantile onset;Onset;PCDH15, DFNB23, USH1F;605514;10q21.1
autosomal recessive nonsyndromic deafness;609706;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;COL11A2, STL3, DFNA13, DFNB53, FBCG2;120290;6p21.32
autosomal recessive nonsyndromic deafness;609823;nonsyndromic deafness;severe sensorineural hearing impairment;Severe hearing impairment;TRIOBP, KIAA1662;609761;22q13.1
autosomal recessive nonsyndromic deafness;610153;nonsyndromic deafness;prelingual sensorineural hearing impairment;Childhood onset sensorineural hearing impairment;MARVELD2, MARVD2, TRIC, DFNB49;610572;5q13.2
autosomal recessive nonsyndromic deafness;610220;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;PJVK, DFNB59;610219;2q31.2
autosomal recessive nonsyndromic deafness;610265;nonsyndromic deafness;sensorineural hearing impairment;Functional abnormality of the inner ear;LHFPL5, TMHS, DFNB67;609427;6p21.31
autosomal recessive nonsyndromic deafness;611022;nonsyndromic deafness;profound sensorineural hearing impairment;Profound hearing impairment;RDX, DFNB24;179410;11q22.3
autosomal recessive nonsyndromic deafness;611451;nonsyndromic deafness;hearing impairment;Hearing abnormality;LRTOMT, LRTOMT1, LRTOMT2, DFNB63;612414;11q13.4
autosomal recessive nonsyndromic deafness;612645;nonsyndromic deafness;vestibular dysfunction;Functional abnormality of the inner ear;GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2;604418;13q12.11
autosomal recessive nonsyndromic deafness;613079;nonsyndromic deafness;hearing impairment;Hearing abnormality;LOXHD1, DFNB77;613072;18q21.1
autosomal recessive nonsyndromic deafness;613285;nonsyndromic deafness;hearing impairment;Hearing abnormality;GRXCR1;613283;4p13
autosomal recessive nonsyndromic deafness;613307;nonsyndromic deafness;delayed speech and language development;Neurodevelopmental delay;TPRN, C9orf75, DFNB79;613354;9q34.3
autosomal recessive nonsyndromic deafness;613391;nonsyndromic deafness;infantile onset;Onset;PTPRQ, PTPGMC1, DFNB84A;603317;12q21.31
autosomal recessive nonsyndromic deafness;613453;nonsyndromic deafness;progressive hearing impairment;Hearing impairment;SERPINB6, PI6, PTI, SPI3, DFNB91;173321;6p25.2
autosomal recessive polycystic kidney;263200;;hypoplasia of the ear cartilage;Abnormality of the pinna;FCYT, PKHD1, ARPKD;606702;6p12.3-p12.2
azoospermia;102530;male infertility;globozoospermia;Sperm head anomaly;GOPC, PIST, FIG, CAL;606845;6q22.1
azoospermia;102530;male infertility;globozoospermia;Sperm head anomaly;SPATA16, SPGF6;609856;3q26.31
azoospermia;243060;male infertility;male infertility;Infertility;STK13, AIE2, SPGF5;603495;19q13.43
azoospermia;270960;male infertility;recurrent spontaneous abortion;Spontaneous abortion;SYCP3, SCP3, COR1, SPGF4;604759;12q23.2
azoospermia;415000;male infertility;y-linked inheritance;Gonosomal inheritance;USP9Y, DFFRY, SPGFY2;400005;Yq11.21
azoospermia;606766;male infertility;autosomal dominant inheritance;Mode of inheritance;SLC26A8, TAT1, SPGF3;608480;6p21.31
azoospermia;612997;male infertility;reduced sperm motility;Abnormal sperm motility;CATSPER1, CATSPER, SPGF7;606389;11q13.1
azoospermia;613957;male infertility;azoospermia;Abnormal spermatogenesis;NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8;184757;9q33.3
azoospermia;613958;male infertility;globozoospermia;Sperm head anomaly;DPY19L2, SPGF9;613893;12q14.2
azoospermia;614822;male infertility;abnormal sperm morphology;Abnormal male germ cell morphology;SEPT12, SPGF10;611562;16p13.3
azoospermia;615081;male infertility;abnormal sperm morphology;Abnormal male germ cell morphology;KLHL10, SPGF11;608778;17q21.2
azoospermia;615413;male infertility;infertility;Decreased fertility;NANOS1, NOS1, SPGF12;608226;10q26.11
azoospermia;615841;male infertility;azoospermia;Abnormal spermatogenesis;TAF4B, TAF2C2, TAFII105, SPGF13;601689;18q11.2
azoospermia;615842;male infertility;azoospermia;Abnormal spermatogenesis;ZMYND15, SPGF14;614312;17p13.2
basal cell carcinoma;605462;skin carcinoma;basal cell carcinoma;Neoplasm of the skin;PTCH1, NBCCS, BCNS, HPE7;601309;9q22.32
basal cell carcinoma;605462;skin carcinoma;basal cell carcinoma;Neoplasm of the skin;PTCH2;603673;1p34.1
basal cell carcinoma;605462;skin carcinoma;basal cell carcinoma;Neoplasm of the skin;RASA1, GAP, CMAVM, PKWS;139150;5q14.3
basal ganglia calcification;213600;basal ganglia disease;abnormal pyramidal signs;Upper motor neuron dysfunction;SLC20A2, MLVAR, GLVR2, IBGC1;158378;8p11.21
basal ganglia calcification;615007;basal ganglia disease;basal ganglia calcification;Cerebral calcification;PDGFRB, PDGFR, IBGC4, IMF1;173410;5q32
basal ganglia calcification;615483;basal ganglia disease;dyskinesia;Abnormality of movement;PDGFB, SIS, IBGC5;190040;22q13.1
benign familial infantile epilepsy;605751;infancy electroclinical syndrome;focal seizures;Seizures;PRRT2, PKC, DYT10, EKD1, BFIS2, BFIC2, ICCA;614386;16p11.2
benign familial infantile epilepsy;607745;infancy electroclinical syndrome;dialeptic seizures;Seizures;SCN2A, SCN2A1, BFIC3, EIEE11, BFIS3, BFNIS;182390;2q24.3
benign neonatal seizures;121200;neonatal period electroclinical syndrome;phenotypic variability;Clinical modifier;KCNQ2, EBN1, EIEE7, BFNS1;602235;20q13.33
benign neonatal seizures;121201;neonatal period electroclinical syndrome;focal clonic seizures;Focal motor seizures;KCNQ3, EBN2, BFNC2;602232;8q24.22
benign neonatal seizures;615812;neonatal period electroclinical syndrome;abdominal obesity;Obesity;DYRK1B, MIRK, AOMS3;604556;19q13.2
bestrophinopathy;611809;macular degeneration;retinal flecks;Abnormality of the retina;BEST1, VMD2, ARB, RP50;607854;11q12.3
beta thalassemia;603902;thalassemia;abnormality of the heme biosynthetic pathway;Abnormality of metabolism/homeostasis;HBB;141900;11p15.4
beta thalassemia;613985;thalassemia;skin ulcer;Localized skin lesion;HBB;141900;11p15.4
beta thalassemia;613985;thalassemia;skin ulcer;Localized skin lesion;LCRB;152424;11p15.5
beta-ketothiolase deficiency;203750;autosomal recessive disease;episodic ketoacidosis;Ketoacidosis;ACAT1;607809;11q22.3
beta-mannosidosis;248510;lysosomal storage disease;cognitive impairment;Abnormality of higher mental function;MANBA, MANB1;609489;4q24
biotin-responsive basal ganglia disease;607483;basal ganglia disease;abnormal pyramidal signs;Upper motor neuron dysfunction;SLC19A3, THMD2, BBGD;606152;2q36.3
biotinidase deficiency;253260;multiple carboxylase deficiency;skin ulcer;Localized skin lesion;BTD;609019;3p25.1
blepharophimosis, ptosis, and epicanthus inversus syndrome;110100;autosomal dominant disease;female infertility;Decreased fertility in females;FOXL2, BPES, BPES1, PFRK, POF3;605597;3q22.3
blepharophimosis-intellectual disability syndrome;603736;Ohdo syndrome;neoplasm of the oral cavity;Neoplasm by anatomical site;KAT6B, MYST4, MORF, GTPTS;605880;10q22.2
blepharospasm;606798;focal dystonia;sporadic;Mode of inheritance;DRD5, DRD1B, DRD1L2;126453;4p16.1
bloom syndrome;210900;autosomal recessive disease;teleangiectasia of the skin;Telangiectasia;RECQL3, RECQ2, BLM, BS;604610;15q26.1
blue color blindness;190900;color blindness;abnormal cone-mediated electroretinogram;Abnormal electroretinogram;OPN1SW, BCP, CBT;613522;7q32.1
blue cone monochromacy;303700;achromatopsia;abnormality of macular pigmentation;Abnormality of the macula;OPN1LW, RCP, CBP, CBBM;300822;Xq28
blue cone monochromacy;303700;achromatopsia;abnormality of macular pigmentation;Abnormality of the macula;OPN1MW, GCP, CBD, CBBM;300821;Xq28
brachydactyly-syndactyly syndrome;610713;autosomal genetic disease;symphalangism affecting the phalanges of the hand;Abnormality of phalanx of finger;HOXD13, HOX4I, SPD, BDSD;142989;2q31.1
brachydactyly;112500;dysostosis;short proximal phalanx of hallux;Short phalanx of hallux;IHH, BDA1;600726;2q35
brachydactyly;112600;dysostosis;aplasia/hypoplasia of the middle phalanges of the toes;Abnormality of the middle phalanges of the toes;BMP2, BMP2A, BDA2;112261;20p12.3
brachydactyly;112600;dysostosis;aplasia/hypoplasia of the middle phalanges of the toes;Abnormality of the middle phalanges of the toes;BMPR1B, ALK6;603248;4q22.3
brachydactyly;112600;dysostosis;aplasia/hypoplasia of the middle phalanges of the toes;Abnormality of the middle phalanges of the toes;GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;20q11.22
brachydactyly;113000;dysostosis;camptodactyly;Flexion contracture of digit;ROR2, BDB1, BDB, NTRKR2;602337;9q22.31
brachydactyly;113100;dysostosis;hypersegmentation of proximal phalanx of third finger;Abnormality of the proximal phalanx of the 3rd finger;GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;20q11.22
brachydactyly;113200;dysostosis;broad distal phalanx of the hallux;Broad distal phalanx of the toes;HOXD13, HOX4I, SPD, BDSD;142989;2q31.1
brachydactyly;113300;dysostosis;short metatarsal;Abnormal morphology of bones of the lower limbs;HOXD13, HOX4I, SPD, BDSD;142989;2q31.1
brachydactyly;611377;dysostosis;cutaneous syndactyly of toes;Cutaneous syndactyly;NOG, SYM1, SYNS1;602991;17q22
brachydactyly;613382;dysostosis;short metatarsal;Abnormal morphology of bones of the lower limbs;PTHLH, BDE2;168470;12p11.22
brachydactyly;615072;dysostosis;brachydactyly syndrome;Short digit;GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;20q11.22
brachyolmia;113500;osteochondrodysplasia;short femoral neck;Aplasia/Hypoplasia involving the femoral head and neck;TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL;605427;12q24.11
bradyopsia;608415;;photophobia;Behavioral abnormality;RGS9, PERRS;604067;17q24.1
bradyopsia;608415;;photophobia;Behavioral abnormality;RGS9BP, R9AP, RGS9, PERRS;607814;19q13.11
branchiooculofacial syndrome;113620;autosomal dominant disease;non-midline cleft lip;Cleft upper lip;TFAP2A, AP2TF, BOFS;107580;6p24.3
branchiootic syndrome;602588;syndrome;branchial fistula;Branchial anomaly;EYA1, BOR, BOS1, OFC1;601653;8q13.3
branchiootic syndrome;608389;syndrome;preauricular pit;Periauricular skin pits;SIX1, BOS3, DFNA23;601205;14q23.1
branchiootorenal syndrome;113650;autosomal dominant disease;gustatory lacrimation;Abnormality of the cranial nerves;EYA1, BOR, BOS1, OFC1;601653;8q13.3
branchiootorenal syndrome;610896;autosomal dominant disease;hemifacial hypoplasia;Facial asymmetry;SIX5, DMAHP, BOR2;600963;19q13.32
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;AKT1, CWS6;164730;14q32.33
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;ATM, ATA, AT1;607585;11q22.3
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;BARD1;601593;2q35
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;BRIP1, BACH1, FANCJ;605882;17q23.2
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;CASP8, MCH5, ALPS2B;601763;2q33.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;CDH1, UVO, LCAM, ECAD;192090;16q22.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;CHEK2, RAD53, CHK2, CDS1, LFS2;604373;22q12.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;ESR1, ESR, ESTRR;133430;6q25.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;HMMR;600936;5q34
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;KRAS, KRAS2, RASK2, NS, CFC2;190070;12p12.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;NQO2, NMOR2;160998;6p25.2
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;PALB2, FANCN, PNCA3;610355;16p12.2
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;PHB;176705;17q21.33
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;PPM1D, WIP1;605100;17q23.2
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;RAD51A, RECA, MRMV2;179617;15q15.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;RAD54L, HR54, HRAD54;603615;1p34.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;RB1CC1, CC1, KIAA0203;606837;8q11.23
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;SLC22A1L, BWSCR1A, IMPT1;602631;11p15.4
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;TP53, P53, LFS1 , BCC7;191170;17p13.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;TSG101;601387;11p15.1
breast cancer;114480;thoracic cancer;breast carcinoma;Neoplasm of the breast;XRCC3, CMM6;600675;14q32.33
bronchiectasis;211400;bronchial disease;elevated sweat chloride;Abnormal sweat homeostasis;CFTR, ABCC7, CF, MRP7;602421;7q31.2
bronchiectasis;211400;bronchial disease;elevated sweat chloride;Abnormal sweat homeostasis;SCNN1B, BESC1;600760;16p12.2
bronchiectasis;613021;bronchial disease;elevated sweat chloride;Abnormal sweat homeostasis;SCNN1A, BESC2;600228;12p13.31
bronchiectasis;613071;bronchial disease;chronic bronchitis;Bronchitis;SCNN1G, PHA1, BESC3;600761;16p12.2
bulimia nervosa;607499;eating disorder;bulimia;Abnormal eating behavior;BDNF, BULN2, ANON2;113505;11p14.1
buphthalmos;231300;hydrophthalmos;late onset congenital glaucoma;Congenital glaucoma;CYP1B1, GLC3A;601771;2p22.2
campomelic dysplasia;114290;osteochondrodysplasia;short palpebral fissure;Abnormal size of the palpebral fissures;SOX9, CMD1, SRA1;608160;17q24.3
carbamoyl phosphate synthetase I deficiency disease;237300;amino acid metabolic disorder;hypoargininemia;Abnormality of arginine metabolism;CPS1, PHN;608307;2q34
cardiofaciocutaneous syndrome;115150;syndrome;tongue thrusting;Stereotypic behavior;BRAF, NS7;164757;7q34
cardiofaciocutaneous syndrome;615278;syndrome;sparse hair;Abnormality of hair density;KRAS, KRAS2, RASK2, NS, CFC2;190070;12p12.1
carnitine palmitoyltransferase II deficiency;255110;lipid metabolism disorder;muscle stiffness;Abnormality of muscle physiology;CPT2, IIAE4;600650;1p32.3
carnitine palmitoyltransferase II deficiency;600649;lipid metabolism disorder;arrhythmia;Abnormality of cardiovascular system physiology;CPT2, IIAE4;600650;1p32.3
carnitine palmitoyltransferase II deficiency;608836;lipid metabolism disorder;elevated serum long-chain fatty acids;Elevated long chain fatty acids;CPT2, IIAE4;600650;1p32.3
carpal tunnel syndrome;115430;nerve compression syndrome;digital flexor tenosynovitis;Abnormal tendon morphology;TTR, PALB;176300;18q12.1
cartilage-hair hypoplasia;250250;autosomal recessive disease;large face;Abnormal facial shape;RMRP, RMRPR, CHH;157660;9p13.3
cataract;115700;lens disease;congenital cataract;Cataract;CRYGD, CRYG4, CTRCT4, CACA, CCA3, PCC;123690;2q33.3
cataract;115900;lens disease;myopia;Abnormality of refraction;CRYBA2, CTRCT42;600836;2q35
cataract;116100;lens disease;membranous cataract;Cataract;CRYGS, CRYG8, CTRCT20;123730;3q27.3
cataract;116200;lens disease;nuclear cataract;Zonular cataract;GJA8, CX50, CTRCT1, CZP1, CAE1;600897;1q21.2
cataract;116300;lens disease;diffuse nuclear cataract;Nuclear cataract;VIM, CTRCT30;193060;10p13
cataract;116400;lens disease;nuclear cataract;Zonular cataract;WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41;606201;4p16.1
cataract;116800;lens disease;nuclear cataract;Zonular cataract;HSF4, CTM, CTRCT5;602438;16q22.1
cataract;302200;lens disease;sutural cataract;Zonular cataract;NHS, CXN, CTRCT40;300457;Xp22.13
cataract;600881;lens disease;posterior y-sutural cataract;Sutural cataract;CRYBA1, CRYB1, CTRCT10;123610;17q11.2
cataract;601547;lens disease;sutural cataract;Zonular cataract;CRYBB2, CRYB2, CTRCT3, CCA2;123620;22q11.23
cataract;601885;lens disease;zonular cataract;Cataract;GJA3, CX46, CZP3, CAE3, CTRCT14;121015;13q12.11
cataract;604219;lens disease;progressive cataract;Cataract;CRYAA, CRYA1, CTRCT9;123580;21q22.3
cataract;604307;lens disease;congenital nuclear cataract;Nuclear cataract;CRYGC, CRYG3, CTRCT2, CCL;123680;2q33.3
cataract;609741;lens disease;nuclear cataract;Zonular cataract;CRYBB3, CRYB3, CATCN2, CTRCT22;123630;22q11.23
cataract;610019;lens disease;cataract;Abnormality of the lens;FYCO1, CATC2, CTRCT18;607182;3p21.31
cataract;610202;lens disease;cerulean cataract;Punctate cataract;MAF, CCA4, CTRCT21;177075;16q23.2
cataract;610425;lens disease;lamellar cataract;Zonular cataract;CRYBA4, CTRCT23;123631;22q12.1
cataract;611391;lens disease;cortical cataract;Zonular cataract;BFSP1, CP115, CTRCT33;603307;20p12.1
cataract;611544;lens disease;nuclear cataract;Zonular cataract;CRYBB1, CATCN3, CTRCT17;600929;22q12.1
cataract;611597;lens disease;progressive cataract;Cataract;BFSP2, CP49, CP47, CTRCT12;603212;3q22.1
cataract;613887;lens disease;cataract;Abnormality of the lens;TDRD7, KIAA1529, TRAP, CATC4, CTRCT36;611258;9q22.33
cataract;615188;lens disease;congenital cataract;Cataract;CRYGB, CRYG2, CTRCT39;123670;2q34
celiac disease;212750;autoimmune disease of gastrointestinal tract;type i diabetes mellitus;Diabetes mellitus;HLA-DQA1, CELIAC1;146880;6p21.32
celiac disease;212750;autoimmune disease of gastrointestinal tract;type i diabetes mellitus;Diabetes mellitus;HLA-DQB1, CELIAC1;604305;6p21.32
central core myopathy;117000;congenital structural myopathy;phenotypic variability;Clinical modifier;RYR1, MHS, CCO;180901;19q13.2
centronuclear myopathy;160150;myopathy;facial palsy;Abnormality of the seventh cranial nerve;DNM2, CMTDIB, CMTDI1, CMT2M, LCCS5;602378;19p13.2
centronuclear myopathy;160150;myopathy;facial palsy;Abnormality of the seventh cranial nerve;MTMR14, C3orf29, HJUMPY;611089;3p25.3
centronuclear myopathy;255200;myopathy;facial palsy;Abnormality of the seventh cranial nerve;BIN1, AMPHL;601248;2q14.3
centronuclear myopathy;310400;myopathy;arrhythmia;Abnormality of cardiovascular system physiology;MTM1, MTMX;300415;Xq28
centronuclear myopathy;614408;myopathy;ring fibers;Abnormality of muscle fibers;MYF6, CNM3;159991;12q21.31
centronuclear myopathy;614807;myopathy;cognitive impairment;Abnormality of higher mental function;CCDC78, C16orf25, CNM4;614666;16p13.3
centronuclear myopathy;615959;myopathy;facial palsy;Abnormality of the seventh cranial nerve;SPEG, APEG1, CNM5;615950;2q35
cerebral amyloid angiopathy;105150;amyloidosis;generalized amyloid deposition;Amyloidosis;CST3, ARMD11;604312;20p11.21
cerebral amyloid angiopathy;117300;amyloidosis;cerebral amyloid angiopathy;Amyloidosis;ITM2B, BRI, ABRI, FBD, RDGCA;603904;13q14.2
cerebral amyloid angiopathy;176500;amyloidosis;cerebral amyloid angiopathy;Amyloidosis;ITM2B, BRI, ABRI, FBD, RDGCA;603904;13q14.2
cerebral amyloid angiopathy;605714;amyloidosis;cerebral amyloid angiopathy;Amyloidosis;APP, AAA, CVAP, AD1;104760;21q21.3
cerebrotendinous xanthomatosis;213700;xanthomatosis;cognitive impairment;Abnormality of higher mental function;CYP27A1, CYP27, CTX;606530;2q35
cerebrovascular disease;601367;artery disease;stroke;Abnormality of the cerebral vasculature;ALOX5AP, FLAP;603700;13q12.3
cerebrovascular disease;601367;artery disease;stroke;Abnormality of the cerebral vasculature;F2, THPH1, RPRGL2;176930;11p11.2
cerebrovascular disease;601367;artery disease;stroke;Abnormality of the cerebral vasculature;F5, THPH2, RPRGL1;612309;1q24.2
cerebrovascular disease;601367;artery disease;stroke;Abnormality of the cerebral vasculature;NOS3;163729;7q36.1
cerebrovascular disease;601367;artery disease;stroke;Abnormality of the cerebral vasculature;PRKCH, PKCL, PRKCL;605437;14q23.1
cervix carcinoma;603956;cervical cancer;abnormality of the cervical spine;Abnormality of the vertebral column;FGFR3, ACH;134934;4p16.3
cherubism;118400;autosomal dominant disease;marcus gunn pupil;Abnormality of the optic nerve;SH3BP2, CRPM;602104;4p16.3
cholecystitis;600803;cholangitis;cholangitis;Abnormal biliary tract morphology;ABCB4, PGY3, MDR3, ICP3;171060;7q21.12
chondrocalcinosis;118600;arthritis;polyarticular chondrocalcinosis;Chondrocalcinosis;ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD;605145;5p15.2
chondrosarcoma;215300;connective tissue cancer;chondrosarcoma;Sarcoma;EXT1;608177;8q24.11
choreatic disease;118700;movement disease;phenotypic variability;Clinical modifier;NKX2-1, TITF1, NKX2A, TTF1;600635;14q13.3
choroid plexus papilloma;260500;papilloma;choroid plexus papilloma;Benign neoplasm of the central nervous system;TP53, P53, LFS1 , BCC7;191170;17p13.1
choroideremia;303100;retinal degeneration;choroidal degeneration;Abnormality of the choroid;CHM, TCD;300390;Xq21.2
chronic granulomatous disease;233690;phagocyte bactericidal dysfunction;discoid lupus erythematosus;Dermatological manifestations of systemic disorders;CYBA;608508;16q24.3
chronic granulomatous disease;233700;phagocyte bactericidal dysfunction;discoid lupus erythematosus;Dermatological manifestations of systemic disorders;NCF1;608512;7q11.23
chronic granulomatous disease;233710;phagocyte bactericidal dysfunction;discoid lupus erythematosus;Dermatological manifestations of systemic disorders;NCF2;608515;1q25.3
chronic granulomatous disease;306400;phagocyte bactericidal dysfunction;discoid lupus erythematosus;Dermatological manifestations of systemic disorders;CYBB, CGD, AMCBX2, IMD34;300481;Xp11.4
chronic granulomatous disease;613960;phagocyte bactericidal dysfunction;perioral eczema;Eczema;NCF4, P40PHOX;601488;22q12.3
chronic mucocutaneous candidiasis;212050;candidiasis;onychomycosis;Recurrent fungal infections;CARD9, CANDF2;607212;9q34.3
chronic mucocutaneous candidiasis;613108;candidiasis;recurrent vulvovaginal candidiasis;Chronic mucocutaneous candidiasis;CLEC7A, CLECSF12, DECTIN1, CANDF4;606264;12p13.2
chronic myeloid leukemia;608232;myeloid leukemia;chronic myelogenous leukemia;Chronic leukemia;BCR, CML, PHL, ALL;151410;22q11.23
citrullinemia;215700;urea cycle disorder;hypoargininemia;Abnormality of arginine metabolism;ASS1, ASS;603470;9q34.11
citrullinemia;603471;urea cycle disorder;elevated hepatic transaminases;Abnormality of the liver;SLC25A13, CTLN2;603859;7q21.3
citrullinemia;605814;urea cycle disorder;elevated plasma citrulline;Abnormality of citrulline metabolism;SLC25A13, CTLN2;603859;7q21.3
cleft palate;119540;orofacial cleft;non-midline cleft lip;Cleft upper lip;UBB;191339;17p11.2
cleidocranial dysplasia;119600;osteochondrodysplasia;short femoral neck;Aplasia/Hypoplasia involving the femoral head and neck;RUNX2, CBFA1, PEBP2A1, AML3, CCD, CLCD;600211;6p21.1
clubfoot;119800;bone development disease;incomplete penetrance;Phenotypic variability;PITX1, PTX1, BFT, POTX, CCF, LBNBG;602149;5q31.1
coenzyme Q10 deficiency disease;607426;mitochondrial metabolism disease;phenotypic variability;Clinical modifier;COQ2, COQ10D1, MSA1;609825;4q21.23
coenzyme Q10 deficiency disease;612016;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;ADCK3, COQ8, CABC1, SCAR9, ARCA2, COQ10D4;606980;1q42.13
coenzyme Q10 deficiency disease;614650;mitochondrial metabolism disease;rapidly progressive;Pace of progression;COQ6, CGI10, COQ10D6;614647;14q24.3
coenzyme Q10 deficiency disease;614651;mitochondrial metabolism disease;peripheral neuropathy;Abnormal peripheral nervous system morphology;PDSS1, TPT, COQ1, COQ10D2;607429;10p12.1
coenzyme Q10 deficiency disease;614652;mitochondrial metabolism disease;cortical visual impairment;Visual impairment;PDSS2, DLP1, C6orf210, COQ10D3;610564;6q21
coenzyme Q10 deficiency disease;614654;mitochondrial metabolism disease;feeding difficulties;Abdominal symptom;COQ9, C16orf49, COQ10D5;612837;16q21
cold-induced sweating syndrome;610313;autosomal dominant disease;clinodactyly;Abnormality of digit;CLCF1, BSF3, CLC, CISS2;607672;11q13.2
coloboma of optic nerve;120430;visual pathway disease;abnormal retinal pigmentation;Abnormality of the retinal pigment epithelium;PAX6, AN2, MGDA, FVH1;607108;11p13
coloboma;120200;eye disease;irido-fundal coloboma;Iris coloboma;PAX6, AN2, MGDA, FVH1;607108;11p13
coloboma;216820;eye disease;lens subluxation;Ectopia lentis;SALL2, HSAL2, COLB;602219;14q11.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;AKT1, CWS6;164730;14q32.33
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;APC, GS, FPC, BTPS2;611731;5q22.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;AURKA, STK15, AURORA2, BTAK, ARK1, STK6, AIK;603072;20q13.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;AXIN2, ODCRCS;604025;17q24.1
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;BAX;600040;19q13.33
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;BUB1B, BUBR1, MVA1;602860;15q15.1
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;CCND1, PRAD1, BCL1;168461;11q13.3
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;CTNNB1, MRD19;116806;3p22.1
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;DCC, MRMV1;120470;18q21.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;EP300, RSTS2;602700;22q13.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;FGFR3, ACH;134934;4p16.3
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;FLCN, BHD;607273;17p11.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;MCC;159350;5q22.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;MLH3, HNPCC7;604395;14q24.3
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;NRAS, ALPS4, NS6, CMNS, NCMS;164790;1p13.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;ODC1;165640;2p25.1
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PDGFRL, PDGRL, PRLTS;604584;8p22
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PLA2G2A, PLA2B, PLA2L, MOM1;172411;1p36.13
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PTPN12, PTPG1;600079;7q11.23
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PTPRJ, DEP1;600925;11p11.2
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;RAD54B;604289;8q22.1
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;TLR2, TIL4;603028;4q31.3
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;TLR4, ARMD10;603030;9q33.1
colon carcinoma;114500;colon cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;TP53, P53, LFS1 , BCC7;191170;17p13.1
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;AKT1, CWS6;164730;14q32.33
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;APC, GS, FPC, BTPS2;611731;5q22.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;AURKA, STK15, AURORA2, BTAK, ARK1, STK6, AIK;603072;20q13.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;AXIN2, ODCRCS;604025;17q24.1
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;BAX;600040;19q13.33
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;BUB1B, BUBR1, MVA1;602860;15q15.1
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;CCND1, PRAD1, BCL1;168461;11q13.3
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;CTNNB1, MRD19;116806;3p22.1
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;DCC, MRMV1;120470;18q21.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;EP300, RSTS2;602700;22q13.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;FGFR3, ACH;134934;4p16.3
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;FLCN, BHD;607273;17p11.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;MCC;159350;5q22.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;MLH3, HNPCC7;604395;14q24.3
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;NRAS, ALPS4, NS6, CMNS, NCMS;164790;1p13.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;ODC1;165640;2p25.1
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PDGFRL, PDGRL, PRLTS;604584;8p22
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PLA2G2A, PLA2B, PLA2L, MOM1;172411;1p36.13
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PTPN12, PTPG1;600079;7q11.23
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;PTPRJ, DEP1;600925;11p11.2
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;RAD54B;604289;8q22.1
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;TLR2, TIL4;603028;4q31.3
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;TLR4, ARMD10;603030;9q33.1
colorectal cancer;114500;large intestine cancer;neoplasm of the stomach;Neoplasm of the gastrointestinal tract;TP53, P53, LFS1 , BCC7;191170;17p13.1
colorectal cancer;612229;large intestine cancer;colon cancer;Neoplasm of the colon;SMAD7, MADH7, CRCS3;602932;18q21.1
colorectal cancer;612591;large intestine cancer;colorectal polyps;Neoplasm of the rectum;POLD1, CRCS10, MDPL;174761;19q13.33
colorectal cancer;615083;large intestine cancer;colorectal polyps;Neoplasm of the rectum;POLE1, CRCS12, FILS;174762;12q24.33
combined T cell and B cell immunodeficiency;312863;primary immunodeficiency disease;decreased number of cd8+ t cells;T lymphocytopenia;IL2RG, SCIDX1, SCIDX, IMD4;308380;Xq13.1
combined oxidative phosphorylation deficiency;300816;mitochondrial metabolism disease;central hypotonia;Abnormality of central motor function;AIFM1, PDCD8, AIF, COXPD6, COWCK, CMTX4;300169;Xq26.1
combined oxidative phosphorylation deficiency;609060;mitochondrial metabolism disease;delayed myelination;Abnormal myelination;GFM1, EFG1, GFM, COXPD1;606639;3q25.32
combined oxidative phosphorylation deficiency;610498;mitochondrial metabolism disease;feeding difficulties in infancy;Feeding difficulties;MRPS16, COXPD2;609204;10q22.2
combined oxidative phosphorylation deficiency;610505;mitochondrial metabolism disease;cognitive impairment;Abnormality of higher mental function;TSFM, COXPD3;604723;12q14.1
combined oxidative phosphorylation deficiency;610678;mitochondrial metabolism disease;lactic acidosis;Acidosis;TUFM, EFTU, COXPD4;602389;16p11.2
combined oxidative phosphorylation deficiency;611719;mitochondrial metabolism disease;delayed myelination;Abnormal myelination;MRPS22, C3orf5, COXPD5;605810;3q23
combined oxidative phosphorylation deficiency;613559;mitochondrial metabolism disease;progressive disorder;Pace of progression;C12orf65, COXPD7, SPG55;613541;12q24.31
combined oxidative phosphorylation deficiency;614096;mitochondrial metabolism disease;generalized muscle weakness;Muscle weakness;AARS2, KIAA1270, MTALARS, COXPD8, LKENP;612035;6p21.1
combined oxidative phosphorylation deficiency;614582;mitochondrial metabolism disease;feeding difficulties;Abdominal symptom;MRPL3, MRL3, COXPD9;607118;3q22.1
combined oxidative phosphorylation deficiency;614702;mitochondrial metabolism disease;cognitive impairment;Abnormality of higher mental function;MTO1, COXPD10;614667;6q13
combined oxidative phosphorylation deficiency;614922;mitochondrial metabolism disease;feeding difficulties;Abdominal symptom;RMND1, COXPD11;614917;6q25.1
combined oxidative phosphorylation deficiency;614924;mitochondrial metabolism disease;decreased activity of mitochondrial complex iii;Decreased activity of mitochondrial respiratory chain;EARS2, KIAA1970, COXPD12;612799;16p12.2
combined oxidative phosphorylation deficiency;614932;mitochondrial metabolism disease;dyskinesia;Abnormality of movement;PNPT1, OLD35, COXPD13, DFNB70;610316;2p16.1
combined oxidative phosphorylation deficiency;614946;mitochondrial metabolism disease;feeding difficulties;Abdominal symptom;FARS2, FARS1, COXPD14;611592;6p25.1
combined oxidative phosphorylation deficiency;614947;mitochondrial metabolism disease;cognitive impairment;Abnormality of higher mental function;MTFMT, COXPD15;611766;15q22.31
combined oxidative phosphorylation deficiency;615395;mitochondrial metabolism disease;variable expressivity;Phenotypic variability;MRPL44, COXPD16;611849;2q36.1
combined oxidative phosphorylation deficiency;615440;mitochondrial metabolism disease;lactic acidosis;Acidosis;ELAC2, HPC2, COXPD17;605367;17p12
combined oxidative phosphorylation deficiency;615578;mitochondrial metabolism disease;variable expressivity;Phenotypic variability;SFXN4, COXPD18;615564;10q26.11
combined oxidative phosphorylation deficiency;615595;mitochondrial metabolism disease;feeding difficulties;Abdominal symptom;LYRM4, ISD11, C6orf149, COXPD19;613311;6p25.1
combined oxidative phosphorylation deficiency;615917;mitochondrial metabolism disease;abnormal facial shape;Abnormality of the face;VARS2, KIAA1885, COXPD20;612802;6p21.33
combined oxidative phosphorylation deficiency;615918;mitochondrial metabolism disease;muscular hypotonia of the trunk;Muscular hypotonia;TARS2, COXPD21;612805;1q21.3
common variable immunodeficiency;240500;agammaglobulinemia;recurrent sinusitis;Recurrent upper respiratory tract infections;TNFRSF13B, TACI, CVID2;604907;17p11.2
common variable immunodeficiency;607594;agammaglobulinemia;recurrent sinusitis;Recurrent upper respiratory tract infections;ICOS, AILIM, CVID1;604558;2q33.2
common variable immunodeficiency;613493;agammaglobulinemia;recurrent sinusitis;Recurrent upper respiratory tract infections;CD19, CVID3;107265;16p11.2
common variable immunodeficiency;613494;agammaglobulinemia;recurrent sinusitis;Recurrent upper respiratory tract infections;TNFRSF13C, BAFFR, CVID4;606269;22q13.2
common variable immunodeficiency;613495;agammaglobulinemia;hypogammaglobulinemia;Abnormal immunoglobulin level;MS4A1, CD20, CVID5;112210;11q12.2
common variable immunodeficiency;613496;agammaglobulinemia;hypogammaglobulinemia;Abnormal immunoglobulin level;CD81, TAPA1, CVID6;186845;11p15.5
common variable immunodeficiency;614699;agammaglobulinemia;immunodeficiency;Abnormality of immune system physiology;CR2, C3DR, SLEB9, CVID7;120650;1q32.2
common variable immunodeficiency;614700;agammaglobulinemia;clubbing of fingers;Clubbing;LRBA, LBA, CDC4L, CVID8;606453;4q31.3
common variable immunodeficiency;615559;agammaglobulinemia;membranous nephropathy;Glomerulonephritis;PRKCD, CVID9, ALPS3;176977;3p21.1
common variable immunodeficiency;615577;agammaglobulinemia;central adrenal insufficiency;Adrenal insufficiency;NFKB2, LYT10, CVID10;164012;10q24.32
common variable immunodeficiency;615767;agammaglobulinemia;hypogammaglobulinemia;Abnormal immunoglobulin level;IL21, CVID11;605384;4q27
complement component 2 deficiency;217000;complement deficiency;systemic lupus erythematosus;Autoimmunity;C2, ARMD14;613927;6p21.33
complement component 3 deficiency;613779;complement deficiency;decreased serum complement c3;Complement deficiency;C3, ARMD9, AHUS5;120700;19p13.3
complement component 4a deficiency;614380;complement deficiency;anaphylactoid purpura;Purpura;C4A, C4S, C4AD;120810;6p21.33
complement component 5 deficiency;609536;complement deficiency;generalized seborrheic dermatitis;Seborrheic dermatitis;C5, C5D, ECLZB;120900;9q33.2
complement component 6 deficiency;612446;complement deficiency;recurrent meningococcal disease;Recurrent Neisserial infections;C6;217050;5p13.1
complement component 7 deficiency;610102;complement deficiency;recurrent meningococcal disease;Recurrent Neisserial infections;C7;217070;5p13.1
complement component 9 deficiency;613825;complement deficiency;decreased serum complement c9;Complement deficiency;C9, C9D, ARMD15;120940;5p13.1
complement factor I deficiency;610984;complement deficiency;pyelonephritis;Nephritis;CFI, FI, AHUS3, ARMD13;217030;4q25
cone dystrophy;610024;retinal disease;progressive cone degeneration;Retinal degeneration;PDE6H, RCD3, ACHM6;601190;12p12.3
cone dystrophy;610356;retinal disease;horizontal nystagmus;Nystagmus;KCNV2, KV11.1, RCD3B;607604;9p24.2
cone dystrophy;610478;retinal disease;reduced amplitude of b-wave (erg);Abnormal electroretinogram;CACNA2D4, RCD4;608171;12p13.33
cone-rod dystrophy;120970;retinal degeneration;peripheral visual field loss;Visual field defect;CRX, CORD2, CRD, LCA7;602225;19q13.33
cone-rod dystrophy;300476;retinal degeneration;abnormal rod and cone electroretinograms;Abnormal electroretinogram;CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2;300110;Xp11.23
cone-rod dystrophy;304020;retinal degeneration;progressive macular scarring;Macular scarring;RPGR, RP3, CRD, RP15, COD1, CORDX1;312610;Xp11.4
cone-rod dystrophy;600977;retinal degeneration;progressive central visual loss;Decreased central vision;PITPNM3, NIR1, CORD5;608921;17p13.2
cone-rod dystrophy;601777;retinal degeneration;childhood onset;Onset;GUCY2D, GUC2D, LCA1, CORD6, RCD2;600179;17p13.1
cone-rod dystrophy;602093;retinal degeneration;photophobia;Behavioral abnormality;GUCA1A, GCAP, COD3, CORD14;600364;6p21.1
cone-rod dystrophy;603649;retinal degeneration;retinal flecks;Abnormality of the retina;RIMS1, RIM1, RIM, KIAA0340, CORD7;606629;6q13
cone-rod dystrophy;604116;retinal degeneration;central scotoma;Scotoma;ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2;601691;1p22.1
cone-rod dystrophy;607476;retinal degeneration;night blindness;Abnormality of vision;RLBP1;180090;15q26.1
cone-rod dystrophy;608194;retinal degeneration;absent rod-and cone-mediated responses on erg;Abnormal rod and cone electroretinograms;RPGRIP1, LCA6, CORD13;605446;14q11.2
cone-rod dystrophy;610283;retinal degeneration;increased lacrimation;Lacrimation abnormality;SEMA4A, SEMB, RP35, CORD10;607292;1q22
cone-rod dystrophy;610381;retinal degeneration;macular degeneration;Abnormality of the macula;RAXL1, QRX, CORD11, ARMD6;610362;19p13.3
cone-rod dystrophy;612657;retinal degeneration;progressive central visual loss;Decreased central vision;PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4;604365;4p15.32
cone-rod dystrophy;612775;retinal degeneration;cone-rod dystrophy;Retinal dystrophy;ADAM9, MDC9, MCMP, CORD9;602713;8p11.22
cone-rod dystrophy;613660;retinal degeneration;night blindness;Abnormality of vision;CDHR1, PCDH21, PRCAD, CORD15, RP65;609502;10q23.1
cone-rod dystrophy;614500;retinal degeneration;postaxial polydactyly;Polydactyly;C8orf37, CORD16, RP64;614477;8q22.1
cone-rod dystrophy;615374;retinal degeneration;severe myopia;Myopia;RAB28, CORD18;612994;4p15.33
cone-rod dystrophy;615860;retinal degeneration;cone-rod dystrophy;Retinal dystrophy;TTLL5, STAMP, KIAA0998, CORD19;612268;14q24.3
cone-rod dystrophy;615973;retinal degeneration;nystagmus;Abnormal involuntary eye movements;POC1B, PIX1, CORD20;614784;12q21.33
congenital adrenal hyperplasia;201710;steroid inherited metabolic disorder;congenital adrenal hyperplasia;Adrenal hyperplasia;STAR;600617;8p11.23
congenital adrenal hyperplasia;201810;steroid inherited metabolic disorder;adrenal hyperplasia;Abnormality of adrenal morphology;HSD3B2;613890;1p12
congenital adrenal hyperplasia;201910;steroid inherited metabolic disorder;adrenal hyperplasia;Abnormality of adrenal morphology;CYP21A2, CYP21, CA21H;613815;6p21.33
congenital adrenal hyperplasia;202010;steroid inherited metabolic disorder;decreased testicular size;Aplasia/Hypoplasia of the testes;CYP11B1, P450C11, FHI;610613;8q24.3
congenital adrenal hyperplasia;202110;steroid inherited metabolic disorder;adrenal hyperplasia;Abnormality of adrenal morphology;CYP17A1, CYP17, P450C17;609300;10q24.32
congenital adrenal insufficiency;613743;adrenal gland disease;sex reversal;Abnormal sex determination;CYP11A1, P450SCC;118485;15q24.1
congenital afibrinogenemia;202400;inherited blood coagulation disease;splenic rupture;Abnormality of the spleen;FGA;134820;4q31.3
congenital afibrinogenemia;202400;inherited blood coagulation disease;splenic rupture;Abnormality of the spleen;FGB;134830;4q31.3
congenital afibrinogenemia;202400;inherited blood coagulation disease;splenic rupture;Abnormality of the spleen;FGG;134850;4q31.3
congenital aphakia;610256;lens disease;anterior segment of eye aplasia;Aplasia/Hypoplasia affecting the anterior segment of the eye;FOXE3, FKHL12, ASMD;601094;1p33
congenital bile acid synthesis defect;214950;steroid inherited metabolic disorder;giant cell hepatitis;Hepatitis;AMACR, CBAS4, AMACRD;604489;5p13.2
congenital bile acid synthesis defect;235555;steroid inherited metabolic disorder;chronic hepatic failure;Hepatic failure;AKR1D1, SRD5B1, CBAS2;604741;7q33
congenital bile acid synthesis defect;607765;steroid inherited metabolic disorder;giant cell hepatitis;Hepatitis;HSD3B7, CBAS1;607764;16p11.2
congenital bile acid synthesis defect;613812;steroid inherited metabolic disorder;hepatitis;Abnormality of the liver;CYP7B1, CBAS3, SPG5A;603711;8q12.3
congenital diaphragmatic hernia;610187;diaphragm disease;congenital diaphragmatic hernia;Hernia;ZFPM2, FOG2, DIH3, SRXY9;603693;8q23.1
congenital disorder of glycosylation type I;212065;congenital disorder of glycosylation;prominent forehead;Abnormality of the forehead;PMM2, CDG1A;601785;16p13.2
congenital disorder of glycosylation type I;601110;congenital disorder of glycosylation;long fingers;Abnormality of finger;ALG3, NOT56L, CDGS4, CDG1D;608750;3q27.1
congenital disorder of glycosylation type I;602579;congenital disorder of glycosylation;villous atrophy;Abnormality of small intestinal villus morphology;MPI, PMI1, CDG1B;154550;15q24.1
congenital disorder of glycosylation type I;603147;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;ALG6, CDG1C;604566;1p31.3
congenital disorder of glycosylation type I;607143;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;ALG12, CDG1G;607144;22q13.33
congenital disorder of glycosylation type I;607906;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;ALG2, CDGII;607905;9q22.33
congenital disorder of glycosylation type I;608093;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;DPAGT1, DPAGT2, DGPT, CDG1J, CMSTA2;191350;11q23.3
congenital disorder of glycosylation type I;608104;congenital disorder of glycosylation;hepatic failure;Decreased liver function;ALG8, CDG1H;608103;11q14.1
congenital disorder of glycosylation type I;608540;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;ALG1, HMAT1, HMT1, CDG1K;605907;16p13.3
congenital disorder of glycosylation type I;608776;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;ALG9, DIBD1, CDG1L;606941;11q23.1
congenital disorder of glycosylation type I;608799;congenital disorder of glycosylation;small hand;Aplasia/hypoplasia involving bones of the hand;DPM1, MPDS, CDGIE;603503;20q13.13
congenital disorder of glycosylation type I;609180;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;MPDU1, SL15, CDGIF;604041;17p13.1
congenital disorder of glycosylation type I;610768;congenital disorder of glycosylation;lipoatrophy;Lipodystrophy;TMEM15, DK1, SEC59, KIAA1094, CDG1M;610746;9q34.11
congenital disorder of glycosylation type I;612015;congenital disorder of glycosylation;abnormality of the coagulation cascade;Abnormality of coagulation;RFT1, CDG1N;611908;3p21.1
congenital disorder of glycosylation type I;612379;congenital disorder of glycosylation;depressed nasal bridge;Abnormality of the nasal bridge;SRD5A3, SRD5A2L, CDG1Q, KRIZI;611715;4q12
congenital disorder of glycosylation type I;612937;congenital disorder of glycosylation;rimmed vacuoles;Abnormality of muscle fibers;DPM3, CDG1O;605951;1q22
congenital disorder of glycosylation type I;613661;congenital disorder of glycosylation;feeding difficulties;Abdominal symptom;ALG11, KIAA1266, CDG1P;613666;13q14.3
congenital disorder of glycosylation type II;212066;congenital disorder of glycosylation;cognitive impairment;Abnormality of higher mental function;MGAT2, CDGS2, CDG2A;602616;14q21.3
congenital disorder of glycosylation type II;266265;congenital disorder of glycosylation;intellectual disability, severe;Intellectual disability;SLC35C1, FUCT1, CDG2C;605881;11p11.2
congenital disorder of glycosylation type II;603585;congenital disorder of glycosylation;infantile onset;Onset;SLC35A1, CST, CDG2F;605634;6q15
congenital disorder of glycosylation type II;606056;congenital disorder of glycosylation;short palpebral fissure;Abnormal size of the palpebral fissures;MOGS, GCS1, CDG2B;601336;2p13.1
congenital disorder of glycosylation type II;607091;congenital disorder of glycosylation;elevated serum creatine phosphokinase;Abnormal levels of creatine kinase in blood;B4GALT1, GGTB2, GT1, GTB, CDG2D;137060;9p21.1
congenital disorder of glycosylation type II;608779;congenital disorder of glycosylation;abnormality of immune system physiology;Abnormality of the immune system;COG7, CDG2E;606978;16p12.2
congenital disorder of glycosylation type II;611182;congenital disorder of glycosylation;elevated serum transaminases during infections;Elevated hepatic transaminases;COG8, DOR1, CDG2H;606979;16q22.1
congenital disorder of glycosylation type II;611209;congenital disorder of glycosylation;rhizomelia;Limb undergrowth;COG1, LDLB, KIAA1381, CDG2G;606973;17q25.1
congenital disorder of glycosylation type II;613489;congenital disorder of glycosylation;thick hair;Abnormality of hair density;COG4, COD1, CDG2J;606976;16q22.1
congenital disorder of glycosylation type II;613612;congenital disorder of glycosylation;atrophy/degeneration affecting the brainstem;Atrophy/Degeneration affecting the central nervous system;COG5, GOLTC1, GTC90, CDG2I;606821;7q22.3
congenital disorder of glycosylation;212065;carbohydrate metabolic disorder;prominent forehead;Abnormality of the forehead;PMM2, CDG1A;601785;16p13.2
congenital disorder of glycosylation;212066;carbohydrate metabolic disorder;cognitive impairment;Abnormality of higher mental function;MGAT2, CDGS2, CDG2A;602616;14q21.3
congenital dyserythropoietic anemia;224100;congenital hemolytic anemia;anemia of inadequate production;Anemia;SEC23B, CDAN2, HEMPAS;610512;20p11.23
congenital dyserythropoietic anemia;224120;congenital hemolytic anemia;erythroid hyperplasia;Abnormal number of erythroid precursors;CDAN1, CDA1, CDAN1A;607465;15q15.2
congenital dyserythropoietic anemia;613673;congenital hemolytic anemia;erythroid hyperplasia;Abnormal number of erythroid precursors;KLF1, EKLF, INLU, HBFQTL6, CDAN4;600599;19p13.2
congenital dyserythropoietic anemia;615631;congenital hemolytic anemia;erythroid hyperplasia;Abnormal number of erythroid precursors;C15orf41;615626;15q14
congenital generalized lipodystrophy;269700;lipodystrophy;lipodystrophy;Abnormality of adipose tissue;BSCL2, SPG17, HMN5, PELD;606158;11q12.3
congenital generalized lipodystrophy;608594;lipodystrophy;lipodystrophy;Abnormality of adipose tissue;AGPAT2, LPAAB, BSCL, BSCL1;603100;9q34.3
congenital generalized lipodystrophy;612526;lipodystrophy;lipodystrophy;Abnormality of adipose tissue;CAV1, BSCL3, CGL3, PPH3, LCCNS;601047;7q31.2
congenital generalized lipodystrophy;613327;lipodystrophy;feeding difficulties;Abdominal symptom;PTRF, CAVIN, CGL4;603198;17q21.2
congenital hypothyroidism;218700;hypothyroidism;ectopic thyroid;Thyroid dysgenesis;PAX8;167415;2q13
congenital hypothyroidism;225250;hypothyroidism;ectopic thyroid;Thyroid dysgenesis;NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;600584;5q35.1
congenital hypothyroidism;274400;hypothyroidism;constipation;Abdominal symptom;SLC5A5, NIS, TDH1;601843;19p13.11
congenital hypothyroidism;274500;hypothyroidism;thyroid defect in oxidation and organification of iodide;Abnormality of thyroid physiology;TPO, TPX, TDH2A;606765;2p25.3
congenital hypothyroidism;274900;hypothyroidism;abnormality of metabolism/homeostasis;Phenotypic abnormality;DUOXA2, TDH5;612772;15q21.1
congenital hypothyroidism;275100;hypothyroidism;intellectual disability, severe;Intellectual disability;TSHB, CHNG4;188540;1p13.2
congenital hypothyroidism;607200;hypothyroidism;congenital hypothyroidism;Hypothyroidism;DUOX2, THOX2, TDH6;606759;15q21.1
congenital hypothyroidism;614450;hypothyroidism;increased t3/t4 ratio;Abnormal T3/T4 ratio;THRA, ERBA1, THRA1, CHNG6;190120;17q21.1
congenital ichthyosiform erythroderma;242100;autosomal recessive disease;short finger;Short digit;ALOX12B, ARCI2;603741;17p13.1
congenital ichthyosis;242300;;nail dystrophy;Abnormality of the nail;TGM1, ICR2, ARCI1;190195;14q12
congenital intrinsic factor deficiency;261000;vitamin B12 deficiency;megaloblastic erythroid hyperplasia;Erythroid hyperplasia;GIF, IF;609342;11q12.1
congenital muscular dystrophy;602541;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;CHKB, CHKL, CKEKB, EKB, MDCMC;612395;22q13.33
congenital muscular dystrophy;602771;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;SEPN1, SELN, RSMD1, CFTD;606210;1p36.11
congenital muscular dystrophy;606612;muscular dystrophy;toe walking;Gait disturbance;FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5;606596;19q13.32
congenital muscular dystrophy;607855;muscular dystrophy;feeding difficulties in infancy;Feeding difficulties;LAMA2, LAMM;156225;6q22.33
congenital muscular dystrophy;608840;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;LARGE, KIAA0609, MDC1D, MDDGA6, MDDGB6;603590;22q12.3
congenital muscular dystrophy;613204;muscular dystrophy;cognitive impairment;Abnormality of higher mental function;ITGA7;600536;12q13.2
congenital muscular dystrophy;613205;muscular dystrophy;cognitive impairment;Abnormality of higher mental function;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;1q22
congenital myasthenic syndrome;254210;neuromuscular junction disease;congenital onset;Onset;CHAT, CMS1A2;118490;10q11.23
congenital myasthenic syndrome;254300;neuromuscular junction disease;facial palsy;Abnormality of the seventh cranial nerve;DOK7, C4orf25, CMS1B;610285;4p16.3
congenital myasthenic syndrome;601462;neuromuscular junction disease;intermittent episodes of respiratory insufficiency due to muscle weakness;Respiratory insufficiency due to muscle weakness;CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS;100690;2q31.1
congenital myasthenic syndrome;601462;neuromuscular junction disease;intermittent episodes of respiratory insufficiency due to muscle weakness;Respiratory insufficiency due to muscle weakness;CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D;100710;17p13.1
congenital myasthenic syndrome;601462;neuromuscular junction disease;intermittent episodes of respiratory insufficiency due to muscle weakness;Respiratory insufficiency due to muscle weakness;CHRND, ACHRD, SCCMS, CMS2A, FCCMS;100720;2q37.1
congenital myasthenic syndrome;601462;neuromuscular junction disease;intermittent episodes of respiratory insufficiency due to muscle weakness;Respiratory insufficiency due to muscle weakness;CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D;100725;17p13.2
congenital myasthenic syndrome;608930;neuromuscular junction disease;variable expressivity;Phenotypic variability;CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS;100690;2q31.1
congenital myasthenic syndrome;608930;neuromuscular junction disease;variable expressivity;Phenotypic variability;CHRND, ACHRD, SCCMS, CMS2A, FCCMS;100720;2q37.1
congenital myasthenic syndrome;608930;neuromuscular junction disease;variable expressivity;Phenotypic variability;CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D;100725;17p13.2
congenital myasthenic syndrome;608931;neuromuscular junction disease;feeding difficulties;Abdominal symptom;CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D;100710;17p13.1
congenital myasthenic syndrome;608931;neuromuscular junction disease;feeding difficulties;Abdominal symptom;CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D;100725;17p13.2
congenital myasthenic syndrome;608931;neuromuscular junction disease;feeding difficulties;Abdominal symptom;MUSK;601296;9q31.3
congenital myasthenic syndrome;608931;neuromuscular junction disease;feeding difficulties;Abdominal symptom;RAPSN, CMS1D, CMS1E;601592;11p11.2
congenital myasthenic syndrome;614198;neuromuscular junction disease;fatigable weakness;Abnormal synaptic transmission at the neuromuscular junction;SCN4A, HYPP, NAC1A, HOKPP2;603967;17q23.3
congenital nonspherocytic hemolytic anemia;300908;congenital hemolytic anemia;unconjugated hyperbilirubinemia;Hyperbilirubinemia;G6PD, G6PD1;305900;Xq28
congenital nonspherocytic hemolytic anemia;613470;congenital hemolytic anemia;impaired neutrophil bactericidal activity;Abnormality of neutrophil physiology;GPI;172400;19q13.11
congenital nystagmus;300814;pathologic nystagmus;x-linked inheritance;Gonosomal inheritance;GPR143, OA1, NYS6;300808;Xp22.2
congenital ptosis;178300;ptosis;congenital ptosis;Ptosis;ZFHX4, ZFH4;606940;8q21.11
congenital secretory chloride diarrhea 1;214700;secretory diarrhea;metabolic alkalosis;Alkalosis;SLC26A3, DRA, CLD;126650;7q31.1
congenital stationary night blindness;163500;night blindness;congenital stationary night blindness;Night blindness;PDE6B, PDEB, RP40, CSNBAD2;180072;4p16.3
congenital stationary night blindness;257270;night blindness;hemeralopia;Abnormality of vision;GRM6, MGLUR6, CSNB1B;604096;5q35.3
congenital stationary night blindness;300071;night blindness;congenital stationary night blindness;Night blindness;CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2;300110;Xp11.23
congenital stationary night blindness;310500;night blindness;hemeralopia;Abnormality of vision;NYX, CSNB1A, NBM1;300278;Xp11.4
congenital stationary night blindness;610427;night blindness;reduced amplitude of b-wave (erg);Abnormal electroretinogram;CABP4, CSNB2B;608965;11q13.2
congenital stationary night blindness;610444;night blindness;congenital stationary night blindness;Night blindness;GNAT1, CSNBAD3;139330;3p21.31
congenital stationary night blindness;610445;night blindness;bony spicule pigmentary retinopathy;Pigmentary retinopathy;RHO, RP4, OPN2, CSNBAD1;180380;3q22.1
congenital stationary night blindness;613216;night blindness;decreased central vision;Visual loss;TRPM1, MLSN1, CSNB1C;603576;15q13.3
cornea plana;217300;corneal disease;decreased corneal thickness;Abnormality of corneal thickness;KERA, CNA2;603288;12q21.33
coronary artery disease;608320;artery disease;hypercholesterolemia;Abnormality of cholesterol metabolism;MEF2A, ADCAD1;600660;15q26.3
coronary artery disease;610947;artery disease;hypercholesterolemia;Abnormality of cholesterol metabolism;LRP6, ADCAD2;603507;12p13.2
coronary artery disease;614293;artery disease;autosomal recessive inheritance;Mode of inheritance;KHDC3L, C6orf221, ECAT1, HYDM2;611687;6q13
craniofrontonasal syndrome;304110;X-linked disease;hemihypotrophy of lower limb;Hemiatrophy;EFNB1, EPLG2, CFNS, CFND;300035;Xq13.1
craniometaphyseal dysplasia;122860;osteosclerosis;concave nasal ridge;Abnormality of the nasal dorsum;SOST, VBCH, CDD, SOST1;605740;17q21.31
craniometaphyseal dysplasia;123000;osteosclerosis;facial palsy;Abnormality of the seventh cranial nerve;ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD;605145;5p15.2
craniometaphyseal dysplasia;218400;osteosclerosis;metaphyseal dysplasia;Skeletal dysplasia;GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR;121014;6q22.31
craniometaphyseal dysplasia;614099;osteosclerosis;sparse hair;Abnormality of hair density;IFT43, C14orf179, CED3;614068;14q24.3
craniometaphyseal dysplasia;614378;osteosclerosis;cutaneous finger syndactyly;Cutaneous syndactyly;WDR19, SRTD5, ATD5, NPHP13, CED4;608151;4p14
craniosynostosis;123100;synostosis;cognitive impairment;Abnormality of higher mental function;TWIST1, ACS3, SCS, CRS1;601622;7p21.1
craniosynostosis;182212;synostosis;cognitive impairment;Abnormality of higher mental function;SKI, SGS;164780;1p36.33
craniosynostosis;600775;synostosis;round ear;Abnormality of the pinna;ERF, PE2, CRS4;611888;19q13.2
craniosynostosis;604757;synostosis;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;MSX2, CRS2, HOX8;123101;5q35.2
craniosynostosis;615314;synostosis;cognitive impairment;Abnormality of higher mental function;TCF12, HTF4, CRS3;600480;15q21.3
craniosynostosis;615529;synostosis;craniosynostosis;Abnormality of cranial sutures;ALX4, PFM2, FPP, FND2, CRS5;605420;11p11.2
creatine transporter deficiency;300352;cerebral creatine deficiency syndrome;cognitive impairment;Abnormality of higher mental function;SLC6A8, CRTR, CCDS1;300036;Xq28
cryptorchidism;219050;physical disorder;unilateral cryptorchidism;Cryptorchidism;INSL3;146738;19p13.11
cryptorchidism;219050;physical disorder;unilateral cryptorchidism;Cryptorchidism;LGR8, GREAT;606655;13q13.1
cutaneous porphyria;263700;porphyria;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;UROS;606938;10q26.1-q26.2
cutis laxa;123700;skin disease;prematurely aged appearance;Generalized abnormality of skin;ELN;130160;7q11.23
cutis laxa;219100;skin disease;vascular tortuosity;Abnormality of the vasculature;FBLN5, ARMD3, ADCL2, ARCL1A;604580;14q32.12
cutis laxa;219150;skin disease;cognitive impairment;Abnormality of higher mental function;ALDH18A1, PYCS, GSAS, ARCL3A;138250;10q24.1
cutis laxa;219200;skin disease;flat face;Abnormal facial shape;ATP6V0A2, WSS, ARCL2A;611716;12q24.31
cutis laxa;612940;skin disease;midface retrusion;Abnormality of the midface;PYCR1, PRO3, ARCL2B, ARCL3B;179035;17q25.3
cutis laxa;613177;skin disease;pulmonary artery stenosis;Abnormality of the pulmonary artery;LTBP4, LTBP4S, LTBP4L, ARCL1C;604710;19q13.2
cutis laxa;614434;skin disease;premature skin wrinkling;Abnormality of skin morphology;FBLN5, ARMD3, ADCL2, ARCL1A;604580;14q32.12
cutis laxa;614437;skin disease;small palpebral fissure;Abnormal size of the palpebral fissures;EFEMP2, FBLN4, UPH1, ARCL1B;604633;11q13.1
cutis laxa;614438;skin disease;prominent forehead;Abnormality of the forehead;PYCR1, PRO3, ARCL2B, ARCL3B;179035;17q25.3
cyclic hematopoiesis;162800;neutropenia;skin ulcer;Localized skin lesion;ELANE, ELA2, SCN1;130130;19p13.3
cystic fibrosis;219700;autosomal recessive disease;elevated sweat chloride;Abnormal sweat homeostasis;CFTR, ABCC7, CF, MRP7;602421;7q31.2
cystic fibrosis;219700;autosomal recessive disease;elevated sweat chloride;Abnormal sweat homeostasis;FCGR2A, IGFR2, CD32;146790;1q23.3
cystic fibrosis;219700;autosomal recessive disease;elevated sweat chloride;Abnormal sweat homeostasis;TGFB1, DPD1, CED;190180;19q13.2
cystinosis;219800;lysosomal storage disease;peripheral retinopathy;Abnormality of the retina;CTNS;606272;17p13.2
cystinuria;220100;amino acid metabolic disorder;variable expressivity;Phenotypic variability;SLC3A1, ATR1, D2H, NBAT;104614;2p21
cystinuria;220100;amino acid metabolic disorder;variable expressivity;Phenotypic variability;SLC7A9, CSNU3;604144;19q13.11
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;APOPT1, APOP;616003;14q32.33
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;COA5, C2orf64, PET191;613920;2q11.2
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;COX10;602125;17p12
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;COX14, C12orf62;614478;12q13.12
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;COX20, FAM36A;614698;1q44
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;COX6B1;124089;19q13.12
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;FASTKD2, KIAA0971;612322;2q33.3
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;PET100, C19orf79;614770;19p13.2
cytochrome-c oxidase deficiency disease;220110;mitochondrial metabolism disease;increased intramyocellular lipid droplets;Increased muscle lipid content;TACO1, CCDC44;612958;17q23.3
deafness dystonia syndrome;304700;mitochondrial metabolism disease;cortical visual impairment;Visual impairment;TIMM8A, DFN1, DDP, MTS, DDP1;300356;Xq22.1
dengue shock syndrome;614371;dengue disease;reduced consciousness/confusion;Abnormality of higher mental function;CD209, CDSIGN;604672;19p13.2
dentatorubral-pallidoluysian atrophy;125370;spinocerebellar degeneration;fetal cystic hygroma;Increased nuchal translucency;ATN1, DRPLA, HRS, NOD;607462;12p13.31
dentin dysplasia;125400;teeth hard tissue disease;dentinogenesis imperfecta limited to primary teeth;Dentinogenesis imperfecta;SMOC2, SMAP2, DTDP1;607223;6q27
dentin dysplasia;125420;teeth hard tissue disease;dentinogenesis imperfecta limited to primary teeth;Dentinogenesis imperfecta;DSPP, DPP, DGI1, DFNA39, DTDP2;125485;4q22.1
dentinogenesis imperfecta;125490;tooth disease;dentinogenesis imperfecta;Abnormality of dentin;DSPP, DPP, DGI1, DFNA39, DTDP2;125485;4q22.1
dentinogenesis imperfecta;125500;tooth disease;dentinogenesis imperfecta;Abnormality of dentin;DSPP, DPP, DGI1, DFNA39, DTDP2;125485;4q22.1
desmoplastic medulloblastoma;155255;;medulloblastoma;Malignant neoplasm of the central nervous system;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
desmoplastic medulloblastoma;155255;;medulloblastoma;Malignant neoplasm of the central nervous system;PTCH2;603673;1p34.1
desmoplastic medulloblastoma;155255;;medulloblastoma;Malignant neoplasm of the central nervous system;SUFU, SUFUXL, SUFUH;607035;10q24.32
diabetic ketoacidosis;612227;type 2 diabetes mellitus;beta-cell dysfunction;Abnormality of the pancreatic islet cells;PAX4, MODY9, KPD;167413;7q32.1
diastrophic dysplasia;222600;osteochondrodysplasia;visceral angiomatosis;Hemangiomatosis;SLC26A2, DTD, DTDST, D5S1708, EDM4;606718;5q32
dihydropyrimidine dehydrogenase deficiency;274270;purine-pyrimidine metabolic disorder;phenotypic variability;Clinical modifier;DPYD, DPD;612779;1p21.3
dilated cardiomyopathy;115200;intrinsic cardiomyopathy;atrial fibrillation;Primary atrial arrhythmia;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;1q22
dilated cardiomyopathy;302045;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;DMD, BMD, CMD3B;300377;Xp21.2-p21.1
dilated cardiomyopathy;601154;intrinsic cardiomyopathy;left bundle branch block;Bundle branch block;SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;600163;3p22.2
dilated cardiomyopathy;601493;intrinsic cardiomyopathy;ventricular arrhythmia;Arrhythmia;LDB3, ZASP, CYPHER, KIAA01613, CMD1C, LVNC3, MFM4;605906;10q23.2
dilated cardiomyopathy;601494;intrinsic cardiomyopathy;atrial fibrillation;Primary atrial arrhythmia;TNNT2, CMH2, CMD1D, RCM3, LVNC6;191045;1q32.1
dilated cardiomyopathy;604145;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC;188840;2q31.2
dilated cardiomyopathy;604765;intrinsic cardiomyopathy;reduced systolic function;Congestive heart failure;DES, CMD1I, MFM1, SCPNK, ARVD7, ARVC7, LGMD2R;125660;2q35
dilated cardiomyopathy;605362;intrinsic cardiomyopathy;sudden cardiac death;Cardiac arrest;EYA4, DFNA10, CMD1J;603550;6q23.2
dilated cardiomyopathy;606685;intrinsic cardiomyopathy;reduced systolic function;Congestive heart failure;SGCD, SGD, LGMD2F, CMD1L;601411;5q33.2-q33.3
dilated cardiomyopathy;607482;intrinsic cardiomyopathy;impaired myocardial contractility;Reduced systolic function;CSRP3, CRP3, CLP, CMD1M, CMH12;600824;11p15.1
dilated cardiomyopathy;607487;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;TCAP, LGMD2G, CMD1N;604488;17q12
dilated cardiomyopathy;608569;intrinsic cardiomyopathy;impaired myocardial contractility;Reduced systolic function;ABCC9, SUR2, CMD1O, ATFB12, CANTU;601439;12p12.1
dilated cardiomyopathy;609909;intrinsic cardiomyopathy;reduced systolic function;Congestive heart failure;PLN, PLB, CMD1P, CMH18;172405;6q22.31
dilated cardiomyopathy;611407;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;VCL, CMD1W, CMH15;193065;10q22.2
dilated cardiomyopathy;611615;intrinsic cardiomyopathy;proximal muscle weakness;Muscle weakness;FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4;607440;9q31.2
dilated cardiomyopathy;611878;intrinsic cardiomyopathy;ventricular tachycardia;Tachycardia;TPM1, CMH3, CMD1Y , LVNC9;191010;15q22.2
dilated cardiomyopathy;611879;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;TNNC1, CMD1Z, CMH13;191040;3p21.1
dilated cardiomyopathy;611880;intrinsic cardiomyopathy;young adult onset;Adult onset;TNNI3, CMH7, CMD2A, RCM1, CMD1FF;191044;19q13.42
dilated cardiomyopathy;612158;intrinsic cardiomyopathy;endocardial fibroelastosis;Abnormality of the endocardium;ACTN2, CMD1AA;102573;1q43
dilated cardiomyopathy;612877;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;DSG2, ARVD10, ARVC10, CMD1BB;125671;18q12.1
dilated cardiomyopathy;613122;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;NEXN, NELIN, CMD1CC, CMH20;613121;1p31.1
dilated cardiomyopathy;613172;intrinsic cardiomyopathy;sudden cardiac death;Cardiac arrest;RBM20;613171;10q25.2
dilated cardiomyopathy;613252;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3;160710;14q11.2
dilated cardiomyopathy;613286;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;TNNI3, CMH7, CMD2A, RCM1, CMD1FF;191044;19q13.42
dilated cardiomyopathy;613424;intrinsic cardiomyopathy;ventricular arrhythmia;Arrhythmia;ACTC1, CMD1R, CMH11, ASD5, LVNC4;102540;15q14
dilated cardiomyopathy;613426;intrinsic cardiomyopathy;tricuspid regurgitation;Abnormality of the tricuspid valve;MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD;160760;14q11.2
dilated cardiomyopathy;613642;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;SDHA, SDH1, SDHF, CMD1GG, PGL5;600857;5p15.33
dilated cardiomyopathy;613694;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;PSEN1, AD3;104311;14q24.2
dilated cardiomyopathy;613697;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;PSEN2, AD4, STM2, CMD1V;600759;1q42.13
dilated cardiomyopathy;613740;intrinsic cardiomyopathy;reduced systolic function;Congestive heart failure;TMPO, LAP2, CMD1T;188380;12q23.1
dilated cardiomyopathy;613881;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;BAG3, MFM6;603883;10q26.11
dilated cardiomyopathy;614672;intrinsic cardiomyopathy;atrial fibrillation;Primary atrial arrhythmia;GATAD1, ODAG, CMD2B;614518;7q21.2
dilated cardiomyopathy;615184;intrinsic cardiomyopathy;mitral regurgitation;Abnormality of the mitral valve;CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2;123590;11q23.1
dilated cardiomyopathy;615235;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;LAMA4, LAMA3, CMD1JJ;600133;6q21
dilated cardiomyopathy;615916;intrinsic cardiomyopathy;ventricular arrhythmia;Arrhythmia;RAF1, CRAF, NS5, CMD1NN;164760;3p25.2
distal arthrogryposis;108120;muscle tissue disease;stiff shoulders;Abnormality of the shoulder;TPM2, TMSB, AMCD1, DA1, DA2B, NEM4;190990;9p13.3
distal arthrogryposis;108145;muscle tissue disease;camptodactyly of finger;Flexion contracture of finger;PIEZO2, FAM38B, DA5, DA3, MWKS;613629;18p11.22-p11.21
distal arthrogryposis;114300;muscle tissue disease;down-sloping shoulders;Abnormality of the shoulder;PIEZO2, FAM38B, DA5, DA3, MWKS;613629;18p11.22-p11.21
distal arthrogryposis;121050;muscle tissue disease;duodenal stenosis;Small intestinal stenosis;FBN2, CCA, EOMD;612570;5q23.3
distal arthrogryposis;158300;muscle tissue disease;feeding difficulties;Abdominal symptom;MYH8;160741;17p13.1
distal arthrogryposis;193700;muscle tissue disease;camptodactyly;Flexion contracture of digit;MYH3;160720;17p13.1
distal arthrogryposis;601680;muscle tissue disease;round ear;Abnormality of the pinna;MYH3;160720;17p13.1
distal arthrogryposis;601680;muscle tissue disease;round ear;Abnormality of the pinna;TNNI2, AMCD2B, DA2B, FSSV;191043;11p15.5
distal arthrogryposis;601680;muscle tissue disease;round ear;Abnormality of the pinna;TNNT3, AMCD2B, DA2B, FSSV;600692;11p15.5
distal arthrogryposis;601680;muscle tissue disease;round ear;Abnormality of the pinna;TPM2, TMSB, AMCD1, DA1, DA2B, NEM4;190990;9p13.3
distal arthrogryposis;614335;muscle tissue disease;joint contracture of the hand;Contractures of the joints of the upper limbs;MYBPC1, LCCS4;160794;12q23.2
distal arthrogryposis;615065;muscle tissue disease;camptodactyly;Flexion contracture of digit;ECEL1, XCE, DA5D;605896;2q37.1
distal hereditary motor neuropathy;158590;motor neuritis;distal lower limb muscle weakness;Abnormality of the lower limb;HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A;608014;12q24.23
distal hereditary motor neuropathy;600794;motor neuritis;distal amyotrophy;Skeletal muscle atrophy;BSCL2, SPG17, HMN5, PELD;606158;11q12.3
distal hereditary motor neuropathy;600794;motor neuritis;distal amyotrophy;Skeletal muscle atrophy;GARS, SMAD1, CMT2D, HMN5;600287;7p14.3
distal hereditary motor neuropathy;607641;motor neuritis;hand muscle weakness;Abnormality of the musculature of the hand;DCTN1, HMN7B;601143;2p13.1
distal hereditary motor neuropathy;608634;motor neuritis;peripheral neuropathy;Abnormal peripheral nervous system morphology;HSPB1, HSP27, CMT2F, HMN2B;602195;7q11.23
distal hereditary motor neuropathy;613376;motor neuritis;peripheral neuropathy;Abnormal peripheral nervous system morphology;HSPB3, HSPL27, HMN2C, DHMN2C;604624;5q11.2
distal muscular dystrophy;160500;muscular dystrophy;toe extensor amyotrophy;Abnormality of the foot musculature;MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD;160760;14q11.2
distal muscular dystrophy;254130;muscular dystrophy;decreased/absent ankle reflexes;Areflexia of lower limbs;DYSF, LGMD2B, MMD1;603009;2p13.2
distal muscular dystrophy;606768;muscular dystrophy;distal amyotrophy;Skeletal muscle atrophy;DYSF, LGMD2B, MMD1;603009;2p13.2
distal muscular dystrophy;613319;muscular dystrophy;quadriceps muscle atrophy;Proximal lower limb amyotrophy;ANO5, TMEM16E, GDD1, LGMD2L;608662;11p14.3
distal muscular dystrophy;614065;muscular dystrophy;distal lower limb amyotrophy;Lower limb amyotrophy;FLNC, FLN2, ABPA, ABPL, MFM5, MPD4;102565;7q32.1
distal muscular dystrophy;614321;muscular dystrophy;calf muscle hypertrophy;Muscle hypertrophy of the lower extremities;CAV3, LGMD1C, LQT9;601253;3p25.3
double outlet right ventricle;217095;ventricular septal defect;abnormality of the pulmonary artery;Abnormality of the pulmonary vasculature;CFC1, CRYPTIC, HTX2, DTGA2;605194;2q21.1
double outlet right ventricle;217095;ventricular septal defect;abnormality of the pulmonary artery;Abnormality of the pulmonary vasculature;GATA6, AVSD5, ASD9, AVSD5, PACHD;601656;18q11.2
double outlet right ventricle;217095;ventricular septal defect;abnormality of the pulmonary artery;Abnormality of the pulmonary vasculature;GDF1, DTGA3, DORV, RAI;602880;19p13.11
double outlet right ventricle;217095;ventricular septal defect;abnormality of the pulmonary artery;Abnormality of the pulmonary vasculature;NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;600584;5q35.1
double outlet right ventricle;217095;ventricular septal defect;abnormality of the pulmonary artery;Abnormality of the pulmonary vasculature;NKX2-6, CSX2, CTHM;611770;8p21.2
double outlet right ventricle;217095;ventricular septal defect;abnormality of the pulmonary artery;Abnormality of the pulmonary vasculature;TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR;602054;22q11.21
dyschromatosis symmetrica hereditaria;127400;pigmentation disease;hyperpigmented/hypopigmented macules;Macule;ADAR, DRADA, DSH, DSRAD, IFI4, G1P1, AGS6;146920;1q21.3
dyschromatosis universalis hereditaria;615402;pigmentation disease;autosomal dominant inheritance;Mode of inheritance;ABCB6, MTABC3, MCOPCB7, LAN, DUH3;605452;2q35
dyskeratosis congenita;127550;skin disease;nail dystrophy;Abnormality of the nail;TERC, TRC3, TR, DKCA1, PFBMFT2;602322;3q26.2
dyskeratosis congenita;224230;skin disease;increased lacrimation;Lacrimation abnormality;NOLA3, NOP10, DKCB1;606471;15q14
dyskeratosis congenita;305000;skin disease;cognitive impairment;Abnormality of higher mental function;DKC1, DKCX;300126;Xq28
dyskeratosis congenita;613988;skin disease;nail dystrophy;Abnormality of the nail;WRAP53, TCAB1, WDR79, DKCB3;612661;17p13.1
dyskeratosis congenita;613989;skin disease;urethral stricture;Urethral stenosis;TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9;187270;5p15.33
dyskeratosis congenita;613990;skin disease;increased lacrimation;Lacrimation abnormality;TINF2, TIN2, DKCA3;604319;14q12
dyskeratosis congenita;615190;skin disease;postnatal growth retardation;Growth delay;RTEL1, C20orf41, NHL, KIAA1088, DKCB5, DKCA4;608833;20q13.33
dyslexia;127700;reading disorder;dyslexia;Specific learning disability;DYX1C1, DYXC1, DYX1, CILD25;608706;15q21.3
dyslexia;600202;reading disorder;dyslexia;Specific learning disability;KIAA0319, DYX2, DYLX2, DLX2;609269;6p22.3
dysplastic nevus syndrome;155600;autosomal dominant disease;cutaneous melanoma;Neoplasm of the skin;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
dysplastic nevus syndrome;155601;autosomal dominant disease;cutaneous melanoma;Neoplasm of the skin;CDKN2A, MTS1, P16, MLM, CMM2;600160;9p21.3
embryonal rhabdomyosarcoma;268210;rhabdomyosarcoma;embryonal rhabdomyosarcoma;Embryonal neoplasm;SLC22A1L, BWSCR1A, IMPT1;602631;11p15.4
endometrial carcinoma;608089;endometrial cancer;endometrial carcinoma;Abnormality of the endometrium;CDH1, UVO, LCAM, ECAD;192090;16q22.1
endometrial carcinoma;608089;endometrial cancer;endometrial carcinoma;Abnormality of the endometrium;MLH3, HNPCC7;604395;14q24.3
endometrial carcinoma;608089;endometrial cancer;endometrial carcinoma;Abnormality of the endometrium;MSH6, GTBP, HNPCC5;600678;2p16.3
endometrial carcinoma;608089;endometrial cancer;endometrial carcinoma;Abnormality of the endometrium;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
enlarged vestibular aqueduct;600791;auditory system disease;enlarged vestibular aqueduct;Morphological abnormality of the vestibule of the inner ear;FOXI1, FKHL10, FREAC6;601093;5q35.1
enlarged vestibular aqueduct;600791;auditory system disease;enlarged vestibular aqueduct;Morphological abnormality of the vestibule of the inner ear;KCNJ10, SESAME;602208;1q23.2
enlarged vestibular aqueduct;600791;auditory system disease;enlarged vestibular aqueduct;Morphological abnormality of the vestibule of the inner ear;SLC26A4, PDS, DFNB4, EVA, TDH2B;605646;7q22.3
epidermal nevus;162900;;numerous nevi;Hamartoma;FGFR3, ACH;134934;4p16.3
epidermal nevus;162900;;numerous nevi;Hamartoma;HRAS;190020;11p15.5
epidermal nevus;162900;;numerous nevi;Hamartoma;NRAS, ALPS4, NS6, CMNS, NCMS;164790;1p13.2
epidermal nevus;162900;;numerous nevi;Hamartoma;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
epidermodysplasia verruciformis;226400;autosomal recessive disease;verrucae;Papilloma;TMC6, EVER1, EV1;605828;17q25.3
epidermodysplasia verruciformis;226400;autosomal recessive disease;verrucae;Papilloma;TMC8, EVER2, EV2;605829;17q25.3
epidermolytic hyperkeratosis;113800;skin disease;abnormal blistering of the skin;Abnormality of skin morphology;KRT1, EPPK, NEPPK, EHK;139350;12q13.13
epidermolytic hyperkeratosis;113800;skin disease;abnormal blistering of the skin;Abnormality of skin morphology;KRT10, EHK, BCIE, BIE;148080;17q21.2
episodic ataxia;108500;neuromuscular disease;downbeat nystagmus;Vertical nystagmus;CACNA1A, CACNL1A4, SCA6;601011;19p13.2
episodic ataxia;160120;neuromuscular disease;abnormality of movement;Abnormality of nervous system physiology;KCNA1, AEMK, EA1;176260;12p13.32
episodic ataxia;612656;neuromuscular disease;hemiplegia;Hemiplegia/hemiparesis;SLC1A3, EAAT1, EA6;600111;5p13.2
episodic ataxia;613855;neuromuscular disease;episodic ataxia;Ataxia;CACNB4, EJM6, EA5, EIG9;601949;2q23.3
erythrokeratodermia variabilis;133200;skin disease;cognitive impairment;Abnormality of higher mental function;GJB3, CX31, DFNA2B;603324;1p34.3
erythrokeratodermia variabilis;133200;skin disease;cognitive impairment;Abnormality of higher mental function;GJB4, CX30.3;605425;1p34.3
erythropoietic protoporphyria;177000;acute porphyria;childhood onset;Onset;FECH, FCE;612386;18q21.31
erythropoietic protoporphyria;300752;acute porphyria;increased erythrocyte protoporphyrin concentration;Abnormality of the heme biosynthetic pathway;ALAS2, ANH1, ASB, XLEPP, XLSA, ANH1;301300;Xp11.21
esophagus squamous cell carcinoma;133239;esophageal carcinoma;chest pain;Abnormality of the thorax;DEC1;604767;9q33.1
esophagus squamous cell carcinoma;133239;esophageal carcinoma;chest pain;Abnormality of the thorax;DLEC1, DLC1;604050;3p22.2
esophagus squamous cell carcinoma;133239;esophageal carcinoma;chest pain;Abnormality of the thorax;LZTS1, F37, FEZ1;606551;8p21.3
esophagus squamous cell carcinoma;133239;esophageal carcinoma;chest pain;Abnormality of the thorax;RNF6;604242;13q12.13
esophagus squamous cell carcinoma;133239;esophageal carcinoma;chest pain;Abnormality of the thorax;TGFBR2, HNPCC6, AAT3, MFS2, LDS2;190182;3p24.1
esophagus squamous cell carcinoma;133239;esophageal carcinoma;chest pain;Abnormality of the thorax;WWOX, FOR, SCAR12, EIEE28;605131;16q23.1-q23.2
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;ADD1;102680;4p16.3
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;AGT, SERPINA8;106150;1q42.2
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;AGTR1, AGTR1A, AT2R1;106165;3q24
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;ATP1B1;182330;1q24.2
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;CYP3A5, P450PCN3;605325;7q22.1
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;ECE1;600423;1p36.12
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;GNB3;139130;12p13.31
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;HYT1;603918;17q
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;HYT2;604329;15q
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;HYT3;607329;2p25-p24
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;HYT4;608742;12p12.2-p12.1
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;HYT5;610261;20q11-q13
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;HYT6;610262;5p13-q12
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;NOS2A, NOS2;163730;17q11.2
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;NOS3;163729;7q36.1
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;PTGIS, CYP8A1, PGIS, CYP8;601699;20q13.13
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;RGS5;603276;1q23.3
essential hypertension;145500;hypertension;elevated diastolic blood pressure;Hypertension;SELE, ELAM1;131210;1q24.2
essential tremor;190300;movement disease;progressive disorder;Pace of progression;DRD3, ETM1, FET1;126451;3q13.31
essential tremor;614782;movement disease;postural tremor;Action tremor;FUS, TLS, ALS6, ETM4;137070;16p11.2
exfoliation syndrome;177650;iris disease;retinal vein occlusion;Abnormality of the retinal vasculature;LOXL1, LOXL;153456;15q24.1
extraskeletal myxoid chondrosarcoma;612237;myxoid chondrosarcoma;chondrosarcoma;Sarcoma;CSMF;600542;9q22.3-q31.1
extraskeletal myxoid chondrosarcoma;612237;myxoid chondrosarcoma;chondrosarcoma;Sarcoma;TAF15, TAF2N, RBP56;601574;17q12
exudative vitreoretinopathy;133780;retinal vascular disease;vitreous hemorrhage;Hemorrhage of the eye;FZD4, EVR1;604579;11q14.2
exudative vitreoretinopathy;305390;retinal vascular disease;subretinal exudate;Retinal exudate;NDP, ND, EVR2;300658;Xp11.3
exudative vitreoretinopathy;601813;retinal vascular disease;tractional retinal detachment;Retinal detachment;LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4;603506;11q13.2
exudative vitreoretinopathy;613310;retinal vascular disease;degenerative vitreoretinopathy;Vitreoretinal abnormalities;TSPAN12, NET2, EVR5;613138;7q31.31
factor V deficiency;227400;inherited blood coagulation disease;prolonged whole-blood clotting time;Abnormality of coagulation;F5, THPH2, RPRGL1;612309;1q24.2
factor XI deficiency;612416;autosomal genetic disease;prolonged partial thromboplastin time;Abnormality of coagulation;F11;264900;4q35.2
factor XII deficiency;234000;autosomal genetic disease;prolonged whole-blood clotting time;Abnormality of coagulation;F12, HAF, HAE3;610619;5q35.3
factor XIII deficiency;613225;inherited blood coagulation disease;reduced factor xiii activity;Abnormality of the common coagulation pathway;F13A1, F13A;134570;6p25.1
factor XIII deficiency;613235;inherited blood coagulation disease;abnormal umbilical stump bleeding;Abnormal bleeding;F13B;134580;1q31.3
familial Mediterranean fever;134610;hypersensitivity reaction type II disease;chest pain;Abnormality of the thorax;MEFV, MEF, FMF;608107;16p13.3
familial Mediterranean fever;249100;hypersensitivity reaction type II disease;elevated erythrocyte sedimentation rate;Abnormality of metabolism/homeostasis;MEFV, MEF, FMF;608107;16p13.3
familial adenomatous polyposis;175100;autosomal dominant disease;epidermoid cyst;Localized skin lesion;APC, GS, FPC, BTPS2;611731;5q22.2
familial adenomatous polyposis;608456;autosomal dominant disease;adenomatous colonic polyposis;Neoplasm of the colon;MUTYH, MYH;604933;1p34.1
familial atrial fibrillation;607554;atrial fibrillation;atrial fibrillation;Primary atrial arrhythmia;KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2;607542;11p15.5-p15.4
familial atrial fibrillation;611493;atrial fibrillation;atrial fibrillation;Primary atrial arrhythmia;KCNE2, MIRP1, LQT6, ATFB4;603796;21q22.11
familial atrial fibrillation;612201;atrial fibrillation;atrial fibrillation;Primary atrial arrhythmia;NPPA, PND, ANP, ATFB6, ATRST2;108780;1p36.22
familial atrial fibrillation;612240;atrial fibrillation;prolonged pr interval;Abnormal EKG;KCNA5, ATFB7;176267;12p13.32
familial atrial fibrillation;613980;atrial fibrillation;paroxysmal atrial fibrillation;Atrial fibrillation;KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9;600681;17q24.3
familial atrial fibrillation;614022;atrial fibrillation;paroxysmal atrial tachycardia;Paroxysmal supraventricular tachycardia;SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;600163;3p22.2
familial atrial fibrillation;614049;atrial fibrillation;atrial fibrillation;Primary atrial arrhythmia;GJA5, CX40, ATFB11;121013;1q21.2
familial atrial fibrillation;614050;atrial fibrillation;paroxysmal atrial fibrillation;Atrial fibrillation;ABCC9, SUR2, CMD1O, ATFB12, CANTU;601439;12p12.1
familial atrial fibrillation;615770;atrial fibrillation;atrial fibrillation;Primary atrial arrhythmia;NUP155, KIAA0791, ATFB15;606694;5p13.2
familial combined hyperlipidemia;144250;familial hyperlipidemia;combined hyperlipidemia;Hyperlipidemia;LPL, LIPD, HDLCQ11;609708;8p21.3
familial encephalopathy with neuroserpin inclusion bodies;604218;neurodegenerative disease;distal sensory impairment;Sensory impairment;SERPINI1, PI12;602445;3q26.1
familial hemiplegic migraine;141500;migraine with aura;auditory hallucinations;Hallucinations;CACNA1A, CACNL1A4, SCA6;601011;19p13.2
familial hemiplegic migraine;602481;migraine with aura;incomplete penetrance;Phenotypic variability;ATP1A2, FHM2, MHP2;182340;1q23.2
familial hemiplegic migraine;609634;migraine with aura;hemiplegia;Hemiplegia/hemiparesis;SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3;182389;2q24.3
familial hypercholesterolemia;143890;familial hyperlipidemia;hypercholesterolemia;Abnormality of cholesterol metabolism;ABCA1, ABC1, HDLDT1, TGD;600046;9q31.1
familial hypercholesterolemia;143890;familial hyperlipidemia;hypercholesterolemia;Abnormality of cholesterol metabolism;APOA2;107670;1q23.3
familial hypercholesterolemia;143890;familial hyperlipidemia;hypercholesterolemia;Abnormality of cholesterol metabolism;EPHX2;132811;8p21.2-p21.1
familial hypercholesterolemia;143890;familial hyperlipidemia;hypercholesterolemia;Abnormality of cholesterol metabolism;GHR, GHIP;600946;5p13-p12
familial hypercholesterolemia;143890;familial hyperlipidemia;hypercholesterolemia;Abnormality of cholesterol metabolism;GSBS;604088;7p14.3
familial hypercholesterolemia;143890;familial hyperlipidemia;hypercholesterolemia;Abnormality of cholesterol metabolism;ITIH4, PK120, ITIHL1;600564;3p21.1
familial hypercholesterolemia;143890;familial hyperlipidemia;hypercholesterolemia;Abnormality of cholesterol metabolism;LDLR, FHC, FH, LDLCQ2;606945;19p13.2
familial hypertriglyceridemia;145750;lipid metabolism disorder;precocious atherosclerosis;Atherosclerosis;APOA5;606368;11q23.3
familial hypertriglyceridemia;145750;lipid metabolism disorder;precocious atherosclerosis;Atherosclerosis;LIPI, LPDL, PRED5;609252;21q11.2
familial juvenile hyperuricemic nephropathy;162000;kidney disease;progressive disorder;Pace of progression;UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2;191845;16p12.3
familial juvenile hyperuricemic nephropathy;613092;kidney disease;chronic kidney disease;Renal insufficiency;REN, HNFJ2;179820;1q32.1
familial lipoprotein lipase deficiency;238600;familial hyperlipidemia;hyperchylomicronemia;Hyperlipoproteinemia;LPL, LIPD, HDLCQ11;609708;8p21.3
familial medullary thyroid carcinoma;155240;thyroid medullary carcinoma;medullary thyroid carcinoma;Thyroid carcinoma;NTRK1, TRKA, MTC;191315;1q23.1
familial medullary thyroid carcinoma;155240;thyroid medullary carcinoma;medullary thyroid carcinoma;Thyroid carcinoma;RET, MEN2A, HSCR1;164761;10q11.21
familial meningioma;607174;meningioma;incomplete penetrance;Phenotypic variability;MN1, MGCR;156100;22q12.1
familial meningioma;607174;meningioma;incomplete penetrance;Phenotypic variability;NF2;607379;22q12.2
familial meningioma;607174;meningioma;incomplete penetrance;Phenotypic variability;PDGFB, SIS, IBGC5;190040;22q13.1
familial meningioma;607174;meningioma;incomplete penetrance;Phenotypic variability;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
familial meningioma;607174;meningioma;incomplete penetrance;Phenotypic variability;SMARCE1, BAF57;603111;17q21.2
familial meningioma;607174;meningioma;incomplete penetrance;Phenotypic variability;SUFU, SUFUXL, SUFUH;607035;10q24.32
familial partial lipodystrophy;151660;lipodystrophy;glomerulopathy;Abnormality of the glomerulus;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;1q22
familial partial lipodystrophy;604367;lipodystrophy;toxemia of pregnancy;Prenatal maternal abnormality;PPARG, PPARG1, PPARG2, CIMT1, GLM1;601487;3p25.2
familial partial lipodystrophy;604367;lipodystrophy;toxemia of pregnancy;Prenatal maternal abnormality;PPP1R3A, PPP1R3;600917;7q31.1
familial partial lipodystrophy;613877;lipodystrophy;lipoatrophy;Lipodystrophy;PLIN1, PLIN, FPLD4;170290;15q26.1
familial partial lipodystrophy;615238;lipodystrophy;lipodystrophy;Abnormality of adipose tissue;CIDEC, FSP27, CIDE3, FPLD5;612120;3p25.3
familial visceral amyloidosis;105200;amyloidosis;generalized amyloid deposition;Amyloidosis;APOA1;107680;11q23.3
familial visceral amyloidosis;105200;amyloidosis;generalized amyloid deposition;Amyloidosis;FGA;134820;4q31.3
familial visceral amyloidosis;105200;amyloidosis;generalized amyloid deposition;Amyloidosis;LYZ;153450;12q15
fatal familial insomnia;600072;prion disease;insomnia;Sleep disturbance;PRNP, PRIP, KURU, CJD;176640;20p13
fatal infantile encephalocardiomyopathy;604377;mitochondrial metabolism disease;feeding difficulties in infancy;Feeding difficulties;SCO2, CEMCOX1, MYP6;604272;22q13.33
fatal infantile encephalocardiomyopathy;615119;mitochondrial metabolism disease;gliosis;Abnormality of the glial cells;COX15, CEMCOX2;603646;10q24.2
fibrodysplasia ossificans progressiva;135100;connective tissue disease;cognitive impairment;Abnormality of higher mental function;ACVR1, ACVRLK2, ALK2, FOP;102576;2q24.1
fibular hypoplasia and complex brachydactyly;228900;autosomal recessive disease;absent toe;Aplasia/Hypoplasia of toe;GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;20q11.22
focal dermal hypoplasia;305600;X-linked disease;verrucae;Papilloma;PORCN, PORC, DHOF, FODH;300651;Xp11.23
focal segmental glomerulosclerosis;603278;glomerulosclerosis;hyperlipidemia;Abnormality of lipid metabolism;ACTN4, FSGS1, FSGS;604638;19q13.2
focal segmental glomerulosclerosis;603965;glomerulosclerosis;chronic kidney disease;Renal insufficiency;TRPC6, TRP6, FSGS2;603652;11q22.1
focal segmental glomerulosclerosis;607832;glomerulosclerosis;hypertension;Abnormality of cardiovascular system physiology;CD2AP, CMS;604241;6p12.3
focal segmental glomerulosclerosis;612551;glomerulosclerosis;polygenic inheritance;Multifactorial inheritance;APOL1, FSGS4;603743;22q12.3
focal segmental glomerulosclerosis;613237;glomerulosclerosis;nephrotic syndrome;Abnormal renal physiology;INF2, FSGS5, C14orf173, CMTDIE;610982;14q32.33
focal segmental glomerulosclerosis;614131;glomerulosclerosis;chronic kidney disease;Renal insufficiency;MYO1E, MYO1C, FSGS6;601479;15q22.2
follicular thyroid carcinoma;188470;thyroid carcinoma;follicular thyroid carcinoma;Thyroid carcinoma;HRAS;190020;11p15.5
follicular thyroid carcinoma;188470;thyroid carcinoma;follicular thyroid carcinoma;Thyroid carcinoma;MINPP1, HIPER1;605391;10q23.2
follicular thyroid carcinoma;188470;thyroid carcinoma;follicular thyroid carcinoma;Thyroid carcinoma;NRAS, ALPS4, NS6, CMNS, NCMS;164790;1p13.2
follicular thyroid carcinoma;188470;thyroid carcinoma;follicular thyroid carcinoma;Thyroid carcinoma;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
fragile X syndrome;300624;neurodegenerative disease;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;FMR1, FRAXA, POF1;309550;Xq27.3
fragile X-associated tremor/ataxia syndrome;300623;neurodegenerative disease;abnormal renal physiology;Abnormality of the urinary system physiology;FMR1, FRAXA, POF1;309550;Xq27.3
frontotemporal dementia;600274;basal ganglia disease;inappropriate sexual behavior;Inappropriate behavior;MAPT, MTBT1, DDPAC, MSTD;157140;17q21.31
frontotemporal dementia;600274;basal ganglia disease;inappropriate sexual behavior;Inappropriate behavior;PSEN1, AD3;104311;14q24.2
frontotemporal dementia;600795;basal ganglia disease;babinski sign;Abnormal pyramidal signs;CHMP2B, DMT1, VPS2B, ALS17;609512;3p11.2
fructose-1,6-bisphosphatase deficiency;229700;carbohydrate metabolic disorder;hyperventilation;Abnormal pattern of respiration;FBP1;611570;9q22.32
fucosidosis;230000;lysosomal storage disease;hernia;Abnormality of connective tissue;FUCA1;612280;1p36.11
fundus albipunctatus;136880;fundus dystrophy;retinal flecks;Abnormality of the retina;PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2, MDBS1;179605;6p21.1
fundus albipunctatus;136880;fundus dystrophy;retinal flecks;Abnormality of the retina;RDH5;601617;12q13.2
fundus albipunctatus;136880;fundus dystrophy;retinal flecks;Abnormality of the retina;RHO, RP4, OPN2, CSNBAD1;180380;3q22.1
fundus albipunctatus;136880;fundus dystrophy;retinal flecks;Abnormality of the retina;RLBP1;180090;15q26.1
galactokinase deficiency;230200;galactosemia;hypergalactosemia;Impairment of galactose metabolism;GALK1;604313;17q25.1
galactosemia;230350;carbohydrate metabolic disorder;cognitive impairment;Abnormality of higher mental function;GALE;606953;1p36.11
galactosemia;230400;carbohydrate metabolic disorder;sepsis;Abnormality of immune system physiology;GALT;606999;9p13.3
gallbladder disease;611465;gastrointestinal system disease;polygenic inheritance;Multifactorial inheritance;ABCG8, GBD4;605460;2p21
gamma chain deficiency;300400;severe combined immunodeficiency;chronic oral candidiasis;Chronic mucocutaneous candidiasis;IL2RG, SCIDX1, SCIDX, IMD4;308380;Xq13.1
gangliosidosis GM1;230500;gangliosidosis;cherry red spot of the macula;Abnormality of the macula;GLB1, MPS4B;611458;3p22.3
gangliosidosis GM1;230600;gangliosidosis;decreased beta-galactosidase activity;Abnormality of galactoside metabolism;GLB1, MPS4B;611458;3p22.3
gangliosidosis GM1;230650;gangliosidosis;anterior beaking of lumbar vertebrae;Beaking of vertebral bodies;GLB1, MPS4B;611458;3p22.3
gastrointestinal stromal tumor;606764;gastrointestinal system cancer;neoplasm of the small intestine;Neoplasm of the gastrointestinal tract;KIT, PBT;164920;4q12
gastrointestinal stromal tumor;606764;gastrointestinal system cancer;neoplasm of the small intestine;Neoplasm of the gastrointestinal tract;PDGFRA;173490;4q12
gastrointestinal stromal tumor;606764;gastrointestinal system cancer;neoplasm of the small intestine;Neoplasm of the gastrointestinal tract;SDHB, SDH2, SDHIP, PGL4, CWS2;185470;1p36.13
gastrointestinal stromal tumor;606764;gastrointestinal system cancer;neoplasm of the small intestine;Neoplasm of the gastrointestinal tract;SDHC, PGL3;602413;1q23.3
generalized dystonia;128100;dystonia;incomplete penetrance;Phenotypic variability;DYT1, TOR1A;605204;9q34.11
generalized epilepsy with febrile seizures plus;604233;idiopathic generalized epilepsy;atonic seizures;Generalized seizures;SCN1B, GEFSP1, BRGDA5, ATFB13;600235;19q13.12
generalized epilepsy with febrile seizures plus;604403;idiopathic generalized epilepsy;childhood onset;Onset;SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3;182389;2q24.3
generalized epilepsy with febrile seizures plus;611277;idiopathic generalized epilepsy;atonic seizures;Generalized seizures;GABRG2, GEFSP3, CAE2, ECA2;137164;5q34
generalized epilepsy with febrile seizures plus;613863;idiopathic generalized epilepsy;atonic seizures;Generalized seizures;SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP, HSAN2D;603415;2q24.3
gestational trophoblastic neoplasm;231090;trophoblastic neoplasm;abnormality of the genitourinary system;Phenotypic abnormality;NALP7, NOD12, PYPAF3, HYDM;609661;19q13.42
glucocorticoid-remediable aldosteronism;103900;hyperaldosteronism;adrenal hyperplasia;Abnormality of adrenal morphology;CYP11B1, P450C11, FHI;610613;8q24.3
glycine encephalopathy;605899;amino acid metabolic disorder;impulsivity;Abnormal aggressive, impulsive or violent behavior;AMT, NKH, GCE;238310;3p21.31
glycine encephalopathy;605899;amino acid metabolic disorder;impulsivity;Abnormal aggressive, impulsive or violent behavior;GCSH, NKH;238330;16q23.2
glycine encephalopathy;605899;amino acid metabolic disorder;impulsivity;Abnormal aggressive, impulsive or violent behavior;GLDC, HYGN1, GCSP, GCE, NKH;238300;9p24.1
glycogen storage disease I;232200;glycogen storage disease;decreased glomerular filtration rate;Abnormal glomerular filtration rate;G6PC, G6PT;613742;17q21.31
glycogen storage disease I;232220;glycogen storage disease;decreased glomerular filtration rate;Abnormal glomerular filtration rate;SLC37A4, G6PT1;602671;11q23.3
glycogen storage disease I;232240;glycogen storage disease;spider hemangioma;Teleangiectasia of the skin;SLC37A4, G6PT1;602671;11q23.3
glycogen storage disease II;232300;glycogen storage disease;cognitive impairment;Abnormality of higher mental function;GAA;606800;17q25.3
glycogen storage disease III;232400;glycogen storage disease;cognitive impairment;Abnormality of higher mental function;AGL, GDE;610860;1p21.2
glycogen storage disease IV;232500;glycogen storage disease;tubulointerstitial fibrosis;Tubulointerstitial abnormality;GBE1, GSD4, APBD;607839;3p12.2
glycogen storage disease IX;261750;glycogen storage disease;short stature;Growth delay;PHKB;172490;16q12.1
glycogen storage disease IX;306000;glycogen storage disease;hypercholesterolemia;Abnormality of cholesterol metabolism;PHKA2, PHK, XLG, PHK, PYKL, GSD9A;300798;Xp22.13
glycogen storage disease IX;613027;glycogen storage disease;infantile onset;Onset;PHKG2, GSD9C;172471;16p11.2
glycogen storage disease V;232600;glycogen storage disease;exercise-induced myalgia;Myalgia;PYGM;608455;11q13.1
glycogen storage disease VI;232700;glycogen storage disease;postnatal growth retardation;Growth delay;PYGL;613741;14q22.1
glycogen storage disease VII;232800;glycogen storage disease;reduced erythrocyte 2,3-diphosphoglycerate concentration;Abnormality of erythrocytes;PFKM, GSD7;610681;12q13.11
glycogen storage disease XV;613507;glycogen storage disease;right bundle branch block;Bundle branch block;GYG1, GSD15;603942;3q24
growth hormone secreting pituitary adenoma;102200;functioning pituitary adenoma;galactorrhea;Abnormality of the breast;AIP, XAP2, ARA9;605555;11q13.2
growth hormone secreting pituitary adenoma;102200;functioning pituitary adenoma;galactorrhea;Abnormality of the breast;GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C;139320;20q13.32
growth hormone secreting pituitary adenoma;102200;functioning pituitary adenoma;galactorrhea;Abnormality of the breast;SSTR5;182455;16p13.3
guanidinoacetate methyltransferase deficiency;612736;cerebral creatine deficiency syndrome;infantile muscular hypotonia;Muscular hypotonia;GAMT, CCDS2;601240;19p13.3
gyrate atrophy;258870;choroid disease;posterior subcapsular cataract;Subcapsular cataract;OAT, GACR;613349;10q26.13
hamartoma of hypothalamus;241800;;glioma;Malignant neoplasm of the central nervous system;GLI3, PAPA, PAPB;165240;7p14.1
head and neck squamous cell carcinoma;275355;head and neck carcinoma;squamous cell carcinoma;Neoplasm of the skin;ING1;601566;13q34
head and neck squamous cell carcinoma;275355;head and neck carcinoma;squamous cell carcinoma;Neoplasm of the skin;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
head and neck squamous cell carcinoma;275355;head and neck carcinoma;squamous cell carcinoma;Neoplasm of the skin;TNFRSF10B, DR5, TRAILR2;603612;8p21.3
hemochromatosis;235200;metal metabolism disorder;arrhythmia;Abnormality of cardiovascular system physiology;BMP2, BMP2A, BDA2;112261;20p12.3
hemochromatosis;235200;metal metabolism disorder;arrhythmia;Abnormality of cardiovascular system physiology;HFE, HLA-H, HFE1, MVCD7, TFQTL2;613609;6p22.2
hemochromatosis;602390;metal metabolism disorder;young adult onset;Adult onset;HJV, HFE2A;608374;1q21.1
hemochromatosis;604250;metal metabolism disorder;increased serum ferritin;Abnormal serum ferritin;TFR2, HFE3;604720;7q22.1
hemochromatosis;606069;metal metabolism disorder;abnormality of iron homeostasis;Abnormality of transition element cation homeostasis;SLC40A1, SLC11A3, FPN1, IREG1, HFE4;604653;2q32.2
hemochromatosis;613313;metal metabolism disorder;abnormality of iron homeostasis;Abnormality of transition element cation homeostasis;HAMP, LEAP1, HEPC, HFE2B;606464;19q13.12
hemolytic anemia;266120;normocytic anemia;hemoglobinuria;Abnormality of urine homeostasis;NT5C3A, NT5C3, UMPH1, PSN1;606224;7p14.3
hemolytic anemia;612631;normocytic anemia;hemolytic anemia;Anemia due to reduced life span of red cells;AK1;103000;9q34.11
hemolytic-uremic syndrome;235400;hemolytic anemia;cognitive impairment;Abnormality of higher mental function;CFHR1, FHR1, HFL1, CFHL1;134371;1q31.3
hemolytic-uremic syndrome;235400;hemolytic anemia;cognitive impairment;Abnormality of higher mental function;CFHR3, FHR3, HLF4, CFHL3;605336;1q31.3
hemolytic-uremic syndrome;235400;hemolytic anemia;cognitive impairment;Abnormality of higher mental function;HF1, CFH, HUS, ARMD4, AHUS1;134370;1q31.3
hemolytic-uremic syndrome;612922;hemolytic anemia;anuria;Decreased urine output;MCP, CD46, AHUS2;120920;1q32.2
hemolytic-uremic syndrome;612923;hemolytic anemia;anuria;Decreased urine output;CFI, FI, AHUS3, ARMD13;217030;4q25
hemolytic-uremic syndrome;612924;hemolytic anemia;anuria;Decreased urine output;CFB, BF, GBG, AHUS4, ARMD14, CFBD;138470;6p21.33
hemolytic-uremic syndrome;612925;hemolytic anemia;anuria;Decreased urine output;C3, ARMD9, AHUS5;120700;19p13.3
hemolytic-uremic syndrome;612926;hemolytic anemia;anuria;Decreased urine output;THBD, THRM, AHUS6, THPH12;188040;20p11.21
hemophagocytic lymphohistiocytosis;603552;lymphatic system disease;hemophagocytosis;Abnormality of macrophages;STX11, FHL4, HPLH4, HLH4;605014;6q24.2
hemophagocytic lymphohistiocytosis;603553;lymphatic system disease;csf pleocytosis;Abnormality of the cerebrospinal fluid;PRF1, HPLH2, FLH2;170280;10q22.1
hemophagocytic lymphohistiocytosis;608898;lymphatic system disease;reduced natural killer cell activity;Abnormal natural killer cell physiology;UNC13D, MUNC13-4, HPLH3, HLH3, FHL3;608897;17q25.1
hemophagocytic lymphohistiocytosis;613101;lymphatic system disease;abnormal natural killer cell physiology;Abnormality of natural killer cells;STXBP2, UNC18B, FHL5;601717;19p13.2
hemophilia B;306900;inherited blood coagulation disease;reduced factor ix activity;Abnormality of the intrinsic pathway;F9, HEMB, THPH8;300746;Xq27.1
hemorrhagic thrombocythemia;187950;chronic myeloproliferative disease;myeloproliferative disorder;Leukemia;CALR, SSA;109091;19p13.2
hemorrhagic thrombocythemia;187950;chronic myeloproliferative disease;myeloproliferative disorder;Leukemia;SH2B3, LNK;605093;12q24.12
hemorrhagic thrombocythemia;187950;chronic myeloproliferative disease;myeloproliferative disorder;Leukemia;THPO, MGDF, MPLLG, TPO, THCYT1;600044;3q27.1
hemorrhagic thrombocythemia;601977;chronic myeloproliferative disease;thrombocytosis;Abnormal platelet count;MPL, TPOR, MPLV, THCYT2;159530;1p34.2
hemorrhagic thrombocythemia;614521;chronic myeloproliferative disease;thrombocytosis;Abnormal platelet count;JAK2, THCYT3;147796;9p24.1
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;APC, GS, FPC, BTPS2;611731;5q22.2
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;AXIN1, AXIN;603816;16p13.3
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;CASP8, MCH5, ALPS2B;601763;2q33.1
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;CTNNB1, MRD19;116806;3p22.1
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;IGF2R, MPRI;147280;6q25.3
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;MET;164860;7q31.2
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;PDGFRL, PDGRL, PRLTS;604584;8p22
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
hepatocellular carcinoma;114550;liver carcinoma;subacute progressive viral hepatitis;Viral hepatitis;TP53, P53, LFS1 , BCC7;191170;17p13.1
hereditary angioedema;106100;angioedema;angioedema;Vascular skin abnormality;C1NH, HAE1, HAE2, SERPING1;606860;11q12.1
hereditary angioedema;610618;angioedema;angioedema;Vascular skin abnormality;F12, HAF, HAE3;610619;5q35.3
hereditary breast ovarian cancer;604370;autosomal dominant disease;breast carcinoma;Neoplasm of the breast;BRCA1, PSCP, BROVCA1, PNCA4;113705;17q21.31
hereditary breast ovarian cancer;612555;autosomal dominant disease;breast carcinoma;Neoplasm of the breast;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
hereditary coproporphyria;121300;acute porphyria;insomnia;Sleep disturbance;CPOX;612732;3q11.2-q12.1
hereditary elliptocytosis;130600;hematopoietic system disease;elliptocytosis;Poikilocytosis;SPTA1, EL2, SPH3, HS3, HPP;182860;1q23.1
hereditary elliptocytosis;611804;hematopoietic system disease;elliptocytosis;Poikilocytosis;EPB41, EL1;130500;1p35.3
hereditary hemorrhagic telangiectasia;187300;autosomal dominant disease;celiac artery aneurysm;Aneurysm of an abdominal artery;ENG, END, HHT1, ORW;131195;9q34.11
hereditary hemorrhagic telangiectasia;600376;autosomal dominant disease;brain abscess;CNS infection;ACVRL1, ACVRLK1, ALK1, HHT2;601284;12q13.13
hereditary hemorrhagic telangiectasia;615506;autosomal dominant disease;spontaneous, recurrent epistaxis;Epistaxis;GDF2, BMP9, HHT5;605120;10q11.22
hereditary lymphedema;153100;lymphedema;hyperkeratosis over edematous areas;Edema;FLT4, VEGFR3, PCL, LMPH1A;136352;5q35.3
hereditary lymphedema;613480;lymphedema;cellulitis;Abnormality of connective tissue;GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C;608803;1q42.13
hereditary lymphedema;615907;lymphedema;toenail dysplasia;Abnormality of the toenails;VEGFC, VRP, LMPH1D;601528;4q34.3
hereditary mucosal leukokeratosis;193900;skin disease;oral leukoplakia;Abnormality of oral mucosa;KRT4, CYK4, WSN1;123940;12q13.13
hereditary mucosal leukokeratosis;615785;skin disease;hyperparakeratosis;Parakeratosis;KRT13, WSN2;148065;17q21.2
hereditary multiple exostoses;133700;exostosis;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;EXT1;608177;8q24.11
hereditary multiple exostoses;133701;exostosis;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;EXT2;608210;11p11.2
hereditary night blindness;258100;night blindness;hemeralopia;Abnormality of vision;SAG, RP47;181031;2q37.1
hereditary night blindness;613411;night blindness;congenital stationary night blindness;Night blindness;GRK1, RHOK, RK;180381;13q34
hereditary sensory neuropathy;162400;peripheral neuropathy;chronic axonal neuropathy;Peripheral axonal neuropathy;SPTLC1, LBC1, SPT1, HSN1, HSAN;605712;9q22.31
hereditary sensory neuropathy;201300;peripheral neuropathy;peripheral neuropathy;Abnormal peripheral nervous system morphology;WNK1, PRKWNK1, KDP, PHA2C, HSAN2, HSN2;605232;12p13.33
hereditary sensory neuropathy;256800;peripheral neuropathy;skin ulcer;Localized skin lesion;NTRK1, TRKA, MTC;191315;1q23.1
hereditary sensory neuropathy;608654;peripheral neuropathy;peripheral neuropathy;Abnormal peripheral nervous system morphology;NGF, NGFB, HSAN5;162030;1p13.2
hereditary sensory neuropathy;613115;peripheral neuropathy;osteolytic defects of the phalanges of the hand;Osteolytic defects of the hand bones;FAM134B, HSAN2B;613114;5p15.1
hereditary sensory neuropathy;613640;peripheral neuropathy;skin ulcer;Localized skin lesion;SPTLC2, KIAA0526, SPT2, LCB2, HSN1C, NSAN1C;605713;14q24.3
hereditary sensory neuropathy;613708;peripheral neuropathy;nail dystrophy;Abnormality of the nail;ATL1, SPG3A, HSN1D;606439;14q22.1
hereditary sensory neuropathy;614116;peripheral neuropathy;impulsivity;Abnormal aggressive, impulsive or violent behavior;DNMT1, MCMT, HSN1E, ADCADN;126375;19p13.2
hereditary sensory neuropathy;614213;peripheral neuropathy;peripheral neuropathy;Abnormal peripheral nervous system morphology;KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9;601255;2q37.3
hereditary sensory neuropathy;614653;peripheral neuropathy;feeding difficulties;Abdominal symptom;DST, BPAG1, DMH, D6S1101, HSAN6, EBSB2;113810;6p12.1
hereditary sensory neuropathy;615548;peripheral neuropathy;pain insensitivity;Impaired pain sensation;SCN11A, HSAN7, FEPS3;604385;3p22.2
hereditary sensory neuropathy;615632;peripheral neuropathy;osteolytic defects of the phalanges of the hand;Osteolytic defects of the hand bones;ATL3, HSN1F;609369;11q12.3-q13.1
hereditary spastic paraplegia;182600;paraplegia;paraplegia;Paraplegia/paraparesis;ATL1, SPG3A, HSN1D;606439;14q22.1
hereditary spastic paraplegia;182601;paraplegia;paraplegia;Paraplegia/paraparesis;SPAST, SPG4;604277;2p22.3
hereditary spastic paraplegia;270685;paraplegia;lower limb muscle weakness;Limb muscle weakness;BSCL2, SPG17, HMN5, PELD;606158;11q12.3
hereditary spastic paraplegia;270700;paraplegia;lower limb muscle weakness;Limb muscle weakness;ZFYVE26, KIAA0321, SPG15;612012;14q24.1
hereditary spastic paraplegia;270800;paraplegia;paraplegia;Paraplegia/paraparesis;CYP7B1, CBAS3, SPG5A;603711;8q12.3
hereditary spastic paraplegia;275900;paraplegia;clinodactyly;Abnormality of digit;SPG20;607111;13q13.3
hereditary spastic paraplegia;312920;paraplegia;cognitive impairment;Abnormality of higher mental function;PLP1, PMD, HLD1, SPG2;300401;Xq22.2
hereditary spastic paraplegia;600363;paraplegia;lower limb muscle weakness;Limb muscle weakness;NIPA1, SPG6;608145;15q11.2
hereditary spastic paraplegia;603563;paraplegia;lower limb muscle weakness;Limb muscle weakness;KIAA0196, SPG8, RTSC;610657;8q24.13
hereditary spastic paraplegia;604187;paraplegia;knee clonus;Clonus;KIF5A, NKHC, SPG10;602821;12q13.3
hereditary spastic paraplegia;604360;paraplegia;tip-toe gait;Gait disturbance;SPG11, KIAA1840, FLJ21439;610844;15q21.1
hereditary spastic paraplegia;604805;paraplegia;knee clonus;Clonus;RTN2, NSPL1, SPG12;603183;19q13.32
hereditary spastic paraplegia;605280;paraplegia;lower limb muscle weakness;Limb muscle weakness;HSPD1, SPG13, HSP60, HLD4;118190;2q33.1
hereditary spastic paraplegia;607259;paraplegia;lower limb muscle weakness;Limb muscle weakness;PGN, SPG7, CMAR, CAR;602783;16q24.3
hereditary spastic paraplegia;609195;paraplegia;dyskinesia;Abnormality of movement;B4GALNT1, GALGT, GALNACT, SPG26;601873;12q13.3
hereditary spastic paraplegia;609340;paraplegia;lower limb muscle weakness;Limb muscle weakness;DDHD1, PAPLA1, KIAA1705, SPG28;614603;14q22.1
hereditary spastic paraplegia;610244;paraplegia;ankle clonus;Abnormality of the ankles;ZFYVE27, SPG33;610243;10q24.2
hereditary spastic paraplegia;610250;paraplegia;ankle clonus;Abnormality of the ankles;REEP1, C2ORF23, SPG31, HMN5B;609139;2p11.2
hereditary spastic paraplegia;610357;paraplegia;ankle clonus;Abnormality of the ankles;KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9;601255;2q37.3
hereditary spastic paraplegia;611225;paraplegia;lower limb muscle weakness;Limb muscle weakness;ERLIN2, SPFH2, C8orf2, SPG18;611605;8p11.23
hereditary spastic paraplegia;612020;paraplegia;distal lower limb muscle weakness;Abnormality of the lower limb;PNPLA6, NTE, SPG39, NTEMND, BNHS;603197;19p13.2
hereditary spastic paraplegia;612319;paraplegia;ankle clonus;Abnormality of the ankles;FA2H, FAAH, FAXDC1, FAH1, SCS7, SPG35;611026;16q23.1
hereditary spastic paraplegia;612539;paraplegia;babinski sign;Abnormal pyramidal signs;SLC33A1, ACATN, AT1, SPG42, CCHLND;603690;3q25.31
hereditary spastic paraplegia;612936;paraplegia;cerebral palsy;Abnormality of movement;AP4M1, SPG50, CPSQ3;602296;7q22.1
hereditary spastic paraplegia;613162;paraplegia;dysplastic corpus callosum;Abnormality of the corpus callosum;NT5C2, NT5B, PNT5, SPG45;600417;10q24.32-q24.33
hereditary spastic paraplegia;613206;paraplegia;upper limb spasticity;Spasticity;GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C;608803;1q42.13
hereditary spastic paraplegia;613647;paraplegia;lower limb muscle weakness;Limb muscle weakness;AP5Z1, KIAA0415, SPG48;613653;7p22.1
hereditary spastic paraplegia;613744;paraplegia;intellectual disability, severe;Intellectual disability;AP4E1, SPG51, CPSQ4;607244;15q21.2
hereditary spastic paraplegia;614066;paraplegia;intellectual disability, severe;Intellectual disability;AP4B1, SPG47, CPSQ5;607245;1p13.2
hereditary spastic paraplegia;614067;paraplegia;cerebral palsy;Abnormality of movement;AP4S1, CPSQ6, SPG52;607243;14q12
hereditary spastic paraplegia;614409;paraplegia;knee clonus;Clonus;GBA2, KIAA1605, SPG46;609471;9p13.3
hereditary spastic paraplegia;614898;paraplegia;kyphosis;Abnormality of the curvature of the vertebral column;VPS37A, HCRP1, SPG53;609927;8p22
hereditary spastic paraplegia;615030;paraplegia;cognitive impairment;Abnormality of higher mental function;CYP2U1, SPG56;610670;4q25
hereditary spastic paraplegia;615031;paraplegia;short stature;Growth delay;TECPR2, KIAA0329, SPG49;615000;14q32.31
hereditary spastic paraplegia;615033;paraplegia;lower limb muscle weakness;Limb muscle weakness;DDHD2, KIAA0725, SPG54;615003;8p11.23
hereditary spastic paraplegia;615035;paraplegia;cognitive impairment;Abnormality of higher mental function;C12orf65, COXPD7, SPG55;613541;12q24.31
hereditary spastic paraplegia;615043;paraplegia;ankle contracture;Contractures of the joints of the lower limbs;C19orf12, NBIA4, SPG43;614297;19q12
hereditary spastic paraplegia;615625;paraplegia;slow progression;Pace of progression;REEP2, C5orf19, SPG72;609347;5q31.2
hereditary spastic paraplegia;615658;paraplegia;babinski sign;Abnormal pyramidal signs;TFG, HMSNP, SPG57;602498;3q12.2
hereditary spherocytosis;182900;congenital hemolytic anemia;spherocytosis;Poikilocytosis;ANK1, SPH2;612641;8p11.21
hereditary spherocytosis;270970;congenital hemolytic anemia;spherocytosis;Poikilocytosis;SPTA1, EL2, SPH3, HS3, HPP;182860;1q23.1
hereditary spherocytosis;612653;congenital hemolytic anemia;increased red cell osmotic fragility;Abnormality of erythrocytes;SLC4A1, AE1, EPB3;109270;17q21.31
hereditary spherocytosis;612690;congenital hemolytic anemia;spherocytosis;Poikilocytosis;EPB42, SPH5;177070;15q15.2
hidradenitis suppurativa;142690;hidradenitis;atypical scarring of skin;Scarring;NCSTN;605254;1q23.2
hidradenitis suppurativa;613736;hidradenitis;recurrent cutaneous abscess formation;Recurrent bacterial skin infections;PSENEN, PEN2;607632;19q13.12
hidradenitis suppurativa;613737;hidradenitis;recurrent cutaneous abscess formation;Recurrent bacterial skin infections;PSEN1, AD3;104311;14q24.2
holocarboxylase synthetase deficiency;253270;multiple carboxylase deficiency;cheilitis;Abnormality of the lip;HLCS, HCS;609018;21q22.13
holoprosencephaly;142945;congenital nervous system abnormality;proboscis;Abnormal nasal morphology;SHH, HPE3, HLP3, SMMCI, MCOPCB5;600725;7q36.3
holoprosencephaly;142946;congenital nervous system abnormality;median cleft lip and palate;Median cleft palate;TGIF, HPE4;602630;18p11.31
holoprosencephaly;157170;congenital nervous system abnormality;midface retrusion;Abnormality of the midface;SIX3, HPE2;603714;2p21
holoprosencephaly;609637;congenital nervous system abnormality;depressed nasal bridge;Abnormality of the nasal bridge;ZIC2, HPE5;603073;13q32.3
holoprosencephaly;610828;congenital nervous system abnormality;abnormality of thalamus morphology;Abnormality of the diencephalon;PTCH1, NBCCS, BCNS, HPE7;601309;9q22.32
holoprosencephaly;610829;congenital nervous system abnormality;midface retrusion;Abnormality of the midface;GLI2, HPE9, CJS;165230;2q14.2
holoprosencephaly;614226;congenital nervous system abnormality;holoprosencephaly;Abnormality of brain morphology;CDON, CDO, HPE11;608707;11q24.2
homocystinuria;236200;amino acid metabolic disorder;hernia;Abnormality of connective tissue;CBS;613381;21q22.3
homocystinuria;236250;amino acid metabolic disorder;paresthesia;Sensory neuropathy;MTHFR;607093;1p36.22
hydrocephalus;236600;intracranial hypertension;congenital onset;Onset;CCDC88C, HKRP2, DAPLE, KIAA1509, HYC, SCA40;611204;14q32.11
hydrocephalus;307000;intracranial hypertension;cognitive impairment;Abnormality of higher mental function;L1CAM, CAML1, HSAS1, MASA, SPG1;308840;Xq28
hydrocephalus;615219;intracranial hypertension;cortical gyral simplification;Abnormal cortical gyration;MPDZ, MUPP1, HYC2;603785;9p23
hydrolethalus syndrome;236680;autosomal recessive disease;bifid nose;Midline defect of the nose;HYLS1, FLJ32915;610693;11q24.2
hydrolethalus syndrome;614120;autosomal recessive disease;postaxial polydactyly;Polydactyly;KIF7, HLS2, ACLS, JBTS12;611254;15q26.1
hyperaldosteronism;613677;adrenal gland hyperfunction;adrenal hyperplasia;Abnormality of adrenal morphology;KCNJ5, GIRK4, KATP1, LQT13;600734;11q24.3
hyperargininemia;207800;urea cycle disorder;cognitive impairment;Abnormality of higher mental function;ARG1;608313;6q23.2
hyperinsulinemic hypoglycemia;256450;carbohydrate metabolic disorder;pancreatic islet-cell hyperplasia;Abnormality of the pancreatic islet cells;ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2;600509;11p15.1
hyperinsulinemic hypoglycemia;601820;carbohydrate metabolic disorder;pancreatic islet-cell hyperplasia;Abnormality of the pancreatic islet cells;KCNJ11, BIR, PHHI, HHF2, TNDM3;600937;11p15.1
hyperinsulinemic hypoglycemia;602485;carbohydrate metabolic disorder;hypoglycemic seizures;Symptomatic seizures;GCK, HHF3;138079;7p13
hyperinsulinemic hypoglycemia;606762;carbohydrate metabolic disorder;asymptomatic hyperammonemia;Hyperammonemia;GLUD1;138130;10q23.2
hyperinsulinemic hypoglycemia;609968;carbohydrate metabolic disorder;fasting hyperinsulinemia;Hyperinsulinemia;INSR, HHF5;147670;19p13.2
hyperinsulinemic hypoglycemia;609975;carbohydrate metabolic disorder;hypoglycemic seizures;Symptomatic seizures;HADHSC, SCHAD, HHF4;601609;4q25
hyperinsulinemic hypoglycemia;610021;carbohydrate metabolic disorder;pancreatic islet-cell hyperplasia;Abnormality of the pancreatic islet cells;SLC16A1, MCT1, HHF7, MCT1D;600682;1p13.2
hyperkalemic periodic paralysis;170500;familial periodic paralysis;chest pain;Abnormality of the thorax;SCN4A, HYPP, NAC1A, HOKPP2;603967;17q23.3
hyperlipoproteinemia type V;144650;familial hyperlipidemia;hyperchylomicronemia;Hyperlipoproteinemia;APOA5;606368;11q23.3
hyperlysinemia;238700;amino acid metabolic disorder;cognitive impairment;Abnormality of higher mental function;AASS;605113;7q31.32
hypermethioninemia;613752;amino acid metabolic disorder;hypermethioninemia;Abnormality of methionine metabolism;AHCY, SAHH;180960;20q11.22
hypermethioninemia;614300;amino acid metabolic disorder;portal fibrosis;Abnormality of the biliary system;ADK;102750;10q22.2
hyperparathyroidism;145000;parathyroid gland disease;primary hyperparathyroidism;Hyperparathyroidism;HRPT2, C1orf28;607393;1q31.2
hyperparathyroidism;145001;parathyroid gland disease;recurrent pancreatitis;Pancreatitis;HRPT2, C1orf28;607393;1q31.2
hyperthyroidism;603373;thyroid gland disease;hyperemesis gravidarum;Prenatal maternal abnormality;TSHR, CHNG1;603372;14q31.1
hyperthyroidism;609152;thyroid gland disease;thyroid hyperplasia;Abnormality of thyroid morphology;TSHR, CHNG1;603372;14q31.1
hypertrophic cardiomyopathy;115195;intrinsic cardiomyopathy;hypertrophic cardiomyopathy;Cardiomyopathy;TNNT2, CMH2, CMD1D, RCM3, LVNC6;191045;1q32.1
hypertrophic cardiomyopathy;115196;intrinsic cardiomyopathy;hypertrophic cardiomyopathy;Cardiomyopathy;TPM1, CMH3, CMD1Y , LVNC9;191010;15q22.2
hypertrophic cardiomyopathy;115197;intrinsic cardiomyopathy;hypertrophic cardiomyopathy;Cardiomyopathy;MYBPC3, CMH4, CMD1MM, LVNC10;600958;11p11.2
hypertrophic cardiomyopathy;192600;intrinsic cardiomyopathy;arrhythmia;Abnormality of cardiovascular system physiology;CAV3, LGMD1C, LQT9;601253;3p25.3
hypertrophic cardiomyopathy;192600;intrinsic cardiomyopathy;arrhythmia;Abnormality of cardiovascular system physiology;MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD;160760;14q11.2
hypertrophic cardiomyopathy;192600;intrinsic cardiomyopathy;arrhythmia;Abnormality of cardiovascular system physiology;MYLK2, MLCK;606566;20q11.21
hypertrophic cardiomyopathy;600858;intrinsic cardiomyopathy;left bundle branch block;Bundle branch block;PRKAG2, WPWS, CMH6;602743;7q36.1
hypertrophic cardiomyopathy;608751;intrinsic cardiomyopathy;endocardial fibrosis;Abnormality of the endocardium;MYL3, CMH8;160790;3p21.31
hypertrophic cardiomyopathy;608758;intrinsic cardiomyopathy;left ventricular septal hypertrophy;Abnormality of the ventricular septum;MYL2, CMH10;160781;12q24.11
hypertrophic cardiomyopathy;612098;intrinsic cardiomyopathy;arrhythmia;Abnormality of cardiovascular system physiology;ACTC1, CMD1R, CMH11, ASD5, LVNC4;102540;15q14
hypertrophic cardiomyopathy;612124;intrinsic cardiomyopathy;paroxysmal atrial fibrillation;Atrial fibrillation;CSRP3, CRP3, CLP, CMD1M, CMH12;600824;11p15.1
hypertrophic cardiomyopathy;613243;intrinsic cardiomyopathy;hypertrophic cardiomyopathy;Cardiomyopathy;TNNC1, CMD1Z, CMH13;191040;3p21.1
hypertrophic cardiomyopathy;613251;intrinsic cardiomyopathy;hypertrophic cardiomyopathy;Cardiomyopathy;MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3;160710;14q11.2
hypertrophic cardiomyopathy;613255;intrinsic cardiomyopathy;dyspnea;Respiratory insufficiency;VCL, CMD1W, CMH15;193065;10q22.2
hypertrophic cardiomyopathy;613690;intrinsic cardiomyopathy;atrial fibrillation;Primary atrial arrhythmia;TNNI3, CMH7, CMD2A, RCM1, CMD1FF;191044;19q13.42
hypertrophic cardiomyopathy;613765;intrinsic cardiomyopathy;dilated cardiomyopathy;Cardiomyopathy;TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC;188840;2q31.2
hypertrophic cardiomyopathy;613838;intrinsic cardiomyopathy;left bundle branch block;Bundle branch block;MYOZ2, CMH16;605602;4q26
hypertrophic cardiomyopathy;613873;intrinsic cardiomyopathy;ventricular tachycardia;Tachycardia;JPH2, JP2, CMH17;605267;20q13.12
hypertrophic cardiomyopathy;613874;intrinsic cardiomyopathy;atrial fibrillation;Primary atrial arrhythmia;PLN, PLB, CMD1P, CMH18;172405;6q22.31
hypertrophic cardiomyopathy;613875;intrinsic cardiomyopathy;asymmetric septal hypertrophy;Hypertrophic cardiomyopathy;CALR3, CRT2, CMH19;611414;19p13.11
hypertrophic cardiomyopathy;613876;intrinsic cardiomyopathy;atrial fibrillation;Primary atrial arrhythmia;NEXN, NELIN, CMD1CC, CMH20;613121;1p31.1
hypochromic microcytic anemia;206100;microcytic anemia;abnormality of metabolism/homeostasis;Phenotypic abnormality;NRAMP2;600523;12q13.12
hypochromic microcytic anemia;615234;microcytic anemia;increased serum ferritin;Abnormal serum ferritin;STEAP3, TSAP6, AHMIO2;609671;2q14.2
hypogonadism;146110;gonadal disease;decreased testicular size;Aplasia/Hypoplasia of the testes;GNRHR, LHRHR, HH7;138850;4q13.2
hypohidrotic ectodermal dysplasia;129490;monogenic disease;slow-growing hair;Abnormality of hair growth rate;EDAR, DL, ED3, EDA3, HRM1, ECTD10A, ECTD10B;604095;2q12.3
hypohidrotic ectodermal dysplasia;224900;monogenic disease;thick vermilion border;Abnormality of the lip;EDAR, DL, ED3, EDA3, HRM1, ECTD10A, ECTD10B;604095;2q12.3
hypohidrotic ectodermal dysplasia;300291;monogenic disease;dysgammaglobulinemia;Hypogammaglobulinemia;IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1, IMD33;300248;Xq28
hypohidrotic ectodermal dysplasia;305100;monogenic disease;type i diabetes mellitus;Diabetes mellitus;ED1, EDA, ECTD1, EDA, HED1, STHAGX1;300451;Xq13.1
hypokalemic periodic paralysis;170400;familial periodic paralysis;periodic hyperkalemic paralysis;Periodic paralysis;CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1;114208;1q32.1
hypokalemic periodic paralysis;613345;familial periodic paralysis;phenotypic variability;Clinical modifier;SCN4A, HYPP, NAC1A, HOKPP2;603967;17q23.3
hypoparathyroidism;146200;hypersensitivity reaction type II disease;hyperphosphatemia;Abnormality of phosphate homeostasis;GCMB;603716;6p24.2
hypoparathyroidism;146200;hypersensitivity reaction type II disease;hyperphosphatemia;Abnormality of phosphate homeostasis;PTH;168450;11p15.2
hypophosphatasia;146300;autosomal dominant disease;premature loss of permanent teeth;Premature loss of teeth;ALPL, HOPS, TNSALP;171760;1p36.12
hypophosphatasia;241500;autosomal dominant disease;elevated plasma pyrophosphate;Abnormality of phosphate homeostasis;ALPL, HOPS, TNSALP;171760;1p36.12
hypophosphatasia;241510;autosomal dominant disease;elevated plasma pyrophosphate;Abnormality of phosphate homeostasis;ALPL, HOPS, TNSALP;171760;1p36.12
hypopituitarism;221750;pituitary gland disease;anterior pituitary hypoplasia;Anterior pituitary dysgenesis;LHX3, CPHD3;600577;9q34.3
hypopituitarism;262600;pituitary gland disease;prolactin deficiency;Abnormal prolactin level;PROP1, CPHD2;601538;5q35.3
hypopituitarism;262700;pituitary gland disease;small sella turcica;Abnormality of the sella turcica;LHX4, CPHD4;602146;1q25.2
hypopituitarism;613038;pituitary gland disease;midface retrusion;Abnormality of the midface;POU1F1, PIT1, CPHD1;173110;3p11.2
hypopituitarism;613986;pituitary gland disease;ectopic posterior pituitary;Posterior pituitary dysgenesis;OTX2, MCOPS5, CPHD6;600037;14q22.3
hypoplastic left heart syndrome;241550;congenital heart disease;hypoplastic left heart;Congenital malformation of the left heart;GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR;121014;6q22.31
hypoplastic left heart syndrome;614435;congenital heart disease;mitral atresia;Abnormal atrioventricular connection;NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;600584;5q35.1
hypospadias;300633;physical disorder;x-linked recessive inheritance;X-linked inheritance;AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1;313700;Xq12
hypospadias;300758;physical disorder;x-linked recessive inheritance;X-linked inheritance;MAMLD1, CXorf6, F18, HYSP2;300120;Xq28
hypotrichosis;146520;hair disease;hypotrichosis of the scalp;Hypotrichosis;CDSN, HTSS1, HYPT2, PSS1;602593;6p21.33
hypotrichosis;146550;hair disease;pili torti;Abnormal hair laboratory examination;HR, AU, MUHH1, HYPT4;602302;8p21.3
hypotrichosis;278150;hair disease;dry hair;Abnormality of hair texture;LPAR6, P2RY5, P2Y5, LAH3, ARWH1, HYPT8;609239;13q14.2
hypotrichosis;601553;hair disease;immunologic hypersensitivity;Abnormality of immune system physiology;CDH3, CDHP, PCAD, HJMD;114021;16q22.1
hypotrichosis;604379;hair disease;woolly hair;Abnormality of hair texture;LIPH, LAH2, ARWH2, HYPT7;607365;3q27.2
hypotrichosis;605389;hair disease;hypotrichosis;Abnormal hair quantity;APCDD1, HHS, HYPT1, HTS;607479;18p11.22
hypotrichosis;607903;hair disease;erythema;Vascular skin abnormality;DSG4, LAH, HYPT6;607892;18q12.1
hypotrichosis;613981;hair disease;hypotrichosis of the scalp;Hypotrichosis;KRT74, K6IRS4, KRT6IRS4, HTSS2, HYPT3, ADWH;608248;12q13.13
hypotrichosis;615059;hair disease;sparse or absent eyelashes;Abnormality of the eyelashes;SNRPE, HYPT11;128260;1q32.1
hypotrichosis;615885;hair disease;sparse or absent eyelashes;Abnormality of the eyelashes;RPL21, HYPT12;603636;13q12.2
ichthyosis vulgaris;146700;autosomal dominant disease;ichthyosis;Epidermal thickening;FLG, ATOD2;135940;1q21.3
idiopathic generalized epilepsy;600669;epilepsy syndrome;eeg with spike-wave complexes (>3.5 hz);EEG with spike-wave complexes;ME2, ODS1;154270;18q21.2
idiopathic generalized epilepsy;607628;epilepsy syndrome;generalized tonic-clonic seizures on awakening;Generalized tonic-clonic seizures;CLCN2, EGMA, ECA2, EGI11, EJM8, LKPAT;600570;3q27.1
idiopathic generalized epilepsy;607682;epilepsy syndrome;generalized tonic-clonic seizures on awakening;Generalized tonic-clonic seizures;CACNB4, EJM6, EA5, EIG9;601949;2q23.3
idiopathic generalized epilepsy;613060;epilepsy syndrome;focal seizures;Seizures;GABRD, GEFSP5, EIG10, EJM7;137163;1p36.33
idiopathic generalized epilepsy;614847;epilepsy syndrome;incomplete penetrance;Phenotypic variability;SLC2A1, GLUT1, DYT18, PED, GLUT1DS, EIG12, DYT9;138140;1p34.2
idiopathic pulmonary fibrosis;178500;idiopathic interstitial pneumonia;clubbing of fingers;Clubbing;MUC5B;600770;11p15.5
idiopathic pulmonary fibrosis;178500;idiopathic interstitial pneumonia;clubbing of fingers;Clubbing;SFTPA1, SFTP1;178630;10q22.3
idiopathic pulmonary fibrosis;178500;idiopathic interstitial pneumonia;clubbing of fingers;Clubbing;SFTPA2, SPA2, COLEC5;178642;10q22.3
immunoglobulin alpha deficiency;609529;B cell deficiency;abnormality of cells of the lymphoid lineage;Abnormality of bone marrow cell morphology;TNFRSF13B, TACI, CVID2;604907;17p11.2
inclusion body myopathy with Paget disease of bone and frontotemporal dementia;167320;syndrome;elevated alkaline phosphatase of bone origin;Elevated tissue non-specific alkaline phosphatase;VCP, IBMPFD1, ALS14;601023;9p13.3
inclusion body myositis;600737;myositis;rimmed vacuoles;Abnormality of muscle fibers;GNE, GLCNE, IBM2, DMRV, NM;603824;9p13.3
inclusion body myositis;605637;myositis;muscle fiber inclusion bodies;Abnormality of muscle fibers;MYH2;160740;17p13.1
inclusion body myositis;605820;myositis;rimmed vacuoles;Abnormality of muscle fibers;GNE, GLCNE, IBM2, DMRV, NM;603824;9p13.3
infantile cerebellar-retinal degeneration;614559;neurodegenerative disease;severe global developmental delay;Global developmental delay;ACO2, ICRD;100850;22q13.2
infantile epileptic encephalopathy;300088;idiopathic generalized epilepsy;atonic seizures;Generalized seizures;PCDH19, KIAA1313, EFMR, EIEE9;300460;Xq22.1
infantile epileptic encephalopathy;300607;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;ARHGEF9, PEM2, KIAA0424, EIEE8;300429;Xq11.1-q11.2
infantile epileptic encephalopathy;300672;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;CDKL5, STK9, ISSX, EIEE2;300203;Xp22.13
infantile epileptic encephalopathy;607208;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3;182389;2q24.3
infantile epileptic encephalopathy;607208;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP, HSAN2D;603415;2q24.3
infantile epileptic encephalopathy;609304;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;SLC25A22, GC1, EIEE3;609302;11p15.5
infantile epileptic encephalopathy;612164;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;STXBP1, UNC18, EIEE4;602926;9q34.11
infantile epileptic encephalopathy;613402;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;PNKP, PNK, MCSZ, EIEE10, MCSZ;605610;19q13.33
infantile epileptic encephalopathy;613477;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;SPTAN1, NEAS, EIEE5;182810;9q34.11
infantile epileptic encephalopathy;613720;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;KCNQ2, EBN1, EIEE7, BFNS1;602235;20q13.33
infantile epileptic encephalopathy;613721;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;SCN2A, SCN2A1, BFIC3, EIEE11, BFIS3, BFNIS;182390;2q24.3
infantile epileptic encephalopathy;613722;idiopathic generalized epilepsy;epileptic encephalopathy;Encephalopathy;PLCB1, KIAA0581, PLCB1A, PLCB1B, EIEE12;607120;20p12.3
infantile onset spinocerebellar ataxia;271245;spinocerebellar ataxia;epileptic encephalopathy;Encephalopathy;C10orf2, TWINKLE, PEO1, PEOA3, IOSCA, MTDPS7, PRLTS5;606075;10q24.31
infantile refsum disease;266510;peroxisomal disease;flat face;Abnormal facial shape;PEX12, PBD3A;601758;17q12
inflammatory bowel disease;266600;intestinal disease;ulcerative colitis;Chronic colitis;IL6, IFNB2, BSF2, HSF, HGF;147620;7p15.3
inflammatory bowel disease;266600;intestinal disease;ulcerative colitis;Chronic colitis;NOD2, CARD15, IBD1, CD, ACUG, PSORAS1;605956;16q12.1
inflammatory bowel disease;612244;intestinal disease;inflammation of the large intestine;Gastrointestinal inflammation;ABCB1, PGY1, MDR1, IBD13, CLCs;171050;7q21.12
inflammatory bowel disease;612278;intestinal disease;inflammation of the large intestine;Gastrointestinal inflammation;IRGM, LRG47, IFI1, IBD19;608212;5q33.1
inflammatory bowel disease;612567;intestinal disease;rectal abscess;Recurrent abscess formation;CRFB4, IBD25;123889;21q22.11
inflammatory bowel disease;613148;intestinal disease;perianal abscess;Recurrent cutaneous abscess formation;IL10RA, IL10R, IBD28;146933;11q23.3
intermediate spinal muscular atrophy;253550;spinal muscular atrophy;spinal muscular atrophy;Skeletal muscle atrophy;SMN1, SMA1, SMA2, SMA3, SMA4;600354;5q13.2
intrahepatic cholestasis;147480;liver disease;increased serum bile acid concentration during pregnancy;Increased serum bile acid concentration;ATP8B1, FIC1, BRIC, PFIC1, ICP1;602397;18q21.31
intrahepatic cholestasis;211600;liver disease;intrahepatic cholestasis with episodic jaundice;Intrahepatic cholestasis;ATP8B1, FIC1, BRIC, PFIC1, ICP1;602397;18q21.31
intrahepatic cholestasis;243300;liver disease;conjugated hyperbilirubinemia;Hyperbilirubinemia;ATP8B1, FIC1, BRIC, PFIC1, ICP1;602397;18q21.31
intrahepatic cholestasis;601847;liver disease;short stature;Growth delay;ABCB11, BSEP, SPGP, PFIC2, BRIC2;603201;2q31.1
intrahepatic cholestasis;602347;liver disease;portal fibrosis;Abnormality of the biliary system;ABCB4, PGY3, MDR3, ICP3;171060;7q21.12
intrahepatic cholestasis;605479;liver disease;elevated alkaline phosphatase;Abnormality of alkaline phosphatase activity;ABCB11, BSEP, SPGP, PFIC2, BRIC2;603201;2q31.1
intrahepatic cholestasis;614972;liver disease;increased serum bile acid concentration during pregnancy;Increased serum bile acid concentration;ABCB4, PGY3, MDR3, ICP3;171060;7q21.12
intrahepatic cholestasis;615878;liver disease;portal hypertension;Abnormality of the hepatic vasculature;TJP2, ZO2, PFIC4;607709;9q21.11
iridogoniodysgenesis syndrome;137600;autosomal dominant disease;hypoplastic iris stroma;Hypoplasia of the iris;PITX2, IDG2, RIEG1, RGS, IGDS2;601542;4q25
iridogoniodysgenesis syndrome;601631;autosomal dominant disease;hypoplastic iris stroma;Hypoplasia of the iris;FOXC1, FKHL7, FREAC3, IRID1, RIEG3;601090;6p25.3
isovaleric acidemia;243500;organic acidemia;cognitive impairment;Abnormality of higher mental function;IVD;607036;15q15.1
juvenile myelomonocytic leukemia;607785;myelodysplastic myeloproliferative cancer;juvenile myelomonocytic leukemia;Myeloid leukemia;ARHGAP26, GRAF;605370;5q31.3
juvenile myelomonocytic leukemia;607785;myelodysplastic myeloproliferative cancer;juvenile myelomonocytic leukemia;Myeloid leukemia;NF1, VRNF, WSS, NFNS;613113;17q11.2
juvenile myelomonocytic leukemia;607785;myelodysplastic myeloproliferative cancer;juvenile myelomonocytic leukemia;Myeloid leukemia;PTPN11, PTP2C, SHP2, NS1;176876;12q24.13
juvenile myoclonic epilepsy;254770;adolescence-adult electroclinical syndrome;eeg with generalized polyspikes;EEG with generalized epileptiform discharges;EFHC1, FLJ10466, EJM1, JAE, EJA1;608815;6p12.2
juvenile myoclonic epilepsy;607631;adolescence-adult electroclinical syndrome;eeg with spike-wave complexes (>3.5 hz);EEG with spike-wave complexes;EFHC1, FLJ10466, EJM1, JAE, EJA1;608815;6p12.2
juvenile polyposis syndrome;174900;autosomal dominant disease;duodenal carcinoma;Neoplasm of the small intestine;BMPR1A, ACVRLK3, ALK3;601299;10q23.2
juvenile polyposis syndrome;174900;autosomal dominant disease;duodenal carcinoma;Neoplasm of the small intestine;MADH4, DPC4, SMAD4, JIP, MYHRS;600993;18q21.2
juvenile rheumatoid arthritis;604302;rheumatoid arthritis;mediastinal lymphadenopathy;Abnormality of the mediastinum;IL6, IFNB2, BSF2, HSF, HGF;147620;7p15.3
juvenile rheumatoid arthritis;604302;rheumatoid arthritis;mediastinal lymphadenopathy;Abnormality of the mediastinum;MIF;153620;22q11.23
juvenile spinal muscular atrophy;253400;survival motor neuron spinal muscular atrophy;limb fasciculations;Fasciculations;SMN1, SMA1, SMA2, SMA3, SMA4;600354;5q13.2
juvenile spinal muscular atrophy;253400;survival motor neuron spinal muscular atrophy;limb fasciculations;Fasciculations;SMN2;601627;5q13.2
keratoconus;148300;corneal disease;young adult onset;Adult onset;VSX1, RINX, PPCD1, PPD, KTCN1, CAASDS;605020;20p11.21
keratosis follicularis;124200;keratosis;acrokeratosis;Skin nodule;ATP2A2, ATP2B, DAR;108740;12q24.11
lactose intolerance;223100;carbohydrate metabolic disorder;lactose intolerance;Malabsorption;MCM6;601806;2q21.3
leprosy;246300;primary bacterial infectious disease;abnormality of the immune system;Phenotypic abnormality;TLR2, TIL4;603028;4q31.3
leukocyte adhesion deficiency;116920;autosomal recessive disease;recurrent staphylococcal infections;Recurrent bacterial infections;ITGB2, CD18, LCAMB, LAD;600065;21q22.3
leukocyte adhesion deficiency;266265;autosomal recessive disease;intellectual disability, severe;Intellectual disability;SLC35C1, FUCT1, CDG2C;605881;11p11.2
leukocyte adhesion deficiency;612840;autosomal recessive disease;infantile onset;Onset;KIND3, URP2, MIG2B, FERMT3;607901;11q13.1
limb-girdle muscular dystrophy;159000;muscular dystrophy;nasal, dysarthic speech;Dysarthria;MYOT, TTOD, MFM3;604103;5q31.2
limb-girdle muscular dystrophy;159001;muscular dystrophy;pelvic girdle amyotrophy;Limb-girdle muscle atrophy;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;1q22
limb-girdle muscular dystrophy;253600;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;CAPN3, CANP3;114240;15q15.1
limb-girdle muscular dystrophy;253601;muscular dystrophy;difficulty running;Functional motor problems.;DYSF, LGMD2B, MMD1;603009;2p13.2
limb-girdle muscular dystrophy;253700;muscular dystrophy;right ventricular dilatation;Abnormality of the right ventricle;SGCG, LGMD2C, DMDA1, SCG3;608896;13q12.12
limb-girdle muscular dystrophy;254110;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;TRIM32, HT2A, LGMD2H, BBS11;602290;9q33.1
limb-girdle muscular dystrophy;601287;muscular dystrophy;proximal amyotrophy;Skeletal muscle atrophy;SGCD, SGD, LGMD2F, CMD1L;601411;5q33.2-q33.3
limb-girdle muscular dystrophy;601954;muscular dystrophy;distal lower limb muscle weakness;Abnormality of the lower limb;TCAP, LGMD2G, CMD1N;604488;17q12
limb-girdle muscular dystrophy;603511;muscular dystrophy;rimmed vacuoles;Abnormality of muscle fibers;DNAJB6, MRJ, DJ4, LGMD1E;611332;7q36.3
limb-girdle muscular dystrophy;604286;muscular dystrophy;pelvic girdle muscle atrophy;Aplasia/Hypoplasia of the musculature of the pelvis;SGCB, LGMD2E;600900;4q12
limb-girdle muscular dystrophy;607155;muscular dystrophy;toe walking;Gait disturbance;FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5;606596;19q13.32
limb-girdle muscular dystrophy;607801;muscular dystrophy;childhood onset;Onset;CAV3, LGMD1C, LQT9;601253;3p25.3
limb-girdle muscular dystrophy;608099;muscular dystrophy;calf muscle hypertrophy;Muscle hypertrophy of the lower extremities;SGCA, ADL, DAG2, LGMD2D, DMDA2;600119;17q21.33
limb-girdle muscular dystrophy;608423;muscular dystrophy;increased connective tissue;Abnormality of connective tissue;TNPO3, TRNSR, LGMD1F;610032;7q32.1
limb-girdle muscular dystrophy;608807;muscular dystrophy;childhood onset;Onset;TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC;188840;2q31.2
limb-girdle muscular dystrophy;609115;muscular dystrophy;proximal lower limb amyotrophy;Proximal amyotrophy;HNRNPDL, HNRPDL, JKTBP, LGMD1G;607137;4q21.22
limb-girdle muscular dystrophy;609308;muscular dystrophy;variable expressivity;Phenotypic variability;POMT1, MDDGA1, MDDGB1, MDDGC1;607423;9q34.13
limb-girdle muscular dystrophy;611307;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;ANO5, TMEM16E, GDD1, LGMD2L;608662;11p14.3
limb-girdle muscular dystrophy;611588;muscular dystrophy;variable expressivity;Phenotypic variability;FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4;607440;9q31.2
limb-girdle muscular dystrophy;613157;muscular dystrophy;fatigue;Behavioral abnormality;POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3;606822;1p34.1
limb-girdle muscular dystrophy;613158;muscular dystrophy;right bundle branch block;Bundle branch block;POMT2, MDDGA2, MDDGB2, MDDGC2;607439;14q24.3
limb-girdle muscular dystrophy;613723;muscular dystrophy;rapidly progressive;Pace of progression;PLEC1, PLEC, PLTN, EBS1, LGMD2Q;601282;8q24.3
limb-girdle muscular dystrophy;613818;muscular dystrophy;ankle contracture;Contractures of the joints of the lower limbs;DAG1, DAG, MDDGC9;128239;3p21.31
limb-girdle muscular dystrophy;615325;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;DES, CMD1I, MFM1, SCPNK, ARVD7, ARVC7, LGMD2R;125660;2q35
limb-girdle muscular dystrophy;615352;muscular dystrophy;phenotypic variability;Clinical modifier;GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14;615320;3p21.31
limb-girdle muscular dystrophy;615356;muscular dystrophy;limb-girdle muscular dystrophy;Limb-girdle muscle atrophy;TRAPPC11, C4orf41, LGMD2S;614138;4q35.1
lipoid proteinosis;247100;lipid metabolism disorder;verrucae;Papilloma;ECM1, URBWD;602201;1q21.3
lissencephaly;257320;congenital nervous system abnormality;thick cerebral cortex;Abnormality of the cerebral cortex;RELN, RL, LIS2;600514;7q22.1
lissencephaly;300067;congenital nervous system abnormality;cognitive impairment;Abnormality of higher mental function;DCX, DBCN, LISX;300121;Xq23
lissencephaly;300215;congenital nervous system abnormality;cognitive impairment;Abnormality of higher mental function;ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32;300382;Xp21.3
lissencephaly;607432;congenital nervous system abnormality;muscular hypotonia of the trunk;Muscular hypotonia;PAFAH1B1, LIS1;601545;17p13.3
lissencephaly;611603;congenital nervous system abnormality;intellectual disability, severe;Intellectual disability;TUBA1A, TUBA3, LIS3;602529;12q13.12
lissencephaly;614019;congenital nervous system abnormality;cortical gyral simplification;Abnormal cortical gyration;NDE1, NUDE, LIS4, MHAC;609449;16p13.11
lissencephaly;615191;congenital nervous system abnormality;severe global developmental delay;Global developmental delay;LAMB1, LIS5;150240;7q31.1
long QT syndrome;170390;autosomal genetic disease;small hand;Aplasia/hypoplasia involving bones of the hand;KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9;600681;17q24.3
long QT syndrome;192500;autosomal genetic disease;torsade de pointes;Ventricular arrhythmia;KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2;607542;11p15.5-p15.4
long QT syndrome;601005;autosomal genetic disease;sudden death;Time of death;CACNA1C, CACNL1A1, CCHL1A1, TS;114205;12p13.33
long QT syndrome;603830;autosomal genetic disease;torsade de pointes;Ventricular arrhythmia;SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;600163;3p22.2
long QT syndrome;611818;autosomal genetic disease;ventricular arrhythmia;Arrhythmia;CAV3, LGMD1C, LQT9;601253;3p25.3
long QT syndrome;611819;autosomal genetic disease;t-wave alternans;EKG: T-wave abnormalities;SCN4B, LQT10, ATFB17;608256;11q23.3
long QT syndrome;611820;autosomal genetic disease;prolonged qt interval;Abnormal EKG;AKAP9, YOTIAO, AKAP450;604001;7q21.2
long QT syndrome;612955;autosomal genetic disease;prolonged qtc interval;Prolonged QT interval;SNT1, LQT12;601017;20q11.21
long QT syndrome;613485;autosomal genetic disease;paroxysmal atrial fibrillation;Atrial fibrillation;KCNJ5, GIRK4, KATP1, LQT13;600734;11q24.3
long QT syndrome;613688;autosomal genetic disease;torsade de pointes;Ventricular arrhythmia;ALG10, KCR1;603313;12p11.1
long QT syndrome;613688;autosomal genetic disease;torsade de pointes;Ventricular arrhythmia;KCNH2, LQT2, HERG, SQT1;152427;7q36.1
long QT syndrome;613693;autosomal genetic disease;torsade de pointes;Ventricular arrhythmia;KCNE2, MIRP1, LQT6, ATFB4;603796;21q22.11
long QT syndrome;613695;autosomal genetic disease;torsade de pointes;Ventricular arrhythmia;KCNE1, JLNS, LQT5, JLNS2;176261;21q22.11-q22.12
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;BRAF, NS7;164757;7q34
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;CASP8, MCH5, ALPS2B;601763;2q33.1
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;CYP2A6, CYP2A3, CYP2A, P450C2A;122720;19q13.2
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;DLEC1, DLC1;604050;3p22.2
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;EGFR, NISBD2;131550;7p11.2
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;ERBB2, NGL, NEU, HER2;164870;17q12
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1;609413;10q11.23
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;FASLG, TNFSF6, APT1LG1, FASL, ALPS1B;134638;1q24.3
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;IRF1, MAR;147575;5q31.1
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;KRAS, KRAS2, RASK2, NS, CFC2;190070;12p12.1
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;MAP3K8, COT, EST, TPL2;191195;10p11.23
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;PPP2R1B;603113;11q23.1
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;PRKN, PARK2, PDJ, LPRS2;602544;6q26
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;RASSF1;605082;3p21.31
lung cancer;211980;respiratory system cancer;alveolar cell carcinoma;Neoplasm of the tracheobronchial system;SLC22A1L, BWSCR1A, IMPT1;602631;11p15.4
lung small cell carcinoma;182280;lung carcinoma;neoplasm;Phenotypic abnormality;RB1;614041;13q14.2
lymphoplasmacytic lymphoma;153600;B-cell lymphoma;waldenstrom macroglobulinemia;Abnormal immunoglobulin level;MYD88, MYD88D;602170;3p22.2
lymphoproliferative disease;300635;;hemophagocytosis;Abnormality of macrophages;XIAP, BIRC4, API3, XLP2;300079;Xq25
lymphoproliferative disease;308240;;recurrent pharyngitis;Recurrent upper respiratory tract infections;SH2D1A, LYP, IMD5, XLP, XLPD1;300490;Xq25
lymphoproliferative disease;613011;;recurrent aphthous stomatitis;Stomatitis;ITK, EMT, LPFS1;186973;5q33.3
macrocephaly;248000;;patellar subluxation;Abnormality of the patella;TBC1D7, PIG51, TBC7, MGCPH;612655;6p24.1
macular corneal dystrophy;217800;corneal dystrophy;punctate opacification of the cornea;Opacification of the corneal stroma;CHST6, MCDC1;605294;16q23.1
malignant glioma;137800;cell type cancer;glioblastoma;Astrocytoma;ERBB2, NGL, NEU, HER2;164870;17q12
malignant glioma;137800;cell type cancer;glioblastoma;Astrocytoma;IDH1;147700;2q34
malignant glioma;137800;cell type cancer;glioblastoma;Astrocytoma;TP53, P53, LFS1 , BCC7;191170;17p13.1
malignant hyperthermia;145600;genetic disease;mixed respiratory and metabolic acidosis;Metabolic acidosis;RYR1, MHS, CCO;180901;19q13.2
malignant mesothelioma;156240;cell type cancer;malignant mesothelioma;Neoplasm by anatomical site;BCL10, IMD37;603517;1p22.3
malignant mesothelioma;156240;cell type cancer;malignant mesothelioma;Neoplasm by anatomical site;WT1, NPHS4;607102;11p13
maple syrup urine disease;246900;organic acidemia;cognitive impairment;Abnormality of higher mental function;DLD, LAD, PHE3, DLDD;238331;7q31.1
maple syrup urine disease;248600;organic acidemia;feeding difficulties in infancy;Feeding difficulties;BCKDHA, MSUD1;608348;19q13.2
maple syrup urine disease;248600;organic acidemia;feeding difficulties in infancy;Feeding difficulties;BCKDHB, E1B;248611;6q14.1
maple syrup urine disease;248600;organic acidemia;feeding difficulties in infancy;Feeding difficulties;DBT, BCATE2;248610;1p21.2
mastocytosis;154800;leukocyte disease;cutaneous mastocytosis;Mastocytosis;KIT, PBT;164920;4q12
maturity-onset diabetes of the young;125850;genetic disease;maturity-onset diabetes of the young;Diabetes mellitus;HNF4A, TCF14, MODY1, FRTS4;600281;20q13.12
maturity-onset diabetes of the young;125851;genetic disease;maturity-onset diabetes of the young;Diabetes mellitus;GCK, HHF3;138079;7p13
maturity-onset diabetes of the young;137920;genetic disease;aplasia/hypoplasia of the pancreas;Abnormal pancreas size;HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11;189907;17q12
maturity-onset diabetes of the young;600496;genetic disease;type ii diabetes mellitus;Diabetes mellitus;HNF1A, TCF1, MODY3, IDDM20;142410;12q24.31
maturity-onset diabetes of the young;606392;genetic disease;type ii diabetes mellitus;Diabetes mellitus;IPF1, MODY4, PAGEN1;600733;13q12.2
maturity-onset diabetes of the young;606394;genetic disease;maturity-onset diabetes of the young;Diabetes mellitus;NEUROD1, NIDDM;601724;2q31.3
maturity-onset diabetes of the young;609812;genetic disease;abnormality of exocrine pancreas physiology;Abnormality of pancreas physiology;CEL, BSSL, CELL, MODY8;114840;9q34.2
maturity-onset diabetes of the young;610508;genetic disease;type ii diabetes mellitus;Diabetes mellitus;KLF11, TIEG2, FKLF1, FKLF, MODY7;603301;2p25.1
maturity-onset diabetes of the young;612225;genetic disease;maturity-onset diabetes of the young;Diabetes mellitus;PAX4, MODY9, KPD;167413;7q32.1
maturity-onset diabetes of the young;613370;genetic disease;maturity-onset diabetes of the young;Diabetes mellitus;INS, MODY10, IDDM2;176730;11p15.5
maturity-onset diabetes of the young;613375;genetic disease;maturity-onset diabetes of the young;Diabetes mellitus;BLK, MODY11;191305;8p23.1
medulloblastoma;155255;infratentorial cancer;medulloblastoma;Malignant neoplasm of the central nervous system;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
medulloblastoma;155255;infratentorial cancer;medulloblastoma;Malignant neoplasm of the central nervous system;PTCH2;603673;1p34.1
medulloblastoma;155255;infratentorial cancer;medulloblastoma;Malignant neoplasm of the central nervous system;SUFU, SUFUXL, SUFUH;607035;10q24.32
megaloblastic anemia;261100;macrocytic anemia;malabsorption of vitamin b12;Abnormality of the vitamin B12 metabolism;AMN;605799;14q32.32
megaloblastic anemia;261100;macrocytic anemia;malabsorption of vitamin b12;Abnormality of the vitamin B12 metabolism;CUBN, IFCR, MGA1;602997;10p13
megaloblastic anemia;613839;macrocytic anemia;delayed myelination;Abnormal myelination;DHFR;126060;5q14.1
melanoma;155600;cell type cancer;cutaneous melanoma;Neoplasm of the skin;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
melorheostosis;155950;osteosclerosis;peripheral arteriovenous fistula;Arteriovenous fistula;LEMD3, MAN1;607844;12q14.3
metachromatic leukodystrophy;249900;sphingolipidosis;peripheral demyelination;Abnormal peripheral myelination;PSAP, SAP1;176801;10q22.1
metachromatic leukodystrophy;250100;sphingolipidosis;peripheral demyelination;Abnormal peripheral myelination;ARSA;607574;22q13.33
methylmalonic acidemia;251100;organic acidemia;methylmalonic aciduria;Dicarboxylic aciduria;MMAA;607481;4q31.21
methylmalonic acidemia;251110;organic acidemia;methylmalonic aciduria;Dicarboxylic aciduria;MMAB;607568;12q24.11
methylmalonic aciduria and homocystinuria type cblC;277400;methylmalonic acidemia;methylmalonic aciduria;Dicarboxylic aciduria;MMACHC;609831;1p34.1
methylmalonic aciduria and homocystinuria type cblD;277410;methylmalonic acidemia;cognitive impairment;Abnormality of higher mental function;C2orf25, MMADHC;611935;2q23.2
methylmalonic aciduria and homocystinuria type cblF;277380;methylmalonic acidemia;methylmalonic aciduria;Dicarboxylic aciduria;LMBRD1, LMBD1, NESI, MAHCF;612625;6q13
mevalonic aciduria;610377;peroxisomal disease;cognitive impairment;Abnormality of higher mental function;MVK, MVLK, POROK3;251170;12q24.11
microcephaly;251200;congenital nervous system abnormality;cognitive impairment;Abnormality of higher mental function;MCPH1;607117;8p23.1
microcephaly;604321;congenital nervous system abnormality;impulsivity;Abnormal aggressive, impulsive or violent behavior;CASC5, AF15Q14, KIAA1570, D40, MCPH4;609173;15q15.1
microcephaly;604804;congenital nervous system abnormality;cortical gyral simplification;Abnormal cortical gyration;CDK5RAP2, KIAA1633, MCPH3;608201;9q33.2
microcephaly;608393;congenital nervous system abnormality;congenital onset;Onset;CENPJ, CPAP, MCPH6, SCKL4;609279;13q12.12
microcephaly;608716;congenital nervous system abnormality;cortical gyral simplification;Abnormal cortical gyration;ASPM, MCPH5;605481;1q31.3
microcephaly;612703;congenital nervous system abnormality;intellectual disability;Neurodevelopmental abnormality;STIL, SIL, MCPH7;181590;1p33
microcytic anemia;206200;anemia;hypochromic microcytic anemia;Microcytic anemia;TMPRSS6, IRIDA;609862;22q12.3
microphthalmia;206900;eye disease;displacement of the external urethral meatus;Abnormality of the urethra;SOX2, MCOPS3;184429;3q26.33
microphthalmia;300166;eye disease;cognitive impairment;Abnormality of higher mental function;BCOR, KIAA1575, MCOPS2, MAA2, ANOP2;300485;Xp11.4
microphthalmia;309801;eye disease;colpocephaly;Abnormality of lateral ventricle;HCCS, MCOPS7;300056;Xp22.2
microphthalmia;601186;eye disease;diaphragmatic eventration;Abnormality of the diaphragm;STRA6, MCOPS9, MCOPCB8;610745;15q24.1
microphthalmia;607932;eye disease;cognitive impairment;Abnormality of higher mental function;BMP4, BMP2B1, BMP2B, MCOPS6, OFC11;112262;14q22.2
microphthalmia;609549;eye disease;microphthalmos;Abnormality of globe size;MFRP, MCOP5, NNO2;606227;11q23.3
microphthalmia;610093;eye disease;microphthalmos;Abnormality of globe size;CHX10, HOX10, MCOP2, MCOPCB3;142993;14q24.3
microphthalmia;610125;eye disease;ectopic posterior pituitary;Posterior pituitary dysgenesis;OTX2, MCOPS5, CPHD6;600037;14q22.3
microphthalmia;611038;eye disease;ankyloblepharon;Abnormality of the eyelid;RAX, RX, MCOP3;601881;18q21.32
microphthalmia;611040;eye disease;optic disc drusen;Abnormality of the optic disc;MFRP, MCOP5, NNO2;606227;11q23.3
microphthalmia;613094;eye disease;postaxial polydactyly;Polydactyly;GDF6, MCOP4, KFS1, MCOPCB6, LCA17;601147;8q22.1
microphthalmia;613704;eye disease;microphthalmos;Abnormality of globe size;GDF3, KFS3, MCOPCB6, MCOP7;606522;12p13.31
microphthalmia;615972;eye disease;optic disc drusen;Abnormality of the optic disc;TMEM98, NNO4;615949;17q11.2
migraine;157300;brain disease;phonophobia;Behavioral abnormality;EDNRA;131243;4q31.22
migraine;157300;brain disease;phonophobia;Behavioral abnormality;ESR1, ESR, ESTRR;133430;6q25.1
migraine;157300;brain disease;phonophobia;Behavioral abnormality;TNF, TNFA;191160;6p21.33
mitochondrial complex V (ATP synthase) deficiency, nuclear type 1;604273;mitochondrial metabolism disease;short stature;Growth delay;ATPAF2, ATP12, MC5DN1;608918;17p11.2
monilethrix;158000;autosomal dominant disease;cognitive impairment;Abnormality of higher mental function;KRT81, KRTHB1, HB1;602153;12q13.13
monilethrix;158000;autosomal dominant disease;cognitive impairment;Abnormality of higher mental function;KRT83, KRTHB3, HB3;602765;12q13.13
monilethrix;158000;autosomal dominant disease;cognitive impairment;Abnormality of higher mental function;KRT86, KRTHB6, HB6;601928;12q13.13
mucolipidosis;252650;lysosomal storage disease;cognitive impairment;Abnormality of higher mental function;MCOLN1, ML4;605248;19p13.2
mucopolysaccharidosis I;607014;mucopolysaccharidosis;hernia;Abnormality of connective tissue;IDUA, IDA;252800;4p16.3
mucopolysaccharidosis I;607015;mucopolysaccharidosis;hernia;Abnormality of connective tissue;IDUA, IDA;252800;4p16.3
mucopolysaccharidosis I;607016;mucopolysaccharidosis;cerebral palsy;Abnormality of movement;IDUA, IDA;252800;4p16.3
mucopolysaccharidosis II;309900;mucopolysaccharidosis;cognitive impairment;Abnormality of higher mental function;IDS, MPS2, SIDS;300823;Xq28
mucopolysaccharidosis III;252900;mucopolysaccharidosis;ovoid thoracolumbar vertebrae;Ovoid vertebral bodies;SGSH, MPS3A, SFMD;605270;17q25.3
mucopolysaccharidosis III;252920;mucopolysaccharidosis;juvenile onset;Onset;NAGLU, MPS3B;609701;17q21.2
mucopolysaccharidosis III;252930;mucopolysaccharidosis;hernia;Abnormality of connective tissue;HGSNAT, TMEM76, MPS3C;610453;8p11.21
mucopolysaccharidosis III;252940;mucopolysaccharidosis;prominent forehead;Abnormality of the forehead;GNS, G6S;607664;12q14.3
mucopolysaccharidosis IV;253000;mucopolysaccharidosis;chondroitin sulfate excretion in urine;Mucopolysacchariduria;GALNS, MPS4A;612222;16q24.3
mucopolysaccharidosis IV;253010;mucopolysaccharidosis;keratan sulfate excretion in urine;Mucopolysacchariduria;GLB1, MPS4B;611458;3p22.3
mucopolysaccharidosis IX;601492;mucopolysaccharidosis;keratan sulfate excretion in urine;Mucopolysacchariduria;HYAL1, MPS9;607071;3p21.31
mucopolysaccharidosis VI;253200;mucopolysaccharidosis;hernia;Abnormality of connective tissue;ARSB, MPS6;611542;5q14.1
mucopolysaccharidosis;607014;lysosomal storage disease;hernia;Abnormality of connective tissue;IDUA, IDA;252800;4p16.3
mucosulfatidosis;272200;sphingolipidosis;cognitive impairment;Abnormality of higher mental function;SUMF1, FGE;607939;3p26.1
mulibrey nanism;253250;autosomal recessive disease;hypoplasia of choroid;Aplasia/Hypoplasia of the choroid;TRIM37, MUL, KIAA0898;605073;17q22
multinodular goiter;138800;goiter;papillary thyroid carcinoma;Thyroid carcinoma;DICER1, HERNA, KIAA0928, MNG1, RMSE2;606241;14q32.13
multiple cutaneous and mucosal venous malformations;600195;autosomal dominant disease;arteriovenous malformation;Abnormality of the vasculature;TEK, TIE2, VMCM;600221;9p21.2
multiple epiphyseal dysplasia;132400;osteochondrodysplasia;short femoral neck;Aplasia/Hypoplasia involving the femoral head and neck;COMP, EDM1, MED, PSACH;600310;19p13.11
multiple epiphyseal dysplasia;226900;osteochondrodysplasia;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;SLC26A2, DTD, DTDST, D5S1708, EDM4;606718;5q32
multiple epiphyseal dysplasia;600204;osteochondrodysplasia;irregular epiphyses;Abnormality of the epiphyses;COL9A2, EDM2, STL5;120260;1p34.2
multiple epiphyseal dysplasia;607078;osteochondrodysplasia;short femoral neck;Aplasia/Hypoplasia involving the femoral head and neck;MATN3, EDM5, HOA, OS2;602109;2p24.1
multiple epiphyseal dysplasia;614135;osteochondrodysplasia;schmorl's node;Abnormality of the vertebrae;COL9A1, EDM6, STL4;120210;6q13
multiple intestinal atresia;243150;autosomal recessive disease;duodenal stenosis;Small intestinal stenosis;TTC7A, TTC7, KIAA1140, MINAT;609332;2p21
multiple myeloma;254500;myeloma;multiple myeloma;Hematological neoplasm;CCND1, PRAD1, BCL1;168461;11q13.3
multiple myeloma;254500;myeloma;multiple myeloma;Hematological neoplasm;LIG4, LIG4S;601837;13q33.3
multiple sclerosis;126200;demyelinating disease;cns demyelination;Abnormal CNS myelination;HLA-DQB1, CELIAC1;604305;6p21.32
multiple sclerosis;126200;demyelinating disease;cns demyelination;Abnormal CNS myelination;HLA-DRB1, SS1;142857;6p21.32
multiple sclerosis;126200;demyelinating disease;cns demyelination;Abnormal CNS myelination;PDCD1, SLEB2;600244;2q37.3
multiple synostoses syndrome;186500;dysostosis;clinodactyly;Abnormality of digit;NOG, SYM1, SYNS1;602991;17q22
multiple synostoses syndrome;610017;dysostosis;carpal synostosis;Synostosis of carpals/tarsals;GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;20q11.22
multiple synostoses syndrome;612961;dysostosis;metacarpal synostosis;Synostosis of metacarpals/metatarsals;FGF9, SYNS3;600921;13q12.11
multiple system atrophy;146500;synucleinopathy;cognitive impairment;Abnormality of higher mental function;COQ2, COQ10D1, MSA1;609825;4q21.23
muscular dystrophy-dystroglycanopathy;613150;congenital muscular dystrophy;intellectual disability, severe;Intellectual disability;POMT2, MDDGA2, MDDGB2, MDDGC2;607439;14q24.3
muscular dystrophy-dystroglycanopathy;613151;congenital muscular dystrophy;hypoplasia of the pons;Abnormality of the pons;POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3;606822;1p34.1
muscular dystrophy-dystroglycanopathy;613152;congenital muscular dystrophy;congenital muscular dystrophy;Muscular dystrophy;FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4;607440;9q31.2
muscular dystrophy-dystroglycanopathy;613153;congenital muscular dystrophy;hypoplasia of the pons;Abnormality of the pons;FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5;606596;19q13.32
muscular dystrophy-dystroglycanopathy;613154;congenital muscular dystrophy;hypoplasia of the pons;Abnormality of the pons;LARGE, KIAA0609, MDC1D, MDDGA6, MDDGB6;603590;22q12.3
muscular dystrophy-dystroglycanopathy;613155;congenital muscular dystrophy;intellectual disability, severe;Intellectual disability;POMT1, MDDGA1, MDDGB1, MDDGC1;607423;9q34.13
muscular dystrophy-dystroglycanopathy;613156;congenital muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;POMT2, MDDGA2, MDDGB2, MDDGC2;607439;14q24.3
muscular dystrophy-dystroglycanopathy;613818;congenital muscular dystrophy;ankle contracture;Contractures of the joints of the lower limbs;DAG1, DAG, MDDGC9;128239;3p21.31
muscular dystrophy-dystroglycanopathy;614643;congenital muscular dystrophy;microtia;Aplasia/Hypoplasia of the external ear;ISPD, MDDGA7, MDDGC7;614631;7p21.2
muscular dystrophy-dystroglycanopathy;614830;congenital muscular dystrophy;retinal dysplasia;Abnormality of the retina;POMGNT2, GTDC2, C3orf39, AGO61, MDDGA8;614828;3p22.1
muscular dystrophy-dystroglycanopathy;615041;congenital muscular dystrophy;retinal dysplasia;Abnormality of the retina;TMEM5, MDDGA10;605862;12q14.2
muscular dystrophy-dystroglycanopathy;615181;congenital muscular dystrophy;hypoplasia of the pons;Abnormality of the pons;B3GALNT2, MGC39558, MDDGA11;610194;1q42.3
muscular dystrophy-dystroglycanopathy;615249;congenital muscular dystrophy;feeding difficulties;Abdominal symptom;POMK, SGK196, MDDGA12, MDDGC12;615247;8p11.21
muscular dystrophy-dystroglycanopathy;615287;congenital muscular dystrophy;decreased testicular size;Aplasia/Hypoplasia of the testes;B3GNT1, IGNT, IGAT, MDDGA13;605517;11q13.2
muscular dystrophy-dystroglycanopathy;615350;congenital muscular dystrophy;hypoplasia of the pons;Abnormality of the pons;GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14;615320;3p21.31
muscular dystrophy-dystroglycanopathy;615351;congenital muscular dystrophy;feeding difficulties;Abdominal symptom;GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14;615320;3p21.31
myelofibrosis;254450;myeloma;myelofibrosis;Abnormality of multiple cell lineages in the bone marrow;CALR, SSA;109091;19p13.2
myelofibrosis;254450;myeloma;myelofibrosis;Abnormality of multiple cell lineages in the bone marrow;JAK2, THCYT3;147796;9p24.1
myelofibrosis;254450;myeloma;myelofibrosis;Abnormality of multiple cell lineages in the bone marrow;MPL, TPOR, MPLV, THCYT2;159530;1p34.2
myelofibrosis;254450;myeloma;myelofibrosis;Abnormality of multiple cell lineages in the bone marrow;SH2B3, LNK;605093;12q24.12
myopia;608908;refractive error;myopia;Abnormality of refraction;SCO2, CEMCOX1, MYP6;604272;22q13.33
myopia;614167;refractive error;severe myopia;Myopia;ZNF644, MYP21;614159;1p22.2
myopia;615420;refractive error;myopia;Abnormality of refraction;CCDC111, MYP22;615421;4q35.1
myopia;615946;refractive error;myopia;Abnormality of refraction;SLC39A5, MYP24;608730;12q13.3
myotonic dystrophy type 1;160900;myotonic disease;cognitive impairment;Abnormality of higher mental function;DMPK, DM, DMK;605377;19q13.32
myotonic dystrophy type 2;602668;myotonic disease;elevated follicle stimulating hormone;Gonadotropin excess;ZNF9, CNBP1, DM2, PROMM;116955;3q21.3
myxoid liposarcoma;613488;liposarcoma;neoplasm of the lung;Neoplasm of the respiratory system;DDIT3, GADD153, CHOP10;126337;12q13.3
nail-patella syndrome;161200;autosomal dominant disease;glomerulopathy;Abnormality of the glomerulus;LMX1B, NPS1;602575;9q33.3
narcolepsy;161400;sleep disorder;narcolepsy;Sleep disturbance;HCRT, OX, NRCLP1;602358;17q21.2
narcolepsy;614250;sleep disorder;narcolepsy;Sleep disturbance;MOG, NRCLP7;159465;6p22.1
nasopharynx carcinoma;607101;pharynx cancer;progressive hearing impairment;Hearing impairment;MYO3A, DFNB30;606808;10p12.1
nemaline myopathy;161800;congenital structural myopathy;facial palsy;Abnormality of the seventh cranial nerve;ACTA1, ASMA, NEM3, CFTD1;102610;1q42.13
nemaline myopathy;256030;congenital structural myopathy;feeding difficulties;Abdominal symptom;NEB, NEM2;161650;2q23.3
nemaline myopathy;605355;congenital structural myopathy;proximal amyotrophy;Skeletal muscle atrophy;TNNT1, ANM, NEM5;191041;19q13.42
nemaline myopathy;609273;congenital structural myopathy;difficulty running;Functional motor problems.;KBTBD13, NEM6;613727;15q22.31
nemaline myopathy;609284;congenital structural myopathy;distal lower limb muscle weakness;Abnormality of the lower limb;TPM3, NEM1, CFTD, CAPM1;191030;1q21.3
nemaline myopathy;609285;congenital structural myopathy;feeding difficulties in infancy;Feeding difficulties;TPM2, TMSB, AMCD1, DA1, DA2B, NEM4;190990;9p13.3
nemaline myopathy;610687;congenital structural myopathy;nemaline bodies;Muscle fiber cytoplasmatic inclusion bodies;CFL2, NEM7;601443;14q13.1
nemaline myopathy;615731;congenital structural myopathy;variable expressivity;Phenotypic variability;KLHL41, KBTBD10, SARCOSIN, NEM9;607701;2q31.1
nephroblastoma;194070;kidney cancer;nephroblastoma (wilms tumor);Embryonal renal neoplasm;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
nephroblastoma;194070;kidney cancer;nephroblastoma (wilms tumor);Embryonal renal neoplasm;GPC3, SDYS, SGBS1;300037;Xq26.2
nephroblastoma;194070;kidney cancer;nephroblastoma (wilms tumor);Embryonal renal neoplasm;WT1, NPHS4;607102;11p13
nephrogenic diabetes insipidus;125800;impaired renal function disease;nephrogenic diabetes insipidus;Diabetes insipidus;AQP2;107777;12q13.12
nephrogenic diabetes insipidus;304800;impaired renal function disease;feeding difficulties in infancy;Feeding difficulties;AVPR2, DIR, DI1, ADHR;300538;Xq28
nephronophthisis;256100;autosomal recessive disease;tubular basement membrane disintegration;Abnormality of the renal tubule;NPHP1, NPH1, SLSN1, JBTS4;607100;2q13
nephronophthisis;602088;autosomal recessive disease;pulmonary insufficiency;Abnormality of the pulmonary valve;INVS, INV, NPHP2, NPH2;243305;9q31.1
nephronophthisis;604387;autosomal recessive disease;tubulointerstitial fibrosis;Tubulointerstitial abnormality;NPHP3, NPH3, RHPD1, MKS7;608002;3q22.1
nephronophthisis;606966;autosomal recessive disease;tubulointerstitial fibrosis;Tubulointerstitial abnormality;NPHP4, SLSN4;607215;1p36.31
nephronophthisis;611498;autosomal recessive disease;stage 5 chronic kidney disease;Chronic kidney disease;GLIS2, NPHP7;608539;16p13.3
nephronophthisis;613159;autosomal recessive disease;arachnoid cyst;Abnormality of the arachnoid mater;XPNPEP3, APP3, NPHPL1;613553;22q13.2
nephronophthisis;613550;autosomal recessive disease;anisocoria;Abnormality of the pupil;TMEM67, MKS3, JBTS6, NPHP11;609884;8q22.1
nephronophthisis;613820;autosomal recessive disease;stage 5 chronic kidney disease;Chronic kidney disease;TTC21B, THM1, NPHP12, SRTD4, ATD4;612014;2q24.3
nephronophthisis;613824;autosomal recessive disease;renal cortical microcysts;Renal cortical cysts;NEK8, JCK, NPHP9, RHPD2;609799;17q11.2
nephronophthisis;614377;autosomal recessive disease;mild proteinuria;Proteinuria;WDR19, SRTD5, ATD5, NPHP13, CED4;608151;4p14
nephronophthisis;614844;autosomal recessive disease;phenotypic variability;Clinical modifier;ZNF423, ZFP423, OAZ, KIAA0760, NPHP14, JBTS19;604557;16q12.1
nephronophthisis;614845;autosomal recessive disease;polydactyly;Abnormality of digit;CEP164, KIAA1052;614848;11q23.3
nephronophthisis;615382;autosomal recessive disease;situs inversus totalis;Abnormal spatial orientation of the cardiac segments;ANKS6, PKDR1, NPHP16;615370;9q22.33
nephronophthisis;615862;autosomal recessive disease;portal fibrosis;Abnormality of the biliary system;CEP83, CCDC41, NPHP18;615847;12q22
nephrotic syndrome;256300;nephrosis;congenital nephrotic syndrome;Nephrotic syndrome;NPHS1, NPHN;602716;19q13.12
nephrotic syndrome;256370;nephrosis;childhood onset;Onset;WT1, NPHS4;607102;11p13
nephrotic syndrome;600995;nephrosis;variable expressivity;Phenotypic variability;PDCN, NPHS2, SRN1;604766;1q25.2
nephrotic syndrome;610725;nephrosis;childhood onset;Onset;PLCE1, KIAA1516, NPHS3;608414;10q23.33
nephrotic syndrome;614196;nephrosis;tubulointerstitial fibrosis;Tubulointerstitial abnormality;PTPRO, GLEPP1, NPHS6;600579;12p12.3
nephrotic syndrome;614199;nephrosis;stage 5 chronic kidney disease;Chronic kidney disease;LAMB2, LAMS, NPHS5;150325;3p21.31
nephrotic syndrome;615008;nephrosis;hemolytic-uremic syndrome;Abnormal renal physiology;DGKE, NPHS7;601440;17q22
nephrotic syndrome;615244;nephrosis;chronic kidney disease;Renal insufficiency;ARHGDIA, GDIA1, NPHS8;601925;17q25.3
nephrotic syndrome;615573;nephrosis;stage 5 chronic kidney disease;Chronic kidney disease;ADCK4, NPHS9;615567;19q13.2
nephrotic syndrome;615861;nephrosis;steroid-resistant nephrotic syndrome;Nephrotic syndrome;EMP2, NPHS10;602334;16p13.13
neurilemmomatosis;162091;neurilemmoma;schwannoma;Neoplasm of the peripheral nervous system;NF2;607379;22q12.2
neurilemmomatosis;162091;neurilemmoma;schwannoma;Neoplasm of the peripheral nervous system;SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1;601607;22q11.23
neurilemmomatosis;615670;neurilemmoma;schwannoma;Neoplasm of the peripheral nervous system;LZTR1, SWNTS2;600574;22q11.21
neuroblastoma;256700;autonomic nervous system neoplasm;skin nodule;Localized skin lesion;KIF1B, CMT2A, CMT2A1, NBLST1;605995;1p36.22
neuroblastoma;256700;autonomic nervous system neoplasm;skin nodule;Localized skin lesion;NME1, NM23;156490;17q21.33
neuroblastoma;613013;autonomic nervous system neoplasm;ganglioneuroblastoma;Neuroblastoma;PMX2B, NBPHOX, PHOX2B, NBLST2;603851;4p13
neurofibromatosis;101000;autosomal dominant disease;epiretinal membrane;Abnormality of the macula;NF2;607379;22q12.2
neurofibromatosis;162200;autosomal dominant disease;neurofibrosarcoma;Sarcoma;NF1, VRNF, WSS, NFNS;613113;17q11.2
neurofibromatosis;162210;autosomal dominant disease;spinal cord tumor;Neoplasm of the central nervous system;NF1, VRNF, WSS, NFNS;613113;17q11.2
neurohypophyseal diabetes insipidus;125700;pancreas disease;short nose;Abnormal nasal morphology;AVP, AVRP, VP;192340;20p13
neuronal ceroid lipofuscinosis;162350;lipid storage disease;auditory hallucinations;Hallucinations;DNAJC5, DNAJC5A, CSP, CLN4B;611203;20q13.33
neuronal ceroid lipofuscinosis;204200;lipid storage disease;increased extraneuronal autofluorescent lipopigment;Increased cerebral lipofuscin;CLN3, BTS;607042;16p11.2
neuronal ceroid lipofuscinosis;204300;lipid storage disease;auditory hallucinations;Hallucinations;CLN6, CLN4A;606725;15q23
neuronal ceroid lipofuscinosis;204500;lipid storage disease;increased extraneuronal autofluorescent lipopigment;Increased cerebral lipofuscin;TPP1, CLN2, SCAR7;607998;11p15.4
neuronal ceroid lipofuscinosis;256730;lipid storage disease;postnatal microcephaly;Microcephaly;PPT1, CLN1;600722;1p34.2
neuronal ceroid lipofuscinosis;256731;lipid storage disease;rectilinear intracellular accumulation of autofluorescent lipopigment storage material;Intracellular accumulation of autofluorescent lipopigment storage material;CLN5;608102;13q22.3
neuronal ceroid lipofuscinosis;600143;lipid storage disease;curvilinear intracellular accumulation of autofluorescent lipopigment storage material;Intracellular accumulation of autofluorescent lipopigment storage material;CLN8, EPMR;607837;8p23.3
neuronal ceroid lipofuscinosis;601780;lipid storage disease;fingerprint intracellular accumulation of autofluorescent lipopigment storage material;Intracellular accumulation of autofluorescent lipopigment storage material;CLN6, CLN4A;606725;15q23
neuronal ceroid lipofuscinosis;610003;lipid storage disease;slow progression;Pace of progression;CLN8, EPMR;607837;8p23.3
neuronal ceroid lipofuscinosis;610127;lipid storage disease;intellectual disability, severe;Intellectual disability;CTSD, CPSD, CLN10;116840;11p15.5
neuronal ceroid lipofuscinosis;610951;lipid storage disease;rapidly progressive;Pace of progression;MFSD8, MGC33302, CLN7, CCMD;611124;4q28.2
neuronal ceroid lipofuscinosis;614706;lipid storage disease;rapidly progressive;Pace of progression;GRN, CLN11;138945;17q21.31
neuronal ceroid lipofuscinosis;615362;lipid storage disease;progressive disorder;Pace of progression;CTSF, CLN13;603539;11q13.2
neutral lipid storage disease;275630;lipid storage disease;microtia;Aplasia/Hypoplasia of the external ear;ABHD5, CGI58, IECN2, NCIE2;604780;3p21.33
nevoid basal cell carcinoma syndrome;109400;autosomal dominant disease;skin ulcer;Localized skin lesion;PTCH1, NBCCS, BCNS, HPE7;601309;9q22.32
nevoid basal cell carcinoma syndrome;109400;autosomal dominant disease;skin ulcer;Localized skin lesion;PTCH2;603673;1p34.1
nevoid basal cell carcinoma syndrome;109400;autosomal dominant disease;skin ulcer;Localized skin lesion;SUFU, SUFUXL, SUFUH;607035;10q24.32
non-Hodgkin lymphoma;605027;lymphoma;lymphoma;Hematological neoplasm;CASP10, MCH4, ALPS2;601762;2q33.1
non-Hodgkin lymphoma;605027;lymphoma;lymphoma;Hematological neoplasm;PRF1, HPLH2, FLH2;170280;10q22.1
non-Hodgkin lymphoma;605027;lymphoma;lymphoma;Hematological neoplasm;RAD54B;604289;8q22.1
non-Hodgkin lymphoma;605027;lymphoma;lymphoma;Hematological neoplasm;RAD54L, HR54, HRAD54;603615;1p34.1
non-syndromic X-linked intellectual disability;300143;non-syndromic intellectual disability;tented upper lip vermilion;Abnormality of upper lip vermillion;IL1RAPL1, IL1R8, MRX21, MRX34;300206;Xp21.3-p21.2
non-syndromic X-linked intellectual disability;300210;non-syndromic intellectual disability;x-linked inheritance;Gonosomal inheritance;TSPAN7, TM4SF2, MXS1, A15, MRX58;300096;Xp11.4
non-syndromic X-linked intellectual disability;300271;non-syndromic intellectual disability;x-linked recessive inheritance;X-linked inheritance;RAB39B, MRX72, WSMN;300774;Xq28
non-syndromic X-linked intellectual disability;300387;non-syndromic intellectual disability;x-linked inheritance;Gonosomal inheritance;ACSL4, FACL4, ACS4, MRX63;300157;Xq23
non-syndromic X-linked intellectual disability;300436;non-syndromic intellectual disability;x-linked recessive inheritance;X-linked inheritance;ARHGEF6, MRX46, COOL2;300267;Xq26.3
non-syndromic X-linked intellectual disability;300498;non-syndromic intellectual disability;x-linked recessive inheritance;X-linked inheritance;ZNF81, MRX45;314998;Xp11.23
non-syndromic X-linked intellectual disability;300558;non-syndromic intellectual disability;flat face;Abnormal facial shape;PAK3, MRX30, MRX47;300142;Xq23
non-syndromic X-linked intellectual disability;300577;non-syndromic intellectual disability;small hand;Aplasia/hypoplasia involving bones of the hand;ZDHHC15, MRX91;300576;Xq13.3
non-syndromic X-linked intellectual disability;300659;non-syndromic intellectual disability;prominent forehead;Abnormality of the forehead;BRWD3, MRX93;300553;Xq21.1
non-syndromic X-linked intellectual disability;300802;non-syndromic intellectual disability;x-linked dominant inheritance;X-linked inheritance;SYP, MRXSYP;313475;Xp11.23
non-syndromic X-linked intellectual disability;300803;non-syndromic intellectual disability;x-linked inheritance;Gonosomal inheritance;ZNF711, ZNF6, CMPX1, MRX97;314990;Xq21.1
non-syndromic X-linked intellectual disability;300844;non-syndromic intellectual disability;x-linked inheritance;Gonosomal inheritance;RPS6KA3, RSK2, MRX19;300075;Xp22.12
non-syndromic X-linked intellectual disability;300849;non-syndromic intellectual disability;x-linked inheritance;Gonosomal inheritance;GDI1, RABGD1A, MRX41, MRX48;300104;Xq28
non-syndromic X-linked intellectual disability;300850;non-syndromic intellectual disability;x-linked inheritance;Gonosomal inheritance;DLG3, NEDLG, SAP102, MRX90;300189;Xq13.1
non-syndromic X-linked intellectual disability;300912;non-syndromic intellectual disability;cognitive impairment;Abnormality of higher mental function;KIAA2022, MRX98;300524;Xq13.3
non-syndromic X-linked intellectual disability;300919;non-syndromic intellectual disability;broad thumb;Broad phalanges of the hand;USP9X, DFFRX, MRX99;300072;Xp11.4
non-syndromic X-linked intellectual disability;300923;non-syndromic intellectual disability;poor speech;Neurological speech impairment;KIF4A, KIF4, MRX100;300521;Xq13.1
non-syndromic X-linked intellectual disability;309530;non-syndromic intellectual disability;x-linked recessive inheritance;X-linked inheritance;IQSEC2, KIAA0522, MRX1;300522;Xp11.22
non-syndromic X-linked intellectual disability;309549;non-syndromic intellectual disability;abnormality of the distal phalanx of finger;Abnormality of phalanx of finger;FTSJ1, JM23, SPB1, MRX44, MRX9;300499;Xp11.23
non-syndromic intellectual disability;613192;intellectual disability;postnatal microcephaly;Microcephaly;TRAPPC9, NIBP, KIAA1882, MRT13;611966;8q24.3
non-syndromic intellectual disability;614202;intellectual disability;broad eyebrow;Abnormality of the eyebrow;MAN1B1, MRT15;604346;9q34.3
nonepidermolytic palmoplantar keratoderma;600962;palmoplantar keratosis;nonepidermolytic palmoplantar keratoderma;Palmoplantar keratoderma;KRT1, EPPK, NEPPK, EHK;139350;12q13.13
nonepidermolytic palmoplantar keratoderma;613000;palmoplantar keratosis;palmoplantar keratoderma;Hyperkeratosis;KRT16, FNEPPK, PC1;148067;17q21.2
nonepidermolytic palmoplantar keratoderma;615735;palmoplantar keratosis;palmoplantar keratoderma;Hyperkeratosis;KRT6C, PPKNEFD;612315;12q13.13
nonpapillary renal cell carcinoma;144700;hereditary renal cell carcinoma;renal cell carcinoma;Renal neoplasm;DIRC2, RCC4;602773;3q21.1
nonpapillary renal cell carcinoma;144700;hereditary renal cell carcinoma;renal cell carcinoma;Renal neoplasm;FLCN, BHD;607273;17p11.2
nonpapillary renal cell carcinoma;144700;hereditary renal cell carcinoma;renal cell carcinoma;Renal neoplasm;HNF1A, TCF1, MODY3, IDDM20;142410;12q24.31
nonpapillary renal cell carcinoma;144700;hereditary renal cell carcinoma;renal cell carcinoma;Renal neoplasm;HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11;189907;17q12
nonpapillary renal cell carcinoma;144700;hereditary renal cell carcinoma;renal cell carcinoma;Renal neoplasm;OGG1;601982;3p25.3
nonpapillary renal cell carcinoma;144700;hereditary renal cell carcinoma;renal cell carcinoma;Renal neoplasm;RNF139, TRC8, RCA1;603046;8q24.13
nonpapillary renal cell carcinoma;144700;hereditary renal cell carcinoma;renal cell carcinoma;Renal neoplasm;VHL;608537;3p25.3
nonphotosensitive trichothiodystrophy;234050;autosomal recessive disease;trichorrhexis nodosa;Abnormal hair laboratory examination;MPLKIP, C7orf11, ABHS, TTDN1;609188;7p14.1
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;ADRB2;109690;5q32
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;ADRB3;109691;8p11.23
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;AGRP, ART, AGRT;602311;16q22.1
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;CART;602606;5q13.2
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED;173335;6q23.2
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;GHRL;605353;3p25.3
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;MC4R;155541;18q21.32
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;NR0B2, SHP;604630;1p36.11
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;POMC;176830;2p23.3
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;PPARG, PPARG1, PPARG2, CIMT1, GLM1;601487;3p25.2
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;PPARGC1B, PGC1B, PERC;608886;5q32
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;PYY;600781;17q21.31
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;SDC3, SYND3, SDCN;186357;1p35.2
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;SIM1;603128;6q16.3
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;UCP1;113730;4q31.1
obesity;601665;overnutrition;abnormality of metabolism/homeostasis;Phenotypic abnormality;UCP3;602044;11q13.4
occult macular dystrophy;613587;macular degeneration;slow decrease in visual acuity;Progressive visual loss;RP1L1;608581;8p23.1
ocular albinism;300500;eye disease;neoplasm of the skin;Neoplasm by anatomical site;GPR143, OA1, NYS6;300808;Xp22.2
oculocerebrorenal syndrome;309000;X-linked disease;skin ulcer;Localized skin lesion;OCRL, LOCR, OCRL1, NPHL2;300535;Xq25-q26
oculocutaneous albinism;203100;autosomal recessive disease;absent skin pigmentation;Hypopigmentation of the skin;TYR, SHEP3, CMM8, OCA1A, ATN;606933;11q14.3
oculocutaneous albinism;203200;autosomal recessive disease;neoplasm of the skin;Neoplasm by anatomical site;MC1R, SHEP2, CMM5;155555;16q24.3
oculocutaneous albinism;203200;autosomal recessive disease;neoplasm of the skin;Neoplasm by anatomical site;OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1;611409;15q12-q13
oculocutaneous albinism;203290;autosomal recessive disease;partial albinism;Hypopigmentation of the skin;TYRP1, CAS2, GP75, SHEP11;115501;9p23
oculocutaneous albinism;606574;autosomal recessive disease;neoplasm of the skin;Neoplasm by anatomical site;SLC45A2, MATP, AIM1, SHEP5, OCA4;606202;5p13.2
oculocutaneous albinism;606952;autosomal recessive disease;neoplasm of the skin;Neoplasm by anatomical site;TYR, SHEP3, CMM8, OCA1A, ATN;606933;11q14.3
oculocutaneous albinism;614473;autosomal recessive disease;hypophosphatemic rickets;Rickets;ABCC6, ARA, ABC34, MLP1, PXE, GACI2;603234;16p13.11
oculodentodigital dysplasia;164200;syndrome;clinodactyly;Abnormality of digit;GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR;121014;6q22.31
oculodentodigital dysplasia;257850;syndrome;4-5 finger syndactyly;Finger syndactyly;GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR;121014;6q22.31
oculopharyngeal muscular dystrophy;164300;muscular dystrophy;facial palsy;Abnormality of the seventh cranial nerve;PABPN1, PABP2, PAB2;602279;14q11.2
olivopontocerebellar atrophy;164400;spinocerebellar ataxia;cognitive impairment;Abnormality of higher mental function;ATXN1, ATX1, SCA1;601556;6p22.3
olivopontocerebellar atrophy;164500;spinocerebellar ataxia;genetic anticipation with paternal anticipation bias;Genetic anticipation;ATXN7, SCA7, OPCA3;607640;3p14.1
olivopontocerebellar atrophy;183090;spinocerebellar ataxia;genetic anticipation;Mode of inheritance;ATXN2, ATX2, SCA2, ASL13;601517;12q24.12
omodysplasia;258315;osteochondrodysplasia;hernia;Abnormality of connective tissue;GPC6, OMIMD1;604404;13q31.3-q32.1
open-angle glaucoma;137750;glaucoma;abnormal iris vasculature;Abnormality of the vasculature of the eye;MYOC, TIGR, GLC1A, JOAG, GPOA;601652;1q24.3
open-angle glaucoma;609887;glaucoma;primary open angle glaucoma;Glaucoma;WDR36, TAWDRP, GLC1G;609669;5q22.1
open-angle glaucoma;613100;glaucoma;primary open angle glaucoma;Glaucoma;NTF4 , NTF5, NT5, NT4, GLC1O;162662;19q13.33
optic atrophy;165300;optic nerve disease;abnormality of extrapyramidal motor function;Abnormality of central motor function;OPA3, MGA3;606580;19q13.32
optic atrophy;165500;optic nerve disease;incomplete penetrance;Phenotypic variability;OPA1, NTG, NPG;605290;3q29
ornithine carbamoyltransferase deficiency;311250;urea cycle disorder;low plasma citrulline;Abnormality of citrulline metabolism;OTC;300461;Xp11.4
ornithine translocase deficiency;238970;amino acid metabolic disorder;acute hepatitis;Hepatitis;SLC25A15, ORNT1, HHH;603861;13q14.11
orofacial cleft;600625;physical disorder;facial cleft;Abnormality of the face;BMP4, BMP2B1, BMP2B, MCOPS6, OFC11;112262;14q22.2
orofacial cleft;608864;physical disorder;polygenic inheritance;Multifactorial inheritance;IRF6, VWS, LPS, PIT, PPS1, OFC6;607199;1q32.2
orofacial cleft;608874;physical disorder;cleft upper lip;Oral cleft;MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3;142983;4p16.2
orofacial cleft;613705;physical disorder;unilateral cleft palate;Non-midline cleft palate;SUMO1, UBL1, SMT3, OFC10;601912;2q33.1
orofaciodigital syndrome;311200;genetic disease;arachnoid cyst;Abnormality of the arachnoid mater;OFD1, CXorf5, SGBS2, JBTS10, RP23;300170;Xp22.2
orotic aciduria;258900;pyrimidine metabolic disorder;cognitive impairment;Abnormality of higher mental function;UMPS, OPRT;613891;3q21.2
osteoarthritis;140600;arthritis;heberden's node;Enlarged interphalangeal joints;MATN3, EDM5, HOA, OS2;602109;2p24.1
osteoarthritis;165720;arthritis;hip osteoarthritis;Osteoarthritis;FRZB, FRZB1, SRFP3, OS1;605083;2q32.1
osteoarthritis;607850;arthritis;osteoarthritis of the distal interphalangeal joint;Osteoarthritis of the small joints of the hand;ASPN, PLAP1, OS3;608135;9q22.31
osteochondritis dissecans;165800;ischemic bone disease;exostoses;Neoplasm of the skeletal system;ACAN, AGC1, CSPG1, MSK16, SEDK;155760;15q26.1
osteogenesis imperfecta;166200;osteochondrodysplasia;biconcave flattened vertebrae;Biconcave vertebral bodies;COL1A1;120150;17q21.33
osteogenesis imperfecta;166210;osteochondrodysplasia;pulmonary insufficiency;Abnormality of the pulmonary valve;COL1A1;120150;17q21.33
osteogenesis imperfecta;166210;osteochondrodysplasia;pulmonary insufficiency;Abnormality of the pulmonary valve;COL1A2;120160;7q21.3
osteogenesis imperfecta;166220;osteochondrodysplasia;femoral bowing present at birth, straightening with time;Femoral bowing;COL1A1;120150;17q21.33
osteogenesis imperfecta;166220;osteochondrodysplasia;femoral bowing present at birth, straightening with time;Femoral bowing;COL1A2;120160;7q21.3
osteogenesis imperfecta;259420;osteochondrodysplasia;neonatal short-limb short stature;Disproportionate short-limb short stature;COL1A1;120150;17q21.33
osteogenesis imperfecta;259420;osteochondrodysplasia;neonatal short-limb short stature;Disproportionate short-limb short stature;COL1A2;120160;7q21.3
osteogenesis imperfecta;259440;osteochondrodysplasia;disproportionate short-limb short stature;Disproportionate short stature;PPIB, CYPB, OI9;123841;15q22.31
osteogenesis imperfecta;610682;osteochondrodysplasia;wide cranial sutures;Abnormality of cranial sutures;CRTAP, CASP, OI7;605497;3p22.3
osteogenesis imperfecta;610915;osteochondrodysplasia;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;P3H1, LEPRE1, GROS1, OI8;610339;1p34.2
osteogenesis imperfecta;610967;osteochondrodysplasia;vertebral wedging;Abnormal form of the vertebral bodies;IFITM5, OI5;614757;11p15.5
osteogenesis imperfecta;610968;osteochondrodysplasia;vertebral wedging;Abnormal form of the vertebral bodies;FKBP10, FKBP65, OI11, BRKS1;607063;17q21.2
osteogenesis imperfecta;613848;osteochondrodysplasia;midface retrusion;Abnormality of the midface;SERPINH1, SERPINH2, PPROM, CBP2, CBP1, OI10;600943;11q13.5
osteogenesis imperfecta;613849;osteochondrodysplasia;midface retrusion;Abnormality of the midface;SP7, OSX, OI12;606633;12q13.13
osteogenesis imperfecta;613982;osteochondrodysplasia;biconcave vertebral bodies;Abnormal form of the vertebral bodies;SERPINF1, PEDF, OI6;172860;17p13.3
osteogenesis imperfecta;614856;osteochondrodysplasia;increased bone mineral density;Abnormality of bone mineral density;BMP1, OI13;112264;8p21.3
osteogenesis imperfecta;615220;osteochondrodysplasia;hypoplasia of the pons;Abnormality of the pons;WNT1, INT1, OI15, BMND16;164820;12q13.12
osteopetrosis;166600;osteosclerosis;osteopetrosis;Increased bone mineral density;CLCN7, CLC7, OPTA2, OPTB4;602727;16p13.3
osteopetrosis;259700;osteosclerosis;osteopetrosis;Increased bone mineral density;TCIRG1, TIRC7, OC116, OPTB1;604592;11q13.2
osteopetrosis;259710;osteosclerosis;osteopetrosis;Increased bone mineral density;TNFSF11, OPGL, TRANCE, OPTB2;602642;13q14.11
osteopetrosis;259720;osteosclerosis;osteopetrosis;Increased bone mineral density;OSTM1, GL, OPTB5;607649;6q21
osteopetrosis;259730;osteosclerosis;osteopetrosis;Increased bone mineral density;CA2;611492;8q21.2
osteopetrosis;607634;osteosclerosis;osteopetrosis;Increased bone mineral density;LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4;603506;11q13.2
osteopetrosis;611490;osteosclerosis;osteopetrosis;Increased bone mineral density;CLCN7, CLC7, OPTA2, OPTB4;602727;16p13.3
osteopetrosis;611497;osteosclerosis;dense metaphyseal bands;Abnormality of the metaphyses;PLEKHM1, AP162, KIAA0356, OPTB6;611466;17q21.31
osteopetrosis;612301;osteosclerosis;abnormal trabecular bone morphology;Abnormal bone structure;TNFRSF11A, RANK, ODFR, OFE, OPTB7;603499;18q21.33
osteopetrosis;615085;osteosclerosis;feeding difficulties;Abdominal symptom;SNX10, OPTB8;614780;7p15.2
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;BMND7;611738;20p12.3
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;BMND8;611739;11p12
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;CALCR, CRT;114131;7q21.3
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;COL1A1;120150;17q21.33
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;COL1A2;120160;7q21.3
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4;603506;11q13.2
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;RIL;603422;5q31.1
osteoporosis;166710;bone resorption disease;osteoporosis;Reduced bone mineral density;VDR;601769;12q13.11
osteosarcoma;259500;bone cancer;retinoblastoma;Neuroepithelial neoplasm;CHEK2, RAD53, CHK2, CDS1, LFS2;604373;22q12.1
osteosarcoma;259500;bone cancer;retinoblastoma;Neuroepithelial neoplasm;RB1;614041;13q14.2
osteosarcoma;259500;bone cancer;retinoblastoma;Neuroepithelial neoplasm;TP53, P53, LFS1 , BCC7;191170;17p13.1
otospondylomegaepiphyseal dysplasia;215150;osteochondrodysplasia;midface retrusion;Abnormality of the midface;COL11A2, STL3, DFNA13, DFNB53, FBCG2;120290;6p21.32
otospondylomegaepiphyseal dysplasia;215150;osteochondrodysplasia;midface retrusion;Abnormality of the midface;COL2A1;120140;12q13.11
ovarian cancer;167000;female reproductive organ cancer;dysgerminoma;Germinoma;AKT1, CWS6;164730;14q32.33
ovarian cancer;167000;female reproductive organ cancer;dysgerminoma;Germinoma;CDH1, UVO, LCAM, ECAD;192090;16q22.1
ovarian cancer;167000;female reproductive organ cancer;dysgerminoma;Germinoma;CTNNB1, MRD19;116806;3p22.1
ovarian cancer;167000;female reproductive organ cancer;dysgerminoma;Germinoma;OPCML;600632;11q25
ovarian cancer;167000;female reproductive organ cancer;dysgerminoma;Germinoma;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
ovarian cancer;167000;female reproductive organ cancer;dysgerminoma;Germinoma;PRKN, PARK2, PDJ, LPRS2;602544;6q26
ovarian hyperstimulation syndrome;608115;ovarian disease;abdominal pain;Abdominal symptom;FSHR, ODG1;136435;2p16.3
pachyonychia congenita;167200;autosomal dominant disease;follicular hyperkeratosis;Hyperkeratosis;KRT16, FNEPPK, PC1;148067;17q21.2
pachyonychia congenita;167210;autosomal dominant disease;epidermoid cyst;Localized skin lesion;KRT17, PC2, PCHC1;148069;17q21.2
pancreatic agenesis;260370;pancreas disease;pancreatic hypoplasia;Aplasia/Hypoplasia of the pancreas;IPF1, MODY4, PAGEN1;600733;13q12.2
pancreatic cancer;613347;endocrine gland cancer;neoplasm of the pancreas;Neoplasm by anatomical site;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
pancreatic carcinoma;260350;pancreatic cancer;neoplasm of the pancreas;Neoplasm by anatomical site;KRAS, KRAS2, RASK2, NS, CFC2;190070;12p12.1
pancreatic carcinoma;260350;pancreatic cancer;neoplasm of the pancreas;Neoplasm by anatomical site;MADH4, DPC4, SMAD4, JIP, MYHRS;600993;18q21.2
pancreatic carcinoma;260350;pancreatic cancer;neoplasm of the pancreas;Neoplasm by anatomical site;STK11, PJS, LKB1;602216;19p13.3
pancreatic carcinoma;260350;pancreatic cancer;neoplasm of the pancreas;Neoplasm by anatomical site;TP53, P53, LFS1 , BCC7;191170;17p13.1
panic disorder;167870;anxiety disorder;anxiety;Abnormal fear/anxiety-related behavior;COMT;116790;22q11.21
pantothenate kinase-associated neurodegeneration;234200;neurodegenerative disease;motor tics;Tics;PANK2, NBIA1, PKAN, HARP;606157;20p13
papillary renal cell carcinoma;605074;renal cell carcinoma;papillary renal cell carcinoma;Renal cell carcinoma;MET;164860;7q31.2
papillary renal cell carcinoma;605074;renal cell carcinoma;papillary renal cell carcinoma;Renal cell carcinoma;PRCC, RCCP1;179755;1q23.1
papillary thyroid carcinoma;188550;thyroid carcinoma;papillary thyroid carcinoma;Thyroid carcinoma;CCDC6, D10S170, H4, TST1, PTC, TPC;601985;10q21.2
papillary thyroid carcinoma;188550;thyroid carcinoma;papillary thyroid carcinoma;Thyroid carcinoma;GOLGA5, RFG5, PTC5;606918;14q32.12
papillary thyroid carcinoma;188550;thyroid carcinoma;papillary thyroid carcinoma;Thyroid carcinoma;NCOA4, ELE1, PTC3;601984;10q11.23
papillary thyroid carcinoma;188550;thyroid carcinoma;papillary thyroid carcinoma;Thyroid carcinoma;PCM1, PTC4;600299;8p22
papillary thyroid carcinoma;188550;thyroid carcinoma;papillary thyroid carcinoma;Thyroid carcinoma;PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1;188830;17q24.2
papillary thyroid carcinoma;188550;thyroid carcinoma;papillary thyroid carcinoma;Thyroid carcinoma;TRIM24, TIF1, TIF1A, PTC6;603406;7q33-q34
papillary thyroid carcinoma;188550;thyroid carcinoma;papillary thyroid carcinoma;Thyroid carcinoma;TRIM33, TIF1G, RFG7, PTC7;605769;1p13.2
paraganglioma;168000;neuroendocrine tumor;chemodectoma;Paraganglioma;SDHD, PGL1, CWS3;602690;11q23.1
paraganglioma;601650;neuroendocrine tumor;chemodectoma;Paraganglioma;SDHAF2, SDH5, PGL2;613019;11q12.2
paraganglioma;605373;neuroendocrine tumor;chemodectoma;Paraganglioma;SDHC, PGL3;602413;1q23.3
paraganglioma;614165;neuroendocrine tumor;paraganglioma;Neuroendocrine neoplasm;SDHA, SDH1, SDHF, CMD1GG, PGL5;600857;5p15.33
parathyroid carcinoma;608266;endocrine gland cancer;parathyroid carcinoma;Neoplasm of the parathyroid gland;HRPT2, C1orf28;607393;1q31.2
parietal foramina;168500;osteochondrodysplasia;aplasia cutis congenita of scalp;Aplasia cutis congenita;MSX2, CRS2, HOX8;123101;5q35.2
parietal foramina;609597;osteochondrodysplasia;wide nasal ridge;Abnormality of the nasal dorsum;ALX4, PFM2, FPP, FND2, CRS5;605420;11p11.2
paroxysmal nocturnal hemoglobinuria;300818;hemoglobinuria;paroxysmal nocturnal hemoglobinuria;Hemoglobinuria;PIGA, PNH1, MCAHS2;311770;Xp22.2
paroxysmal nocturnal hemoglobinuria;615399;hemoglobinuria;fatigue;Behavioral abnormality;PIGT, NDAP, PNH2, MCAHS3;610272;20q13.12
partial central choroid dystrophy;613105;hereditary choroidal atrophy;choroidal dystrophy;Abnormality of the choroid;PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2, MDBS1;179605;6p21.1
peeling skin syndrome;270300;skin disease;erythema;Vascular skin abnormality;CDSN, HTSS1, HYPT2, PSS1;602593;6p21.33
peripheral primitive neuroectodermal tumor;612219;bone cancer;ewing's sarcoma;Sarcoma;EWSR1, EWS;133450;22q12.2
periventricular nodular heterotopia;300049;congenital nervous system abnormality;abnormality of the coagulation cascade;Abnormality of coagulation;FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS;300017;Xq28
periventricular nodular heterotopia;300537;congenital nervous system abnormality;hernia;Abnormality of connective tissue;FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS;300017;Xq28
periventricular nodular heterotopia;608097;congenital nervous system abnormality;periventricular gray matter heterotopia;Gray matter heterotopias;ARFGEF2, BIG2, PVNH2;605371;20q13.13
periventricular nodular heterotopia;615544;congenital nervous system abnormality;hypsarrhythmia;EEG with generalized epileptiform discharges;ERMARD, C6orf70, PVNH6;615532;6q27
peroxisomal acyl-CoA oxidase deficiency;264470;peroxisomal disease;cognitive impairment;Abnormality of higher mental function;ACOX1, ACOX, SCOX;609751;17q25.1
persistent fetal circulation syndrome;265380;pulmonary hypertension;duodenal stenosis;Small intestinal stenosis;FOXF1, FKHL5, ACDMPV;601089;16q24.1
persistent hyperplastic primary vitreous;221900;vitreous disease;pendular nystagmus;Nystagmus;ATOH7, PHPVAR, NCRNA;609875;10q21.3
persistent mullerian duct syndrome;261550;pseudohermaphroditism;bilateral cryptorchidism;Cryptorchidism;AMH, MIF;600957;19p13.3
persistent mullerian duct syndrome;261550;pseudohermaphroditism;bilateral cryptorchidism;Cryptorchidism;AMHR2, AMHR;600956;12q13.13
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;GDNF, HSCR3;600837;5p13.2
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;KIF1B, CMT2A, CMT2A1, NBLST1;605995;1p36.22
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;MAX;154950;14q23.3
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;RET, MEN2A, HSCR1;164761;10q11.21
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;SDHB, SDH2, SDHIP, PGL4, CWS2;185470;1p36.13
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;SDHD, PGL1, CWS3;602690;11q23.1
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;TMEM127;613403;2q11.2
phaeochromocytoma;171300;cell type benign neoplasm;positive regitine blocking test;Hypertension associated with pheochromocytoma;VHL;608537;3p25.3
phenylketonuria;261600;amino acid metabolic disorder;maternal hyperphenylalaninemia;Abnormality of phenylalanine metabolism;PAH, PKU1;612349;12q23.2
photosensitive trichothiodystrophy;601675;autosomal dominant disease;lack of subcutaneous fatty tissue;Adipose tissue loss;ERCC2, EM9, XPD, COFS2;126340;19q13.32
photosensitive trichothiodystrophy;601675;autosomal dominant disease;lack of subcutaneous fatty tissue;Adipose tissue loss;ERCC3, XPB;133510;2q14.3
photosensitive trichothiodystrophy;601675;autosomal dominant disease;lack of subcutaneous fatty tissue;Adipose tissue loss;GTF2H5, TTDA, TFB5, C6orf175;608780;6q25.3
piebaldism;172800;autosomal dominant disease;cognitive impairment;Abnormality of higher mental function;KIT, PBT;164920;4q12
piebaldism;172800;autosomal dominant disease;cognitive impairment;Abnormality of higher mental function;SNAI2, SLUG, WS2D;602150;8q11.21
pilomatrixoma;132600;hair follicle neoplasm;neoplasm of the skin;Neoplasm by anatomical site;CTNNB1, MRD19;116806;3p22.1
pilomatrixoma;132600;hair follicle neoplasm;neoplasm of the skin;Neoplasm by anatomical site;MUTYH, MYH;604933;1p34.1
pityriasis rubra pilaris;173200;psoriasis;pustule;Inflammatory abnormality of the skin;CARD14, CARMA2, BIMP2, PSORS2, PSS1, PRP;607211;17q25.3
pleomorphic adenoma;181030;gastrointestinal system benign neoplasm;neoplasm;Phenotypic abnormality;PLAG1, SGPA, PSA;603026;8q12.1
pleuropulmonary blastoma;601200;pulmonary blastoma;pleuropulmonary blastoma;Neoplasm of the tracheobronchial system;DICER1, HERNA, KIAA0928, MNG1, RMSE2;606241;14q32.13
polycystic kidney disease;173900;;cerebral aneurysm;Abnormality of cerebral artery;PKD1;601313;16p13.3
polycystic kidney disease;173900;autosomal dominant disease;cerebral aneurysm;Abnormality of cerebral artery;PKD1;601313;16p13.3
polycystic kidney disease;263200;autosomal dominant disease;hypoplasia of the ear cartilage;Abnormality of the pinna;FCYT, PKHD1, ARPKD;606702;6p12.3-p12.2
polycystic kidney disease;613095;autosomal dominant disease;polycystic kidney dysplasia;Renal cyst;PKD2;173910;4q22.1
polycystic liver disease;174050;;feeding difficulties in infancy;Feeding difficulties;PRKCSH, G19P1, PCLD;177060;19p13.2
polycystic liver disease;174050;;feeding difficulties in infancy;Feeding difficulties;SEC63;608648;6q21
polycystic liver disease;174050;autosomal dominant disease;feeding difficulties in infancy;Feeding difficulties;PRKCSH, G19P1, PCLD;177060;19p13.2
polycystic liver disease;174050;autosomal dominant disease;feeding difficulties in infancy;Feeding difficulties;SEC63;608648;6q21
polycythemia vera;263300;polycythemia;increased megakaryocyte count;Abnormality of cells of the megakaryocyte lineage;JAK2, THCYT3;147796;9p24.1
polydactyly;174200;physical disorder;postaxial hand polydactyly;Postaxial polydactyly;GLI3, PAPA, PAPB;165240;7p14.1
polydactyly;174500;physical disorder;duplication of phalanx of hallux;Duplication of phalanx of toe;LMBR1, ACHP, C7orf2, PPD2, THYP, LSS;605522;7q36.3
polydactyly;174700;physical disorder;preaxial polydactyly;Polydactyly;GLI3, PAPA, PAPB;165240;7p14.1
pontocerebellar hypoplasia type 10;615803;pontocerebellar hypoplasia;delayed myelination;Abnormal myelination;CLP1, HEAB, PCH10;608757;11q12.1
pontocerebellar hypoplasia type 1A;607596;pontocerebellar hypoplasia;neuronal loss in basal ganglia;Abnormality of the basal ganglia;VRK1, PCH1A;602168;14q32.2
pontocerebellar hypoplasia type 1B;614678;pontocerebellar hypoplasia;tongue atrophy;Abnormality of the tongue;EXOSC3, RRP40, PCH1B;606489;9p13.2
pontocerebellar hypoplasia type 2A;277470;pontocerebellar hypoplasia;hypoplasia of the pons;Abnormality of the pons;TSEN54, SEN54, PCH2A, PCH4, PCH5;608755;17q25.1
pontocerebellar hypoplasia type 2B;612389;pontocerebellar hypoplasia;extrapyramidal dyskinesia;Dyskinesia;TSEN2, SEN2, PCH2B;608753;3p25.2
pontocerebellar hypoplasia type 2C;612390;pontocerebellar hypoplasia;cerebellar hemisphere hypoplasia;Cerebellar hypoplasia;TSEN34, PCH2C, LENG5, SEN34;608754;19q13.42
pontocerebellar hypoplasia type 2D;613811;pontocerebellar hypoplasia;delayed myelination;Abnormal myelination;SEPSECS, SLA, LP, PCH2D;613009;4p15.2
pontocerebellar hypoplasia type 2E;615851;pontocerebellar hypoplasia;short stature;Growth delay;VPS53, HCCS1, PCH2E;615850;17p13.3
pontocerebellar hypoplasia type 4;225753;pontocerebellar hypoplasia;hypoplasia of the pons;Abnormality of the pons;TSEN54, SEN54, PCH2A, PCH4, PCH5;608755;17q25.1
pontocerebellar hypoplasia type 5;610204;pontocerebellar hypoplasia;olivopontocerebellar hypoplasia;Hypoplasia of the pons;TSEN54, SEN54, PCH2A, PCH4, PCH5;608755;17q25.1
pontocerebellar hypoplasia type 6;611523;pontocerebellar hypoplasia;upper limb spasticity;Spasticity;RARS2, RARSL, PCH6;611524;6q15
pontocerebellar hypoplasia type 8;614961;pontocerebellar hypoplasia;cortical visual impairment;Visual impairment;CHMP1A, PCOLN3, PRSM1, PCH8;164010;16q24.3
pontocerebellar hypoplasia type 9;615809;pontocerebellar hypoplasia;cortical visual impairment;Visual impairment;AMPD2, SPG63, PCH9;102771;1p13.3
popliteal pterygium syndrome;119500;syndrome;cognitive impairment;Abnormality of higher mental function;IRF6, VWS, LPS, PIT, PPS1, OFC6;607199;1q32.2
popliteal pterygium syndrome;263650;syndrome;aplasia/hypoplasia of the eyebrow;Abnormality of the eyebrow;RIPK4, NKRD3, DIK, PPS2;605706;21q22.3
porencephaly;175780;brain disease;schizencephaly;Abnormality of the cerebrum;COL4A1, POREN1, HANAC, ICH, BSVD;120130;13q34
porencephaly;614483;brain disease;incomplete penetrance;Phenotypic variability;COL4A2, POREN2, ICH;120090;13q34
porphyria cutanea tarda;176100;acute porphyria;scleroderma;Thickened skin;HFE, HLA-H, HFE1, MVCD7, TFQTL2;613609;6p22.2
porphyria cutanea tarda;176100;acute porphyria;scleroderma;Thickened skin;UROD;613521;1p34.1
port-wine stain;163000;;skin ulcer;Localized skin lesion;GNAQ, SWS, CMC1;600998;9q21.2
posterior polar cataract;116600;cataract;total cataract;Cataract;EPHA2, ECK, ARCC2, CTPP1, CTPA, ARCC2, CTRCT6;176946;1p36.13
posterior polar cataract;605387;cataract;posterior subcapsular cataract;Subcapsular cataract;CHMP4B, SNF7, CTPP3, CTRCT31;610897;20q11.22
posterior polar cataract;610623;cataract;cataract;Abnormality of the lens;PITX3, CTPP4, CTRCT11;602669;10q24.32
posterior polar cataract;613763;cataract;posterior polar cataract;Polar cataract;CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2;123590;11q23.1
pre-eclampsia;189800;hypertension;preeclampsia;Toxemia of pregnancy;EPHX1;132810;1q42.12
pre-eclampsia;189800;hypertension;preeclampsia;Toxemia of pregnancy;NOS3;163729;7q36.1
pre-eclampsia;609404;hypertension;preeclampsia;Toxemia of pregnancy;STOX1, PEE4;609397;10q21.3-q22.1
pre-eclampsia;614592;hypertension;midface retrusion;Abnormality of the midface;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
premature ovarian failure;300510;ovarian disease;gonadal hypoplasia;Abnormal internal genitalia;BMP15, GDF9B, ODG2, POF4;300247;Xp11.22
premature ovarian failure;300511;ovarian disease;premature ovarian failure;Abnormality of the ovary;DIAPH2, DIA, POF2;300108;Xq21.33
premature ovarian failure;300604;ovarian disease;premature ovarian failure;Abnormality of the ovary;FLJ22792, POF1B, POF2B;300603;Xq21.1-q21.2
premature ovarian failure;311360;ovarian disease;premature ovarian failure;Abnormality of the ovary;FMR1, FRAXA, POF1;309550;Xq27.3
premature ovarian failure;608996;ovarian disease;premature ovarian failure;Abnormality of the ovary;FOXL2, BPES, BPES1, PFRK, POF3;605597;3q22.3
premature ovarian failure;611548;ovarian disease;premature ovarian failure;Abnormality of the ovary;NOBOX, POF5;610934;7q35
premature ovarian failure;612310;ovarian disease;premature ovarian failure;Abnormality of the ovary;FIGLA, POF6;608697;2p13.3
premature ovarian failure;612964;ovarian disease;premature ovarian failure;Abnormality of the ovary;NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8;184757;9q33.3
premature ovarian failure;615723;ovarian disease;premature ovarian failure;Abnormality of the ovary;STAG3, POF8;608489;7q22.1
premature ovarian failure;615724;ovarian disease;premature ovarian failure;Abnormality of the ovary;HFM1, MER3, POF9;615684;1p22.2
primary ciliary dyskinesia;244400;autosomal recessive disease;nasal polyposis;Abnormality of the nasal mucosa;DNAI1, CILD1, ICS, PCD;604366;9p13.3
primary ciliary dyskinesia;606763;autosomal recessive disease;nasal polyposis;Abnormality of the nasal mucosa;DNAAF3, PF22, DAB1, CILD2;614566;19q13.42
primary ciliary dyskinesia;608644;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;DNAH5, HL1, PCD, CILD3;603335;5p15.2
primary ciliary dyskinesia;608647;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;HYDIN, HYDIN1, CILD5;610812;16q22.2
primary ciliary dyskinesia;610852;autosomal recessive disease;absent/shortened outer dynein arms;Shortened outer dynein arms;NME8, TXNDC3, SPTRX2, CILD6;607421;7p14.1
primary ciliary dyskinesia;611884;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;DNAH11, DNAHC11, CILD7, DNAHBL;603339;7p15.3
primary ciliary dyskinesia;612444;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;DNAI2, CILD9;605483;17q25.1
primary ciliary dyskinesia;612518;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;KTU, C14orf104, CILD10;612517;14q21.3
primary ciliary dyskinesia;612649;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;RSPH4A, CILD11;612647;6q22.1
primary ciliary dyskinesia;612650;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;RSPH9, CILD12;612648;6p21.1
primary ciliary dyskinesia;613193;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;LRRC50, ODA7, CILD13;613190;16q23.3-q24.1
primary ciliary dyskinesia;613807;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;CCDC39;613798;3q26.33
primary ciliary dyskinesia;613808;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;CCDC40, KIAA1640;613799;17q25.3
primary ciliary dyskinesia;614017;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;DNAL1, C14orf168, CILD16;610062;14q24.3
primary ciliary dyskinesia;614679;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;CCDC103, SMH, PR46B, CILD17;614677;17q21.31
primary ciliary dyskinesia;614874;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;HEATR2, CILD18;614864;7p22.3
primary ciliary dyskinesia;614935;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;LRRC6, LRTP, CILD19;614930;8q24.22
primary ciliary dyskinesia;615067;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;CCDC114, CILD20;615038;19q13.33
primary ciliary dyskinesia;615294;autosomal recessive disease;atelectasis;Abnormality of the lung;DRC1, CCDC164, C2orf39, CILD21;615288;2p23.3
primary ciliary dyskinesia;615444;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;ZMYND10, BLU;607070;3p21.31
primary ciliary dyskinesia;615451;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;ARMC4, CILD23;615408;10p12.1
primary ciliary dyskinesia;615481;autosomal recessive disease;rhinitis;Abnormality of the nose;RSPH1, TSGA2, TSA2, CILD24;609314;21q22.3
primary ciliary dyskinesia;615482;autosomal recessive disease;ciliary dyskinesia;Abnormal ciliary motility;DYX1C1, DYXC1, DYX1, CILD25;608706;15q21.3
primary ciliary dyskinesia;615500;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;C21ORF59, CILD26;615494;21q22.11
primary ciliary dyskinesia;615504;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;CCDC65, CILD27;611088;12q13.12
primary ciliary dyskinesia;615505;autosomal recessive disease;respiratory insufficiency due to defective ciliary clearance;Abnormal respiratory motile cilium physiology;SPAG1, CILD28;603395;8q22.2
primary ciliary dyskinesia;615872;autosomal recessive disease;atelectasis;Abnormality of the lung;CCNO, UNG2, CILD29;607752;5q11.2
primary congenital glaucoma;613086;glaucoma;primary congenital glaucoma;Congenital glaucoma;LTBP2, LTBP3, GLC3D, MSPKA, WMS3;602091;14q24.3
primary cutaneous amyloidosis;105250;amyloidosis;amyloidosis;Abnormality of metabolism/homeostasis;OSMR, OSMRB, PLCA1;601743;5p13.1
primary cutaneous amyloidosis;613955;amyloidosis;cutaneous amyloidosis;Amyloidosis;IL31RA, GLMR, GPL, PLCA2;609510;5q11.2
primary hyperoxaluria;260000;kidney disease;calcium oxalate nephrolithiasis;Calcium nephrolithiasis;GRHPR, GLXR;604296;9p13.2
primary hyperoxaluria;613616;kidney disease;calcium oxalate nephrolithiasis;Calcium nephrolithiasis;HOGA1, DHDPSL, HP3;613597;10q24.2
primary hypertrophic osteoarthropathy;259100;syndrome;clubbing of toes;Abnormality of the phalanges of the toes;HPGD, PGDH1, PHOAR1;601688;4q34.1
primary open angle glaucoma;137760;open-angle glaucoma;primary open angle glaucoma;Glaucoma;OPTN, GLC1E, FIP2, HYPL, NRP, ALS12;602432;10p13
primary pigmented nodular adrenocortical disease;610475;adrenal cortex disease;onset;Clinical modifier;PDE11A, PDE11A1, PDE11A2, PDE11A3, PPNAD2;604961;2q31.2
primary pigmented nodular adrenocortical disease;610489;adrenal cortex disease;onset;Clinical modifier;PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1;188830;17q24.2
primary pigmented nodular adrenocortical disease;614190;adrenal cortex disease;adrenal hyperplasia;Abnormality of adrenal morphology;PDE8B, PPNAD3, ADSD;603390;5q13.3
primary pigmented nodular adrenocortical disease;615830;adrenal cortex disease;adrenal hyperplasia;Abnormality of adrenal morphology;PRKACA;601639;19p13.12
primary pulmonary hypertension;178600;chronic pulmonary heart disease;arterial intimal fibrosis;Abnormality of the systemic arterial tree;BMPR2, PPH1, POVD1;600799;2q33.1-q33.2
primary pulmonary hypertension;615342;chronic pulmonary heart disease;increased pulmonary vascular resistance;Abnormality of the pulmonary vasculature;MADH9, SMAD9, MADH6, PPH2;603295;13q13.3
primary pulmonary hypertension;615343;chronic pulmonary heart disease;increased pulmonary vascular resistance;Abnormality of the pulmonary vasculature;CAV1, BSCL3, CGL3, PPH3, LCCNS;601047;7q31.2
progeria;176670;autosomal recessive disease;lack of skin elasticity;Abnormal elasticity of skin;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;1q22
progressive myoclonus epilepsy;254900;variable age at onset electroclinical syndrome;rapidly progressive;Pace of progression;SCARB2, CD36L2, LIMPII, AMRF, EPM4;602257;4q21.1
progressive myoclonus epilepsy;611726;variable age at onset electroclinical syndrome;progressive disorder;Pace of progression;KCTD7, EPM3, CLN14;611725;7q11.21
progressive myoclonus epilepsy;612437;variable age at onset electroclinical syndrome;atonic seizures;Generalized seizures;PRICKLE1, RILP, EPM1B;608500;12q12
progressive myoclonus epilepsy;613832;variable age at onset electroclinical syndrome;peripheral neuropathy;Abnormal peripheral nervous system morphology;PRICKLE2, EPM5;608501;3p14.1
progressive myoclonus epilepsy;614018;variable age at onset electroclinical syndrome;atonic seizures;Generalized seizures;GOSR2, GS27, EPM6;604027;17q21.32
progressive supranuclear palsy;601104;movement disease;adult onset;Onset;MAPT, MTBT1, DDPAC, MSTD;157140;17q21.31
prolactinoma;600634;functioning pituitary adenoma;pituitary prolactin cell adenoma;Pituitary adenoma;AIP, XAP2, ARA9;605555;11q13.2
propionic acidemia;606054;organic acidemia;cognitive impairment;Abnormality of higher mental function;PCCA;232000;13q32.3
propionic acidemia;606054;organic acidemia;cognitive impairment;Abnormality of higher mental function;PCCB;232050;3q22.3
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1;313700;Xq12
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;13q13.1
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;CD82, SAR2, KAI1, ST6;600623;11p11.2
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;CDH1, UVO, LCAM, ECAD;192090;16q22.1
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;CHEK2, RAD53, CHK2, CDS1, LFS2;604373;22q12.1
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;HIP1;601767;7q11.23
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;HPC3;608656;20q13
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;HPC4;608658;7p11-q21
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;HPC5;609299;3p26
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;HPC6;609558;22q12.3
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;HPCQTL19;607592;19q
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;KLF6, COPEB, BCD1, ZF9;602053;10p15.1
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;MAD1L1, TXBP181;602686;7p22.3
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;MSR1, SCARA1, SRA;153622;8p22
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;MXI1;600020;10q25.2
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;PCAP;602759;1q42.2-q43
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
prostate cancer;176807;male reproductive organ cancer;prostate cancer;Prostate neoplasm;ZFHX3, ATBF1;104155;16q22.2-q22.3
prostate cancer;601518;male reproductive organ cancer;prostate cancer;Prostate neoplasm;RNASEL, RNS4, PRCA1, HPC1;180435;1q25.3
prothrombin deficiency;613679;autosomal recessive disease;reduced prothrombin activity;Abnormality of prothrombin;F2, THPH1, RPRGL2;176930;11p11.2
proximal symphalangism;185800;autosomal dominant disease;aplasia/hypoplasia of the middle phalanges of the toes;Abnormality of the middle phalanges of the toes;NOG, SYM1, SYNS1;602991;17q22
pseudo-TORCH syndrome;251290;autosomal recessive disease;abnormality of movement;Abnormality of nervous system physiology;OCLN, BLCPMG;602876;5q13.2
pseudoachondroplasia;177170;osteochondrodysplasia;fragmented epiphyses;Abnormality of the epiphyses;COMP, EDM1, MED, PSACH;600310;19p13.11
pseudohypoparathyroidism;603233;metal metabolism disorder;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C;139320;20q13.32
pseudohypoparathyroidism;603233;metal metabolism disorder;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;GNASAS1, GNASAS, SANG, NESPAS;610540;20q13.32
pseudohypoparathyroidism;603233;metal metabolism disorder;short metacarpal;Aplasia/Hypoplasia involving the metacarpal bones;STX16, SYN16;603666;20q13.32
pseudohypoparathyroidism;612462;metal metabolism disorder;cognitive impairment;Abnormality of higher mental function;GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C;139320;20q13.32
pseudopseudohypoparathyroidism;612463;pseudohypoparathyroidism;cognitive impairment;Abnormality of higher mental function;GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C;139320;20q13.32
pseudoxanthoma elasticum;177850;autosomal recessive disease;calcification of falx cerebri;Abnormality of the falx cerebri;ABCC6, ARA, ABC34, MLP1, PXE, GACI2;603234;16p13.11
pseudoxanthoma elasticum;264800;autosomal recessive disease;renovascular hypertension;Abnormal renal physiology;ABCC6, ARA, ABC34, MLP1, PXE, GACI2;603234;16p13.11
pseudoxanthoma elasticum;264800;autosomal recessive disease;renovascular hypertension;Abnormal renal physiology;XYLT1, XT1, DBQD2;608124;16p12.3
pseudoxanthoma elasticum;264800;autosomal recessive disease;renovascular hypertension;Abnormal renal physiology;XYLT2, XT2;608125;17q21.33
psoriasis;177900;skin disease;psoriasis;Inflammatory abnormality of the skin;HLA-C, PSORS1;142840;6p21.33
pulmonary alveolar microlithiasis;265100;lung disease;progressive pulmonary function impairment;Decreased pulmonary function;SLC34A2;604217;4p15.2
pulmonary alveolar proteinosis;265120;lung disease;interstitial pulmonary disease;Abnormality of the lung;SFTPB, SFTB3, SMDP1;178640;2p11.2
pulmonary alveolar proteinosis;300770;lung disease;alveolar proteinosis;Abnormality of the lung;CSF2RA, SMDP4;306250;Xp22.33
pulmonary alveolar proteinosis;610913;lung disease;alveolar proteinosis;Abnormality of the lung;SFTPC, SFTP2, SMDP2;178620;8p21.3
pulmonary alveolar proteinosis;610921;lung disease;alveolar proteinosis;Abnormality of the lung;ABCA3, ABC3, SMDP3;601615;16p13.3
pulmonary alveolar proteinosis;614370;lung disease;alveolar proteinosis;Abnormality of the lung;CSF2RB, SMDP5;138981;22q12.3
pulmonary venoocclusive disease;265450;pulmonary hypertension;pulmonary venoocclusive disease;Abnormality of the lung;BMPR2, PPH1, POVD1;600799;2q33.1-q33.2
purine nucleoside phosphorylase deficiency;613179;combined T cell and B cell immunodeficiency;markedly reduced t cell function;Impaired T cell function;PNP, NP;164050;14q11.2
pyridoxine-refractory autosomal recessive sideroblastic anemia;205950;sideroblastic anemia;infantile onset;Onset;GLRX5, C14orf87, PRO1238, FLB4739, PRSA;609588;14q32.13
pyridoxine-refractory autosomal recessive sideroblastic anemia;205950;sideroblastic anemia;infantile onset;Onset;SLC25A38;610819;3p22.1
pyruvate carboxylase deficiency disease;266150;carbohydrate metabolic disorder;neuronal loss in the cerebral cortex;Abnormality of the cerebral cortex;PC;608786;11q13.2
pyruvate decarboxylase deficiency;245348;carbohydrate metabolic disorder;jerky head movements;Abnormal head movements;DLAT, PDCE2;608770;11q23.1
pyruvate decarboxylase deficiency;245349;carbohydrate metabolic disorder;poor gross motor coordination;Poor motor coordination;PDX1;608769;11p13
pyruvate decarboxylase deficiency;312170;carbohydrate metabolic disorder;basal ganglia cysts;Intracranial cystic lesion;PDHA1, PHE1A, PDHAD;300502;Xp22.12
pyruvate decarboxylase deficiency;608782;carbohydrate metabolic disorder;infantile onset;Onset;PDP1, PPM2C, PDP1, PDPC;605993;8q22.1
pyruvate decarboxylase deficiency;614111;carbohydrate metabolic disorder;lactic acidosis;Acidosis;PDHB, PDHBD;179060;3p14.3
rapadilino syndrome;266280;autosomal recessive disease;sarcoma;Neoplasm by histology;RECQL4, RTS, RECQ4;603780;8q24.3
red-green color blindness;303800;color blindness;deuteranomoly;Anomalous trichromacy;OPN1MW, GCP, CBD, CBBM;300821;Xq28
renal agenesis;191830;kidney disease;congenital onset;Onset;ITGA8, RHDA1;604063;10p13
renal agenesis;191830;kidney disease;congenital onset;Onset;PAX2, PAPRS, FSGS7;167409;10q24.31
renal agenesis;191830;kidney disease;congenital onset;Onset;RET, MEN2A, HSCR1;164761;10q11.21
renal cell carcinoma;300854;renal carcinoma;renal cell carcinoma;Renal neoplasm;TFE3, RCCX1;314310;Xp11.23
renal glycosuria;233100;renal tubular transport disease;enuresis nocturna;Enuresis;SLC5A2, SGLT2;182381;16p11.2
renal tubular acidosis;602722;renal tubular transport disease;bilateral sensorineural hearing impairment;Sensorineural hearing impairment;ATP6V0A4, ATP6N1B, VPP2, RTA1C, RTADR;605239;7q34
renal-hepatic-pancreatic dysplasia;208540;physical disorder;pancreatic fibrosis;Abnormality of pancreas morphology;NPHP3, NPH3, RHPD1, MKS7;608002;3q22.1
renal-hepatic-pancreatic dysplasia;615415;physical disorder;stillbirth;Time of death;NEK8, JCK, NPHP9, RHPD2;609799;17q11.2
restrictive cardiomyopathy;115210;intrinsic cardiomyopathy;ventriculomegaly;Abnormality of the cerebral ventricles;TNNI3, CMH7, CMD2A, RCM1, CMD1FF;191044;19q13.42
restrictive cardiomyopathy;612422;intrinsic cardiomyopathy;cardiomyopathy;Abnormality of the myocardium;TNNT2, CMH2, CMD1D, RCM3, LVNC6;191045;1q32.1
reticular dysgenesis;267500;severe combined immunodeficiency;skin ulcer;Localized skin lesion;AK2;103020;1p35.1
reticulate acropigmentation of Kitamura;615537;pigmentation disease;autosomal dominant inheritance;Mode of inheritance;ADAM10, MADM, RAK, AD18;602192;15q21.3
retinal drusen;126700;degeneration of macula and posterior pole;progressive visual loss;Visual loss;HF1, CFH, HUS, ARMD4, AHUS1;134370;1q31.3
retinitis pigmentosa;120970;retinal degeneration;peripheral visual field loss;Visual field defect;CRX, CORD2, CRD, LCA7;602225;19q13.33
retinitis pigmentosa;180100;retinal degeneration;bony spicule pigmentary retinopathy;Pigmentary retinopathy;RP1, ORP1;603937;8q12.1
retinitis pigmentosa;180104;retinal degeneration;macular edema;Abnormality of the macula;RP9, PAP1;607331;7p14.3
retinitis pigmentosa;180105;retinal degeneration;bony spicule pigmentary retinopathy;Pigmentary retinopathy;IMPDH1, RP10, LCA11;146690;7q32.1
retinitis pigmentosa;300029;retinal degeneration;x-linked inheritance;Gonosomal inheritance;RPGR, RP3, CRD, RP15, COD1, CORDX1;312610;Xp11.4
retinitis pigmentosa;300424;retinal degeneration;posterior subcapsular cataract;Subcapsular cataract;OFD1, CXorf5, SGBS2, JBTS10, RP23;300170;Xp22.2
retinitis pigmentosa;312600;retinal degeneration;choroidoretinal degeneration;Chorioretinal abnormality;RP2;300757;Xp11.23
retinitis pigmentosa;600059;retinal degeneration;hypopigmented fundi;Abnormality of the fundus;PRPF8, PRPC8, RP13;607300;17p13.3
retinitis pigmentosa;600105;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;CRB1, RP12, LCA8;604210;1q31.3
retinitis pigmentosa;600132;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;TULP1, RP14, LCA15;602280;6p21.31
retinitis pigmentosa;600138;retinal degeneration;macular edema;Abnormality of the macula;PRPF31, PRP31, RP11;606419;19q13.42
retinitis pigmentosa;600852;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;CA4, RP17;114760;17q23.1
retinitis pigmentosa;601414;retinal degeneration;retinal arteriolar constriction;Abnormality of retinal arteries;HPRP3, RP18;607301;1q21.2-q21.3
retinitis pigmentosa;601718;retinal degeneration;absent retinal pigment epithelium;Abnormality of the retinal pigment epithelium;ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2;601691;1p22.1
retinitis pigmentosa;602772;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;EYS, RP25;612424;6q12
retinitis pigmentosa;606068;retinal degeneration;bony spicule pigmentary retinopathy;Pigmentary retinopathy;FAM161A, RP28;613596;2p15
retinitis pigmentosa;607921;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;FSCN2, RFSN, RP30;607643;17q25.3
retinitis pigmentosa;608133;retinal degeneration;peripheral visual field loss;Visual field defect;PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2, MDBS1;179605;6p21.1
retinitis pigmentosa;608133;retinal degeneration;peripheral visual field loss;Visual field defect;ROM1, ROSP1, RP7;180721;11q12.3
retinitis pigmentosa;608380;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;CERKL, RP26;608381;2q31.3
retinitis pigmentosa;609923;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;TOPORS, P53BP3, LUN, RP31;609507;9p21.1
retinitis pigmentosa;610282;retinal degeneration;abnormality of skin pigmentation;Abnormality of skin morphology;SEMA4A, SEMB, RP35, CORD10;607292;1q22
retinitis pigmentosa;610359;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;SNRNP200, ASCC3L1, KIAA0788, RP33;601664;2q11.2
retinitis pigmentosa;610599;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;PRCD, RP36;610598;17q25.1
retinitis pigmentosa;611131;retinal degeneration;cystoid macular degeneration;Macular degeneration;NR2E3, PNR, ESCS, RP37;604485;15q23
retinitis pigmentosa;612095;retinal degeneration;night blindness;Abnormality of vision;PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4;604365;4p15.32
retinitis pigmentosa;612572;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;IDH3B, RP46;604526;20p13
retinitis pigmentosa;612712;retinal degeneration;retinal dystrophy;Abnormality of the retina;RDH12, LCA13;608830;14q24.1
retinitis pigmentosa;612943;retinal degeneration;pallor;Abnormality of skin morphology;KLHL7, RP42;611119;7p15.3
retinitis pigmentosa;613194;retinal degeneration;retinal flecks;Abnormality of the retina;BEST1, VMD2, ARB, RP50;607854;11q12.3
retinitis pigmentosa;613428;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;C2orf71;613425;2p23.2
retinitis pigmentosa;613464;retinal degeneration;abnormal rod and cone electroretinograms;Abnormal electroretinogram;TTC8, BBS8, RP51;608132;14q31.3
retinitis pigmentosa;613575;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;ARL6, BBS3, RP55;608845;3q11.2
retinitis pigmentosa;613581;retinal degeneration;posterior subcapsular cataract;Subcapsular cataract;IMPG2, IPM200, RP56, VMD5;607056;3q12.3
retinitis pigmentosa;613582;retinal degeneration;cystoid macular edema;Macular edema;PDE6G, PDEG, RP57;180073;17q25.3
retinitis pigmentosa;613617;retinal degeneration;abnormal rod and cone electroretinograms;Abnormal electroretinogram;ZNF513, RP58;613598;2p23.3
retinitis pigmentosa;613731;retinal degeneration;visual field defect;Abnormality of vision;RHO, RP4, OPN2, CSNBAD1;180380;3q22.1
retinitis pigmentosa;613750;retinal degeneration;macular edema;Abnormality of the macula;NRL, D14S46E, RP27;162080;14q11.2
retinitis pigmentosa;613756;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;CNGA1, CNCG1, RP49;123825;4p12
retinitis pigmentosa;613758;retinal degeneration;pigmentary retinal degeneration;Abnormality of the retinal pigment epithelium;SAG, RP47;181031;2q37.1
retinitis pigmentosa;613767;retinal degeneration;peripheral visual field loss;Visual field defect;CNGB1, CNCG3L, CNCG2, RP45;600724;16q21
retinitis pigmentosa;613769;retinal degeneration;depigmented lesions of the retinal pigment epithelium;Hypopigmentation of the fundus;RGR, RP44;600342;10q23.1
retinitis pigmentosa;613794;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;RPE65, RP20, LCA2;180069;1p31.3-p31.2
retinitis pigmentosa;613801;retinal degeneration;abnormal rod and cone electroretinograms;Abnormal electroretinogram;PDE6B, PDEB, RP40, CSNBAD2;180072;4p16.3
retinitis pigmentosa;613810;retinal degeneration;peripheral visual field loss;Visual field defect;PDE6A, PDEA, RP43;180071;5q32
retinitis pigmentosa;613827;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;GUCA1B, GCAP2, GUCA2, RP48;602275;6p21.1
retinitis pigmentosa;613861;retinal degeneration;cystoid macular edema;Macular edema;DHDDS, HDS, RP59;608172;1p36.11
retinitis pigmentosa;613862;retinal degeneration;peripheral retinal atrophy;Retinal atrophy;MERTK, RP38;604705;2q13
retinitis pigmentosa;613983;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;PRPF6, PRP6, ANT1, TOM, C20orf14;613979;20q13.33
retinitis pigmentosa;614180;retinal degeneration;attenuation of retinal blood vessels;Abnormality of the retinal vasculature;CLRN1, USH3A, USH3, RP61;606397;3q25.1
retinitis pigmentosa;614181;retinal degeneration;night blindness;Abnormality of vision;MAK, RP62;154235;6p24.2
retinitis pigmentosa;615233;retinal degeneration;posterior subcapsular cataract;Subcapsular cataract;RBP3, RP66;180290;10q11.22
retinitis pigmentosa;615434;retinal degeneration;situs inversus totalis;Abnormal spatial orientation of the cardiac segments;ARL2BP, BART;615407;16q13
retinitis pigmentosa;615565;retinal degeneration;retinitis pigmentosa;Abnormal retinal pigmentation;NEK2, RP67;604043;1q32.3
retinitis pigmentosa;615725;retinal degeneration;visual field defect;Abnormality of vision;SLC7A14, KIAA1613, RP68;615720;3q26.2
retinitis pigmentosa;615780;retinal degeneration;peripheral retinal pigmentation abnormalities;Abnormal retinal pigmentation;KIZ, KIZUNA, C20orf19, RP69;615757;20p11.23
retinitis pigmentosa;615922;retinal degeneration;retinal degeneration;Abnormality of the retina;PRPF4, PRP4, HPRP4, RP70;607795;9q32
retinoblastoma;180200;retinal cell cancer;ewing's sarcoma;Sarcoma;RB1;614041;13q14.2
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;CD244, NAIL, NKR2B4, SLAMF4;605554;1q23.3
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;HLA-DRB1, SS1;142857;6p21.32
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;IL10, CSIF, GVHDS;124092;1q32.1
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;MHC2TA, C2TA;600005;16p13.13
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;NFKBIL1;601022;6p21.33
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;PADI4, PADI5, PAD;605347;1p36.13
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;PTPN22, PEP, PTPN8, LYP;600716;1p13.2
rheumatoid arthritis;180300;arthritis;abnormality of the immune system;Phenotypic abnormality;SLC22A4, OCTN1;604190;5q31.1
rhizomelic chondrodysplasia punctata;215100;chondrodysplasia punctata;flat face;Abnormal facial shape;PEX7, RCDP1, PBD9B;601757;6q23.3
rhizomelic chondrodysplasia punctata;222765;chondrodysplasia punctata;rhizomelia;Limb undergrowth;GNPAT, DHAPAT;602744;1q42.2
rhizomelic chondrodysplasia punctata;600121;chondrodysplasia punctata;epiphyseal stippling;Ectopic calcification;AGPS, ADHAPS;603051;2q31.2
rickets;264700;bone remodeling disease;fibular bowing;Abnormal morphology of bones of the lower limbs;CYP27B1, VDD1, PDDR;609506;12q14.1
rickets;277440;bone remodeling disease;fibular bowing;Abnormal morphology of bones of the lower limbs;VDR;601769;12q13.11
rickets;600081;bone remodeling disease;fibular bowing;Abnormal morphology of bones of the lower limbs;CYP2R1;608713;11p15.2
rippling muscle disease;606072;muscle tissue disease;exercise-induced muscle stiffness;Muscle stiffness;CAV3, LGMD1C, LQT9;601253;3p25.3
sarcoidosis;181000;hypersensitivity reaction type IV disease;cough;Functional respiratory abnormality;HLA-DRB1, SS1;142857;6p21.32
sarcoidosis;609464;hypersensitivity reaction type IV disease;non-caseating epithelioid cell granulomatosis;Granulomatosis;NOD2, CARD15, IBD1, CD, ACUG, PSORAS1;605956;16q12.1
scapuloperoneal myopathy;181430;muscular dystrophy;scapuloperoneal myopathy;Amyotrophy involving the shoulder musculature;MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD;160760;14q11.2
scapuloperoneal myopathy;300695;muscular dystrophy;arrhythmia;Abnormality of cardiovascular system physiology;FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B;300163;Xq26.3
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;AKT1, CWS6;164730;14q32.33
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;APOL2;607252;22q12.3
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;APOL4;607254;22q12.3
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;CHI3L1, GP39, YKL40, ASRT7;601525;1q32.1
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;COMT;116790;22q11.21
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;DAO, DAMOX;124050;12q24.11
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;DAOA, G72;607408;13q33.2
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;DISC1, SCZD9;605210;1q42.2
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;DISC2;606271;1q42.2
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;DRD3, ETM1, FET1;126451;3q13.31
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;DTNBP1, HPS7;607145;6p22.3
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;HTR2A;182135;13q14.2
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;MTHFR;607093;1p36.22
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;RTN4R, NOGOR;605566;22q11.21
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD11;608078;10q22.3
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD12;608543;1p36.2
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD1;181510;5q23-q35
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD2;603342;11q14-q21
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD3;600511;6p23
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD5;603175;6q13-q26
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD6;603013;8p21
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD7;603176;13q32
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SCZD8;603206;18p
schizophrenia;181500;psychotic disorder;schizophrenia;Behavioral abnormality;SYN2;600755;3p25.2
schizophrenia;600850;psychotic disorder;schizophrenia;Behavioral abnormality;PRODH, PRODH2, SCZD4;606810;22q11.21
schizophrenia;613950;psychotic disorder;schizophrenia;Behavioral abnormality;SHANK3, PSAP2, PROSAP2, KIAA1650, DEL22q13.3, SCZD15;606230;22q13.33
schneckenbecken dysplasia;269250;osteochondrodysplasia;disproportionate short-limb short stature;Disproportionate short stature;SLC35D1, UGTREL7, KIAA0260;610804;1p31.3
sclerosteosis;269500;SOST-related sclerosing bone dysplasia;cognitive impairment;Abnormality of higher mental function;SOST, VBCH, CDD, SOST1;605740;17q21.31
sclerosteosis;614305;SOST-related sclerosing bone dysplasia;facial palsy;Abnormality of the seventh cranial nerve;LRP4, MEGF7, CLSS, SOST2;604270;11p11.2
sea-blue histiocyte syndrome;269600;non-langerhans-cell histiocytosis;mediastinal lymphadenopathy;Abnormality of the mediastinum;APOE, AD2, LPG, LDLCQ5;107741;19q13.32
seborrheic keratosis;182000;keratosis;verrucae;Papilloma;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
seminoma;273300;germ cell cancer;teratoma;Germ cell neoplasia;BCL10, IMD37;603517;1p22.3
seminoma;273300;germ cell cancer;teratoma;Germ cell neoplasia;FGFR3, ACH;134934;4p16.3
seminoma;273300;germ cell cancer;teratoma;Germ cell neoplasia;KIT, PBT;164920;4q12
seminoma;273300;germ cell cancer;teratoma;Germ cell neoplasia;STK11, PJS, LKB1;602216;19p13.3
sensorineural hearing loss;304400;inner ear disease;dilatated internal auditory canal;Abnormality of the internal auditory canal;POU3F4, DFN3, DFNX2;300039;Xq21.1
severe congenital neutropenia;202700;neutropenia;monocytosis;Abnormal monocyte count;ELANE, ELA2, SCN1;130130;19p13.3
severe congenital neutropenia;300299;neutropenia;congenital neutropenia;Neutropenia;WAS, IMD2, THC1, SCNX;300392;Xp11.23
severe congenital neutropenia;610738;neutropenia;infantile onset;Onset;HAX1, SCN3;605998;1q21.3
severe congenital neutropenia;612541;neutropenia;sepsis;Abnormality of immune system physiology;G6PC3, UGRP, SCN4;611045;17q21.31
severe congenital neutropenia;613107;neutropenia;monocytosis;Abnormal monocyte count;GFI1, ZNF163, SCN2;600871;1p22.1
severe congenital neutropenia;615285;neutropenia;hypergammaglobulinemia;Abnormal immunoglobulin level;VPS45A, VPS45, SCN5;610035;1q21.2
short QT syndrome;609620;autosomal dominant disease;shortened qt interval;Abnormal EKG;KCNH2, LQT2, HERG, SQT1;152427;7q36.1
short QT syndrome;609621;autosomal dominant disease;shortened qt interval;Abnormal EKG;KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2;607542;11p15.5-p15.4
short QT syndrome;609622;autosomal dominant disease;shortened qt interval;Abnormal EKG;KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9;600681;17q24.3
sialuria;269921;lysosomal storage disease;prominent forehead;Abnormality of the forehead;GNE, GLCNE, IBM2, DMRV, NM;603824;9p13.3
sialuria;604369;lysosomal storage disease;thickened calvaria;Abnormality of the calvaria;SLC17A5, SIASD, SLD;604322;6q13
sick sinus syndrome;163800;sinoatrial node disease;sick sinus syndrome;Heart block;HCN4, SSS2;605206;15q24.1
sick sinus syndrome;608567;sinoatrial node disease;sick sinus syndrome;Heart block;SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;600163;3p22.2
sickle cell anemia;603903;autosomal recessive disease;priapism;Erectile abnormalities;HBB;141900;11p15.4
situs inversus;270100;visceral heterotaxy;abdominal situs inversus;Abnormality of abdominal situs;NODAL, HTX5;601265;10q22.1
skin melanoma;155600;skin cancer;cutaneous melanoma;Neoplasm of the skin;PTEN, MMAC1, GLM2, CWS1;601728;10q23.31
skin melanoma;609048;skin cancer;cutaneous melanoma;Neoplasm of the skin;CDK4, CMM3;123829;12q14.1
skin melanoma;614456;skin cancer;cutaneous melanoma;Neoplasm of the skin;MITF, WS2A, CMM8;156845;3p14-p13
soldiers heart;604715;;orthostatic tachycardia;Abnormal autonomic nervous system physiology;SLC6A2, NAT1, NET1;163970;16q12.2
spastic quadriplegia;603513;spastic cerebral palsy;cerebral palsy;Abnormality of movement;GAD1, SCP, CPSQ1;605363;2q31.1
spastic quadriplegia;612900;spastic cerebral palsy;cerebral palsy;Abnormality of movement;KANK1, KANK, ANKRD15, KIAA0172, CPSQ2;607704;9p24.3
specific language impairment;615432;language disorder;incomplete penetrance;Phenotypic variability;TM4SF20, SLI5;615404;2q36.3
spinocerebellar ataxia type 5;600224;spinocerebellar ataxia;impaired smooth pursuit;Abnormality of ocular smooth pursuit;SPTBN2, SCA5, SCAR14;604985;11q13.2
spinocerebellar ataxia;117210;spinocerebellar degeneration;gaze-evoked horizontal nystagmus;Horizontal nystagmus;BEAN, SCA31;612051;16q21
spinocerebellar ataxia;164400;spinocerebellar degeneration;cognitive impairment;Abnormality of higher mental function;ATXN1, ATX1, SCA1;601556;6p22.3
spinocerebellar ataxia;183086;spinocerebellar degeneration;impaired smooth pursuit;Abnormality of ocular smooth pursuit;CACNA1A, CACNL1A4, SCA6;601011;19p13.2
spinocerebellar ataxia;603516;spinocerebellar degeneration;abnormal pyramidal signs;Upper motor neuron dysfunction;ATXN10, SCA10;611150;22q13.31
spinocerebellar ataxia;604326;spinocerebellar degeneration;sensorimotor neuropathy;Peripheral neuropathy;PPP2R2B;604325;5q32
spinocerebellar ataxia;604432;spinocerebellar degeneration;adult onset;Onset;TTBK2, SCA11;611695;15q15.2
spinocerebellar ataxia;605259;spinocerebellar degeneration;abnormal pyramidal signs;Upper motor neuron dysfunction;KCNC3, SCA13;176264;19q13.33
spinocerebellar ataxia;605361;spinocerebellar degeneration;attention deficit hyperactivity disorder;Hyperactivity;PRKCG, PKCC, PKCG, SCA14;176980;19q13.42
spinocerebellar ataxia;606002;spinocerebellar degeneration;impaired proprioception;Sensory impairment;SETX, SCAR1, AOA2, ALS4;608465;9q34.13
spinocerebellar ataxia;606658;spinocerebellar degeneration;gaze-evoked horizontal nystagmus;Horizontal nystagmus;ITPR1, SCA15, SCA16, SCA29;147265;3p26.1
spinocerebellar ataxia;606937;spinocerebellar degeneration;ankle clonus;Abnormality of the ankles;ZNF592, KIAA0211, SCAR5, CAMOS;613624;15q25.3
spinocerebellar ataxia;607136;spinocerebellar degeneration;paranoia;Delusions;TBP, SCA17, HDL4;600075;6q27
spinocerebellar ataxia;607250;spinocerebellar degeneration;distal amyotrophy;Skeletal muscle atrophy;TDP1;607198;14q32.11
spinocerebellar ataxia;608768;spinocerebellar degeneration;peripheral neuropathy;Abnormal peripheral nervous system morphology;ATXN8;613289;13q21
spinocerebellar ataxia;608768;spinocerebellar degeneration;peripheral neuropathy;Abnormal peripheral nervous system morphology;ATXN8OS, SCA8, KLHL1AS;603680;13q21.33
spinocerebellar ataxia;609307;spinocerebellar degeneration;impaired smooth pursuit;Abnormality of ocular smooth pursuit;FGF14, FHF4, SCA27;601515;13q33.1
spinocerebellar ataxia;610245;spinocerebellar degeneration;cns demyelination;Abnormal CNS myelination;PDYN, SCA23;131340;20p13
spinocerebellar ataxia;610246;spinocerebellar degeneration;slow progression;Pace of progression;AFG3L2, SCA28, SPAX5;604581;18p11.21
spinocerebellar ataxia;610743;spinocerebellar degeneration;incoordination;Abnormality of coordination;SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4;608441;6q25.1-q25.2
spinocerebellar ataxia;612016;spinocerebellar degeneration;increased intramyocellular lipid droplets;Increased muscle lipid content;ADCK3, COQ8, CABC1, SCAR9, ARCA2, COQ10D4;606980;1q42.13
spondyloarthropathy;106300;arthropathy;enthesitis;Abnormality of Sharpey fibers;HLA-B, SPDA1;142830;6p21.33
spondylocostal dysostosis;122600;dysostosis;short thorax;Abnormality of the thorax;TBX6, SCDO5;602427;16p11.2
spondylocostal dysostosis;277300;dysostosis;disproportionate short-trunk short stature;Abnormal axial skeleton morphology;DLL3, SCDO1;602768;19q13.2
spondylocostal dysostosis;608681;dysostosis;disproportionate short-trunk short stature;Abnormal axial skeleton morphology;MESP2, SCDO2;605195;15q26.1
spondylocostal dysostosis;609813;dysostosis;supernumerary vertebral ossification centers;Abnormal vertebral ossification;LFNG, SCDO3;602576;7p22.3
spondylocostal dysostosis;613686;dysostosis;short thorax;Abnormality of the thorax;HES7, SCDO4;608059;17p13.1
spondyloepimetaphyseal dysplasia, Missouri type;602111;spondyloepimetaphyseal dysplasia;small epiphyses;Abnormality of the epiphyses;MMP13, CLG3, MANDP1;600108;11q22.2
spondyloepimetaphyseal dysplasia, Pakistani type;612847;spondyloepimetaphyseal dysplasia;lower limb undergrowth;Limb undergrowth;PAPSS2, ATPSK2, BCYM4;603005;10q23.2-q23.3
spondyloepimetaphyseal dysplasia, Strudwick type;184250;spondyloepimetaphyseal dysplasia;metaphyseal dappling;Metaphyseal sclerosis;COL2A1;120140;12q13.11
spondyloepiphyseal dysplasia congenita;183900;spondyloepimetaphyseal dysplasia;flat face;Abnormal facial shape;COL2A1;120140;12q13.11
spondyloepiphyseal dysplasia with congenital joint dislocations;143095;spondyloepimetaphyseal dysplasia;short femoral neck;Aplasia/Hypoplasia involving the femoral head and neck;CHST3, C6ST, C6ST1, HSD;603799;10q22.1
stomach cancer;137215;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;CDH1, UVO, LCAM, ECAD;192090;16q22.1
stomach cancer;137215;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;IL1B;147720;2q13
stomach cancer;137215;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;IL1RN, MVCD4, DIRA;147679;2q13
stomach cancer;137215;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;KRAS, KRAS2, RASK2, NS, CFC2;190070;12p12.1
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;APC, GS, FPC, BTPS2;611731;5q22.2
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;CASP10, MCH4, ALPS2;601762;2q33.1
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;ERBB2, NGL, NEU, HER2;164870;17q12
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;10q26.13
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;IRF1, MAR;147575;5q31.1
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;KLF6, COPEB, BCD1, ZF9;602053;10p15.1
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;MUTYH, MYH;604933;1p34.1
stomach cancer;613659;gastrointestinal system cancer;stomach cancer;Neoplasm of the stomach;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;3q26.32
striatonigral degeneration;271930;multiple system atrophy;pendular nystagmus;Nystagmus;NUP62, SNDI, IBSN;605815;19q13.33
striatonigral degeneration;609161;multiple system atrophy;degeneration of the striatum;Abnormality of the striatum;PDE8B, PPNAD3, ADSD;603390;5q13.3
sudden infant death syndrome;272120;syndrome;apneic episodes in infancy;Apnea;SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;600163;3p22.2
supravalvular aortic stenosis;185500;aortic valve stenosis;arrhythmia;Abnormality of cardiovascular system physiology;ELN;130160;7q11.23
syndactyly;185900;synostosis;finger syndactyly;Syndactyly;CUP2q35, C2DUPq35, SDTY1, SD1;185900;2q34-q36
syndactyly;186100;synostosis;camptodactyly of finger;Flexion contracture of finger;GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR;121014;6q22.31
syndactyly;186200;synostosis;camptodactyly of finger;Flexion contracture of finger;LMBR1, ACHP, C7orf2, PPD2, THYP, LSS;605522;7q36.3
syndactyly;186300;synostosis;camptodactyly of finger;Flexion contracture of finger;HOXD13, HOX4I, SPD, BDSD;142989;2q31.1
syndromic X-linked intellectual disability;300055;syndromic intellectual disability;cognitive impairment;Abnormality of higher mental function;MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16;300005;Xq28
syndromic X-linked intellectual disability;300220;syndromic intellectual disability;cognitive impairment;Abnormality of higher mental function;HSD17B10, HADH2, ERAB, MRXS10;300256;Xp11.22
syndromic X-linked intellectual disability;300676;syndromic intellectual disability;prominent forehead;Abnormality of the forehead;UPF3B, RENT3B, MRXS14;300298;Xq24
syndromic X-linked intellectual disability;300886;syndromic intellectual disability;contractures of the large joints;Flexion contracture;CLIC2, XAP121, MRXS32;300138;Xq28
syndromic X-linked intellectual disability;304340;syndromic intellectual disability;self-injurious behavior;Abnormal aggressive, impulsive or violent behavior;AP1S2, MRX59, MRXSF, MRXS21, MRXS5, PGS;300629;Xp22.2
syndromic intellectual disability;300486;intellectual disability;cognitive impairment;Abnormality of higher mental function;OPHN1, MRX60;300127;Xq12
syndromic intellectual disability;300860;intellectual disability;midface retrusion;Abnormality of the midface;UBE2A, RAD6A, MRXSN, MRXS30;312180;Xq24
syndromic intellectual disability;309583;intellectual disability;long fingers;Abnormality of finger;SMS, SRS, MRSR;300105;Xp22.11
synovial sarcoma;300813;synovium cancer;synovial sarcoma;Sarcoma;SSX1, SSRC;312820;Xp11.23
synovial sarcoma;300813;synovium cancer;synovial sarcoma;Sarcoma;SSX2;300192;Xp11.22
synpolydactyly;186000;syndactyly;contracture of the proximal interphalangeal joint of the 5th finger;Camptodactyly of finger;HOXD13, HOX4I, SPD, BDSD;142989;2q31.1
synpolydactyly;608180;syndactyly;polydactyly;Abnormality of digit;FBLN1;135820;22q13.31
systemic lupus erythematosus;152700;lupus erythematosus;antiphospholipid antibody positivity;Autoimmune antibody positivity;BANK1, FLJ20706, BANK;610292;4q24
systemic lupus erythematosus;152700;lupus erythematosus;antiphospholipid antibody positivity;Autoimmune antibody positivity;C4A, C4S, C4AD;120810;6p21.33
systemic lupus erythematosus;152700;lupus erythematosus;antiphospholipid antibody positivity;Autoimmune antibody positivity;CTLA4, IDDM12, CELIAC3, ALPS5;123890;2q33.2
systemic lupus erythematosus;152700;lupus erythematosus;antiphospholipid antibody positivity;Autoimmune antibody positivity;DNASE1, DNL1;125505;16p13.3
systemic lupus erythematosus;152700;lupus erythematosus;antiphospholipid antibody positivity;Autoimmune antibody positivity;FCGR2B, CD32;604590;1q23.3
systemic lupus erythematosus;152700;lupus erythematosus;antiphospholipid antibody positivity;Autoimmune antibody positivity;PTPN22, PEP, PTPN8, LYP;600716;1p13.2
systemic lupus erythematosus;152700;lupus erythematosus;antiphospholipid antibody positivity;Autoimmune antibody positivity;TREX1, AGS1, CRV, HERNS;606609;3p21.31
systemic lupus erythematosus;609939;lupus erythematosus;polygenic inheritance;Multifactorial inheritance;ITGAM, CR3A, CD11B, MAC1A, SLEB6;120980;16p11.2
systemic lupus erythematosus;614420;lupus erythematosus;systemic lupus erythematosus;Autoimmunity;DNASE1L3, SLEB16;602244;3p14.3
systemic primary carnitine deficiency disease;212140;amino acid metabolic disorder;impaired gluconeogenesis;Abnormal glucose homeostasis;SLC22A5, OCTN2, CDSP, SCD;603377;5q31.1
tarsal-carpal coalition syndrome;186570;autosomal dominant disease;clinodactyly;Abnormality of digit;NOG, SYM1, SYNS1;602991;17q22
temtamy preaxial brachydactyly syndrome;605282;autosomal recessive disease;talon cusp;Abnormality of incisor morphology;CHSY1, KIAA0990, TPBS;608183;15q26.3
testicular cancer;273300;male reproductive organ cancer;teratoma;Germ cell neoplasia;BCL10, IMD37;603517;1p22.3
testicular cancer;273300;male reproductive organ cancer;teratoma;Germ cell neoplasia;FGFR3, ACH;134934;4p16.3
testicular cancer;273300;male reproductive organ cancer;teratoma;Germ cell neoplasia;KIT, PBT;164920;4q12
testicular cancer;273300;male reproductive organ cancer;teratoma;Germ cell neoplasia;STK11, PJS, LKB1;602216;19p13.3
testicular germ cell cancer;273300;testicular cancer;teratoma;Germ cell neoplasia;BCL10, IMD37;603517;1p22.3
testicular germ cell cancer;273300;testicular cancer;teratoma;Germ cell neoplasia;FGFR3, ACH;134934;4p16.3
testicular germ cell cancer;273300;testicular cancer;teratoma;Germ cell neoplasia;KIT, PBT;164920;4q12
testicular germ cell cancer;273300;testicular cancer;teratoma;Germ cell neoplasia;STK11, PJS, LKB1;602216;19p13.3
tetralogy of Fallot;187500;congenital heart disease;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;GATA4, ASD2, VSD1, TACHD, TOF;600576;8p23.1
tetralogy of Fallot;187500;congenital heart disease;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;GATA6, AVSD5, ASD9, AVSD5, PACHD;601656;18q11.2
tetralogy of Fallot;187500;congenital heart disease;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;GDF1, DTGA3, DORV, RAI;602880;19p13.11
tetralogy of Fallot;187500;congenital heart disease;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;JAG1, AGS, AHD;601920;20p12.2
tetralogy of Fallot;187500;congenital heart disease;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;600584;5q35.1
tetralogy of Fallot;187500;congenital heart disease;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR;602054;22q11.21
tetralogy of Fallot;187500;congenital heart disease;underdeveloped supraorbital ridges;Abnormality of the supraorbital ridges;ZFPM2, FOG2, DIH3, SRXY9;603693;8q23.1
thalassemia;604131;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;HBA1, HBH;141800;16p13.3
thalassemia;604131;autosomal recessive disease;cognitive impairment;Abnormality of higher mental function;HBA2, HBH;141850;16p13.3
thanatophoric dysplasia;187600;osteochondrodysplasia;abnormality of the sacroiliac joint;Abnormality of the sacrum;FGFR3, ACH;134934;4p16.3
thanatophoric dysplasia;187601;osteochondrodysplasia;lethal short-limbed short stature;Disproportionate short-limb short stature;FGFR3, ACH;134934;4p16.3
thiourea tasting;171200;;abnormality of the endocrine system;Phenotypic abnormality;TAS2R38, T2R61, PTC;607751;7q34
thoracic aortic aneurysm;132900;aortic aneurysm;cystic medial necrosis;Abnormality of the systemic arterial tree;MYH11, AAT4, FAA4;160745;16p13.11
thoracic aortic aneurysm;611788;aortic aneurysm;moyamoya phenomenon;Abnormality of circle of Willis;ACTA2, ACTSA, AAT6, MYMY5;102620;10q23.31
thoracic aortic aneurysm;613780;aortic aneurysm;aortic aneurysm;Aneurysm;MYLK, MLCK, AAT7;600922;3q21.1
thoracic aortic aneurysm;615436;aortic aneurysm;thoracic aortic aneurysm;Dilatation of the abdominal aorta;PRKG1, PRKG1B, PRKGR1B, AAT8;176894;10q11.2-q21.1
thrombocytopenia-absent radius syndrome;274000;chromosomal disease;tibial torsion;Abnormality of the tibia;RBM8A, RBM8B, TAR, C1DELq21.1, DEL1q21.1;605313;1q21.1
thrombocytopenia;188000;blood platelet disease;thrombocytopenia;Abnormal platelet count;ANKRD26, KIAA1074, THC2;610855;10p12.1
thrombocytopenia;188000;blood platelet disease;thrombocytopenia;Abnormal platelet count;MASTL, FLJ14813, GWL, THC2;608221;10p12.1
thrombocytopenia;300367;blood platelet disease;anemia of inadequate production;Anemia;GATA1, GF1, ERYF1, NFE1, XLTDA, XLTT, XLANP;305371;Xp11.23
thrombocytopenia;313900;blood platelet disease;decreased mean platelet volume;Abnormal platelet volume;WAS, IMD2, THC1, SCNX;300392;Xp11.23
thrombocytopenia;612004;blood platelet disease;thrombocytopenia;Abnormal platelet count;CYCS, CYC, THC4;123970;7p15.3
thrombophilia;188050;blood coagulation disease;childhood onset;Onset;F13A1, F13A;134570;6p25.1
thrombophilia;188050;blood coagulation disease;childhood onset;Onset;F2, THPH1, RPRGL2;176930;11p11.2
thrombophilia;188050;blood coagulation disease;childhood onset;Onset;HABP2, PHBP, HGFAL, FSAP;603924;10q25.3
thrombophilia;188050;blood coagulation disease;childhood onset;Onset;MTHFR;607093;1p36.22
thyroid hormone resistance syndrome;188570;hypothyroidism;increased serum free triiodothyronine (ft3);Abnormality of thyroid physiology;THRB, ERBA2, THR1, PRTH;190160;3p24.2
thyroid hormone resistance syndrome;274300;hypothyroidism;epiphyseal stippling;Ectopic calcification;THRB, ERBA2, THR1, PRTH;190160;3p24.2
tooth agenesis;106600;tooth disease;hypodontia;Reduced number of teeth;MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3;142983;4p16.2
tooth agenesis;150400;tooth disease;peg-shaped maxillary lateral incisors;Conical incisor;WNT10A, SSPS, STHAG4, OODD;606268;2q35
tooth agenesis;313500;tooth disease;x-linked dominant inheritance;X-linked inheritance;ED1, EDA, ECTD1, EDA, HED1, STHAGX1;300451;Xq13.1
tooth agenesis;604625;tooth disease;oligodontia;Reduced number of teeth;PAX9, STHAG3;167416;14q13.3
tooth agenesis;613097;tooth disease;increased bone mineral density;Abnormality of bone mineral density;LTBP3, LTBP2, STHAG6;602090;11q13.1
tooth and nail syndrome;189500;syndrome;reduced number of teeth;Abnormal number of teeth;MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3;142983;4p16.2
transcobalamin II deficiency;275350;vitamin B12 deficiency;methylmalonic aciduria;Dicarboxylic aciduria;TCN2, TC2;613441;22q12.2
transthyretin amyloidosis;105210;amyloidosis;amyloidosis;Abnormality of metabolism/homeostasis;TTR, PALB;176300;18q12.1
trichorhinophalangeal syndrome type I;190350;autosomal dominant disease;chin with horizontal crease;Abnormality of the chin;TRPS1;604386;8q23.3
trichotillomania;613229;impulse control disorder;hair-pulling;Self-injurious behavior;SLITRK1, KIAA1910, TTM;609678;13q31.1
trilateral retinoblastoma;180200;retinoblastoma;ewing's sarcoma;Sarcoma;RB1;614041;13q14.2
triosephosphate isomerase deficiency;615512;glucose metabolism disease;abnormality of immune system physiology;Abnormality of the immune system;TPI1, TPID;190450;12p13.31
triple-A syndrome;231550;autosomal recessive disease;childhood onset;Onset;AAAS, AAA;605378;12q13.13
tuberous sclerosis;191100;autosomal dominant disease;premature chromatid separation;Abnormality of chromosome segregation;TSC1, LAM;605284;9q34.13
tuberous sclerosis;613254;autosomal dominant disease;infantile spasms;Epileptic spasms;IFNG, IFG, IFI;147570;12q15
tuberous sclerosis;613254;autosomal dominant disease;infantile spasms;Epileptic spasms;TSC2, LAM;191092;16p13.3
type 1 diabetes mellitus;125852;diabetes mellitus;type i diabetes mellitus;Diabetes mellitus;INS, MODY10, IDDM2;176730;11p15.5
type 1 diabetes mellitus;222100;diabetes mellitus;hyperglycemia;Abnormality of blood glucose concentration;FOXP3, IPEX, AIID, XPID, PIDX;300292;Xp11.23
type 1 diabetes mellitus;222100;diabetes mellitus;hyperglycemia;Abnormality of blood glucose concentration;HNF1A, TCF1, MODY3, IDDM20;142410;12q24.31
type 1 diabetes mellitus;222100;diabetes mellitus;hyperglycemia;Abnormality of blood glucose concentration;ITPR3;147267;6p21.31
type 1 diabetes mellitus;222100;diabetes mellitus;hyperglycemia;Abnormality of blood glucose concentration;OAS1, OIAS;164350;12q24.13
type 1 diabetes mellitus;222100;diabetes mellitus;hyperglycemia;Abnormality of blood glucose concentration;PTPN22, PEP, PTPN8, LYP;600716;1p13.2
type 1 diabetes mellitus;601942;diabetes mellitus;diabetes mellitus;Abnormal glucose homeostasis;IL2RA, IL2R, IDDM10;147730;10p15.1
type 1 diabetes mellitus;612520;diabetes mellitus;type i diabetes mellitus;Diabetes mellitus;HNF1A, TCF1, MODY3, IDDM20;142410;12q24.31
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2;600509;11p15.1
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;AKT2, HIHGHH;164731;19q13.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;CDKAL1;611259;6p22.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED;173335;6q23.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;GCGR;138033;17q25.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;GCK, HHF3;138079;7p13
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;GPD2;138430;2q24.1
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;HMGA1, HMGIY;600701;6p21.31
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;HNF1A, TCF1, MODY3, IDDM20;142410;12q24.31
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11;189907;17q12
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;HNF4A, TCF14, MODY1, FRTS4;600281;20q13.12
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;IGF2BP2, IMP2;608289;3q27.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;IL6, IFNB2, BSF2, HSF, HGF;147620;7p15.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;IPF1, MODY4, PAGEN1;600733;13q12.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;IRS1;147545;2q36.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;IRS2;600797;13q34
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;KCNJ11, BIR, PHHI, HHF2, TNDM3;600937;11p15.1
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;LIPC, HL, LIPH, HDLCQ12;151670;15q21.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;MAPK8IP1, IB1;604641;11p11.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;MTNR1B;600804;11q14.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;NEUROD1, NIDDM;601724;2q31.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;NIDDM3;603694;20q12-q13.1
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;NIDDM4;608036;5q34-q35.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;PAX4, MODY9, KPD;167413;7q32.1
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;PPARG, PPARG1, PPARG2, CIMT1, GLM1;601487;3p25.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;PTPN1, PTP1B;176885;20q13.13
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;RETN, RSTN, FIZZ3;605565;19p13.2
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;SLC30A8, ZNT8;611145;8q24.11
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;TCF7L2, TCF4;602228;10q25.2-q25.3
type 2 diabetes mellitus;125853;diabetes mellitus;type ii diabetes mellitus;Diabetes mellitus;WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41;606201;4p16.1
type I Ehlers-Danlos syndrome;130000;Ehlers-Danlos syndrome;infantile muscular hypotonia;Muscular hypotonia;COL1A1;120150;17q21.33
type I Ehlers-Danlos syndrome;130000;Ehlers-Danlos syndrome;infantile muscular hypotonia;Muscular hypotonia;COL5A1;120215;9q34.3
type I Ehlers-Danlos syndrome;130000;Ehlers-Danlos syndrome;infantile muscular hypotonia;Muscular hypotonia;COL5A2;120190;2q32.2
type I complement component 8 deficiency;613790;complement deficiency;c8 deficiency;Complement deficiency;C8A;120950;1p32.2
type II complement component 8 deficiency;613789;complement deficiency;recurrent neisserial infections;Recurrent gram-negative bacterial infections;C8B;120960;1p32.2
type III Ehlers-Danlos syndrome;130020;Ehlers-Danlos syndrome;decreased corneal thickness;Abnormality of corneal thickness;COL3A1;120180;2q32.2
type III Ehlers-Danlos syndrome;130020;Ehlers-Danlos syndrome;decreased corneal thickness;Abnormality of corneal thickness;TNXB, TNX, TNXB1, TNXBS, TNXB2, EDS3, VUR8;600985;6p21.33
type VI Ehlers-Danlos syndrome;225400;Ehlers-Danlos syndrome;decreased corneal thickness;Abnormality of corneal thickness;PLOD1, LH1, LLH, EDS6;153454;1p36.22
type VI Ehlers-Danlos syndrome;229200;Ehlers-Danlos syndrome;decreased corneal thickness;Abnormality of corneal thickness;ZNF469, KIAA1858, BCS1;612078;16q24.2
tyrosinemia type I;276700;tyrosinemia;episodic peripheral neuropathy;Peripheral neuropathy;FAH;613871;15q25.1
tyrosinemia type II;276600;tyrosinemia;cognitive impairment;Abnormality of higher mental function;TAT;613018;16q22.2
tyrosinemia type III;276710;tyrosinemia;4-hydroxyphenylacetic aciduria;Abnormality of monocarboxylic acid metabolism;HPD;609695;12q24.31
ulcerative colitis;266600;colitis;ulcerative colitis;Chronic colitis;IL6, IFNB2, BSF2, HSF, HGF;147620;7p15.3
ulcerative colitis;266600;colitis;ulcerative colitis;Chronic colitis;NOD2, CARD15, IBD1, CD, ACUG, PSORAS1;605956;16q12.1
urinary bladder cancer;109800;urinary system cancer;transitional cell carcinoma of the bladder;Bladder carcinoma;FGFR3, ACH;134934;4p16.3
urinary bladder cancer;109800;urinary system cancer;transitional cell carcinoma of the bladder;Bladder carcinoma;HRAS;190020;11p15.5
urinary bladder cancer;109800;urinary system cancer;transitional cell carcinoma of the bladder;Bladder carcinoma;KRAS, KRAS2, RASK2, NS, CFC2;190070;12p12.1
urinary bladder cancer;109800;urinary system cancer;transitional cell carcinoma of the bladder;Bladder carcinoma;RB1;614041;13q14.2
urinary bladder cancer;109800;urinary system cancer;transitional cell carcinoma of the bladder;Bladder carcinoma;TACC3;605303;4p16.3
urofacial syndrome;236730;autosomal recessive disease;urethral valve;Urethral obstruction;HPSE2, HPA2, UFS1;613469;10q24.2
urofacial syndrome;615112;autosomal recessive disease;constipation;Abdominal symptom;LRIG2, LIG2, KIAA0806, UFS2;608869;1p13.2
urticaria pigmentosa;154800;cutaneous mastocytosis;cutaneous mastocytosis;Mastocytosis;KIT, PBT;164920;4q12
uterine fibroid;150699;uterine benign neoplasm;somatic mutation;Mode of inheritance;HMGA2, HMGIC, BABL;600698;12q14.3
variegate porphyria;176200;acute porphyria;porphyrinuria;Abnormality of the heme biosynthetic pathway;HFE, HLA-H, HFE1, MVCD7, TFQTL2;613609;6p22.2
variegate porphyria;176200;acute porphyria;porphyrinuria;Abnormality of the heme biosynthetic pathway;PPOX;600923;1q23.3
velocardiofacial syndrome;192430;chromosomal disease;retinal vascular tortuosity;Abnormality of the retinal vasculature;TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR;602054;22q11.21
ventricular septal defect;614429;heart septal defect;pulmonic stenosis;Abnormality of the pulmonary valve;GATA4, ASD2, VSD1, TACHD, TOF;600576;8p23.1
ventricular septal defect;614431;heart septal defect;perimembranous ventricular septal defect;Ventricular septal defect;CITED2, MRG1, P35SRJ, VSD2, ASD8;602937;6q24.1
ventricular septal defect;614432;heart septal defect;pulmonary artery stenosis;Abnormality of the pulmonary artery;NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;600584;5q35.1
vesicoureteral reflux;610878;ureteral disease;renal hypoplasia;Renal hypoplasia/aplasia;ROBO2, SAX3, KIAA1568;602431;3p12.3
vesicoureteral reflux;613674;ureteral disease;polyhydramnios;Abnormality of the amniotic fluid;SOX17, VUR3;610928;8q11.23
vesicoureteral reflux;614674;ureteral disease;recurrent spontaneous abortion;Spontaneous abortion;HTR1A, ADRB2RL1, PFMCD;109760;5q12.3
vesicoureteral reflux;615963;ureteral disease;joint hypermobility;Abnormality of joint mobility;TNXB, TNX, TNXB1, TNXBS, TNXB2, EDS3, VUR8;600985;6p21.33
visceral heterotaxy;306955;physical disorder;abdominal situs inversus;Abnormality of abdominal situs;ZIC3, HTX1, HTX, VACTERLX;300265;Xq26.3
visceral heterotaxy;605376;physical disorder;mesocardia;Abnormal anatomic location of the heart;CFC1, CRYPTIC, HTX2, DTGA2;605194;2q21.1
visceral heterotaxy;613751;physical disorder;right aortic arch;Abnormal branching pattern of the aortic arch;ACVR2B, ACTRIIB, HTX4;602730;3p22.2
visceral heterotaxy;614779;physical disorder;variable expressivity;Phenotypic variability;CCDC11, HTX6;614759;18q21.1
vitelliform macular dystrophy;153700;macular degeneration;cystoid macular degeneration;Macular degeneration;BEST1, VMD2, ARB, RP50;607854;11q12.3
vitelliform macular dystrophy;608161;macular degeneration;metamorphopsia;Abnormality of vision;PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2, MDBS1;179605;6p21.1
von Hippel-Lindau disease;193300;hemangioblastoma;neoplasm of the middle ear;Neoplasm of the ear;CCND1, PRAD1, BCL1;168461;11q13.3
von Hippel-Lindau disease;193300;hemangioblastoma;neoplasm of the middle ear;Neoplasm of the ear;VHL;608537;3p25.3
von Willebrand's disease;193400;inherited blood coagulation disease;prolonged whole-blood clotting time;Abnormality of coagulation;VWF, F8VWF;613160;12p13.31
von Willebrand's disease;277480;inherited blood coagulation disease;reduced von willebrand factor activity;Abnormality of von Willebrand factor;VWF, F8VWF;613160;12p13.31
von Willebrand's disease;613554;inherited blood coagulation disease;variable expressivity;Phenotypic variability;VWF, F8VWF;613160;12p13.31
xanthinuria;278300;purine-pyrimidine metabolic disorder;pyelonephritis;Nephritis;XDH;607633;2p23.1
xeroderma pigmentosum;278700;autosomal recessive disease;dermal atrophy;Aplasia/Hypoplasia of the skin;XPA, XPAC;611153;9q22.33
xeroderma pigmentosum;278720;autosomal recessive disease;cutaneous melanoma;Neoplasm of the skin;XPC, XPCC;613208;3p25.1
xeroderma pigmentosum;278730;autosomal recessive disease;dermal atrophy;Aplasia/Hypoplasia of the skin;ERCC2, EM9, XPD, COFS2;126340;19q13.32
xeroderma pigmentosum;278740;autosomal recessive disease;squamous cell carcinoma of the skin;Squamous cell carcinoma;DDB2;600811;11p11.2
xeroderma pigmentosum;278750;autosomal recessive disease;verrucae;Papilloma;POLH, XPV;603968;6p21.1
xeroderma pigmentosum;278760;autosomal recessive disease;papule;Localized skin lesion;ERCC4, XPF, FANCQ;133520;16p13.12
xeroderma pigmentosum;278780;autosomal recessive disease;defective dna repair after ultraviolet radiation damage;Abnormality of DNA repair;ERCC5, XPG, COFS3;133530;13q33.1
xeroderma pigmentosum;610651;autosomal recessive disease;cutaneous melanoma;Neoplasm of the skin;ERCC3, XPB;133510;2q14.3
